Abbott Annual Report

Abbott India Limited Registered Office: Tel: (91-22) 5046 1000/2000
Godrej BKC, Plot C-68,”G”Block, 3, Corporate Park, Fax : (91-22) 5016 9400
15-16th Floor, Bandra-Kurla Complex, Sion Trombay Road, E-mail : [email protected]
Near MCA Club, Bandra (E), Mumbai - 400 071.India Website : www.abbott.co.in
Mumbai - 400 051. India CIN: L24239MH1944PLC007330
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
August 16, 2020
Scrip Code: 500488
Dear Sir/Madam,
Sub: Submission of Annual Report for the year ended March 31, 2020 as per Regulation 34(1)
of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015
This is to inform you that the Seventy-sixth Annual General Meeting (“AGM”) of the Company is
scheduled to be held on Monday, September 7, 2020 at 9:00 a.m. (IST) through Video-
Conferencing (‘‘VC’’)/Other Audio-Visual Means (“OAVM”) in accordance with the relevant
circulars issued by the Ministry of Corporate Affairs (“MCA”) and the Securities and Exchange Board
of India (“SEBI”). We hereby enclose a copy of the Annual Report of the Company for the financial
year ended March 31, 2020, for your reference.
In compliance with the relevant circulars issued by MCA and SEBI, the Annual Report for the
financial year 2019-20, comprising the Notice of the 76th AGM and the Standalone Financial
Statements for the financial year 2019-20, along with Board's Report, Auditors’ Report and other
documents required to be attached thereto, is sent to all the Members of the Company whose email
address are registered with the Company/Depository Participant(s).
The detailed procedure to be followed for remote e-voting or e-voting during the AGM, Speaker
Registration, posting of queries and joining the AGM through VC/OAVM and live webcast has been
provided in the Notice of the AGM and on the website of the Company at www.abbott.co.in
Further final dividend of Rs. 107/- and special dividend of Rs. 143/- per Equity Share of Rs. 10/- each,
as recommended by the Board of Directors at its Meeting held on June 8, 2020, if approved by the
Members at the Annual General Meeting, will be paid on and from September 14, 2020 to the
Members whose names appear on the Register of Members as on September 7, 2020 and to the
Beneficial Owners of the Shares as on August 31, 2020, as per the details furnished by the
Depositories for this purpose. Further, please note that the cut-off date for determining the eligibility
of members to vote through remote e-voting or during the AGM is Monday, August 31, 2020.
You are requested to take the same on record.
Thank you.
Yours faithfully,
Abbott India Limited
Digitally signed by
KRUPA KRUPA KETAN
KETAN ANANDPARA
Date: 2020.08.16
ANANDPARA 11:34:47 +05'30'
Krupa Anandpara
Company Secretary
Membership No.: ACS 16536
Encl: a/a
PASSION
TO DELIVER
ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20
PASSION
TO DELIVER
Fueled by passion, Abbott India Limited has been delivering
value across the healthcare ecosystem for over 75 years.
A Passion to Deliver Excellence allows us to face

challenging opportunities and explore newer avenues.
Our leadership is the outcome of our dedication and
staying true to our business ethos.
Our Passion to Deliver Innovation to our wide

cross-section of patients and other stakeholders ensures
that we maintain our winning form. It helps us achieve a
qualitative and quantitative edge over the board.
And Passion to Deliver with Compassion remains the

driving force behind each one of us working toward a
unified cause - that of helping people live healthier lives.
Continuing on our journey to deliver on our commitment,

we are proud to take you through another exciting
year of our work.
ABOUT THE REPORT

At Abbott India Limited (Abbott India), we are furthering our commitment to transparent
stakeholder communications. In this Annual Report, we have adopted certain elements,
principles and concepts of integrated reporting to demonstrate how our strategic priorities are
aligned to improve the lives of people we serve and create long-term value for all stakeholders.
The Report is guided by the framework issued by the International Integrated Reporting
Council (IIRC). In the coming years', we will continue to incorporate more of these elements
toward communicating both the financial and non-financial aspects of the business.
CONTENTS CORPORATE INFORMATION
BOARD OF DIRECTORS REGISTERED OFFICE
CORPORATE OVERVIEW Munir Shaikh - Chairman 3, Corporate Park
4 Abbott India at a Glance Anil Joseph - Managing Director Sion - Trombay Road
8 Our Capitals Anisha Motwani - Independent Director Mumbai - 400 071
Sudarshan Jain - Independent Director T: +91-22-6797 8888
EXCELLENCE Shalini Kamath - Independent Director F: +91-22-6797 8727
12 Chairman’s Message Ambati Venu - Non-Executive Director E: [email protected]
14 10-year Financial Highlights Kaiyomarz Marfatia - Non-Executive Director
16 Message from Ambati Venu, Non-Executive Director Rajiv Sonalker - CFO and Whole-time Director CORPORATE OFFICE
18 Key Performance Indicators 16th Floor, Godrej BKC
20 Managing Director’s Message KEY MANAGEMENT TEAM Plot C- 68, G Block
22 Business Model Anil Joseph - Managing Director Bandra-Kurla Complex
24 Strategic Priorities Rajiv Sonalker - CFO and Whole-time Director Bandra (East), Mumbai 400 051
26 Operating Environment Prakash Maheshwari - Commercial Director T: +91-22-5046 2000
Milind Tendulkar - Commercial Director F: +91-22-5016 2400
INNOVATION T. Ramakrishna Prasad - Commercial Director
30 Therapy-shaping Initiatives Mandar Keskar - Associate Director, Commercial FACTORY
34 Transformation across Product Lifecycle Keya Phatnani - Director, Human Resources L-18/19, Verna Industrial Estate, Goa
36 Unique Solutions Sridhar Kadangode - Director, Finance
Dr Srirupa Das - Director, Medical Affairs REGISTRAR & SHARE
COMPASSION Dr Vijay Patil - Associate Director, NPI and TAS TRANSFER AGENT
KFin Technologies Private Limited
40 Environment
COMPANY SECRETARY Selenium Tower B
44 People Plot 31-32, Gachibowli
Krupa Anandpara
48 Corporate Social Responsibility Financial District
50 Ethics and Governance STATUTORY AUDITORS Nanakramguda
52 Board of Directors S R B C & CO LLP Hyderabad - 500 032
54 Management Team Chartered Accountants T: +91-40-6716 2222
55 Rewards and Recognition F: +91-40-2300 1153
INTERNAL AUDITORS
STATUTORY REPORTS M/s KPMG
56 Board of Directors Report and Chartered Accountants 76TH ANNUAL GENERAL
Management Discussion and Analysis
84 Business Responsibility Report COST AUDITORS MEETING
98 Corporate Governance Report M/s Kishore Bhatia & Associates DATE: SEPTEMBER 7, 2020
Cost Accountants DAY: MONDAY
FINANCIAL STATEMENTS TIME: 9:00 AM
114 Independent Auditor's Report SECRETARIAL AUDITOR THROUGH VIDEO-CONFERENCING
122 Balance Sheet Neena Bhatia (VC)/OTHER-AUDIO VISUAL MEANS
123 Statement of Profit and Loss Practicing Company Secretary (OAVM)
124 Statement of Changes in Equity
125 Statement of Cash Flow FORWARD-LOOKING STATEMENT
127 Notes to the Financial Statements In this Annual Report, we might have disclosed forward-looking statements that set out
anticipated results based on the management’s plans and assumptions. We cannot guarantee that
176 NOTICE these forward-looking statements will be realised, although we believe we have been prudent in
our assumptions. The achievements of results are subject to risks, uncertainties, and inaccurate
assumptions. We undertake no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise. References to ‘Abbott India’ in
this Annual Report shall mean ‘Abbott India Limited’.
3
ABBOTT INDIA AT A GLANCE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
ABBOTT INDIA, A TRUSTED PARTNER

OF CHOICE FOR HEALTHCARE
For over 75 years, Abbott India has been the partner of choice for
health providers, enabling the people of India to live their best
possible life with our high-quality products and services.
A subsidiary of Abbott Laboratories, Abbott India geographic expansions and improved ways of using
offers a broad portfolio of products in multiple therapy our medicines to help shape a new-age healthcare
areas that help treat some of the most persistent health ecosystem. We are motivated by our belief that health is
conditions. We tailor our product offerings to meet the essential to achieving full potential.
specific needs of the people in India.
Our strong leadership positions in every therapy we
Our consistent value creation is backed by our serve, ability to achieve continued above-market growth
continuous efforts and investment in innovating, and deliver consistent shareholder returns, truly make
building on market presence with newer indications, us one of India’s most valued companies.
KEY THERAPY AREAS

WOMEN’S HEALTH MULTI-SPECIALTY
Products under this therapy enjoy a strong equity Differentiated products and marketing over conventional
and have a high level of credibility and trust, which is preparations for pain management, nutritional supplements, ABBOTT LABORATORIES
essential owing to their sensitive indications, with a vitamins and insomnia. At Abbott, we are dedicated to helping people live We have market-leading positions in every
high bar on safety (especially in pregnancy). more fully, in everything they do. We are creating business such as remote heart-failure monitoring,
the future of healthcare through life-changing transcatheter mitral-valve repair, heart pumps
technologies and products that make people (LVADs), stents, continuous glucose monitoring,
CENTRAL NERVOUS SYSTEM healthier and stronger, quickly identify when they chronic-pain devices, point-of-care testing, blood
GASTROENTEROLOGY Highly innovative and trusted products under this therapeutic have a medical need, and treat conditions to help and plasma screening, pediatric and
The products under this portfolio focus on upper and segment to alleviate the suffering of patients with vertigo, them get back to doing what they love. adult nutrition and multiple therapies in our
lower gastrointestinal tract (GI) issues along with epilepsy, migraine and depression, among others. medicines portfolio.
hepatic care. Our differentiated offerings beyond pills in We serve people in more than 160 countries with
this area and strong equity amongst the consumers are leading medical devices, diagnostics, nutrition To know more about Abbott visit
behind the sustained growth. products and branded generic medicines. Our www.abbott.com/
107,000 colleagues are helping millions of people
VACCINES to live better and healthier, every day around
A highly diverse portfolio catering to the immunology segment the world.
with products targeting influenza, typhoid, and diarrhoea.
METABOLICS
Products cater to hypothyroidism, hyperthyroidism KEY FACTS
and also for newer sub-therapies. Increasing patient
awareness and reducing reluctance to seek treatment
US$ 31.9 Billion 160+ countries 130+ years 1,07,000
CONSUMER HEALTH WORLDWIDE SALES (2019) PRESENCE OF LEADERSHIP WORKFORCE
as well as our approach toward continuum of care Consumer-directed products, including all variants of antacids
differentiate us from others in this segment. (antiflatulent) tablets, liquids and powders.
4 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 5

ABBOTT INDIA AT A GLANCE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
OUR KEY BRANDS
16 OF OUR TOP 20 BRANDS RANK # 1 AND # 2 IN THEIR RESPECTIVE

PARTICIPATED MARKET* 14 OF OUR TOP 20 BRANDS ARE GROWING FASTER THAN THE MARKET*

Irritable Bowel Exocrine Pancreatic Constipation Miscarriage and Constipation Preterm Labor Antacid Prevention of Typhoid GI Disorders Chronic Liver Diseases
Syndrome Insufficiency Infertility
Manage Vitamin D3 deficiency
Smarter technology. Better absorption

Prevention of Gastroesophageal Depression and Anxiety Hypothyroidism Vertigo Vitamin D Deficiency Liver Disease Bacterial Vaginosis Menopause Insomnia
Influenza Reflux Disease
Disclaimer: All products displayed/mentioned in this Annual Report are for

*Source: IQVIA: MAT March 2020
illustration purpose only. Consult your Physician for professional medical advice.
Backed by Abbott India's 75+ year Highly performance-driven Market leadership Approach to lead
STRENGTHS reputation for quality, a reliable culture and powerful teams in multiple therapies from the front with our
supply chain, and expertise committed to our purpose and niche segments first-to-market healthcare
solutions, unique services
and execution excellence
OUR CAPITALS CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
A COMMITMENT TO KEEP
DOING MORE
In our journey of value creation at Abbott India, we continue to cross
milestones, driven by our empathy for the consumer. We derive support from
the strength of our relationships with our key stakeholders. Our six capital
assets are aimed at helping to improve these relationships in service of our
aspiration, which is to improve performance across the continuum of care.
FINANCIAL CAPITAL MANUFACTURED CAPITAL HUMAN CAPITAL INTELLECTUAL CAPITAL SOCIAL AND RELATIONSHIP NATURAL CAPITAL
Financial Capital is the internal Manufactured Capital is the Human Resource is the strongest Our Intellectual Capital CAPITAL Natural Capital refers to the natural
retained earnings generated by company’s tangible and intangible asset for the Company. Human Capital consists of strong heritage brands, Social and Relationship Capital refers resources we use to create value
the company and is used to grow infrastructure used for value creation refers to our employees’ competencies, highly experienced people, world- to the relationships we establish for our stakeholders and efforts
and support business activities. We through business activities. We knowledge and experience and their class technology, robust processes with our ecosystem of stakeholders, that we undertake to promote
judiciously and efficiently deploy have state-of-the-art manufacturing capability to utilize these to meet and systems. We rigorously make including the communities integral to natural resource preservation and
the funds to expand our business plant at Goa. The plant is critical for stakeholder needs. Our employees are the investments in new product our work, to create societal value. As environmental mitigation. We are
operations and deliver sustained the manufacturing of some of our key to our success and our focus remains developments, scientific research, a responsible corporate citizen, our committed to safeguarding a healthy
growth year after year. We key products such as Cremaffin, on attracting, engaging and developing clinical studies, improvised sustainability strategy is focused on environment for all by reducing
consistently enhance fixed assets Duphalac and Digene. We undertake the best set of talented people who packaging and enhancing our human achieving sustainable growth, delivering our environmental impact. This
productivity, working capital turns, a comprehensive review from time to share our vision and values and deliver capabilities to cater to the needs of innovative solutions and building shapes the way that we source our
and operating margins through time to improve our manufacturing exceptional outcomes for our customers. our customers. stronger communities. In addition to raw materials within India and how
robust planning and budgeting operations, enhance efficiency and We are committed to helping our people our philanthropic programs, we also we manufacture and distribute our
process. We ensure that we enhance productivity, while reducing cost. fully realize their potential, and this is support the training and education of products. Our approach is guided by
and add value to the financial We also undertake responsible done through providing unique career healthcare providers to improve access our internal policies and applicable
resources that our business generates partnerships with various local paths, customized learning experiences, to healthcare. laws of the land. We have set clear
for our stakeholders. manufacturers for manufacturing our development programs and job-specific environmental goals and made rapid
products to optimize cost efficiency training to help employees be successful progress in using energy and water
while ensuring highest quality in their current roles and develop their resources more efficiently while
standards. potential for future career paths. minimizing waste.
25.4% > 95% 3,551 1 ` 12 Crore 2,879 KL

INCREASE IN CASH GENERATED OF LOCAL PERMANENT EMPLOYEES INNOVATION & CSR SPEND WATER SAVED
FROM OPERATIONS MANUFACTURING DEVELOPMENT CENTER
75 ~25,000 44,372 KWH

` 4,208 Crore 9,745 KL LEADERSHIP FILLED THROUGH 21 HEALTH CLINICS CONDUCTED ENERGY SAVED
TOTAL REVENUE LIQUID PER ANNUM - INTERNAL TALENT PIPELINE NEW PRODUCTS
CAPACITY AT OUR PLANT LAUNCHED
3 Successful CSR 83%
9.3% 1,54,721 partnerships
TOTAL REVENUE
2,257 Million MAN-HOURS OF 12 WITH SEWA, MALARIA
SCORE AS PER BAROMETER
SURVEY CONDUCTED BY
CAGR OVER PAST 5 YEARS MIO TABLETS/ ANNUM - TRAINING CLINICAL STUDIES NO MORE, AMERICARES NATIONAL SAFETY COUNCIL, USA
CAPACITY AT OUR PLANT
Read more 18 Read more 41 Read more 44 Read more 30 Read more 48 Read more 40

ABBOTT AT A GLANCE
PASSION
TO DELIVER
EXCELLENCE
At Abbott India, we are passionate about enabling people
to enjoy good health and their best possible lives. This
drives us to deliver excellence in everything we do. Our
market-leading growth is a strong testimony to
this endeavor.
A consistent brand focus, changing product-mix, and

robust business capabilities are some of the factors that
have ensured delivery of sustainable success and value
to our stakeholders. We continue to pursue our strategic
priorities, focus on our financial commitments and build
on our growth momentum.
12 20
CHAIRMAN’S MESSAGE MANAGING DIRECTOR’S MESSAGE
14 22
10 YEAR FINANCIAL HIGHLIGHTS BUSINESS MODEL
16 24
MESSAGE FROM AMBATI VENU, STRATEGIC PRIORITIES
NON-EXECUTIVE DIRECTOR
26
18 OPERATING ENVIRONMENT
KEY PERFORMANCE INDICATORS
CHAIRMAN’S MESSAGE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
DELIVERING LONG-TERM During this challenging time,

healthcare companies are
GROWING DIVIDEND ` provide all necessary support to
ensure that products are available
SUSTAINABLE VALUE
relentlessly working alongside the for the well-being of our community.
government, to ensure continued
manufacturing of medicines We have had a few changes in our
250*
65*
with increased efforts on focused Board this year. Krishna Mohan
55*
research and development, to bring Sahni retired from the Board at
appropriate medical solutions. Your the end of his tenure. Jawed Zia
Company is no exception to that, and Mark Murphy also resigned
"To drive better growth, we will continue and we have taken extraordinary from the Board. We thank them
to incorporate the learnings from our efforts to remain committed for their valuable contributions.
to our customers by ensuring Shalini Kamath was appointed as
dynamic operating environment and uninterrupted supply of products
2018 2019 2020
an Independent Director and we
deep industry knowledge of today into while keeping the health and welcome her on the Board.
safety of our employees a priority. *includes Special Dividend
tomorrow’s business models." I would like to recognize Ambati
Resilience and adaptability shown
by our people during these critical
times has been and continues to be,
` 593 Crore Venu's contributions as Managing
Director and congratulate him
Dear Shareholders, PAT
commendable. on his elevation to a senior
The start of the new decade has been eventful for everyone. management position within the
I am proud to say that many of our
products, patient support programs
14.1% Abbott Group effective March 2020.
Your Company achieved several
At Abbott India, our purpose leads us, and we believe that PAT (% OF REVENUE)
through better health outcomes we will be able to build and and differentiated marketing and milestones under his leadership and
sustain a healthier, enriching world. I am happy to inform digital initiatives have received are privileged that we will continue
you that despite volatility and uncertainty, your Company external recognitions. Your to receive his guidance as
Company was also recognized The Indian pharmaceutical Non-Executive Director on our
once again delivered a strong performance in
as the Most Innovative MNC of sector which stands at the cusp of Board. I welcome Anil Joseph
FY 2019-20. Through our innovation and agility, we
the Year 2019 at the 12th Pharma innovation and transformation will as Managing Director effective
continued to create and deliver long-term sustainable value
Leaders Award. be led by the changing healthcare July 1, 2020. Anil has had several
across the healthcare ecosystem.
trends. To drive better growth, years of management experience
Keeping in mind our 75th year we will continue to incorporate with Abbott based in Singapore.
Over the last several years, we have continued to
in India and the remarkable the learnings from our dynamic
adapt to the changing environment. One of our critical
performance by the Company, your operating environment and deep On behalf of all Board members, I
success factors has been our agility in adapting to digital
Board has recommended a final industry knowledge of today into would like to extend my sincerest
transformation that is the norm. Last year, we created
dividend ` 107 and special dividend tomorrow’s business models. During gratitude to our employees for their
several ‘first-in-pharma’ ecosystems, pioneering initiatives
of ` 143 per equity share. the year, we laid out our plans to perseverance and commitment, our
in therapies such as vertigo, liver, thyroid, influenza and
reprioritize resources within key shareholders for their continued
others. We have taken a lead in imbibing an innovative
Abbott India stands for quality, trust growth areas, streamline operations trust in our endeavors and our
culture. We have partnered with health-tech start-ups
and partnership. We know how to and redefine our brand strategy. consumers for their confidence in
that endeavour to solve problems in the healthcare space
and developed a service plus open ecosystem, a necessity deliver high-quality healthcare, and our products.
our heritage is proof that we remain We are paving the way for greater
in today’s healthcare system. Also, keeping in mind the
committed for the long-term. collaboration amongst our Thank you
increasing healthcare needs of our consumers, we have
As part of our social initiatives, we employees and are always open
augmented our portfolio and successfully launched
have enabled access to essential to new ideas to facilitate possible
21 new products.
healthcare services and information, breakthroughs.
with support from qualified
healthcare professionals that As the COVID-19 situation evolves,
enhance disease diagnosis. we will continue to navigate and Munir Shaikh
MUNIR SHAIKH
CHAIRMAN

10 YEAR FINANCIAL HIGHLIGHTS CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
MEASURING OUR PROGRESS

(AMOUNTS IN ` LAKH, UNLESS OTHERWISE STATED)
INDIAN GAAP IND AS @
2010 2014
OPERATING RESULTS 2011* 2012 2015 2016 2017 2018 2019 2020
(13 M) (15M)
Total Revenue (Inclusive of excise duty/net of GST) 1031,97 1528,07 1696,93 2358,39 2364,56 2696,23 2996,33 3424,11 3791,89 4207,53
Material Cost 647,30 861,21 971,65 1297,41 1311,96 1492,03 1712,06 1904,74 2088,60 2315,65
Employee Benefit Expenses 111,20 167,35 206,20 299,74 305,40 341,09 345,27 393,69 435,58 476,11
Other Expenses 168,03 304,32 294,97 444,68 387,40 448,14 484,04 484,19 549,69 544,94
Depreciation and Amortization 11,25 15,00 19,49 21,93 14,94 14,44 16,43 16,19 16,92 59,61
Finance Cost 4 3 2 8 50 2,52 2,04 3,82 2,25 8,53
Profit Before Tax and Exceptional Items 94,15 180,16 204,60 294,55 344,36 398,01 436,49 621,48 698,85 802,69
Exceptional Items - - 10,39 - - - - - - -
Provision for Taxation 33,21 59,77 70,29 96,10 115,40 142,76 159,84 220,26 248,52 209,76
Profit After Tax and Exceptional Items 60,94 120,39 144,70 198,45 228,96 255,25 276,65 401,22 450,33 592,93
Earning Per Share - Basic & Diluted (`) 44.56 56.66 68.10 93.39 107.75 120.12 130.19 188.81 211.93 279.04
Dividend Per Share (`) 17.00 17.00 17.00 23.00 31.00 35.00 40.00 50.00 50.00 107.00
Special Dividend Per Share (`) - - - - - - - 5.00 15.00 143.00
ASSETS EMPLOYED
Fixed Assets (Net) 50,57 80,02 109,18 99,52 99,95 111,29 115,88 83,55 105,69 271,47
Other Assets (Net) 254,82 464,12 537,68 688,33 837,58 1084,31 1271,06 1609,21 1902,90 2160,24
Total Assets 305,39 544,14 646,86 787,85 937,53 1195,60 1386,94 1692,76 2008,59 2431,71
FINANCED BY
Share Capital 13,68 21,25 21,25 21,25 21,25 21,25 21,25 21,25 21,25 21,25
Other Equity 291,71 522,89 625,61 766,60 916,28 1174,35 1365,69 1671,51 1987,34 2410,46
Total Equity 305,39 544,14 646,86 787,85 937,53 1195,60 1386,94 1692,76 2008,59 2431,71
NUMBER OF SHAREHOLDERS 14,461 19,354 20,826 18,270 19,407 21,250 23,004 22,583 27,559 51,442
HEADCOUNT 1,767 2,425 2,667 2,766 2,867 2,956 3,083 3,322 3,485 3,551
* Post Merger with Solvay Pharma India Limited

@The Company transitioned into IND AS from April 1, 2015, hence these numbers are not comparable with previous years.

MESSAGE FROM AMBATI VENU, NON-EXECUTIVE DIRECTOR CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
EVOLVED HEALTHCARE SOLUTIONS EBITDA ` IN CRORE we are working to improve patient

experiences across the board.
Our product, Femoston provides
us the opportunity to reach out
FOR A CHANGING WORLD to patients in the pre-and post-
871
Consumer needs are driving our menopause phase. We added our
core focus on innovation. We added global products – Duphalac Bears
718
21 new products to our portfolio and Duphalac Chews to our portfolio,
641
during the year. We have led with catering to a niche audience for their
improvements across the product gastrointestinal needs.
lifecycle by introducing new
packaging solutions, a new range of All of this has been made possible
flavours, simplified dosing and more. through an exceptionally positive,
productive and focused culture
"We are aiming at improving Our future-focused approach at our workplace. We introduced
2018 2019 2020
health outcomes across the has helped us navigate diverse several new talent management and
macroeconomic conditions. We leadership grooming initiatives such
continuum of care comprising undertook several restructuring as ‘Accelerate’ and ‘LEAP’ that aim to
awareness, diagnosis, treatment It is a privilege to welcome Anil
measures to improve our market build strong managerial capabilities.
Joseph as the new Managing
and compliance." Director. He is an Abbott veteran
opportunities and I am proud of As a part of Women Leaders of
our success – as many as 16* of our Abbott (WLA), we also launched the
and I am sure with his diverse
top 20 brands continue to dominate Wo-Mentoring program to mentor
experience, he will lead your
Dear Shareholders, the market. We have retained our more women leaders at the Head
Company to greater heights.
leadership position in most of the Office, plant and on field. Various
I am delighted to share that we were able to therapy areas we target, including wellness initiatives were undertaken
In my first message to you, I had
clock impressive results once again for women’s health, gastroenterology, to empower employees to face the
spoken about how Abbott India
FY 2019-20. Our Total Revenue stood at metabolics, pain management, dynamic environment around us.
as an organization ‘goes the extra
` 4,208 Crore, registering a growth of 11.0% central nervous system and vaccines.
mile’ in its steadfast commitment
over the previous year, while Net Profit grew Similarly, members of our ecosystem
to provide quality, affordable
by 31.7%. Even in the current challenging Patients today are more aware and such as healthcare providers,
healthcare solutions to people. As
times, we remain resilient and are able to hence, more empowered. They vendors, stockists and service
I look back, I realize that we are
continue providing products and services to look for more holistic customer providers play an extremely
constantly doing so. Not only have
our customers with the same commitment experiences. In response to this important role as enablers of our
we been able to restructure and
as always. growing consumerisation, we success. I thank them all sincerely for
redesign business as per the need
undertook several robust initiatives. having the same passion
of the hour, but we also continue to
The year brought a personal change for One of our oldest brands, Cremaffin, to deliver.
pioneer healthcare innovations.
me as I have now moved to a new role within became the newest entrant into the
Abbott Group. The last three-and-a-half years Over-the-Counter (OTC) category. I assure you that Abbott India
Over the years, we have aligned
of my work as Managing Director of Abbott remains ‘at the forefront of change’,
our priorities closely to our
India Limited will remain close to my heart. This year, we introduced India’s determined to grow sustainably
strategic intent. We are aiming at
I am grateful for the trust my colleagues only sub-unit quadrivalent flu and to create lasting value for all
improving health outcomes across
had in me during this time, as we continued vaccine. We have also formed our stakeholders.
the continuum of care comprising
to build on our achievements. I extend my an activation team for the
awareness, diagnosis, treatment
gratitude to all our shareholders and members vaccines division so that we can Sincerely,
and compliance. We continue to
of the Board for their faith in my leadership. It increase our reach in the adult
expand our service offerings to
has been an honor to serve you all. vaccination segment.
reach out to stakeholders beyond
the pill. With our pill-plus programs We pioneered the launch of a
in liver health, gut health, pancreas division focusing on menopausal
health, vertigo and thyroid health, health – the Miliana division.
AMBATI VENU
NON–EXECUTIVE DIRECTOR Ambati Venu
(MANAGING DIRECTOR UNTIL FEBRUARY 29, 2020)
* Source : IQVIA MAT March 2020
KEY PERFORMANCE INDICATORS CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
DELIVERING ON OUR COMMITMENTS

RESERVES AND SURPLUS CONTRIBUTION TO
REVENUE GROWTH 11.0% EBITDA MARGIN 20.7% *
GROWTH 21.3% EXCHEQUER
TOTAL REVENUE (` IN LAKH) EBITDA (` IN LAKH) RESERVES AND (` IN LAKH)
SURPLUS (` IN LAKH)
4207,53 870,83 2410,46 836,58
3791,89 775,09
3424,11 718,02 1987,34 644,65
2996,33 641,49 1671,51
2696,23 454,96 1365,69 499,81
414,97 1174,35 437,23
2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020
14.0% 11.1% 14.3% 10.7% 11.0% 15.4% 15.2% 18.7% 18.9% 20.7% 28.2% 16.3% 22.4% 18.9% 21.3%
RETURN (PAT) ON AVERAGE

PAT MARGIN 14.1% *
CAPITAL EMPLOYED 26.7% BOOK VALUE GROWTH 21.1% SHARE PRICE 15,451
PAT (` IN LAKH) AVERAGE CAPITAL BOOK VALUE PER SHARE (`) MARKET CAPITALIZATION (` IN LAKH)
EMPLOYED (` IN LAKH)
592,93 2220,15 1,144 32832,51
450,33 1850,68 945

401,22 1539,85
1291,27 797 15503,49
276,65 1066,57 11578,96
255,25 653 10003,11
563 9857,23
2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020
9.5% 9.2% 11.7% 11.9% 14.1% 23.9% 21.4% 26.1% 24.3% 26.7% 27.7% 16.0% 22.1% 18.6% 21.1% 4,708 4,639 5,449 7,296 15,451
*
Percentage to Total Revenue

MANAGING DIRECTOR’S MESSAGE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
BUILDING FOR THE FUTURE We are sharpening our focus on

making a measurable impact in
everything we do. Our talent, our
also on our differentiated business
capability. We are embracing unique
ways of doing business through
commit ourselves to finding creative
solutions to challenges known
and unknown. As a team, we are
innovation-led approach, our digital means which have been progressing with momentum and
compassionate culture, are going to necessitated due to the COVID-19 agility to surmount these challenges.
be key to excellent delivery in pandemic. These may lead, in some
future. We will continue to cases, to rethink the way we operate. We have seen that ultimately, what
leverage our existing strengths This change in approach could makes us at Abbott India different
in being able to strike a balance come in the form of medium and/ is our passion to deliver. With the
between accessibility and or delivery methods, and we will support of our shareholders and our
high-quality medicines to create continue to remain competitive leadership team, as well the Abbott
holistic solutions. We will also and work with speed on these areas India family, I am confident that we
nurture newer strengths to help as well. Strengthening our digital will continue to stand out.
"To remain one of the leading us scale even more heights in the ecosystem and upgrading our
healthcare companies in India, new normal that is shaping up. technological capacities will remain Warm regards,
it is imperative for us to depend We are driven to expanding our key to our processes.
portfolios across our offerings and
not only on our leading brands, strengthening our brand equity While the post-pandemic world
but also on our differentiated through contemporary means of will be a different place, I am
engaging with our customers and confident that we will come out
business capability." of this situation even stronger.
end-users.
As we embark on our journey
To remain one of the leading of charting the course for the Anil Joseph
Dear Shareholders,
healthcare companies in India, it next year, we anticipate another
I am extremely proud to take over the is imperative for us to depend not year of good growth and stable
responsibility as the Managing Director of only on our leading brands, but operations. However, we need to
Abbott India Limited. It is wonderful to see
the contribution of our colleagues over the
years in building such a robust foundation and
a sustainable, value-adding business model. I REVENUE DISTRIBUTION
consider it my privilege to take over from my
predecessor, Ambati Venu. I am excited to ` IN CRORE (%) ` IN CRORE (%)
continue the good work and to lead such an 2,089 55.1 2,316 55.0
accomplished team of people.
281 7.4 57 1.3
We have a legacy to grow here – a legacy of 167 4.4 531 12.6

75 years of helping millions of Indians live
healthier, better lives. We have consistently 247 6.6 209 5.1
led with innovative medicines and been
first-to-market in several key therapies, giving FY 2018-19 FY 2019-20
555 14.6 559 13.3
us a distinct edge as a market leader. Today, as
we all try to work our way out of a pandemic, 17 0.4 60 1.4
expectations from us are even greater. It is an
opportunity to do much more. 436 11.5 476 11.3
MATERIAL COST OTHER EXPENSES PROPOSED DIVIDEND (INCLUDE

EMPLOYEE COST TAX CORPORATE DIVIDEND TAX)
ANIL JOSEPH,
RETAINED EARNINGS AND OTHER
MANAGING DIRECTOR, EFFECTIVE JULY 1, 2020 DEPRECIATION
COMPREHENSIVE INCOME (OCI)

BUSINESS MODEL CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
GROWING CONSISTENTLY AND WELL

We operate in a highly regulated and competitive industry. Our diversified
business model allows us to respond to the many opportunities and challenges we
face, while delivering value for all our stakeholders. It enables us to remain agile
in responding to evolving market trends, with the belief that everyone deserves a
healthy and fulfilling life.
OUR PURPOSE INPUTS OUTPUTS OUTCOMES

FINANCIAL
11.0%
To help people live Our focused investments on innovation, research and
INCREASE IN TOTAL REVENUE
development, manufacturing and marketing, enable us to OUR CUSTOMERS
better and healthier expand our product portfolio, services, technical capabilities Delivery of high-quality, affordable medicines
OVER FY 2018-19
and operations to stay relevant and ahead of market trends.

lives through our 26.0%
products and PEOPLE RETURN ON NET WORTH
differentiated We have a highly skilled, diverse and effective workforce. OUR INVESTORS
21
Through continuous training of our people and by hiring Consistent financial performance and strong returns
offerings. new talent, we secure sustainable future growth. to shareholders NEW PRODUCTS LAUNCHED
VALUES ~25,000
HEALTH CLINICS CONDUCTED
Guided by core values of Pioneering, Achieving, Caring
and Enduring at each stage, we are committed to OUR PEOPLE
conducting business ethically and strive to achieve the Dynamic, safe and rewarding place to work with clear 1,379 KL
highest quality standards. development opportunities, happy and fulfilling career and RAINWATER HARVESTED
be 'employer of choice' AT GOA PLANT
RELATIONSHIPS
Strong relationships with regulators and health
authorities across all our markets, and successful
collaborations with industry partners, enable us to OUR PARTNERS
E 1971,92 Lakh
achieve our purpose. Critical to our business, their expertise supports us in TOTAL VALUE ADDED
the delivery of medicines to patients in India. We aim to
DISTRIBUTED AMONG:
develop collaborative relationships to help them improve
CAPABILITIES EXCHEQUER: D 836,58 Lakh
their sustainability performance
Through our strong supply chain and distribution channels, EMPLOYEES: D 476,11 Lakh
we increase outreach to untapped urban and rural areas. SHAREHOLDERS*: D 531,23 Lakh
SOCIETY (CSR): D 11,64 Lakh
PROCESSES REPLACEMENT AND
OUR ENVIRONMENT AND LOCAL COMMUNITIES
We have clearly defined systems and robust processes EXPANSION#: D 116,36 Lakh
Reduction in carbon footprint, offering quality
focused on internal controls, operational excellence employment opportunities and better access to
effective risk operating model and governance structure, health outcomes and awareness
which are aligned to business objectives.
* Proposed dividend
22 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 # Replacement and expansion is Retained earnings + Depreciation 23
STRATEGIC PRIORITIES CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
A COMPREHENSIVE FRAMEWORK
THAT CONTINUES TO DELIVER
At Abbott India, we remain guided by United by a common overarching framework, at Abbott Our strategy aims to deliver strong returns to
India, our strategy ensures that our customers’ needs shareholders, best-in-class services to customers and
a singular belief that every individual are addressed, and we continue to remain relevant. continue being a sustainable business that adds value
deserves to live a healthy life. to the society.
FOCUS AREAS
PIONEERING STRENGTHENING THE CARE INSPIRE AND BUILD REMAIN DO GOOD

PATIENT-CENTRIC CARE CONTINUUM A DIVERSE WORKFORCE SUSTAINABLE FOR THE SOCIETY
OBJECTIVE OBJECTIVE
Being at the top helps us maximize Driven by a need to drive differentiation for our doctors To ensure that the strategic intent is We operate as a responsible business, Developing differentiated solutions to
opportunities, deliver unique solutions as well as patients and a commitment to bring high-quality, being delivered through a dedicated focusing on achieving ‘zero harm, zero alleviate the burden of Non-Communicable
for ‘now’ and ‘next’ therapies as per the affordable care across the patient ecosystem, continuum- talent strategy aimed at building discharge and zero waste’ thereby Diseases (NCDs) through community-
dynamic environment around us. centered care is essential to our offerings. Capacity, Capability and Culture. minimising environmental impact. based and community-led models that
demonstrate both sustainability and scale.
OUTLOOK FOR FY 2020-21 OUTLOOK FOR FY 2020-21
Our long-term intent is to cater AWARENESS TREATMENT Adapting to new ways of working Move toward a greener way of Continue adding value to the
to the need-gaps across the We will continue to improve Our clinical science efforts, KOL and investment in unique business; reduce absolute CO2 society.
healthcare ecosystem, and pioneer awareness among suspects through advocacy groups, and global capabilities – e.g. Digital. emissions, which would help
services that leverage our core advanced disease prevention guidelines and findings will continue ensure a smaller environment Committed to disease elimination
strength. education programmes and to improve and enhance scientific Talent development, engagement footprint. through Point of Care diagnosis,
on-ground interventions. knowledge, and thus treatment, for and retention. capacity building for healthcare
We have a robust pipeline of our patients. Promote circular economy workers, and improvements in
products for the next few years, DIAGNOSIS Driving a culture of principles increasing recycling and surveillance systems for effective
which along with our portfolio Digital therapeutics (DTx) will help COMPLIANCE intrapreneurship, diversity and beneficial use of waste. and efficient monitoring.
approach will help us establish our with evidence-based interventions It takes beyond treatment to solve inclusion.
presence across several therapy for improving the health outcome of the healthcare challenges. We will Address water scarcity by being
areas. patients across the care continuum; continue to increment innovations good water stewards.
partnering with key providers will in our efforts to improve compliance
Further raise the innovation bar for remain essential. along the care continuum with the
treatment and services for our key help of differentiated packaging and
therapies such as Women’s Health, patient support programs.
Thyroid and Gut Health.
Read more 34 Read more 30 Read more 44 Read more 40 Read more 48

OPERATING ENVIRONMENT CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
ADAPTING TO MARKET DYNAMICS

Factoring in key aspects like demographics to patient
behavior to technology, the market for pharmaceuticals is
evolving rapidly. The core proposition, however, remains THE ABBOTT INDIA APPROACH
delivery of reliable solutions with quality. To create sustainable value for our stakeholders, we
are always prepared to handle the volatile environment
GROWING, AGING POPULATION NEWER WAYS FOR ENGAGEMENT around us. Our strategic plans are always aligned to meet
WITH HEALTHCARE PROFESSIONALS the potential risks Volatility, Uncertainty, Complexity and
Global population is expected to reach 9.7 Billion by
Ambiguity poses to our business both on a short and long-
2050 and ~16% of this will be aged 60 and above by that THROUGH MULTI CHANNELS term basis and we continuously evolve with them. Our
time. An increasingly aging population means increase Face-to-face interactions with healthcare providers foresight, agility and trust of our stakeholders help us keep
in disease burden due to NCDs. Thus, over the long- are declining. At the same time, a greater responsibility steady in such an environment.
term, we expect demand for pharmaceutical products as is being placed on pharmaceutical representatives to
well as for long-term treatments to increase. understand and convey complex therapies and their
9.7 Billion value through various appropriate channels. Companies
are driving improved models for dissemination of large
GLOBAL POPULATION BY 2050 volumes of data and scientific information. INNOVATION SHAPING THERAPIES
Companies are adopting patient-centric strategies At Abbott India, we are seeking new ways of We are developing varied products for different
GLOBAL RISE IN MEDICINE USAGE across marketing, sales and support for more doing business in the short and long run. For our therapies and across dosage forms. While we are
AND SPENDING comprehensive messaging. Impetus is on transforming stakeholders we work to deliver solutions to help increasing the breadth and depth of our presence
Global medicine spending is expected to increase by healthcare personnel relationships with customers them lead a fuller life. We led pioneering initiatives in in various key portfolios, in the long run we
2-5% annually and exceed US$ 1.1 Trillion in 2024, and including omni-channel engagement. Such an therapies such as vertigo, liver, thyroid, influenza also intend to leverage the new regulations and
driven by increased medicine usage stemming from integrated approach serves to create greater trust, and others. broadened provisions for pharma companies.
lifestyle practices and greater access to healthcare, leading to improved adherence to treatment and
among others. Medicine spending in India is projected ultimately, better outcomes.
to grow by 9 to 12% over the next five years, which
would bring India amongst the top 10 countries in ENGAGE WITH HEALTHCARE CONSUMERIZATION OF HEALTHCARE
DIGITIZATION AND TECHNOLOGICAL
medicine spending. PROFESSIONALS
BREAKTHROUGHS It is time to recognize the new expectations of
We are developing innovative models to engage
US$ 1.1 Trillion
patients and respond with innovative and inclusive
New technologies and scientific innovations are opening
with healthcare professionals through multiple healthcare solutions. Use of digital media and
GLOBAL MEDICINE SPENDING BY 2024 new possibilities across the pharmaceutical value chain.
channels. We are also engaging with patients through outreach in a strategic manner is helping to
Big data is generating new insights into diseases and
industry-first patient programs to provide education, communicate better with our end-consumers and
‘digital’ is transforming care delivery.
R&D INNOVATIONS AND IMPROVEMENTS counselling and support services. build trust in our brands.
R&D comprises the greatest competitive advantage CONSUMERIZATION
for a pharma company. For a more efficient R&D, Consumerism in the healthcare industry is a growing
it is important to shorten the process by leveraging trend. The end consumers are more aware today; and
scientific and technological acumen, helping to bring FOCUS ON DIGITAL
are therefore taking an increasingly active role in their
down clinical trial costs and boost success rates. It also healthcare decisions. Factors such as cost of care and We emphasize using digital innovation to deliver
ensures shorter go-to-market times. quality as well as ease of service are crucial factors in value to patients, people, partners and business.
determining the preferred mode of treatment. These include shaping the digital healthcare
ecosystem, leveraging cutting-edge technology
across R&D to achieve scientific excellence,
Sources
manufacturing backed by Artificial Intelligence
• United Nations (AI)/Machine Learning (ML).
• Global Medicine Spending and Usage Trends Outlook by IQVIA Institute
• India Brand Equity Foundation (IBEF)
• Global Newswire

PASSION
TO DELIVER
INNOVATION
For improving access and affordability
of quality healthcare, we continue to
resonate with and respond to the call for
breakthroughs. We continued our journey
to transform and worked resolutely to be
the first-to-market in providing innovative
and inclusive healthcare solutions, advanced
packaging, unique campaigns and awareness
programs to create differentiated value,
optimize costs and set benchmarks.
30
THERAPY-SHAPING INITIATIVES
34
TRANSFORMATION ACROSS PRODUCT LIFECYCLE
36
UNIQUE SOLUTIONS
THERAPY-SHAPING INITIATIVES CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
DRIVING INNOVATION
DIFFERENTIATED ENGAGEMENT
AND AWARENESS
Today, our consumers are more aware than
Close engagement with consumers is ever before. Moreover, they believe in being
imperative to deliver quality solutions across actively engaged with brands. At Abbott India,
the care continuum. We undertake unique we consider this an opportunity to get to know
initiatives to reach out to patients and our consumers better. New-age marketing
caregivers, aimed at spreading awareness and technology is helping to drive this connect.
building confidence.
MAKING INDIA THYROID AWARE (MITA) We engaged with several leading doctors across the
With a continued focus on the metabolic health of country and created an experiential activation activity
REACHING OUT TO STAKEHOLDERS women, we partnered with the Indian Thyroid Society around the Balance Test. We hosted online videos
(ITS) to launch the MITA campaign, which promotes that showcased a credible and impactful way to drive
a holistic understanding of the thyroid condition awareness around vertigo.
among doctors, patients and the masses.
D ACTIVE
We also rolled out an e-signature pledge activity, where This campaign is aimed at improving awareness on
for every endorsement from a doctor, we provided one Vitamin D and providing affordable diagnosis. We
free-of-cost thyroid screening for an underprivileged organized over 500 such clinics.
woman in India.
~ 250 Million We disseminated patient education material and used
CONSUMERS REACHED
GUTFIT multi-media channels to share findings from a recent
THROUGH VARIOUS CAMPAIGNS The unique patient support program has emerged study on the high prevalence of Vitamin D deficiency in
as one of the largest Lifestyle Management (LSM) hypertensive and diabetic patients.
programs in the GI space.
As a part of our program, we also developed India’s

first-ever clinical dietary recommendations, endorsed
18,000 + by Nutritional Society of India (NSI). This year, we also
launched "Virtual Gutfit" which is an app-based LSM
DOCTORS REACHED/
service. It is the result of a collaboration with GoQii
PARTICIPATED IN OUR
(unique combination of health coaching with smart
MULTIPLE PROGRAMS
ACROSS INDIA fitness tracker powered by an integrated mobile app)
where among other gratuitous services for patients,
virtual diet counselling is also possible.
BALANCE AWARENESS CHALLENGE

The program is aimed at creating awareness on
neglected balance disorders such as vertigo and to
encourage people to take the balance test and seek early
medical intervention.

THERAPY-SHAPING INITIATIVES CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
#WINOVEREPILEPSY PANCRECARE
This was our multi-city program aimed at increasing Launched in 2018, Pancrecare provides comprehensive
BETTER INFORMATION FOR BETTER
awareness and challenging the social taboo around disease management solution for Chronic Pancreatitis/ HEALTH DELIVERY
epilepsy. With doctor driven content, we could Pancreatic Exocrine Insufficiency (PEI) patients.
reach a substantial population across 47 cities through The platform supports healthcare professionals in
the program. managing patient needs and enables disease awareness
To help provide the latest science and information, we
and counselling. This year, there was a 100% increase are connecting with various stakeholders, including
in patient enrollment and a 80% higher average therapy medical professionals and other healthcare providers,
adherence among patients.
across a range of platforms. We are working on a
number of digital-led solutions to be able to drive our
customer engagement and enhance their experience
with our brands.
ITS FOGSI METABOLIC WOMEN’S

HEALTH WORKSHOP
To help improve diagnosis and treatment of thyroid
disorders, bacterial vaginosis and Vitamin D, we
collaborated with Indian Thyroid Society (ITS) and
Federation of Obstetric and Gynecological Societies
of India (FOGSI) to initiate the Metabolic Women’s
Health workshops. We conducted these workshops in
over 20 cities.
THE EXTENDED ABBOTT CLINILEAD PANCREOSCOPIE

INDIA ECOSYSTEM An innovative academic social skill development This is India’s only portal dedicated to
We are extending our reach to wider program was launched to enhance social and creating awareness about pancreatic diseases
cross-section of customers in Nepal and interpersonal skills in association with the Indian (www. pancreoscopieonline.com). The on-ground
Sri Lanka through focused activities Institute of Management (IIM), Ahmedabad. and online (monthly emailers) touchpoints and right
in multiple therapy areas, including selection of articles helped strengthen our reputation
The program covered aspects such as impact of
Vitamin D, Women’s Health, thyroid, as a preferred scientific partner.
digitization and social media relevant to the medical
IVF, fatty liver, vertigo and more.
fraternity in the modern world.

TRANSFORMATION ACROSS PRODUCT LIFECYCLE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
IMPROVING PATIENT
HEALTH OUTCOMES
Innovation is a core element of our culture at Abbott India. Our
approach to product development is holistic, with an ultimate
aim to improve consumer experience. We innovate with an aim
to drive impactful health outcomes. Our proactive approach to
innovation is to understand the patients’ needs and experiences
with and through treatments.
R&D EXPERTISE
R&D remains relevant to our business and is
instrumental in driving its growth. Our operational THOUGHT LEADERSHIP
R&D and business development teams constantly Science-led innovation remains at the
focus on developing solutions tailored to Indian
forefront of our novel endeavors at Abbott
healthcare requirements.
As a leading player in several therapies, we have access

India. During the year, our team spearheaded
the following initiatives:
INNOVATIVE PACKAGING
to a wide cross-section of stakeholders and their We work to deliver solutions that ensure patients face minimal disruption due to
preferences are integrated into our activities across packaging and dosing challenges. To enhance and improve patient adherence to
categories. This continuous exchange allows us to therapy, we introduced new packs and designs for some of our key brands this year.
identify unmet needs, lying at the intersection of science
and marketing.
12 16 21
CLINICAL PUBLICATIONS PRODUCT
We want to create an innovative healthcare ecosystem STUDIES LAUNCHES Launched Thyronorm in a To ensure correct and efficient dose
that improves access and is based on technology new-age innovative flip top pack to titration, we introduced Creon SD
and insights, for both ‘now’ and ‘next’ therapies. We offer control on tablet dispensing in a unique form - G’DoCon®. This
are an experienced Company and can comprehend (dispenses approximately 1 to 2 is the World’s First Granule Dosing
contemporary demands. tablets when bottle is tapped gently in Concept for dispensing Pancreatin
horizontal position) and ease of use. Mini-microsphere, and correct dosing
It includes a smart code for patients’ requirement are achieved with a “push”
reference. The security label is to dispense.
marked as genuine to reduce spurious
drug supply and ease of use. The granule dosing concept won
several packaging awards, internally
and externally, for its unique
mechanism and design.

UNIQUE SOLUTIONS CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
HOLISTIC SOLUTIONS
FOR HOLISTIC CARE
Our approach to improve product development PRODUCTS LAUNCHED DURING THE YEAR*
is holistic, with an ultimate aim to improve
consumer experience. We go beyond quality as
a fundamental requirement and bring in various
aspects to improve compliance to treatment.
WINFLUENZA
We launched the first-ever sub-unit quadrivalent
flu vaccine, Influvac Tetra, in India this year, the
Drug Controller General of India (DCGI) approved Fidonal, VIADEK, UDISTRONG Orange, Udistrong sachet – Cranberry, Evitol, Udisyp, Creon SD,
vaccine for children between 6 months and 3 years Digene Ultra Fizz, Duphalac Bears 1.6, Duphalac Chews 3.3, Tenfoplus, Cremadiet + 300, Antoxipan sachet
of age. We also ran a multi-media PR campaign
‘Mother against Influenza’ across India; this included
an influencer-led digital campaign and ‘Ek Faisla Alvida
Influenza’ radio campaign.
LIFESTYLE-INDUCED ACIDITY AND CHOOSE CREMAFFIN -

HIGH ANC-DIGENE DIRECT-TO-CONSUMER CAMPAIGN
The Digene campaign showcased the brand as a Cremaffin launched its first direct to consumer
scientific solution to lifestyle-related acidity. campaign targeting key consumer need gap of assured
The campaign reached out to consumers in and gentle relief from constipation. With a new brand Epishield Brufen Rapid
key markets through TV commercials, print ambassador, the campaign reached out to urban
campaigns, and was also amplified on digital media. consumers via multi-media channels.
ADULT VACCINATION
OUTREACH PROGRAM
We launched an Adult Vaccination Program
which includes vaccines for flu, typhoid and more, in
order to help safeguard people’s health. The campaign
aims to create awareness regarding adult immunization Femoston, Femilon, Cetropro, Novelon, Parihep Influvac Tetra
and better health outcomes as well as educate
clinicians on the management of infectious diseases in
adult populations.
Gastroenterology Women's Health Central Pain Vaccines

Nervous System
*Includes products under Distribution arrangements

ABBOTT AT A GLANCE
PASSION TO
DELIVER WITH
COMPASSION
Since inception, Abbott has been driven by a
strong sense of compassion to use our knowledge,
expertise and execution capabilities to help
alleviate suffering and improve patient lives
globally. The same purpose courses through
Abbott India as well. Our compassion extends to
our partners on our journey, which includes the
communities among which we operate as well as
the environment at large.
40 52
ENVIRONMENT BOARD OF DIRECTORS
44 54
PEOPLE MANAGEMENT TEAM
48 55
CORPORATE SOCIAL REWARDS AND RECOGNITION
RESPONSIBILITY
50
ETHICS AND GOVERNANCE
ENVIRONMENT CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
PRIORITIZING
RESPONSIBLE OPERATIONS
We strive to reduce our environmental We are committed to making our operations more
sustainable. We are increasingly driving measures
impact by conducting our business to utilize resources such as water and energy more
efficiently and in accordance with judiciously, reduce waste and minimize emissions.
environmental laws, regulations and We prioritize supply partners who adhere to similar
standards of efficiency and environmental performance.
industry standards.
IN FY 2019-20, 2,879 KL 44,372 KWH

WE SAVED WATER ENERGY
MEASURES TO OPTIMIZE RESOURCES AND FOR

CURTAILMENT OF ENVIRONMENTAL IMPACT
PROCESS EFFICIENCY MEASURES SAFETY ENERGY CONSERVATION

• Introduced chilled water to control inlet air humidity
• Improvised process cycle at various stages of • The plant continues to register record performance on • Saving of ~70 KWH energy per day as a result of
for drying operations - reducing drying cycle time.
manufacturing - leading to increase in capacity safety with zero Lost Time Injury (LTI) through eight optimizing air compressor settings.
without any additional capex, Liquids by 14% and • Outsourced non-value added activity such as years.
• Annually saving ~40,000 KWH energy due to use of LED
Tablets by 25%. pre-sleeving of bottles for liquids - Digene, Cremaffin
• Upgraded the entire fire protection system at the lights in streetlight fixtures.
and Duphalac - to external vendors, thereby
• Modified Brufen manufacturing HVAC with humidity manufacturing site, which includes adding sprinklers, a
achieving greater operation efficiency by reduction of • Reduced energy consumption by ~12,000 KWH p.a. by
control - helping to utilize idle manufacturing new water tank in addition to the existing one as well as
inventory holding costs, elimination of separate space installing Variable Frequency Drive (VFD) for surface
capacity and added flexibility in manufacturing. a fire engine.
requirements, QC inspection and material handling. aerator of Effluent Treatment Plant (ETP).
• Conducted a Safety Barometer survey at the site, as per
• Developed new process design by adding new energy
guidelines established by the National Safety Council
efficient blower directly to filter press. As a result, there
(NSC), USA. Results indicated a high score of 83% placing
was reduction of sludge drying per lot from three to two
it in the top quartile as compared to the safety culture of
days and savings of 108 KWH per drying cycle.
around 1,800 organizations world-wide.
REDUCTION IN COST (OVER 2017 LEVELS) BY ACHIEVED WITHOUT CAPEX
15% 0.5% ~25% ~14% 83% Zero Lost Time Injury 108 KWH
TABLETS LIQUID IN TABLET CAPACITY IN LIQUID CAPACITY SCORE AS PER BAROMETER SURVEY EIGHT YEARS IN A ROW SAVINGS PER DRYING
CONDUCTED BY NATIONAL SAFETY COUNCIL CYCLE OF SLUDGE

ENVIRONMENT CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
Our Plant at Goa
WASTE MANAGEMENT
WATER CONSERVATION FOR FY 2019-20 (%)
EFFICIENCY THROUGH SUPPLY CHAIN WASTE REDUCTION
• 2 KL/day of water saved by installing new vacuum pump AND DISTRIBUTION NETWORK We adhere to the requirements of Plastic Waste
with Hydropack system, which cools and circulates We improved our speed and agility in servicing Management Rules as laid down by the Central
water for vacuum pump operation. institutional orders through the Barwala stamping Pollution Control Board.
• Free flowing taps fitted with shower orifice reduced the
water consumption by 25% used in washrooms.
facility. We are the first in the industry to have a
stamping facility that follows Good Manufacturing
During the year, we collected around 1,400 MT of Zero Waste
post-consumer waste through our Extended Producer
Practices (GMP), quality and regulatory compliance.
Responsibility (EPR) partners. This waste is recycled or to Landfill 38
• Significantly reduced our water consumption through Benefits achieved through this facility:
disposed of in a scientific manner. 60
introduction of pre-sleeved bottles in both liquid lines.
• Substantial speed gain in reducing logistics time
(ZWL)
It has also eliminated the requirement of steam at the The site continued sending hazardous waste for co-
rate of ~12 KL per day. from 45 days to 7 days
processing.
• Flexibility in servicing small institutional orders 2
• Adopted ways to ensure that all the waste generated
• Significant reduction in logistics cost
at site is either recycled, reused for beneficial use,
Moreover, we also established Online Temperature composted, or sent to co-processing for energy recovery.
Monitoring System (OTMS) for all warehouses. FOR FOR CO- FOR
• Continued to be internally certified as Zero Waste to
QUALITY Temperature sensors are kept in warehouses at
Landfill site. RECYCLING PROCESSING COMPOSTING
• Completed World Health Organization (WHO) extreme hot and cold spots. Sensors wirelessly update
evaluation, Food and Drug Administration (FDA) temperature to the online portal every minute. Hooters
audits and Audit Quality Review (AQR) successfully at the warehouses give an alarm any time there is a
with zero critical and zero major observations temperature excursion.
• No product action during 2019
• No high impact and recurring complaints

PEOPLE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
VALUING TALENT, REWARDING

COMMITMENT AND DEVELOPING
LEADERS FOR THE FUTURE
We do our utmost to enable and empower our people
Human capital is our fundamental with a view to fulfilling our employee value proposition
strength, connected deeply to all our which is to ‘grow with the leader’.
value creation efforts. We value talent, Our Human Resource (HR) team implements integrated
knowhow, confidence and leadership talent management practices, which encompass the
capabilities. entire employee lifecycle, including recruitment, career
progression and recognitions, among others.
TALENT STRATEGY
Our India Talent Strategy (ITS) aims to attract and certification programs and designed clear career paths
retain talent aligned with the organizational vision. We for field employees; our HR and talent strategy teams
carry out periodic assessments to gauge readiness for meet every month to monitor and maintain oversight.
first and second line manager roles. We have launched
FIVE PILLARS OF OUR INDIA TALENT STRATEGY
A DIVERSE AND INCLUSIVE WORKPLACE

We believe in equal opportunities and have developed a HEADCOUNT (NUMBER)
LEADERSHIP NO. 1 FIELD MANAGERIAL BEST-IN-CLASS STRONG truly inclusive work environment. Gender diversity is a
ENGINE FORCE EFFECTIVENESS SUPPORT EMPLOYEE priority for us and, to this end; we small make conscious
FUNCTIONS VALUE efforts to hire more women in leadership roles and provide
3,551
PROPOSITION
3,485
strong encouragement to our women leaders through our
3,322
Women Leaders of Abbott (WLA) employee network.
PERFORMANCE SOUND DIGITAL
WLA helps women advance their careers through
CULTURE GOVERNANCE INNOVATION
structured training, development and networking events,
supports them through various initiatives and allowances
needed at critical life stages, conducts diversity drive that
2018 2019 2020
covers five cities and the Head Office to share insights
from our WLA activities.

PEOPLE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
ABBOTT INDIA SALES TRAINING LEAP 2020

ACADEMY (ASTA) This program was initiated with an objective to WO-MENTORING
To succeed in a digital-first world, our on-ground force assess for and develop managerial capabilities within
The program is part of the Women
has to have digital skills in order to drive meaningful the organization and encourage talent mobility
Leaders of Abbott (WLA). The initiative
engagement with our customers and consumers alike. across businesses.
includes an on-boarding process of
ASTA provides them training through a blended learning
Orientation Sessions to enable the
approach that includes the use of several online tools
and platforms.
221 mentoring conversations, identification of
FIELD EMPLOYEES development goals coupled with enablers
ASSESSED DURING FY 2019-20 in the form of employee connects and
EMPLOYEE ASSISTANCE PROGRAM (EAP)
related learning interventions.
Balancing work and personal life is imperative for LEARNING AND DEVELOPMENT
productive performance and a fulfilling career as well
We conduct a talent management review of our internal
as life in general. Our Employee Assistance Program is
leadership pipeline, identify capabilities and execute
aimed at enabling our colleagues to deal better with life’s
development plans for high potential employees through
challenges equipped as it is with features such as:
acceleration programs such as InStride and FLDP -
• 24X7 availability for employees and their families – Future Leaders Development Program.
via phone, e-mail or live chat
Our customized global leadership development programs
• Calls answered by expert psychologists such as Global Citizen Development Program, Emerging
• Assistance over personal issues that could affect health Leaders Program and more, emphasize cultivating global
• Counselling to maintain work life balance, stress leaders from within the organization.
management, management skills, and family support,
including legal and financial information. We have created easy opportunities for employees to
access newer modes of e-learning:
MIND STRONG PROGRAM
Dedicated to emotional wellness, the program
complements our Employee Assistance Program in our
Skillsoft Mindsoft
effort to provide holistic support to our employees. 120,000 PIECES OF MORE THAN 2,000+
CONTENT, INCLUDING ARTICLES, VIDEOS,
TALENT MANAGEMENT REVIEW (TMR) OVER 7,000 COURSES QUIZZES, PODCASTS AND
AND 65,000 VIDEOS WORKBOOKS
Our scheduled in-depth Talent Management Review
help identify successors for critical roles within the
organization, determine their preparedness to take accel5 Linkedin Learning
up these roles and extend accurate and actionable
OVER 7,000+ 24/7 UNLIMITED
development plans to elevate to identified critical roles.
HARVARD BUSINESS ACCESS TO OVER 16,000
REVIEW ARTICLES, EXPERT-LED COURSES
ACCELERATE EXECUTIVE SUMMARIES COVERING TOPICS
Building the first line managerial capability is the key OF TOP BUSINESS BOOKS, SUCH AS BUSINESS,
to the success of any organization. Toward this, we VIDEOS FROM TOP THOUGHT CREATIVE AND TECHNOLOGY.
launched the Accelerate program to train participants LEADERS AND MORE
in managerial capabilities, enhance overall team
performance and drive higher employee engagement.
330
AREA BUSINESS MANAGERS
UNDERWENT EXTERNAL ASSESSMENT

CORPORATE SOCIAL RESPONSIBILITY CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
CREATING SOCIAL IMPACT

Our strategy lays down the focus and construct of
Over the years, our CSR engagements our programs. We support communities with quality
have demonstrated shared impact, with infrastructure, training, people, tech platforms and
scale and sustainability at every step of partnerships with healthcare providers. We also help
create livelihood opportunities through capacity
the way. building, empowerment, and market linkages.
HEALTH CLINICS FOR ENHANCING communities. The key objectives of the program are
ACCESS TO HEALTHCARE improving health outcomes and creating livelihood
We have successfully developed 25,000 health opportunities. We are also helping build capacity for
clinics and impacted over 5.5 Million people across livelihood interventions within and beyond the program.
650 locations in India. These clinics have facilitated
access to essential healthcare services and information. DISEASE ELIMINATION PROGRAM
These are being supported and advanced by qualified We are supporting a partnership between the
doctors and healthcare professionals that help expand Government Odisha and Malaria No More with
disease diagnosis and access to care. The clinic also help technology, expertise and funding to advance efforts
raise awareness on and improve care for epilepsy and to end malaria in the state. We have supplied 1 million
liver diseases. of Abbott’s Rapid Diagnostic Tests (RDTs) for Malaria
and technical expertise to strengthen Odisha's malaria
CREATING LIVELIHOODS detection and surveillance system, and develop a
We support Self-Employed Women’s Association comprehensive elimination strategy. Through persistent
(SEWA) and are working to develop novel models to interventions around these and innovative approaches,
make quality healthcare accessible among low-income Odisha achieved an 80 percent reduction in cases in
populations at affordable prices. These engagements less than one year, and another 50 percent drop in the
demand community mobilization (20,000 SEWA following year. We now have a model that has proven its
women and their families involved), sensitization, efficacy in eliminating malaria and is ready for adoption CSR SPEND
behavioral change, improvements in surveillance across other malaria-affected states in the country.
systems, partnerships with healthcare providers ` 9,12 Lakh ` 11,28 Lakh ` 11,64 Lakh
90%
and government assistance. With SEWA, we launched
two community clinics that provide primary, acute 2018 2019 2020
and NCD care. The SEWA health master trainers were REDUCTION IN THE NUMBER OF
trained in making screening and care accessible to MALARIA CASES AND DEATHS IN ODISHA

ETHICS AND GOVERNANCE CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
DOING THINGS THE RIGHT WAY GEOGRAPHY AND

CROSS-CULTURAL EXPERIENCE
FINANCE, RISK MANAGEMENT,
REGULATORY AND GOVERNANCE
We are committed to strong corporate

governance and ethical behavior OUR APPROACH
ACTING RESPONSIBLY IS AN INTEGRAL PART
across every aspect of the business. OF ABBOTT INDIA CULTURE. WE FOLLOW HIGH
Our reputation as an ethical and STANDARDS OF BUSINESS ETHICS AND INTEGRITY, HUMAN RESOURCES CORPORATE STRATEGY
AS DEMONSTRATED THROUGH OUR AND COMMUNITY AND STRATEGIC
trustworthy company is our most BEST-IN-CLASS GOVERNANCE PRACTICES THAT DEVELOPMENT BOARD PLANNING
important asset. ALIGNS WITH STAKEHOLDERS’ INTEREST.
DIVERSITY–
We believe that consistently focusing on good GOVERNANCE STRUCTURE
EXPERTISE
governance and applying the highest ethical practices
in all our activities enables us to uphold the trust of The Board of Directors clearly understands the business
our stakeholders. We are firmly committed to sound dynamics and environment under which the Company
operates, challenges and opportunities associated SALES, MARKETING GENERAL MANAGEMENT
and effective practices in corporate governance and
with the business operations and provides guidance, AND BUSINESS AND LEADERSHIP
full and fair disclosure. Our pursuit of new approaches
to achieve higher standards sets us apart and leads to oversight and strategic direction to our management. DEVELOPMENT EXPERIENCE
greater transparency and integrity in our actions. Business strategies are presented to the Board on an
annual basis. The Board always acts in good faith, with
ETHICS due diligence and care, and in the best interests of the
shareholders.
Abbott India is committed to the highest standards of
ethics and integrity. We have the ‘Code of Conduct’
EXPERTISE
BOARD COMPOSITION Our Board is an ideal mix of analytical, strategic The Board represents diverse skill sets and expertise
with the underlying belief of conducting business in a
principled manner. It covers a wide range of principles Abbott India’s Board is well-balanced and currently and leadership skills. The Directors are seasoned in Accounting, Sales and Development, Information
and requirements that touch upon all aspects of our consists of two Executive, three Non-Executive and professionals and are familiar with the organizational Technology, Public Relations, Digital Marketing,
business activities and operations. We ensure that three Independent Directors. and industrial aspects of operations and have adequate Strategy Development and Implementation, in
ethical conduct is embedded across our operations and competencies to bring value additions to our functions. alignment with our long-term strategic plans.
we expect all our employees, and external partners BOARD OF DIRECTORS AT ABBOTT INDIA
to do the same. Our policies and procedures comply
with and incorporate all relevant laws, regulations BOARD EXPERIENCE (%) BOARD AGE PROFILE (%) BOARD DIVERSITY (%)
and promotional standards in India. Our policies also
consider industry best practices, including provisions of
2 3 37 50 25
global and local codes for pharmaceuticals. The Office
of Ethics and Compliance (OEC) has developed a third-
8
party compliance process to identify potential risks 50 50 75
when doing business with third parties, and to address 3
such risks where they do exist.
13
EXECUTIVE NON-EXECUTIVE INDEPENDENT
DIRECTORS DIRECTORS DIRECTORS 21-30 YEARS 36-55 YEARS FEMALE
> 30 YEARS 56-70 YEARS MALE
>70 YEARS

BOARD OF DIRECTORS CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
BACKED BY AN
UNMATCHED LEADERSHIP
MUNIR SHAIKH ANIL JOSEPH AMBATI VENU SHALINI KAMATH

CHAIRMAN MANAGING DIRECTOR NON-EXECUTIVE DIRECTOR INDEPENDENT DIRECTOR
SUDARSHAN JAIN KAIYOMARZ MARFATIA ANISHA MOTWANI RAJIV SONALKER

INDEPENDENT DIRECTOR NON-EXECUTIVE DIRECTOR INDEPENDENT DIRECTOR CFO AND WHOLE-TIME DIRECTOR

MANAGEMENT TEAM | REWARDS AND RECOGNITION CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
THE FORCE BEHIND

LIFE-CHANGING WORK VALIDATING OUR EFFORTS
ANIL JOSEPH RAJIV SONALKER DR SRIRUPA DAS PRAKASH MAHESHWARI

Managing Director CFO and Whole-Time Director Director – Medical Affairs Commercial Director -
Women's Health,
Gastroenterology
THE MOST INNOVATIVE MNC OF THE YEAR 2019 GUTFIT - BEST PATIENT EDUCATION PROJECT AWARD
at the 12 Pharma Leaders Award
th at ZEE Business’s - National Healthcare Leadership
Awards
BEST FINANCIAL CONTENT FOR THE 75TH ANNUAL
REPORT at India Content Leadership Awards GUTFIT - OUTSTANDING PATIENT SUPPORT PROGRAM
MILIND TENDULKAR KEYA PHATNANI SRIDHAR KADANGODE MANDAR KESKAR at ET Now’s World Mental Health Congress Awards
Commercial Director - Director – Director – Finance Associate Director -
GenNext & Vaccines Business Human Resources Consumer Care BEST ONLINE COMMERCIAL - for #MomvsFlu at the
Drivers of Digital (DOD) Awards UDILIV - BRAND OF THE YEAR -BRONZE
at the AWACS Award - Acute category
BEST USE OF MOBILE LEARNING’ from the World HRD
Congress, in the 7th Global Training & Development THYRONORM - BRAND OF THE YEAR - SILVER at the
Leadership Award AWACS Award - Chronic/Subchronic Category
BEST PATIENT-CENTRIC DESIGN AT PHARMAPACK

CREMAFFIN PLUS - BRAND EXCELLENCE AWARD - in
EUROPE - G’DoCon® - Granule Dosing Concept of
Pharmaceutical sector at ABP Brand Excellence Award
CREON SD
CREMAFFIN PLUS - MARKETING CAMPAIGN OF THE
YEAR IN PHARMACEUTICAL SECTOR - at ET Now BEST DIGITAL MEDIA CONTENT by a Healthcare
Marketing for Fast Forward campaign Enterprise for Mother Against Influenza (MAI) at the
India Content Leadership Awards
KRUPA ANANDPARA T RAMAKRISHNA PRASAD DR VIJAY PATIL
Associate Director - Secretarial Commercial Director - Associate Director – New Product
and Company Secretary Specialty Care Introductions and Therapy Area Strategy

BOARD’S REPORT AND MDA
BOARD OF DIRECTORS REPORT

AND MANAGEMENT DISCUSSION AND ANALYSIS
TO THE MEMBERS Company’s website at https://www.abbott.co.in/investor-
Your Directors have pleasure in presenting their Seventy- relations/policies.html The said Policy lays down various
sixth Report and the Audited Financial Statements of the factors which are considered by the Board while
Company for the financial year 2019-20. recommending dividend for the year.
FINANCIAL HIGHLIGHTS MANAGEMENT DISCUSSION AND ANALYSIS

(` in Lakhs) ECONOMIC OUTLOOK
Particulars For the year For the year
ended March ended March
India’s GDP growth has been the most phenomenal in the past
31, 2020 31, 2019 decade regularly achieving an annual growth of 6-7 percent.
Sales of Products 4054,47 3640,30 The rise in GDP is largely credited to factors including
Other Operating Income 38,67 38,30 urbanization and improvement in the efficiency and
Other Income 114,39 113,29 productivity of technologies. However, growth in India
Total Income 4207,53 3791,89 softened in 2019 as economic and regulatory uncertainty,
Profit Before Tax 802,69 698,85 together with concerns about the health of the non-banking
Profit After Tax 592,93 450,33 financial sector, weighed on demand. The GDP growth for
Retained Earnings and financial year 2019-20 touched 4.2% vis-à-vis 6.1% in financial
Other Comprehensive year 2018-19, the COVID-19 pandemic further aggravating the
Income (OCI) slowdown from the end of the last quarter. The Government of
Balance brought forward 1567,49 1305,17 India and the Reserve Bank of India (RBI) have acted swiftly
Profit After Tax 592,93 450,33 to help offset the pandemic-induced disruptions.
OCI arising from (4,95) (2,09)
remeasurement of Growth in 2020 is expected to remain low due to a sharp
employee benefits decline in trade, investments and private consumption owing
Dividend - FY 2018-19 (138,12) -- to the COVID-19 crisis. Fiscal incentives announced by the
Dividend - FY 2017-18 -- (116,87) Government as well as liquidity measures may help the
Dividend Distribution Tax (28,39) (24,02) economy to come back on the normal growth trajectory.
Transfer to Reserves (59,29) (45,03)
But the recovery across economies is expected to be gradual,
Impact of Ind AS 116- (7,12) --
fragile and susceptible to multiple headwinds.
Leases (Net of Tax)*
Balance carried forward 1922,55 1567,49 INDUSTRY REVIEW
*Under modified retrospective method. The healthcare environment has been dynamic and, at times,
volatile. As per IQVIA, a leading global provider of
DIVIDEND information and research services in the medical sector,
Your Directors recommend a final dividend of ` 107/- and Indian Pharmaceutical Market (IPM) is estimated at ` 149,900
special dividend of ` 143/- per share for the year ended Crore in 2020, its growth up by 2% from 2019. Acute therapies
March 31, 2020 on 2,12,49,302 fully paid-up Equity Shares dominate IPM with 64% of the total sales; however, the
of ` 10/- each. The proposed dividend, if approved at the chronic segment shows faster growth of 10.9% in comparison
Annual General Meeting, will absorb a sum of ` 531,23 Lakhs to 7.9% for acute therapies (3 year CAGR). The domestic
(Previous year : ` 166,51 Lakhs including dividend Tax of pharmaceutical market is highly fragmented with the top 10
` 28,39 Lakhs) The Corporate Dividend Tax is provided at the companies making up 43% of the share, and the top 150
rate applicable on the day on which the accounts were companies accounting for 96% of share. Local players enjoy a
approved by the Board of Directors. In view of the changes dominant position, occupying 4 of the top 5 positions.
made under the Income-tax Act, 1961, by the Finance Act,
2020, dividends paid or distributed by the Company shall be India is often referred to as the “pharmacy to the world”,
taxable in the hands of the Shareholders. Your Company shall, ranking 3rd worldwide in total pharmaceutical production
accordingly, make the payment of the proposed dividend for volume and 10th by value. As per National Indian Promotion
the year ended March 31, 2020 after deduction of tax at source. Agency, it is the largest producer of generic medicines and
DIVIDEND DISTRIBUTION POLICY vaccines, occupying 20% volume share in generics and 62% in
vaccines.
Dividend Distribution Policy adopted by the Company in
terms of requirements under the Securities and Exchange The face of the market itself is changing because the informed
Board of India (Listing Obligations and Disclosure consumer has brought a shift in demand. Given that customer
Requirements) Regulations, 2015, is available on the experience can have a transformational impact on business,
56 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20

CORPORATE OVERVIEW STATUTORY REPORTS FINANCIAL STATEMENTS
the informed consumer today is kept at the heart of business - Price controls and regulations : Downward pressure
operations. In the emerging markets, pharma businesses are on drug prices is likely to intensify due to the inclusion of
increasingly leveraging insights and adapting to changing more medicines in the 2020 update of the National List of
consumer needs – emotional and behavioral, and not merely Essential Medicines (NLEM). Additional downward
clinical - to stay relevant and build a sustainable business. pressure could come from the government’s plans to
OPPORTUNITIES AND CHALLENGES implement trade margin caps more widely in 2020.
Increase in the price of APIs imported from China due to
There are multiple factors which impact industry growth and rate hike in 2019 and supply disruption in 2020 is likely to
profitability. Severe price pressure is expected due to create upward pressure on drug prices. NLEM could be
expansion of pricing regulations and increasing regulatory updated more frequently in the future.
interventions. Influx of first-time patients from the National
Health Protection Scheme (NHPS) into the healthcare The 2019 amendment to the Drug Price Control Order
ecosystem, relaxation of regulations for patented drugs, and (DPCO) broadens provisions for exemptions from price
controls to cover all patented medicines as well as
increasing spend on preventive healthcare could emerge as
products granted orphan drug status. Together with the
major growth drivers over the next few years. In the medium
new rules governing drug registration and clinical
term, successfully navigating the COVID-19 crisis will be on
research activity notified in March 2019, this is likely to
top of the mind for all companies.
encourage investment from originators and result in
Factors which impact industry and Company growth include : early launches of more innovative, patented drugs.
- Technology and Digitalization : Technology led Frequent and unexpected changes in the domestic
revolutionization of the healthcare industry is likely to pricing policy have created an uncertain environment
be expedited in the year 2020 due to the global for investments and innovation. The Government and
pandemic. While healthcare professionals will remain stakeholders would need to productively engage in
the single largest influencers of treatment and medicine order to develop a framework that ensures availability
choice, changes in the way doctors interact with both and accessibility of affordable drugs for citizens, while
patients as well as sales representatives will open up a ensuring a workable pricing structure for pharmaceutical
new array of opportunities for pharmaceutical companies.
companies. Remote healthcare, patient empowerment - OTC drug regulations : With rising patient
and multichannel engagement are likely to be some of empowerment and growing willingness to self-medicate,
the important emerging trends. Rapid adoption of new there is a growing demand for the drafting of a well-
working models will be key to success for pharmaceutical defined over-the counter (OTC) drug policy. Creation of a
companies in 2020 and beyond. regulated OTC market coupled with stricter enforcement
of prescribing and dispensing regulations will drive
- National Health Protection Scheme : NHPS was
growth in the OTC space. The Company is well placed to
launched by the Government of India in 2018 with the
benefit from such a policy with its dedicated OTC vertical.
objective of providing free health coverage at the
secondary and tertiary level to the poor and vulnerable - Uniform Code of Pharmaceuticals Marketing
sections of the population. NHPS has expected to cover Practices (UCPMP) : UCPMP, while currently
50 Crore beneficiaries in 10 Crore families. The National voluntary, could become mandatory shortly. A
Health Agency projects a four-fold increase in the mandatory code would require ethical marketing
number of patients treated annually in India, rising to practices to be followed by all companies. Given that the
10 Million over the next few years. The pharmaceutical Company has a strong compliance process in place, it
industry stands to be a prime beneficiary from the massive would be well positioned under a strict enforcement of
influx of first-time patients in the healthcare system who UCPMP.
are prescribed medicines at the primary care level. REVIEW OF OPERATIONS
- Specialty medicines : These will witness increased The Company has consistently grown in the Indian market,
demand across both developed and pharmerging supported by the quality care it offers by way of innovative and
markets, and are projected to account for more spending trusted products, and backed by expert clinical support.
than previously. Its position has been further enhanced through strong
57
customer insights, wider geographical reach, better Key Financial Ratios :

innovation, differentiated marketing, pill-plus-service Particulars 2020 2019 Change
approach and commercial expertise. Debtors Turnover (Days) 13.8 13.6 1.5%
To continue its leadership position, the Company is Inventory Turnover (Days) 7.2 6.2 16.1%
Interest coverage ratio* 95.1 311.8 (69.5%)
strengthening its leading brands and distinctive business
Current Ratio 3.6 3.2 12.5%
capabilities. We are focused on creating innovative products
Debt Equity Ratio 0.5 0.5 0.0%
and services for patients, doctors, caregivers and pharmacies Operating profit margin (%) 20.0% 19.0% 5.3%
across the continuum of care, increasing the breadth and Net profit margin (%) 14.0% 12.0% 16.7%
depth of our portfolio and strengthening our urban coverage. Return on Net Worth (%) 26.0% 24.0% 8.3%
A consistent brand focus, changing product mix, and value *Interest coverage ratio has dropped because of accounting impact of
creation across stakeholder groups are some of the attributes Ind AS 116.
that have ensured delivery of sustainable success. There is no significant change (i.e. change of 25% or more as
Financial Performance compared to the immediately previous financial year) in the
key financial ratios except Interest coverage ratio.
Total Revenue : Total Revenue for the year ended March 31,
2020 is ` 4207,53 Lakhs in comparison to ` 3791,89 Lakhs last Detailed explanation of ratios :
year, recording a robust growth of 11.0% over the previous (i) Debtors Turnover (Days)
financial year.
The above ratio is used to quantify a Company’s
Profit Before Tax : Profit Before Tax for the year ended effectiveness in collecting its receivables or money owed
March 31, 2020 at ` 802,69 Lakhs grew by 14.9% over the by customers. The ratio shows how well a Company uses
previous year. and manages the credit it extends to customers. It is
calculated by dividing Revenue from operations by
Other Income : The Other Income stood at ` 114,39 Lakhs, average trade receivables.
mainly comprising interest income from bank fixed deposits.
The Company continues to invest in fixed deposits with banks (ii) Inventory Turnover (Days)
that have high credit ratings, with a view to safeguarding the
Inventory Turnover is the number of times a Company
principal and maintaining liquidity. Income from bank deposits sells and replaces its inventory during a period. It is
grew by 27.5%. The investment strategy is reviewed calculated by dividing Revenue from operations by
periodically by the Finance Committee. The Company has an average inventory.
investment portfolio of ` 2168,68 Lakhs as on March 31, 2020. (iii) Interest Coverage Ratio
Material Cost : The Material Cost increased on account of The Interest Coverage Ratio measures how many times a
inflation, but was compensated by improved sales price Company can cover its current interest payment with its
realisation, resulting in a marginal decrease in Material Cost available earnings. It is calculated by dividing Earnings
as a percentage to Sales from 57.4% in financial year 2018-19 to Before Interest and Taxes by finance cost.
57.1% in the current year. (iv) Current Ratio
Employee Cost : The Company increased its employee The Current Ratio is a liquidity ratio that measures a
strength to 3,551. The Employee Cost as a percentage to Sales Company’s ability to pay short-term obligations or those
shows a marginal decrease at 11.7% in the current year vis-à- due within one year. It is calculated by dividing the
vis 12.0% in the financial year 2018-19. The increase in current assets by current liabilities.
Employee Cost by 9.3% over last year is mainly due to merit
(v) Debt Equity Ratio
increase.

The ratio is used to evaluate a Company’s financial
Other Expenses : Other Expenses including Depreciation and leverage. It is a measure of the degree to which a Company
Finance Cost increased by 7.8% over the last year. However as is financing its operations through debt versus wholly
a percentage to Sales, it has decreased to 15.1% vis-à-vis 15.6% owned funds. It is calculated by dividing a Company’s
in the previous year. total liabilities by its shareholder’s equity.

(vi) Operating Profit Margin (%) Gastroenterology : The Company grew by 9.9% in this area
during the year, mainly driven by Cremaffin, Udiliv and
Operating Profit Margin is a profitability or performance
Duphalac. Our differentiated offerings beyond pills, a strong
ratio used to calculate the percentage of profit a Company
portfolio - from Gastro to GPs - and strong equity amongst the
produces from its operations. It is calculated by dividing
consumers are behind the sustained growth. A new, robust
the Earnings Before Interest and Taxes by Revenue from
operations. product introduction process through extensive market
research has helped to further enhance the portfolio.
(vii) Net Profit Margin (%) The focus remains on the launch of new products in the
The net profit margin is equal to how much net income or Gastrointestinal (GI) space.
profit is generated as a percentage of revenue. It is
During the year, 12 new products viz. Evitol (Non alcoholic
calculated by dividing the profit for the year by Revenue
fatty liver disease or NAFLD), Fidonal (Anal Fissures), Udisyp
from operations.
(Liver Disorders), Tenfoplus (Hepatitis B), Viadek (Pancreatic
(viii) Return on Net Worth (%) Exocrine Insufficiency or PEI), Udistrong Orange (Liver
Diseases), Creon SD (Pancreatic Exocrine Insufficiency or
Return on Net Worth is a measure of profitability of a
Company expressed in percentage. It is calculated by PEI), Cremadiet + 300 (Constipation), Udistrong sachet –
dividing total comprehensive income for the year by Cranberry (Liver Diseases), Antoxipan sachet, Duphalac Bears
average capital employed during the year. 1.6 (Constipation – Pediatrics) and Duphalac Chews 3.3
(Constipation - Pregnancy) were launched.
Business Performance
Metabolics : This portfolio grew by 27.9%, driven mainly by
The Company operates in a single reportable business segment NeoMercazole and Thyronorm, which retains flagship
i.e. “Pharmaceuticals”. The Company provides products and position* in its respective segment. Integration of the thyroid
solutions across various therapy areas such as Women’s portfolio to optimise spend and increase market share,
Health, Gastroenterology, Central Nervous System, introduction and improvement of line extensions to facilitate
Metabolics, Multi-Specialty (Pain Management, Insomnia, differentiation, and entering bacterial vaginosis with new sub-
Nutritional supplements and Vitamins), Vaccines, Consumer therapy (pre-probiotics) to leverage equity with Gynecs are
Health, etc. some of the major drivers of performance. Increasing
Performance for the year under review in respect of the awareness remains the key priority for sustained growth.
Company’s various therapeutic segments are highlighted Central Nervous System : This portfolio showed a growth of
below : 12.6% during the year. Vertin and Prothiaden continue as the
Women’s Health : This portfolio has consistently shown market leaders* in their segments. Creation of hybrid
strong growth over the last several years. This year it grew by structure, marketing resource allocation strategy and
21.9% led by Duphaston. Strong brand equity, coverage of reduction of attrition on account of team engagement have
gynecologists and high level of trust and credibility owing to helped this portfolio to show good performance during the
sensitive indications with a high premium on safety (especially year. Introducing new sub-therapies and life-cycle
in pregnancy) are drivers of growth. Introduction of newer management support for older molecules
indications, addition of new products to expand the portfolio, remain key priorities. Also, during the year, Epishield
setting up separate sales and marketing teams to increase (Micronutrients/Epilepsy) was launched.
focus on In Vitro Fertilisation (IVF) are some of the initiatives Multi-Specialty : Under this segment, the Company offers
undertaken during the year to sustain the growth. Increasing products for Pain Management, Insomnia, Nutritional
awareness and widening the portfolio to strengthen market supplements and Vitamins. This portfolio showed a growth of
presence remain the key focus areas. 4.4% during the year which was mainly driven by Zolfresh,
During the year, 5 new products viz. Femoston (Hormone Arachitol Nano and Brufen. Promotion of specialty brand
replacement therapy or HRT), Femilon (Contraception), matrix and creation of the leadership academy for capacity
Novelon (Contraception), Cetropro (Prevention of premature building have helped maintain growth. Introduction of new
ovulation) and Parihep (Thromboembolic conditions) were molecules and expanding the portfolio through scientific
launched. research and market studies remain the key priority.
*Source : IQVIA 59
Vaccines : The key brands in the vaccines portfolio are MEDICAL RESEARCH AND KNOWLEDGE SHARING
Influvac, Enteroshield and Rotasure. The portfolio showed INITIATIVES
strong double-digit growth of 20.4% and contributed 3.9% of Evidence-based medicine is gaining importance in
Sales for the year. The growth was mainly driven by Influvac, empowering healthcare professionals to ensure better patient
a number 1* product in its participated market. A separate task care. Research studies undertaken by the Company, ranging
force was set up to target the untapped adult vaccination from real-world evidence based studies (observational or
market. Focus is to expand the portfolio beyond the current epidemiological) to registration studies, have been
instrumental in defining and driving organizational
set of vaccines and target segments. The Company has a
strategies and creating high-quality scientific evidence, thus
licensing arrangement with Bharat Biotech India Limited to
aiding the optimisation of healthcare.
market vaccines in the immunology segment.
During the year, the Company executed 12 new studies,
During the year, Influvac Tetra (Flu vaccine) was launched published 16 articles in major indexed journals, along with
and was a big hit in the first three months of its launch. making four international presentations. The Company
Consumer Health : The Company offers a few consumer- conducted registration studies for Influvac Quadrivalent
directed products, including all variants of Digene - tablets, vaccine, which was approved by the Indian health authorities
during the year and the vaccine is now available in the market.
liquids and powders. During the year, this portfolio showed
This new vaccine boosts protection against influenza by
strong growth of 19.5%. Cremaffin was consumerised to targeting an additional strain. All the studies were conducted
revitalise the brand. Good strategy and sustained investment in compliance with Good Clinical Practice (GCP) and
have helped achieve growth. Our focus remains on expanding regulatory requirements.
this portfolio.
Capability building of healthcare professionals has remained
During the year, two new products - Brufen Rapid (Analgesics) a high strategic priority for the Company. During the year,
and Digene Ultra Fizz (Antacid) were launched. more than 2,500 medical education programs were conducted
towards achieving this objective. The Company also
IMPACT OF COVID-19 partnered with over 12 medical associations to drive
The novel coronavirus continues to wreak havoc throughout capability building in various therapy areas. Furthermore, as a
the globe. It has forced millions across the world to remain continued commitment towards knowledge dissemination,
locked down in their homes and caused businesses to either 100 workshops were conducted, training approximately 1,800
medical staff. Over and above these, over 3,000 patient
close down or realign operations. The pharma industry has
awareness programs were conducted across India.
been energised by the fight against COVID-19 that has given
an impetus to research for new drugs or vaccines, but industrial OUTLOOK
work has been greatly affected by the pandemic, primarily We are positive that our continuous endeavor to help patients
through the disruption of supply chains. in all possible ways, sustained services and culture of trust-
building across stakeholders will hold us in good stead
Initially, the lockdown posed certain challenges for the
through this challenging year. Our values and resilience keep
Company. The Goa plant could not operate at optimum supporting us while we adapt to the new normal. We continue
capacity, availability of raw materials and finished stock from to enjoy the confidence of our consumers, business partners
third party manufacturers, supply chain and the distribution and investors. Additionally, new products and differentiated
were impacted marginally on account of disruption of services offered are contributing to the Company’s growth.
transportation. However, sufficient levels of inventory The Company continues to drive a faster growth rate, beating
maintained at various points in the distribution chain helped the market year-after-year.
in meeting the market demand. There was no significant As a Company we will continue to navigate during these
impact on the Company’s business operations. Manufacturing, difficult times and accelerate transforming our business. The
supply chain and distribution have substantially resumed to following are expected to be major enablers as we try to better
normal levels. The Company, its employees as well as its our service to customers and accelerate growth :
business partners remain committed and continue to ensure • Innovative models to engage with healthcare
the uninterrupted supply of products to meet the needs of professionals through multiple channels : Developing
our customers. presence across the entire customer journey through
60 *Source : IQVIA ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20

innovative multiple channels of engagement, and Proposed expansion of drugs covered by the National List of
leveraging data collected from digital channels to Essential Medicines (NLEM) and restrictions on trade
augment capabilities of the sales force; enabling them to margin mark-ups will create uncertainties at market place.
engage with doctors and healthcare professionals and Growing awareness about cheaper alternatives to branded
create product awareness continue to remain a priority. generics and more channels providing access to them also
impact volume growth.
• Supporting patients beyond the pill : As healthcare
information becomes more readily available on the INTERNAL CONTROL SYSTEM AND ITS ADEQUACY
internet, we are witnessing a change in consumer The Company has an internal control mechanism
behavior, with patients starting to be more involved in commensurate with its size and nature of business. These
making healthcare choices. The Company has been systems provide a reasonable assurance on achievement of its
engaging with patients directly through industry-first operational, compliance and reporting objectives, including
patient programs to provide education, counselling and safeguarding the Company’s assets, prevention and detection
support services. As these programs have shown success of frauds, accuracy and completeness of accounting records
in ensuring therapy adoption and adherence, we plan to and ensuring compliance with corporate policies.
explore targeted partnerships with other industry This mechanism is sound in design and the framework is
players and start-ups to expand to additional therapies. continuously evaluated for effectiveness and adequacy.
The Company has already scaled up the Knowledge The mechanism operates through well-documented standard
Genie platform and also plans to introduce a pregnancy operating procedures, policies and process guidelines.
focused patient support programme in 2020. Periodic analysis and reviews are conducted by the Senior
• Scaling up pharmacy engagement : Strengthening our Management to assess its efficiency. Also, the same is
discussed with auditors on a regular basis.
channel management capabilities and resources can
be a key differentiator in minimizing prescription The Internal audit plan is finalized based on current
substitution. India is rapidly moving towards a uniform perception of internal control risk and compliance requirement
quality standard and building capabilities for in consultation with the operating divisions. The Internal
pharmacists is critical to enable them to play a greater role Auditors, as a part of their audits, review the design of key
in the market. The Company’s dedicated OTC vertical will processes to assess the adequacy of controls.
continue to expand its coverage in this regard. The Internal audit reports issued by the Internal Auditors are
• Shaping therapies to accelerate key brands : We are discussed with the Senior Management and presented to the
prepared to accelerate growth of current brands and plan Audit Committee on a quarterly basis. An independent and
our future launches with clearly defined strategies empowered Audit Committee reviews the significant
developed through in-depth analysis of market trends observations and assesses the adequacy of the actions
along with a careful evaluation of our capabilities and proposed while monitoring their implementation. The Internal
strengths. Shaping of key therapies is critical to driving Auditors conduct a quarterly follow up for implementation/
remediation of all audit recommendations and the status report
therapy leadership and ensuring that we continue on our
is presented to the Audit Committee regularly.
path of consistent growth.
The Company has implemented both preventive and
RISKS AND CONCERNS
detection controls. Appropriate corrective actions taken to
The pharmaceutical Industry in India is strictly regulated by reduce the risks include the following :
the Government due to implications on health and safety.
• The Abbott Code of Business Conduct requires annual
This control is likely to increase in the future as the industry
certification by all employees;
grows in size and expands its presence in the international
markets. While regulators are committed to ensuring a positive • The Compliance Committee is formed with
business environment for pharmaceutical companies, representatives from all the operating groups;
synergies in policy and implementation will be something to • Senior Management has oversight of the compliance
look out for. programs;
61
• The Business Compliance Cell is assigned the readiness for first and second-line manager roles, we create a
responsibility of training, monitoring and ensuring common talent pool. Additionally, we have launched
employees’ compliance with the Company’s policies certification programs and career paths for field employees.
and procedures;
Several leadership development programs such as In-Stride,
• The Company has a Whistle Blower mechanism in Global Citizen Development Program, Emerging Leaders
place; Program, New Leaders Program, etc. were conducted during
• Internal investigation reports are presented before the the year.
Audit Committee on a quarterly basis; - An in-depth Talent Management Review was conducted
• Business divisions have periodic meetings with the with the aim of identifying successors for critical roles
Director, Office of Ethics and Compliance, to monitor within the organization, to determine the readiness of
and discuss compliance with various business processes. successors and provide them with an accurate actionable
development plan to move into identified critical roles.
The Company Management has assessed the effectiveness of
internal controls over financial reporting for the year ended - The ‘Accelerate’ programme was launched to develop
March 31, 2020 and basis the assessment, believes that the managerial capability, to increase team performance
processes are working efficiently and effectively. and drive higher employee engagement.
All First-Line Managers (FLMs) i.e. 330 Area Business
The Statutory Auditors have issued unmodified audit report
on the adequacy of the internal controls over financial Managers (ABMs) underwent an external assessment,
reporting and its operating effectiveness. and on the basis of this assessment result, an individual
development plan has been created for every manager.
HUMAN RESOURCES
- LEAP 2020 was a programme launched with the objective
At Abbott India, people are our strong and formidable assets. to assess and develop managerial capabilities within the
The Company provides holistic capabilities to its employees to organization and encourage talent mobility across
boost organizational performance. Their skill, dedication, zeal businesses. A competency framework was designed to
and agility are helping the business understand and respond to
measure managerial behavioral competencies; 221 field
changing healthcare needs so that the Company can live up to
its promise of helping people live fuller, healthier lives. employees (Territory Business Managers or TBMs)
underwent the assessment and will have customized
The Company encouraged employees to stay upbeat during the development plans to increase their readiness to take up
tough situation by conducting Mental Resilience workshops
FLM roles.
and COVID-19 awareness sessions. All employees were
supported with remote working tools viz. Global IT microsite, - ‘Wo-mentoring’ initiative was introduced, which provide
myHR portal, etc. a platform to accelerate development for women
During the time, employees were upskilled through the conduct employees through ‘Mentoring’. The programme aims at
of various ASK workshops, soft skills training programs, sales supporting women employees to ‘Build their Career with
and product refresher trainings and training on digital tools Confidence’. The initiative includes an on-boarding
and new ways of working. The training team delivered over process of Orientation Sessions to enable the mentoring
1600 sessions/topics virtually to engage the field. conversations, identification of development goals
Diversity continued to be a big priority last year. We conducted coupled with enablers in the form of employee connects
diversity drives across sales offices across India and at the and related learning interventions. Mentors share their
head office. At these events, our Women Leaders at Abbott expertise and guide proteges in their identified
(WLA) gave an insight of our Diversity initiatives. development areas. The said programme was extended
The Company’s Human Resource team has developed to the head office, plant and field employees.
and deployed integrated talent management practices that Periodic meetings are held between HR Leadership and the
encompass the entire employee life cycle - recruitment,
Talent Strategy teams to closely monitor progress on the
induction, development, career progression, rewards and
recognitions. various aspects of talent strategy and take necessary action.
Our Talent Management process is well embedded in our The Company believes in motivating and engaging employees
system and supports leadership, sales, marketing and support through shared goals, capability-building initiatives, career
functions. Through our uniform assessments to gauge the growth opportunities and provide an environment of

transparency, accountability and positive reinforcement. Various training programs are conducted at the plant on
The Company has 3,551 employees as on March 31, 2020. health and safety issues to build technical capabilities.
Employees are also encouraged to attend external training
Prevention of Sexual Harassment at Workplace programs on various topics such as regulatory requirements,
The Company has an Internal Complaints Committee (ICC) in ergonomics, machine guarding, hot work safety, road safety,
place as required under the Sexual Harassment of Women at industrial hygiene and industrial safety. The employees also
Workplace (Prevention, Prohibition and Redressal) Act, 2013. attend various training programs/seminars arranged by the
Inspectorate of factories and Green Triangle Society.
Appropriate training is imparted to employees regularly
through the online learning portal. In 2019-20, all employees A cross-functional team for emergency response and
completed the mandatory online training programme on firefighting is in place. Mock drills for fire-fighting and rescue
POSH (Prevention of Sexual Harassment). This training also operations are conducted in association with the local fire
brigade to keep the staff in a state of preparedness for any
forms a part of the new Employee Orientation programme.
emergencies.
During the year, one complaint was received by the
Special focus is maintained on critical safe work initiatives like
Company/ICC under the aforesaid Act and the same was
contractor safety, hand safety and working on heights.
appropriately closed.
Additionally, several employee engagement programs,
HEALTH, SAFETY AND ENVIRONMENT such as celebration of National Safety Week, World
Environment Day and Abbott EHS Month, were conducted
Health and Safety : to help build a sustainable EHS culture.
At Abbott, employees’ health and safety are the utmost During the year, the following initiatives took place at the Goa
priority and hence during the COVID-19 pandemic, the plant –
Company took key steps to protect and safeguard employees.
- Installed a new diesel pump and automated sprinkler
A crisis action team was formed on Day 1 of the outbreak.
system to reduce risk of business interruption and meet
Work from home transition for the pan-India sales workforce recommendations provided by Factory Mutual.
and HO employees was announced on March 19, 2020.
For employees at the plant, local transport was provided, - Safety retrieval system for confined space entry was
cleaning frequency was increased, and social distancing was installed for safe entry and retrieval of a person entering
ensured at the premises. the liquid manufacturing tanks, thus minimizing the risk
associated during confined space entry.
We are committed to keeping employees safe by preventing
dangerous incidents in and around the workplace. - 411 employees (including contractual employees)
underwent the Global EHS induction module, and 117
In educating our employees, we also empower them to
employees were trained on various aspects and on the
promote safer and healthier lives in their wider communities.
proper use of personal protective equipment, leading to
We strive to maintain the highest standards of Environment,
improved PPE compliance. To further improve Behavior
Health and Safety (EHS) practices.
Based Safety programs, 20 new observers were trained
The EHS Policy has been implemented through our Global through Abbott Global resources. Around 111 employees
EHS standards based on ISO 14001 and OHSAS 45001, attended training on Lockout Tagout (LOTO) and Slip Trip
supported by a well-defined EHS organizational structure, Falls (STF). A few employees attended various programs,
EHS Standard Operating Procedures and EHS specific such as effective functioning of safety committee, OSHE
programs that ensure that we meet all the local regulatory legal requirements, sharing best practices on OSHE, beat
requirements. air pollution, stress management etc.
The Safety Committee, comprising representatives from the Various Road Safety programs were conducted for field
workforce and Management, constantly work towards employees during the year. About 400 sales employees
resolving issues impacting plant safety and employee health. attended the one-day two-wheeler riding safety programme
Regular self-audits and third-party safety audits are conducted as part of the Behind the Bar training activity. This program
to verify compliance with the regulatory and internal safety was conducted by third-party consultants. 100% of the sales
requirements. The plant has a record of completing eight years employees completed the online defensive driving refresher
without lost time injury. training module.
63
There is continuous improvement on the Behavior Based The details of energy conservation measures and water
Safety (BBS) program and a visible improvement in safety conservation initiatives are provided in Annexure III.
culture has been observed. The Stop for Safety initiative is
The Company is adhering to the requirements of Plastic
being practiced in order to support the BBS program.
Waste Management Rules as laid down by the Central
Environment : Pollution Control Board. During the year, we have collected
around 1400 MT of post-consumer waste through our
A responsibility towards the environment is part of Abbott’s
Extended Producer Responsibility (EPR) partners. This waste
mandate. We continuously endeavour to minimize the use of
is recycled or disposed of in a scientific way. The Company is
renewable resources and cut down on carbon emission.
also working towards several upstream eco-initiatives that
In all our initiatives, we adopt a holistic approach and make
will help in plastic waste minimization, which is fundamental
efforts to curtail adverse environmental impact, if any. The
to the concept of EPR.
Goa site continued to implement multiple water conservation
and emission reduction projects. We provide training to our EHS employees on applicable EHS
regulations and internal technical standards through both
The Company has a state-of-the-art effluent treatment plant internal and external trainings and conferences. We promote
with parameters of treated effluents well below the limit EHS awareness and share best practices across Abbott
set by the local State Pollution Control Board. The plant is a through a dedicated month highlighting EHS topics, as well as
zero discharge plant. a monthly webinar series by subject matter experts.
Over the period of the last five years, the plant has achieved
more than 20% absolute water reduction in usage.
DIRECTORS
The rainwater harvesting project was effectively continued Mr Krishna Mohan Sahni (DIN : 02103128) retired as
at the plant this year. Total rainwater utilized during Independent Director from the Board effective close of
financial year 2019-20 was 1,379 kl, which reduced the intake business hours on October 28, 2019 upon completion of his
of purchased water. term. Mr Jawed Zia (DIN : 00191276) and Mr Mark Murphy II
(DIN : 08385393) resigned as the Non-Executive Directors
Major focus during the year was process optimization and effective February 29, 2020 and June 30, 2020. The Board
yield improvement. Along with increasing productivity, this places on record its sincere appreciation for the guidance and
initiative has helped prevent the discharge of raw materials support received from Mr Sahni, Mr Zia and Mr Murphy II
and solvents into the environment. We are continuously over these years.
improving our product yields, thus reducing wastages.
Ms Shalini Kamath (DIN : 06993314) has been appointed
Furthermore, gas emissions from the boiler and generator as Additional and Independent Director of the Company
stacks as well as the ambient air quality are monitored for a period of 3 (three) years effective October 29, 2019.
regularly, and they are well below the limits set by the State Ms Kamath holds a varied experience and expertise in the
Pollution Control Board. There is also a vermi-composting area of Human Resources, Business Development and
unit in place to convert canteen waste into organic manure, Social & Community Development. In the opinion of the
which is used in the lawns and in the plantation inside the Board, skills, integrity and experience possessed by
factory premises. Ms Kamath will be beneficial to the Company.
The plant retains its Zero Waste to Landfill (ZWL) Mr Ambati Venu (DIN : 07614849) was elevated to a new role
certification in matters of waste disposal. In financial year within the Abbott Group and, therefore, resigned as the
2019-20, 60% of the waste was sent for recycling, 38% for Managing Director of the Company effective February 29, 2020.
co-processing and 2% for composting. The plant continued The Board places on record its sincere appreciation for the
sending hazardous waste for co-processing. We ensure that accelerated growth of the Company during his tenure. Upon
energy from the waste is recovered, thus contributing to the recommendation of the Nomination and Remuneration
reduction of CO2 emission and global warming. 38% of plant Committee, he was appointed as Non-Executive Director,
waste was incinerated with energy recovery. eligible to retire by rotation, effective March 1, 2020.
During the year, World Environment Day was celebrated The Board at its Meeting held on June 8, 2020, based on the
with the participation of all plant employees. Environment recommendation of the Nomination and Remuneration
awareness sessions were conducted, and tree plantation was Committee, appointed Mr Anil Joseph (DIN : 08753233) as an
undertaken by the employees on this day. Additional and Managing Director of the Company for a

period of 5 (five) years with effect from July 1, 2020, subject to ii) appointment mechanism for Managing Director/
approval by the Central Government and Members at the Executive and Non-Executive Directors/Independent
ensuing Annual General Meeting. Directors/Key Managerial Personnel and Senior
Management;
In compliance with Section 152 of the Companies Act, 2013,
Mr Kaiyomarz Marfatia (DIN : 03449627) and Mr Munir iii) tenure of Managing Director/Executive Directors/
Shaikh (DIN : 00096273) retire by rotation at the ensuing Independent Directors;
Annual General Meeting and, being eligible, offer themself for iv) their removal process and succession planning.
re-appointment.
Remuneration Policy lays down the Company’s philosophy
In accordance with the provisions of the Securities and
and criteria as well as manner of determining the
Exchange Board of India (Listing Obligations and Disclosure
remuneration of Managing Directors, Executive/Non-
Requirements) Regulations, 2015, as amended from time to
Executive Directors, Independent Directors, Senior
time, approval of Members is sought through Special
Management, Key Managerial Personnel and other employees.
Resolution for the re-appointment of Mr Munir Shaikh, who
has attained the age of seventy-five years. Performance Evaluation of the Board, Board Committees
and Directors
Declaration of Independence
The Company has received declarations from all the The Company has adopted the Board Evaluation Framework
Independent Directors confirming that they meet with the and Policy, which sets a mechanism and criteria for the
criteria of independence prescribed under sub-section (6) of evaluation of the Board, Board Committees and Directors,
Section 149 of the Companies Act, 2013 and the Securities including Independent Directors. The same is available at
and Exchange Board of India (Listing Obligations and https://www.abbott.co.in/investor-relations/policies.html
Disclosure Requirements) Regulations, 2015, as amended As per the aforesaid Framework, Board and Board
from time to time. All the Independent Directors have Committees are evaluated by the Board through self-
registered themselves in the Independent Director’s assessment and group discussions. Parameters for evaluation
Database as managed by Indian Institute of Corporate Affairs. include structure and composition, frequency of meetings,
Number of Board Meetings devotion of time for important business, adequate access to
information, discussion with management and cohesiveness
Five Board Meetings were held during the year on May 27,
in the overall working which facilitates open discussion.
2019; August 8, 2019, August 22, 2019, November 12, 2019 and
February 7, 2020. The intervening gap between the Meetings Evaluation of the Directors is done by the Board (excluding
was within the period prescribed under the Companies Act, the director who is being evaluated) basis the suggested set
2013, Rules framed thereunder read with the Secretarial of questions/parameters set out in the aforesaid framework
Standards on Meetings of the Board of Directors. by the Nomination and Remuneration Committee.
Policy on Nomination and Appointment of Directors/ These criteria comprise Directors’ attendance, effective
Criteria for appointment of Senior Management and participation at Board/Committee Meetings, their
Remuneration Policy contribution at the Meetings, leveraging on his/her
The Company has adopted the Policy on Nomination and experience to provide the necessary insights/guidance on
Appointment of Directors/Criteria for appointment of Senior Board discussions and display of candor in expressing
Management and Remuneration Policy as per the provisions views even when they are in divergence with the rest of the
of Section 178(3) of the Companies Act, 2013 and the Rules Board, etc. Independent Directors at their separate meeting
framed thereunder. The said Policies are available on the evaluate the performance of the Board, Non-Independent
Company’s website at https://www.abbott.co.in/investor- Directors and the Chairman.
relations/policies.html
During the year 2019-20, questionnaire along with feedback
Nomination Policy acts as a guideline for determining forms were circulated to the Directors for evaluation of the
qualifications, positive attributes and independence of Board, Committees and Directors. The Board discussed the
Directors and matters related to the appointment and removal responses received from each of the Directors on the same.
of Directors and Senior Management. The Policy lays down – The Board also confirmed that the Independent Directors
i) criteria and terms and conditions with regard to continue to fulfil criteria prescribed under the Companies Act,
identifying suitable candidates who are qualified to 2013 and the Securities and Exchange Board of India (Listing
become Directors and Senior Management; Obligations and Disclosure Requirements) Regulations, 2015
65
and remain independent from the Management. Independent b) they have selected such accounting policies and applied
Directors, at their separate meeting, reviewed the them consistently and made judgments and estimates that
performance of Non-Independent Directors, Board and the are reasonable and prudent so as to give a true and fair
Chairman, considering the views of the other Executive and view of the state of affairs of the Company as at March 31,
Non-Executive Directors. 2020 and of the profits of the Company for that year;
KEY MANAGERIAL PERSONNEL c) they have taken proper and sufficient care for the
maintenance of adequate accounting records in
Mr Rajiv Sonalker, Chief Financial Officer and Ms Krupa accordance with the provisions of the Companies Act,
Anandpara, Company Secretary, are the Key Managerial 2013 for safeguarding the assets of the Company and for
Personnel of the Company as on March 31, 2020. Mr Ambati preventing and detecting fraud and other irregularities;
Venu ceased to be the Key Managerial Personnel effective
d) they have prepared the Annual Accounts of the Company
February 29, 2020. Mr Anil Joseph, Managing Director is
on a going concern basis;
appointed as the Key Managerial Personnel effective
July 1, 2020. e) they have laid down adequate Internal Financial Controls
to be followed by the Company and that such Internal
AUDIT COMMITTEE Financial Controls are adequate and are operating
The Audit Committee comprises Ms Anisha Motwani effectively;
(Chairperson), Mr Munir Shaikh, Mr Sudarshan Jain and f) they have devised proper systems to ensure compliance
Ms Shalini Kamath. Role of the Committee is provided in with the provisions of all applicable laws and that such
detail in the Corporate Governance Report, forming part of systems are adequate and operating effectively.
this Report. All the recommendations made by the Audit
RELATED PARTY TRANSACTIONS
Committee during the year were accepted by the Board.
Policy on dealing with Related Party Transactions and
VIGIL MECHANISM/WHISTLE BLOWER POLICY Materiality
The Company has in place Vigil Mechanism/Whistle Blower The Company has in place the Policy on dealing with Related
Policy called “Abbott India Limited – Procedure for Internal Party Transactions and Materiality in terms of requirements
Investigations”. It lays down a mechanism for reporting and of the Companies Act, 2013 and the Securities and Exchange
investigation of all unethical behavior, alleged or potential Board of India (Listing Obligations and Disclosure
violations of laws, regulations or Abbott Code of Business Requirements) Regulations, 2015. The said Policy is available on
Conduct, policies, procedures or other standards. the Company’s website at https://www.abbott.co.in/investor-
relations/policies.html
The said Policy is available on the website of the Company at
https://www.abbott.co.in/investor-relations/policies.html As per the said Policy, all Related Party Transactions are
pre-approved by the Audit Committee and Board, as and when
Employees have numerous ways to voice their concerns and
required. The details of such transactions are also reviewed by
are encouraged to report the same internally for resolution.
the Audit Committee on a quarterly/annual basis. Material
The said Policy provides for adequate safeguards against
transactions (transactions exceeding 10% of the annual
retaliation and access to the Chairperson of the Audit
turnover as per the last audited financial statements), if any,
Committee.
with any Related Party are pre-approved by the Shareholders.
Any concerns/grievances can be communicated through
various sources as provided under the said Policy or via Details of Related Party Transactions
toll free number 0008001001058 or online at The Company enters into the business transactions with
https://speakup.abbott.com various Abbott affiliate companies (“Related Parties”) in the
normal course of business and on arm’s length basis.
DIRECTORS’ RESPONSIBILITY STATEMENT All the transactions with the Related Parties during the
Pursuant to Section 134(5) of the Companies Act, 2013, your financial year 2019-20 were pre-approved by the Audit
Directors state that : Committee. Prior approvals of the shareholders are in place
a) in the preparation of the Annual Accounts for the year for the Material Related Party transactions. Actual
ended March 31, 2020, the applicable accounting transactions were reviewed by the Audit Committee on a
standards have been followed and there are no material quarterly basis. The details of the same are provided in Note
departures from the same; 40 to the Financial Statements.

Pursuant to Regulation 23(9) of the Securities and Exchange • Reducing operational surprises and losses – The
Board of India (Listing Obligations and Disclosure Company strives to gain enhanced capability to identify
Requirements) Regulations, 2015, the Company has filed potential events and establish responses, reducing
half yearly reports on Related Party Transactions with the surprises and associated costs or losses.
BSE Limited.
• Identifying and managing multiple and cross-enterprise
INVESTOR EDUCATION AND PROTECTION FUND risks – The Company faces a variety of risks affecting
(IEPF) different parts of the organization, and risk management
Pursuant to the applicable provisions of the Companies Act, facilitates effective response to the interrelated impacts,
2013, read with the IEPF Authority (Accounting, Audit, and integrated responses to multiple risks.
Transfer and Refund) Rules, 2016 (“the IEPF Rules”), all
unpaid or unclaimed dividends are required to be transferred • Seizing opportunities – By considering a full range of
by the Company to the IEPF, established by the Government potential events, the Company is positioned to identify
of India, after the completion of seven years. Further, and proactively realise opportunities.
according to the IEPF Rules, the shares on which dividend has • Improving deployment of capital – Obtaining robust risk
not been paid or claimed by the shareholders for seven information allows management to effectively assess
consecutive years or more shall also be transferred to the overall capital needs and enhance capital allocation.
demat account of the IEPF Authority.
These capabilities, inherent in this Framework, enable the
During the year, the unpaid dividend and shares were
Company to achieve the performance and profitability targets
transferred in line with the above, the details of which have
and guard against loss of resources. It is also directed to help
been given in the Corporate Government Report.
ensure effective reporting and compliance with laws and
CORPORATE SOCIAL RESPONSIBILITY regulations, avoid damage to the entity’s reputation and
Corporate Social Responsibility (CSR) Policy associated consequences. The Company’s operations and its
business divisions are included in the scope of the Risk
The CSR Policy is available on the Company’s website at
Management Framework.
https://www.abbott.co.in/investor-relations/policies.html
A comprehensive exercise is done by the Risk Management
CSR initiatives undertaken during the financial year 2019-20
Core Team comprising of representatives of relevant
The Company incurred an amount of ` 11,64 Lakhs on various functional experts on an annual basis who help to identify
CSR programs during the financial year 2019-20. additional mitigating actions that may be required to ensure
The Annual Report of the CSR activities undertaken by the risk management keeps pace with the business strategy.
Company is annexed as “Annexure I” and forms part of this
The Company’s Chief Financial Officer presents an overall
Report.
Risk Management update to the Risk Management
RISK MANAGEMENT FRAMEWORK Committee, Audit Committee and Board once a year.
The Company recognises Risk Management as an integrated, STATUTORY AUDITORS
forward-looking and process-oriented approach. It has
developed a Risk Framework which is directed to enable the S R B C & CO LLP, Chartered Accountants (ICAI Firm
Management to effectively deal with uncertainty and Registration No.: 324982E/E300003), were appointed as the
associated risk and opportunity, enhancing the capacity to Statutory Auditors at the Seventy-fifth Annual General
build value. It enables to avoid pitfalls and surprises along Meeting of the Company held on August 22, 2019 for a period
the way. of five years i.e. from financial year 2019-20 to financial year
2023-24, to hold office till the conclusion of the Eightieth
• Aligning risk appetite and strategy – The Company
considers its risk appetite in evaluating strategic Annual General Meeting of the Company.
alternatives, setting related objectives and developing In terms of Section 40 of the Companies (Amendment) Act,
mechanisms to manage related risks. 2017 notified on May 7, 2018, the requirement for ratification
• Enhancing risk response decisions – Risk Management of appointment of Statutory Auditors by Members at every
provides the rigor to identify and select among Annual General Meeting has been omitted and accordingly,
alternative risk responses – risk avoidance, reduction, Members’ approval is not required for ratification of their
sharing and acceptance. appointment annually.
67
AUDITORS’ REPORT observation that the name of the Company is appearing in the
The Auditors’ Report for the financial year 2019-20 does not breach list displayed at the BSE Limited website for having
contain any adverse remarks, qualifications or reservations or foreign investment in excess of prescribed sectoral cap.
disclaimers, which require explanations/comments by the The Company has a view that there is no breach; however, is in
the process of taking appropriate action to regularize the
Board.
same.
COST AUDITORS
The said Report is annexed as “Annexure II” and forms part of
M/s Kishore Bhatia & Associates, Cost Accountants this Report.
(Registration No. 00294), are appointed as the Cost Auditors
of the Company for the financial year 2020-21 at a
CONSERVATION OF ENERGY, TECHNOLOGY
remuneration of ` 7.50 Lakhs plus taxes as applicable and
ABSORPTION AND FOREIGN EXCHANGE
reimbursement of out-of-pocket expenses.
EARNINGS AND OUTGO
The required information under the provisions of Section
The said remuneration to the Cost Auditors shall be subject to
134(3)(m) of the Companies Act, 2013 read with Rule 8 of the
ratification by the Members at the ensuing Annual General
Companies (Accounts) Rules, 2014 in respect of Conservation
Meeting.
of Energy, Technology Absorption, Foreign Exchange
Earnings and Outgo, etc. are annexed as “Annexure III” and
COST AUDIT REPORT
forms part of this Report.
As per the provisions of the Section 148(1) of the Companies
Act, 2013, the Company has maintained the cost records, as ANNUAL RETURN
specified by the Central Government.
The Annual Return of the Company has been placed on the
Cost Audit Report along with the Compliance Report for the website of the Company at https://www.abbott.co.in/investor-
financial year 2018-19, issued by M/s Kishore Bhatia & relations/financials.html
Associates, Cost Auditors, was filed with the Ministry of
Extract of Annual Return as provided under sub-section (3) of
Corporate Affairs on August 27, 2019 (due date of filing was
Section 92 of the Companies Act, 2013 and Rules framed
September 27, 2019).
thereunder is annexed as “Annexure IV” and forms part of this
Report.
INTERNAL AUDITORS
DISCLOSURE UNDER SECTION 197(12) OF
M/s KPMG, Chartered Accountants, (ICAI Firm Registration
THE COMPANIES ACT, 2013 AND OTHER
No. BA62445) are the Internal Auditors of the Company.
DISCLOSURES AS PER RULE 5 OF THE COMPANIES
Internal Audit Report, their significant observations and
(APPOINTMENT AND REMUNERATION OF
follow up actions taken by the Management is reviewed by the
MANAGERIAL PERSONNEL) RULES, 2014
Audit Committee on a quarterly basis.
Disclosures required in accordance with the provisions of
SECRETARIAL AUDITOR Section 197(12) of the Companies Act, 2013, read with
Rule 5(1) of the Companies (Appointment and Remuneration of
Ms Neena Bhatia, Practising Company Secretary (Membership
Managerial Personnel) Rules, 2014 is annexed as “Annexure V”
No. FCS 9492 and Certificate of Practice No. 2661) is the
and forms part of this Report. Statement containing Particulars
Secretarial Auditor of the Company for the financial year
of Employees pursuant to Section 197(12) of the Companies
2019-20.
Act, 2013 read with Rule 5(2) of the Companies (Appointment
and Remuneration of Managerial Personnel) Rules, 2014
SECRETARIAL AUDIT REPORT
forms part of this Report. However, as per the provisions of
The Secretarial Audit Report issued by Ms Neena Bhatia, Sections 134 and 136 of the Companies Act, 2013, the Report
Practising Company Secretary (Membership No. FCS 9492 and Financial Statements are being sent to the Members and
and Certificate of Practice No. 2661) for the financial year others entitled thereto, excluding the Statement containing
ended March 31, 2020 does not contain any adverse remark, Particulars of Employees, which is available for inspection by
qualifications, reservations or declaimer except the the Members up to the date of ensuing Annual General

Meeting. Any Member interested in obtaining a copy of such PARTICULARS OF LOANS, INVESTMENTS AND
Statement may write to the Company Secretary at GUARANTEES
[email protected] The Company has not granted any loan or provided any
guarantees to or invested in securities of any other body
CORPORATE GOVERNANCE REPORT corporate during the year.
Corporate Governance Report and Certificate from the
Statutory Auditors of the Company on compliance of the GENERAL
conditions of Corporate Governance pursuant to the No disclosure or reporting is required in respect of the
requirements of the Securities and Exchange Board of India following items as there were no transactions relating to these
(Listing Obligations and Disclosure Requirements) items during the year under review :
Regulations, 2015, form part of this Report. 1. Issue of equity shares with differential rights as to
dividend, voting or otherwise;
BUSINESS RESPONSIBILITY REPORT
Business Responsibility Report, as required under Regulation 2. Issue of shares (including sweat equity shares) to
34 of the Securities and Exchange Board of India (Listing employees of the Company under any scheme;
Obligations and Disclosure Requirements) Regulations, 2015, 3. The Company does not have any joint venture or
forms part of this Report. subsidiaries.
COMPLIANCE WITH SECRETARIAL STANDARDS AWARDS AND RECOGNITIONS

The Board of Directors affirms that the Company has complied The Company was awarded with Most Innovative MNC of the
Year 2019–12th Pharma Leaders Award. The Company also
with the applicable Secretarial Standards issued by the
received various other awards and recognitions for its brands,
Institute of Company Secretaries of India (SS1 and SS2)
campaigns, patient awareness programs and digital initiatives.
respectively relating to Meetings of Board and its Committees
and General Meetings. ACKNOWLEDGEMENT
Your Board expresses gratitude towards all our employees,
DISCLOSURES OF ORDERS PASSED BY business partners, institutions, banks and, the Members, for
REGULATORS OR COURTS OR TRIBUNAL their steadfast trust and support to the Company.
No orders have been passed by any Regulator or Court or
For and on behalf of the Board
Tribunal which can have impact on the going concern status
and the Company’s operations in future.
Munir Shaikh Rajiv Sonalker
FIXED DEPOSITS Mumbai Chairman CFO and Whole-time Director
No fixed deposits were accepted during the year. August 7, 2020 DIN : 00096273 DIN : 07900178
ANNEXURE I
Annual Report of CSR Activities for the financial year 2019-20
[In compliance with Section 135 of the Companies Act, 2013 and Companies (Corporate Social Responsibility) Rules, 2014]
1. Brief outline of the Company’s CSR Policy
Policy Statement :
At Abbott, we believe that innovative, responsible and sustainable business plays an important role in building a healthy,
thriving society. The CSR policy of the Company is focused on fostering economic, environmental and social well-being.
Through our CSR initiatives, we strive to enhance people’s health and well-being and provide sustainable and scalable
solutions to development challenges.
Core CSR areas identified by the Company :
In accordance with the statutory requirements and keeping the Company philosophy high on priority, the CSR Committee
identified the following thrust areas in line with our CSR goals :
• Enhancing access to healthcare across the country for a healthy society; conducting wellness camps for improving
lives of the underprivileged community;
69
• Charitable donations and educational grants for Sr. Name of the Member Category
serving the underserved sections of society; No.
• Reaching out to Government to advance sound public 1. Mr Munir Shaikh1 Chairman Non-Executive Director
policy and expand patient access to healthcare; 2. Mr Ambati Venu Non-Executive Director
• Disease awareness projects/activities that support 3. Ms Anisha Motwani Independent Director
subsidized screening and treatment; 4. Mr Rajiv Sonalker Whole-time Director
• Product donations through trusted partners 1. appointed as Chairman effective April 1, 2019.
in the context of Abbott’s global policies and
3. Average Net Profit of the Company for last three
international standards;
financial years* :
• Extending support to various NGOs through
monetary grants for education, healthcare and ` 567,80 Lakhs
livelihood of underprivileged children and women; *calculated on the basis of Net Profits for the financial
years, 2016-17, 2017-18 and 2018-19
• Environment protection measures;
• Such other projects that fall within the purview 4. Prescribed CSR Expenditure (two percent of the
of the activities included in Schedule VII of the amount as in item 3 above) :
Companies Act, 2013 and Rules framed thereunder,
as amended from time to time. ` 11,36 Lakhs
The CSR policy is available on the Company’s website at
5. Details of CSR spent during the financial year :
2. Composition of CSR Committee : a) Total amount spent during the financial year :
The CSR Committee, as on the date of this Report, is ` 11,64 Lakhs
comprised of the following Directors : b) Amount unspent, if any : Nil
c) Manner in which the amount was spent during the financial year is detailed below : (` in Lakhs)
Sr. CSR Project Name Schedule VII Location Amount Amount spent on Cumulative Amount Spent :
No. Category Outlay the projects or Expenditure Direct or through
(Budget) programs Implementing
1) Direct Agency
2) Overheads
1 Improving Access to Promoting PAN India 4,42 4,42 4,42 Direct

Healthcare through Health Healthcare Implementation
Clinics
2 Quality and Affordable Promoting Mehsana, 3,51 3,51 3,51 Direct
Healthcare Delivery Healthcare; Ahmedabad Implementation
Program with SEWA Empowering (Gujarat)
Women
3 Malaria Elimination Promoting Odisha 3,44 3,44 3,44 Direct
Program with Malaria No Healthcare Implementation
More
4 Administrative Expenses 27 27 27
Total 11,64 11,64 11,64
The Responsibility Statement of the CSR Committee of the Board of Directors –
“The implementation and monitoring of CSR Policy are in compliance with CSR Objectives and Policy of the Company.”
Munir Shaikh Anisha Motwani

Chairman, CSR Committee Member, CSR Committee
DIN : 00096273 DIN : 06943493

ANNEXURE II
Secretarial Audit Report for the financial year ended March 31, 2020
[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No 9 of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014 and Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulation 2015]
To, b. The Securities and Exchange Board of India

The Members, (Prohibition of Insider Trading) Regulations, 2015,
Abbott India Limited as amended from time to time; and
I, Neena Bhatia, Company Secretary in Practice (Membership c. The Securities and Exchange Board of India
No.: FCS 9492 and CP No.: 2661) appointed as the Secretarial (Registrars to an Issue and Share Transfer Agents)
Auditor of the Company by the Board of Directors, have Regulations, 1993 regarding the Companies Act
conducted the Secretarial Audit of the compliance with and dealing with client.
applicable statutory provisions and the adherence to good
corporate practices by Abbott India Limited (hereinafter I have also examined compliance with the applicable clauses
called “the Company”). Secretarial Audit was conducted in a of the following :
manner that provided me a reasonable basis for evaluating the (i) Secretarial Standards issued by The Institute of
corporate conducts/statutory compliances and expressing my Company Secretaries of India, as amended
opinion thereon. from time to time.
Based on my verification of the Company’s books, papers, (ii) The Securities and Exchange Board of India
minute book, forms and returns filed and other records
(Listing Obligations and Disclosure Requirements)
maintained by the Company and also information provided
Regulations, 2015.
by the Company, its officers, agents and authorized
representatives during the conduct of Secretarial Audit, I, To best of my understanding I am of the view that during
hereby report that in my opinion, the Company has during the period under review the Company has complied
the audit period covering the financial year ended on March with the provisions of the Act, Rules, Regulations, and
31, 2020, complied with the statutory provisions listed Guidelines, Standards, etc mentioned above subject to the
hereunder and also that the Company has proper Board following observation :
processes and compliance mechanism in place to the extent,
in the manner and subject to the reporting made hereinafter : The name of the Company appears in the breach list
displayed on the website of the Depositories and Bombay
I have examined the books, papers, minutes book, forms and
Stock Exchange for having foreign investments in excess of
returns filed and other records maintained by the Company
sectoral cap. The Company has taken a view that there is no
for the financial year ended on March 31, 2020 according to
breach; however, is in a process of taking appropriate action
the provisions of :
to regularize the same.
1. The Companies Act, 2013, amendments thereto and
Rules made thereunder; I further report that :
2. The Securities Contracts (Regulation) Act, 1956 and Having regard to the compliance system prevailing in the
Rules made thereunder; Company and on examination of the relevant documents
3. The Depositories Act, 1996 and Regulations and Bye- and records in pursuance thereof, on test-check basis, the
laws framed thereunder; Company has complied with the following laws applicable
4. Foreign Exchange Management Act, 1999 and Rules and specifically to the Company :
Regulations made thereunder to the extent of Foreign a. Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics
Direct Investment, as amended from time to time; Rules, 1945, as amended from time to time;
5. The following Regulations and Guidelines prescribed
b. Drugs and Magic Remedies (Objectionable
under the Securities and Exchange Board of India Act,
1992 (‘SEBI Act’) viz. : Advertisement) Act, 1954, as amended from
time to time; and
a. The Securities and Exchange Board of India
(Substantial Acquisition of Shares and Takeover) c. Drugs (Price Control) Order, 2013, as amended
Regulations, 2011, as amended from time to time; from time to time.
71
I further report that : operations of the Company to monitor and ensure compliance
The Board of Directors of the Company is duly constituted with applicable laws, rules, regulations and guidelines.
with proper balance of Executive Directors, Non-Executive I further report that during the audit period there was
Directors and Independent Directors.
no other events/actions having major bearing on the
Adequate notice is given to all Directors to schedule the Company’s affairs.
Board Meetings, agenda and detailed notes on agenda were
sent at least seven days in advance and a system exists for This report is to be read with my letter of even date which is
seeking and obtaining further information and clarifications annexed as Annexure and forms integral part of this report.
on the agenda items before the meeting and for meaningful
participation at the meeting.
Decision is carried through Majority while the dissenting Neena Bhatia
member’s views, if any are captured and recorded as part Practicing Company Secretary
of the minutes. Place : Mumbai Membership No. FCS 9492
I further report that there are adequate systems and Date : June 8, 2020 Certificate of Practice No. 2661
processes in the Company commensurate with the size and UDIN : F009492B000323971
Annexure to the Secretarial Audit Report of Abbott India Limited for financial year ended March 31, 2020
To,
The Members
My Report of even date is to be read along with this letter.
1. Maintenance of secretarial record is the responsibility of the Management of the Company. My responsibility is to express
an opinion on these secretarial records based on my audit. Due to nationwide lock down on account of the continuing
Covid-19 pandemic, I was not able to physically examine and verify certain information. However, in such cases, I verified
the records based on authenticated soft copies of documents furnished by the Company.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness
of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected
in secretarial records. I believe that the processes and practices, I followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. Wherever required, I have obtained the Management Representation about the compliance of laws, rules and regulations
and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility
of Management. My examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or
effectiveness with which the Management has conducted the affairs of the Company.
Neena Bhatia
Practicing Company Secretary
Place : Mumbai Membership No. FCS 9492
Date : June 8, 2020 Certificate of Practice No. 2661

ANNEXURE III
Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo
[In compliance with the provisions of Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014]
A. Conservation of Energy - Improved operational efficiencies in Goa plant
i. Energy conservation measures adopted at the plant by outsourcing pre-sleeving of bottles for liquids
during the year 2019-20 include : Digene, Cremaffin and Duphalac to vendor
thereby eliminating non-value added activity,
- Optimization of air compressor efficiency in terms reducing inventory holding costs, elimination of
of energy saving of around 70 KWH per day. separate space requirements, QC inspection and
- Replacement of all the streetlight fixtures with material handling.
energy-efficient LED fixture together with variable ii. The benefits derived like product improvement,
activation timings for energy saving resulting in cost reduction, product development or import
annualized savings of approximately 40,000 KWH. substitution
- Installation of Variable Frequency Drives (VFDs) - Cost per 1000 tablets has reduced by
for surface aerators in effluent treatment plants 15% (2017 vs 2019)
(ETP) for optimum energy usage. This led to
reduction in energy consumption by almost 12,000 - Cost per 1000 liquid bottles has reduced by
KWH on annualized basis. 0.5% (2017 vs 2019)
- New process design developed by adding new - Tablet capacity increased from 1.8 to 2.2 Billion
energy efficient blower directly to filter. As a result, (Approx. 25% improvement without capex.)
press, sludge drying per lot is reduced from three to
iii.
Details of technology imported during last three
two days with saving of 108 KWH per drying cycle.
financial years
Water conservation initiatives during the year include :
a. the details of technology imported : Nil
- Installation of new vacuum pump with Hydro pack
b. the year of import : NA
system; cools and circulates water for vacuum pump
operation; resulting in water saving of 700 kl/year. c. whether the technology been fully absorbed : NA
- Installation of steam sanitiser for washing of d. if not fully adsorbed, areas where adsorption has
in-process container, resulted in reduced water not taken place, and the reasons thereof : NA
consumption for container washing. iv. Expenditure on Research & Development
- Free flowing taps fitted with shower orifice reduced Sr. Particulars ` in Lakhs
water consumption by 25% in the washrooms.
No.
- Use of treated water from the wastewater treatment (a) Capital 12
plant in the cooling towers for top up. (b) Recurring 69
- The water conservation initiatives helped the plant (c) Total 81
to save approximately 2,879 kl of water. (d) Total R&D expenditure as a 0.02%
ii. The steps taken by the Company for utilizing Percentage of total turnover
alternate sources of energy
C. Foreign Exchange Earnings and Outgo
Nil
Particulars ` in Lakhs
iii. The Capital Investment on Energy Conservation
Equipment A. Total Foreign Exchange used
a. On import of raw materials, finished 519,52
Nil
goods, consumable stores and capital
B. Technology Absorption goods
i. The efforts made towards Technology Absorption b. On professional charges, sales 8,60
promotion expenses, commission
- Modification of Brufen Manufacturing HVAC with
on export sales, registration fees,
humidity control areas to utilize idle manufacturing
business travel, software, etc.
capacity and gave flexibility in manufacturing
Total 528,12
- Introduction of chilled water to control in let B. Total Foreign Exchange earned
air humidity for drying operations which a. Exports of goods 11,77
resulted in reduced drying cycle time and the b. Service income 6,25
subsequent increase in the granulation capacity.
c. Recovery of expenses 2,32
This supported the tablet capacity increasing
d. Other earnings 12,86
initiative and removed granulation as a bottleneck
Total 33,20
on manufacturing.
73
ANNEXURE IV
Extract of Annual Return as on financial year ended March 31, 2020
FORM NO. MGT 9
Pursuant to Section 92 (3) of the Companies Act, 2013 and Rule 12 (1) of the Companies (Management & Administration) Rules, 2014
I. REGISTRATION AND OTHER DETAILS
CIN : L24239MH1944PLC007330
Registration Date : August 22, 1944
Name of the Company : Abbott India Limited
Category/Sub-Category of the Company : Company Limited by Shares/Indian Non-Government Company
Address of the Registered Office and Contact Details : 3, Corporate Park, Sion-Trombay Road, Mumbai – 400071
Telephone No.:+91-22-6797 8888/ +91-22-5046 1000/2000
Fax:+91-22-5016 9400
Whether Listed Company : Yes
Name, Address and Contact details of Registrar and : KFin Technologies Private Limited
Share Transfer Agent Unit – Abbott India Limited
Address – Selenium Tower B, Plot 31-32, Gachibowli,
Financial District, Nanakramguda, Hyderabad-500 032
Tel No.: +91-40-6716 2222, Fax No.: +91-40-2300 1153
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
All the business activities contributing 10% or more of the total turnover of the Company shall be stated :
Sr. Name and Description of main Products/Services NIC Code of the Product/Service % to total turnover of the Company
No.
1 Pharmaceuticals 21002 100%
III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES
Sr. Name and address of the Company CIN/ Holding/Subsidiary/ % of Shares Applicable section
No. GLN Associate held
1. Abbott Capital India Limited NA Holding 50.45 2(46) of the Companies Act,
Address : Abbott House, Vanvall Business Park, 2013
Maidenhead, Berkshire SL64XE
IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)
i Category-wise Shareholding
Category of Shareholders No. of Shares held at the beginning of the year No. of Shares held at the end of the year % Change
Demat Physical Total % of total Demat Physical Total % of total during
Shares Shares the year
A. Promoters
1) Indian
a) Individual /HUF - - - - - - - - -
b) Central Govt - - - - - - - - -
c) State Govt(s) - - - - - - - - -
d) Bodies Corp. - - - - - - - - -
e) Banks/FI - - - - - - - - -
f ) Any other - - - - - - - - -
Sub-total (A)(1) : - - - - - - - - -
2) Foreign
a) NRIs–Individuals - - - - - - - - -
b) Other–Individuals - - - - - - - - -
c) Bodies Corp. 15934048 - 15934048 74.99 15934048 - 15934048 74.99 -
d) Banks/FI - - - - - - - - -
e) Any other - - - - - - - - -
Sub-total (A)(2) : 15934048 - 15934048 74.99 15934048 - 15934048 74.99 -
Total Shareholding of Promoter
(A)=(A)(1)+(A)(2) 15934048 - 15934048 74.99 15934048 - 15934048 74.99 -

Category of Shareholders No. of Shares held at the beginning of the year No. of Shares held at the end of the year % Change
Demat Physical Total % of total Demat Physical Total % of total during
Shares Shares the year
B. Public Shareholding
1) Institutions
a) Mutual Funds 1197095 50 1197145 5.63 1017845 50 1017895 4.79 -0.84%
b) Banks/FI 30924 308 31232 0.15 72777 308 73085 0.34 0.19%
c) Central Govt - - - - - - - - -
d) State Govt(s) - - - - - - - - -
e) Venture Capital Funds - - - - - - - - -
f ) Insurance Companies 140042 - 140042 0.66 35994 - 35994 0.17 -0.49%
g) FIIs 31430 - 31430 0.15 - - - - 0.15%
h) Foreign Venture Capital - - - - - - - - -
Investors
i) Qualified Foreign Investor - - - - - - - - -
j) Others (specify)
Foreign Portfolio – Corp 402692 - 402692 1.90 348692 - 348692 1.64 -0.26%
Sub-total (B)(1) : 1802183 358 1802541 8.48 1475308 358 1475666 6.94 -1.54%
2) Non-Institutions
a) Bodies Corp.
i) Indian 136129 2666 138795 0.65 246013 2666 248679 1.17 0.52%
ii) Overseas - - - - - - - -
b) Individuals
i) Individual shareholders 2560115 436241 2996356 14.10 2693042 362913 3055955 14.38 0.28%
holding nominal share
capital upto ` 1 Lakh
ii) Individual shareholders 46642 - 46642 0.22 46642 - 46642 0.22 -
holding nominal share
capital in excess of ` 1 Lakh
c) Others (specify)
Alternative Investment Fund 118123 - 118123 0.56 163986 - 163986 0.77 0.21%
Trust 202 - 202 - 295 - 295 - -
NRI(Rep) 23293 1400 24693 0.12 21430 200 21630 0.10 -0.02%
Clearing Member 26471 - 26471 0.12 27450 - 27450 0.13 0.01%
NRI (Non-Rep) 58826 3824 62650 0.29 81862 1130 82992 0.39 0.10%
Foreign Corp Bodies - 471 471 - - 471 471 - -
Investor Education and 66989 - 66989 0.32 96925 - 96925 0.46 0.14%
Protection Fund
Unclaimed Suspense Account 23993 - 23993 0.11 4711 - 4711 0.02 -0.09%
NBFC 454 - 454 - 67 - 67 - -
HUF - - - - 79430 - 79430 0.37 0.37%
Directors and Directors 6874 - 6874 0.03 250 - 250 - -0.03%
Relatives
Qualified Foreign Investor - - - - 10105 - 10105 0.05 0.05%
Foreign National/Bodies/OCB - - - - - - - - -
NSDL in transit - - - - - - - - -
Sub-total (B)(2) : 3068111 444602 3512713 16.53 3472208 367380 3839588 18.07 1.54%
Total Public Shareholding
(B)=(B)(1)+(B)(2) 4870294 444960 5315254 25.01 4947516 367738 5315254 25.01 -
C. Shares held by Custodian for GDRs & - - - - - - - - -
ADRs
Grand Total (A+B+C) 20804342 444960 21249302 100.00 20881564 367738 21249302 100.00 -
75
ii. Shareholding of Promoters

Sr. Shareholder’s Shareholding at the beginning of the year Shareholding at the end of the year %
No. Name change
No. of % of total % of Shares No. of % of total % of Shares
in share
Shares Shares of the Pledged/ Shares Shares Pledged/
holding
Company encumbered of the encumbered to
during
to total shares Company total shares
the year
1. Abbott Capital India Limited 10719097 50.45 - 10719097 50.45 - -
2. Abbott Healthcare Products Limited 3744951 17.6 2 - 3744951 17.6 2 - -
3. British Colloids Limited 1470000 6.92 - 1470000 6.92 - -
Total 15934048 74.99 - 15934048 74.99 - -
iii. No change in the Shareholding of the Promoters during the year
iv. Shareholding Pattern of Top Ten Shareholders (Other than Directors, Promoters and Holders of GDRS and ADRS)
Sr. Name Shareholding Cumulative Shareholding

No. during the year (01/04/2019 to
31/03/2020)
No. of Shares at % of total Date Increase / Reason No. of % of total
the beginning Shares Decrease in Shares Shares
of the year of the Shareholding of the
(01/04/2019) Company Company
1. FRANKLIN TEMPLETON 375000 1.76% 01/04/2019 - - 375000 1.76%
MUTUAL FUND 05/04/2019 25000 Transfer 400000 1.88%
23/08/2019 -100000 Transfer 300000 1.41%
30/08/2019 -25000 Transfer 275000 1.29%
06/09/2019 -7431 Transfer 267569 1.26%
13/09/2019 -16277 Transfer 251292 1.18%
20/09/2019 -26292 Transfer 225000 1.06%
27/09/2019 -25000 Transfer 200000 0.94%
04/10/2019 -2018 Transfer 197982 0.93%
11/10/2019 -1267 Transfer 196715 0.93%
18/10/2019 -7368 Transfer 189347 0.89%
25/10/2019 -14347 Transfer 175000 0.82%
01/11/2019 -10000 Transfer 165000 0.78%
08/11/2019 -184 Transfer 164816 0.78%
15/11/2019 -4816 Transfer 160000 0.75%
22/11/2019 -3029 Transfer 156971 0.74%
29/11/2019 -1487 Transfer 155484 0.73%
06/12/2019 -3045 Transfer 152439 0.72%
13/12/2019 -152439 Transfer - -
31/03/2020 - - - -
2. L & T MUTUAL FUND 313347 1.47% 01/04/2019 - - 313347 1.47%
TRUSTEE LIMITED 26/04/2019 3380 Transfer 316727 1.49%
31/05/2019 12020 Transfer 328747 1.55%
14/06/2019 226 Transfer 328973 1.55%
21/06/2019 2385 Transfer 331358 1.56%
28/06/2019 3998 Transfer 335356 1.58%
12/07/2019 1126 Transfer 336482 1.58%
26/07/2019 599 Transfer 337081 1.59%
02/08/2019 4134 Transfer 341215 1.61%
09/08/2019 1467 Transfer 342682 1.61%
16/08/2019 4897 Transfer 347579 1.64%
30/08/2019 2525 Transfer 350104 1.65%
13/09/2019 -2811 Transfer 347293 1.63%


31/03/2020)
20/09/2019 -1838 Transfer 345455 1.63%
27/09/2019 -20240 Transfer 325215 1.53%
11/10/2019 -7527 Transfer 317688 1.50%
18/10/2019 -12721 Transfer 304967 1.44%
25/10/2019 -17017 Transfer 287950 1.36%
01/11/2019 -2685 Transfer 285265 1.34%
13/12/2019 -14265 Transfer 271000 1.28%
10/01/2020 -7415 Transfer 263585 1.24%
17/01/2020 -832 Transfer 262753 1.24%
24/01/2020 -1464 Transfer 261289 1.23%
31/01/2020 -32 Transfer 261257 1.23%
21/02/2020 -5000 Transfer 256257 1.21%
20/03/2020 38200 Transfer 294457 1.39%
27/03/2020 5863 Transfer 300320 1.41%
31/03/2020 - - 300320 1.41%
3. RELIANCE CAPITAL 212927 1.00% 01/04/2019 - - 212927 1.00%
TRUSTEE COMPANY 05/04/2019 -32122 Transfer 180805 0.85%
LIMITED 31/05/2019 -3346 Transfer 177459 0.84%
19/07/2019 -2026 Transfer 175433 0.83%
23/08/2019 316 Transfer 175749 0.83%
20/09/2019 -10000 Transfer 165749 0.78%
30/09/2019 1210 Transfer 166959 0.79%
30/09/2019 -6432 Transfer 160527 0.76%
04/10/2019 4 Transfer 160531 0.76%
04/10/2019 -2649 Transfer 157882 0.74%
11/10/2019 24 Transfer 157906 0.74%
11/10/2019 -8662 Transfer 149244 0.70%
18/10/2019 6 Transfer 149250 0.70%
18/10/2019 -95 Transfer 149155 0.70%
25/10/2019 -808 Transfer 148347 0.70%
01/11/2019 9 Transfer 148356 0.70%
08/11/2019 3 Transfer 148359 0.70%
08/11/2019 -3844 Transfer 144515 0.68%
22/11/2019 -1713 Transfer 142802 0.67%
29/11/2019 -3362 Transfer 139440 0.66%
06/12/2019 36 Transfer 139476 0.66%
06/12/2019 -47 Transfer 139429 0.66%
13/12/2019 -12 Transfer 139417 0.66%
20/12/2019 3 Transfer 139420 0.66%
27/12/2019 50 Transfer 139470 0.66%
31/12/2019 8 Transfer 139478 0.66%
03/01/2020 30 Transfer 139508 0.66%
10/01/2020 24 Transfer 139532 0.66%
17/01/2020 51 Transfer 139583 0.66%
24/01/2020 46 Transfer 139629 0.66%
31/01/2020 -33 Transfer 139596 0.66%
07/02/2020 53 Transfer 139649 0.66%
14/02/2020 33 Transfer 139682 0.66%
14/02/2020 -13319 Transfer 126363 0.59%
21/02/2020 -2237 Transfer 124126 0.58%
77

31/03/2020)
28/02/2020 -14 Transfer 124112 0.58%
06/03/2020 30 Transfer 124142 0.58%
06/03/2020 -7200 Transfer 116942 0.55%
13/03/2020 170 Transfer 117112 0.55%
13/03/2020 -30515 Transfer 86597 0.41%
20/03/2020 -55 Transfer 86542 0.41%
27/03/2020 -7 Transfer 86535 0.41%
31/03/2020 53 Transfer 86588 0.41%
31/03/2020 - - 86588 0.41%
4. GOLDMAN SACHS INDIA 162126 0.76% 01/04/2019 - - 162126 0.76%
LIMITED 31/03/2020 - - 162126 0.76%
5. CANARA ROBECO 4970 0.02% 01/04/2019 - - 4970 0.02%
MUTUAL FUND 05/04/2019 685 Transfer 5655 0.03%
19/04/2019 435 Transfer 6090 0.03%
05/07/2019 -42 Transfer 6048 0.03%
12/07/2019 -1000 Transfer 5048 0.02%
09/08/2019 -176 Transfer 4872 0.02%
23/08/2019 16000 Transfer 20872 0.10%
30/08/2019 27000 Transfer 47872 0.23%
06/09/2019 1200 Transfer 49072 0.23%
27/09/2019 28000 Transfer 77072 0.36%
04/10/2019 4500 Transfer 81572 0.38%
18/10/2019 2600 Transfer 84172 0.40%
25/10/2019 11550 Transfer 95722 0.45%
01/11/2019 6500 Transfer 102222 0.48%
31/01/2020 6500 Transfer 108722 0.51%
14/02/2020 36325 Transfer 145047 0.68%
31/03/2020 -2504 Transfer 142543 0.67%
6. TATA AIA LIFE - - 01/04/2019 - - - 0.00%
INSURANCE COMPANY 02/08/2019 1459 Transfer 1459 0.01%
LIMITED 09/08/2019 17500 Transfer 18959 0.09%
16/08/2019 8037 Transfer 26996 0.13%
23/08/2019 98257 Transfer 125253 0.59%
31/03/2020 - - 125253 0.59%
7. INDIA WHIZDOM FUND 104187 0.49% 01/04/2019 - - 104187 0.49%
18/10/2019 -2854 Transfer 101333 0.48%
31/03/2020 - - 101333 0.48%
8. LIFE INSURANCE 100411 0.47% 01/04/2019 - - 100411 0.47%
CORPORATION OF INDIA 19/07/2019 -912 Transfer 99499 0.47%
26/07/2019 -15822 Transfer 83677 0.39%
02/08/2019 -7430 Transfer 76247 0.36%
09/08/2019 -26500 Transfer 49747 0.23%
16/08/2019 -10990 Transfer 38757 0.18%
23/08/2019 -10151 Transfer 28606 0.13%
30/08/2019 -16258 Transfer 12348 0.06%
06/09/2019 -12348 Transfer - -
31/03/2020 - - - -


31/03/2020)
9. AXIS MUTUAL FUND - - 01/04/2019 - - - -
TRUSTEE LIMITED 10/01/2020 3930 Transfer 3930 0.02%
14/02/2020 6765 Transfer 10695 0.05%
21/02/2020 25150 Transfer 35845 0.17%
28/02/2020 10877 Transfer 46722 0.22%
06/03/2020 6421 Transfer 53143 0.25%
13/03/2020 10542 Transfer 63685 0.30%
20/03/2020 28300 Transfer 91985 0.43%
27/03/2020 479 Transfer 92464 0.44%
31/03/2020 - - 92464 0.44%
10. SBI MAGNUM GLOBAL 9892 0.05% 01/04/2019 - - 9892 0.05%
FUND 05/04/2019 24514 Transfer 34406 0.16%
10/05/2019 5594 Transfer 40000 0.19%
31/05/2019 916 Transfer 40916 0.19%
07/06/2019 36845 Transfer 77761 0.37%
20/03/2020 -4000 Transfer 73761 0.35%
27/03/2020 3252 Transfer 77013 0.36%
31/03/2020 - - 77013 0.36%
11. INVESTOR EDUCATION 66989 0.32 01/04/2019 - - 66989 0.32%
AND PROTECTION 28/06/2019 31106 Transfer 98095 0.46%
FUND AUTHORITY, 05/07/2019 6 Transfer 98101 0.46%
MINISTRY OF 19/07/2019 -160 Transfer 97941 0.46%
CORPORATE AFFAIRS 02/08/2019 -12 Transfer 97929 0.46%
07/02/2020 -1004 Transfer 96925 0.46%
31/03/2020 - - 96925 0.46%
12. GOLDMAN SACHS FUNDS 61790 0.29% 01/04/2019 - - 61790 0.29%
31/03/2020 - - 61790 0.29%
13. TATA INDIA PHARMA & 46701 0.22% 01/04/2019 - - 46701 0.22%
HEALTHCARE FUND 05/04/2019 5000 Transfer 51701 0.24%
19/04/2019 27000 Transfer 78701 0.37%
19/07/2019 -7000 Transfer 71701 0.34%
26/07/2019 -1500 Transfer 70201 0.33%
20/09/2019 -7034 Transfer 63167 0.30%
27/09/2019 -1701 Transfer 61466 0.29%
18/10/2019 -5000 Transfer 56466 0.27%
01/11/2019 -10000 Transfer 46466 0.22%
06/12/2019 -6466 Transfer 40000 0.19%
13/12/2019 -2500 Transfer 37500 0.18%
20/12/2019 -2850 Transfer 34650 0.16%
27/12/2019 -500 Transfer 34150 0.16%
10/01/2020 -2000 Transfer 32150 0.15%
28/02/2020 -500 Transfer 31650 0.15%
20/03/2020 -3200 Transfer 28450 0.13%
31/03/2020 -7000 Transfer 21450 0.10%
79

31/03/2020)
14. MOTILAL OSWAL NIFTY 44296 0.21% 01/04/2019 - - 44296 0.21%
MIDCAP 150 INDEX FUND 26/04/2019 101 Transfer 44397 0.21%
03/05/2019 650 Transfer 45047 0.21%
10/05/2019 270 Transfer 45317 0.21%
17/05/2019 3098 Transfer 48415 0.23%
24/05/2019 86 Transfer 48501 0.23%
31/05/2019 2231 Transfer 50732 0.24%
07/06/2019 1983 Transfer 52715 0.25%
14/06/2019 2028 Transfer 54743 0.26%
09/08/2019 818 Transfer 55561 0.26%
27/09/2019 1485 Transfer 57046 0.27%
30/09/2019 47 Transfer 57093 0.27%
04/10/2019 83 Transfer 57176 0.27%
04/10/2019 -1300 Transfer 55876 0.26%
11/10/2019 27 Transfer 55903 0.26%
25/10/2019 2 Transfer 55905 0.26%
08/11/2019 1 Transfer 55906 0.26%
15/11/2019 3 Transfer 55909 0.26%
22/11/2019 4 Transfer 55913 0.26%
29/11/2019 4 Transfer 55917 0.26%
06/12/2019 7 Transfer 55924 0.26%
13/12/2019 3 Transfer 55927 0.26%
20/12/2019 3 Transfer 55930 0.26%
31/12/2019 2 Transfer 55932 0.26%
03/01/2020 5 Transfer 55937 0.26%
10/01/2020 8 Transfer 55945 0.26%
17/01/2020 19 Transfer 55964 0.26%
24/01/2020 17 Transfer 55981 0.26%
31/01/2020 13 Transfer 55994 0.26%
31/01/2020 -2400 Transfer 53594 0.25%
07/02/2020 22 Transfer 53616 0.25%
14/02/2020 12 Transfer 53628 0.25%
28/02/2020 5 Transfer 53633 0.25%
06/03/2020 2 Transfer 53635 0.25%
06/03/2020 -1521 Transfer 52114 0.25%
13/03/2020 15 Transfer 52129 0.25%
20/03/2020 9 Transfer 52138 0.25%
27/03/2020 26 Transfer 52164 0.25%
31/03/2020 - - 52164 0.25%
v. Shareholding of Directors and Key Managerial Personnel

Sr. For each of the Directors and KMP Shareholding at the beginning Cumulative Shareholding
No. (along with relatives) of the year during the year
Mr Sudarshan Jain (along with relatives)* No. of % of total Shares No. of % of total Shares
Shares of the Company Shares of the Company
1. At the beginning of the year 250 - 250 -
2. Date wise increase/decrease in Shareholding during the year - - - -
specifying the reasons for increase/decrease (e.g. allotment/transfer/
bonus/sweat equity etc.)
3. At the end of the year 250 - 250 -
*appointed as Independent Director effective April 1, 2019.
None of the other Directors and Key Managerial Personnel except Mr Sudarshan Jain along which his relatives hold shares
in the Company.

vi. INDEBTEDNESS
Indebtedness of the Company including interest outstanding/accrued but not due for payment.
Secured Loans Unsecured Deposits Total
excluding deposits Loans Indebtedness
Indebtedness at the beginning of the financial year
i) Principal Amount
ii) Interest due but not paid
iii) Interest accrued but not due
Total (i+ii+iii)
Change in Indebtedness during the financial year
Addition
NIL
Reduction
Net Change
Indebtedness at the end of the financial year
i) Principal Amount
ii) Interest due but not paid
iii) Interest accrued but not due
Total (i+ii+iii)
vii. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL
A. Remuneration to Managing Director, Whole-time Directors and/or Manager
(` in Lakhs)
Sr. Particulars of Remuneration Name of MD/WTD Total
No. Ambati Venu Rajiv Sonalker Amount
Managing Director CFO and Whole-
(upto February 29, time Director
2020)
1. Gross Salary
a. Salary as per provisions contained in section 17(1) of the Income-tax 3,71 2,36 6,07
b. Value of perquisites u/s 17(2) Income-tax Act, 1961* 3,31 83 4,14
c. Profits in lieu of salary under section 17(3) Income-tax Act, 1961 - - -
2. Stock Option - - -
3. Sweat Equity - - -
4. Commission - - -
-as % of profit - - -
-others, specify - - -
5. Others
Contribution to Provident Fund 12 11 23
Contribution to Superannuation Fund 1 - 1
Total (A) 7,15 3,30 10,45
Ceiling as per the Act ` 81,93 Lakhs (being 10% of the net profits of
the Company calculated as per Section 198
of the Companies Act, 2013)
*The Company does not have any Stock Option Plan for its employees. However, Managing Director and Whole-time Director are entitled
to Stock Option of Abbott Laboratories, USA under its “Incentive Stock Option Program” and is also eligible to purchase shares of Abbott
Laboratories, USA, under its “Affiliate Employee Stock Purchase Plan”, the perquisite value of which is included above.
B. Remuneration to Other Directors
(` in Lakhs)
Sr. Particulars of Remuneration Name of Directors Total
No. Amount
Munir Anisha Sudarshan Shalini Krishna
Shaikh Motwani Jain$ Kamath* Mohan
Sahni#
1. Independent Directors
Fee for attending Board/Committee Meetings - 13.50 12.00 5.50 9.00 40.00
Commission - - - - - -
Others - - - - - -
Total (1) - 13.50 12.00 5.50 9.00 40.00
81
Sr. Particulars of Remuneration Name of Directors Total

No. Amount
Munir Anisha Sudarshan Shalini Krishna
Shaikh Motwani Jain$ Kamath* Mohan
Sahni#
2. Other Non-Executive Directors
Fee for attending Board/Committee Meetings 10.50 - - - - 10.50
Commission - - - - - -
Others - - - - - -
Total (2) 10.50 - - - - 10.50
Total (B)=(1+2) 10.50 13.50 12.00 5.50 9.00 50.50
Ceiling as per the Act ` 8,19 Lakhs (being 1% of the net profits of the Company calculated as per Section
198 of the Companies Act, 2013)
$ appointed as Independent Director effective April 1, 2019
* appointed as Independent Director effective October 29, 2019
# retired as Independent Director effective October 28, 2019
C. Remuneration to Key Managerial Personnel (KMP) other than Managing Director and Whole-time Director
(` in Lakhs)
Sr. Particulars of Remuneration Krupa Anandpara
No. Company Secretary
1 Gross salary
(a)6 Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 63
(b)6 Value of perquisites u/s 17(2) Income-tax Act, 1961* 11
(c)6 Profits in lieu of salary under section 17(3) Income tax Act, 1961 -
2 Stock Option -
3 Sweat Equity -
4 Commission
- as % of profit -
- others -
5 Others
Contribution to Provident Fund 3
Total 77
*The Company does not have any Stock Option Plan for its employees. However, above KMP is entitled to Stock Option of Abbott
Laboratories, USA under its “Incentive Stock Option Program” and is also eligible to purchase shares of Abbott Laboratories,
USA, under its “Affiliate Employee Stock Purchase Plan”, the perquisite value of which is included above.
VII. Penalties/Punishment/Compounding of Offences

Type Section of the Brief Description Details of Penalty/Punishment Authority Appeal made,
Companies Act /Compounding fees imposed [RD/NCLT / if any
COURT]
A. COMPANY
Penalty
Punishment NIL
Compounding
B. DIRECTORS
Penalty
Punishment NIL
Compounding
C. OTHER OFFICERS IN DEFAULT
Penalty
Punishment NIL
Compounding

ANNEXURE V
Disclosure under Section 197 (12) of the Companies Act, 2013 and other disclosures as per Rule 5 of the Companies
(Appointment and Remuneration of Key Managerial Personnel) Rules, 2014 :
i. (a) The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary of
the Company and (b) ratio of the remuneration of each director to the median remuneration of the employees of
the Company for the financial year 2019-20 :
Name of the Director/KMP % Increase in the remuneration Ratio of remuneration of each Director/to
(a) median remuneration of employees (b)
Mr Munir Shaikh* - 1.3
(Non-Executive Chairman)
Mr Sudarshan Jain^* - 1.5
(Independent Director)
Ms Anisha Motwani* - 1.7
Mr Krishna Mohan Sahni*$ - 1.1
Ms Shalini Kamath*% - 0.7
Mr Ambati Venu# 9.8 90.9
(Non-Executive Director)
Mr Rajiv Sonalker 8.2 42.0
(CFO and Whole-time Director)
Ms Krupa Anandpara 12.7 NA
(Company Secretary)
* Entitled for Sitting fees of ` 1,00,000 for attending each Board, Audit Committee and Independent Directors Meetings and ` 50,000 for
attending each other Committee Meetings.
$ Mr Krishna Mohan Sahni retired as Independent Director upon completion of his term effective close of business hours on October 28, 2019.
# Mr Ambati Venu ceased as Managing Director effective close of business hours on February 29, 2020.
^ appointed as Independent Director effective April 1, 2019
% appointed as Independent Director effective October 29, 2019
ii. The percentage increase in the median remuneration of employees in the financial year :
0.6%
iii. Number of permanent employees on the rolls of the Company :

3,551
iv. Average percentile increase made in the salaries of employees other than managerial personnel in the last financial
year and its comparison with the percentile increase in the managerial remuneration and justification thereof :
Average percentage increase made in the salaries of employees other than the managerial personnel in the financial year
2019-20 is 2.3% vis-a-vis 9.5% in managerial remuneration. This is due to change in employee mix though average merit
increase given to employees is in the range of 8% to 11%.
v. It is affirmed that the remuneration paid to Directors, Key Managerial Personnel and other Employees is as per
the Remuneration Policy of the Company.
83

At Abbott India, we aim to deliver sustainable, responsible growth that improves lives and creates value in communities
around the world.
We continue to focus on areas where opportunities for our business intersect with possibilities of creating a positive social and
environmental impact. We strive to bring new and innovative quality products to meet the unmet needs of the people we serve.
We protect the health and well-being of our employees while operating award-winning programmes to help them fulfil their
potential. We operate responsibly and ethically, towards promoting and preserving healthy living environments by reducing our
environmental impact, mitigating the effects of climate change and safeguarding clean water resources. We work closely with
our suppliers to apply the highest standards of environmental and social responsibility throughout our supply chain, including
the protection of human rights. Our endeavor remains to foster economic, environmental and social well-being through our
operations and in our interaction with our stakeholders.
The Company’s Board approved policies and Code of Business Conduct are available on the Company’s website i.e.
SECTION A : GENERAL INFORMATION ABOUT THE COMPANY

Sr. Particulars Company Information
No.
1. Corporate Identity Number (CIN) L24239MH1944PLC007330
2. Registered address 3, Corporate Park, Sion-Trombay Road, Mumbai-400 071
3. Website www.abbott.co.in
4. E-mail id [email protected]
5. Financial Year 2019-20
6. Sector(s) that the Company is engaged in (industrial NIC Code : 21002
activity code-wise) (Activity : Pharmaceuticals)
7. List three key products/services that the Company Duphaston
manufactures/provides (as in balance sheet) Thyronorm
Udiliv
8. Total number of locations where business activity is
undertaken
a) Number of international locations NIL
b) Number of national locations Manufacturing plant at Goa, registered office and corporate office
at Mumbai, Sales offices and distribution hubs Pan-India
9. Markets served by the Company local/state/national/ Pan-India, Sri Lanka, Nepal, Maldives and Bhutan
international
SECTION B : FINANCIAL DETAILS OF THE COMPANY
Sr. Particulars Company Information
No.
1. Paid Up Capital ` 21,24,93,020
2. Total Turnover ` 4054,47 Lakhs
3. Total Profit After Tax ` 592,93 Lakhs
4. Total Spending on Corporate Social
Responsibility (CSR)
a) IN ₹` ` 11,64 Lakhs
b) As a percentage of Profit After Tax (%) 2.0%
5. List of activities in which expenditure in 4 above a. Improving Access to Healthcare through Health Clinics
has been incurred b. Quality and Affordable Healthcare Delivery Programme
with SEWA
c. Malaria Elimination Programme with Malaria No More

SECTION C : OTHER DETAILS

The Company does not have any subsidiaries. Hence, the other details pertaining to subsidiary companies, as required under
the section, is not applicable.
SECTION D : BUSINESS RESPONSIBILITY (BR) INFORMATION

1. Details of Director/Directors responsible for BR
(a)
Details of the Director responsible for implementation of the BR policy/policies :
Mr Anil Joseph - Managing Director
(b) Details of BR Head :
Particulars Company Information
Director Identification Number 08753233

Name Anil Joseph
Designation Managing Director
Telephone Number +91-22-5046 1000/2000
E-mail ID [email protected]
[email protected]
2. Principle-wise (as per National Voluntary Guidelines) Business Responsibility Policy/Policies

National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business (NVGs) released in
July 2011, which is essentially a set of nine principles that offer businesses an Indian understanding and approach to
inculcating responsible business conduct. These principles are :
Principle 1 Businesses should govern with Ethics, Transparency and Accountability.
Principle 2 Businesses should provide goods and services that are safe and contribute to sustainability
throughout their life cycle.
Principle 3 Businesses should promote the well-being of all employees.
Principle 4 Businesses should respect the interests of and be responsive towards all stakeholders, especially the
marginalized ones.
Principle 5 Businesses should respect and promote human rights.
Principle 6 Businesses should respect, protect and make efforts to restore the environment.
Principle 7 Businesses, when engaged in influencing public and regulatory policy, should do so in a responsible
manner.
Principle 8 Businesses should support inclusive growth and equitable development.
Principle 9 Businesses should engage with and provide value to their customers and consumers in a responsible
manner.
85
a. Details of Compliance (Y/N)
Question Business Product Well-being of Stakeholder Human Environment Public CSR Customer
Ethics Responsibility Employees Engagement Rights Policy Relations
P1 P2 P3 P4 P5 P6 P7 P8 P9
Do you have policy/policies for? Y Y Y Y Y Y N Y Y
Has the policy being formulated Y Y Y Y Y Y NA Y Y
in consultation with the relevant
stakeholders?
Does the policy conform to any These policies, aligned to/form part of the Abbott Code of Business Conduct and adopted globally, are
national/international standards? in compliance with Indian laws and regulations and meet international standards. The said policies are
If yes, specify? adopted by the Board of Directors. CSR Policy is signed by the Chairman of the CSR Committee.
Has the policy been approved by the
Board? If yes, has it been signed by
MD/owner/CEO/appropriate Board
Director?
Does the Company have a specified Y Y Y Y Y Y NA Y Y
Committee of the Board/Director/
Official to oversee the implementation
of the policy?
Indicate the link for the policy to be https://www.abbott.co.in/investor-relations/policies.html
viewed online?
Has the policy been formally Y Y Y Y Y Y NA Y Y
communicated to all relevant internal
and external stakeholders?
Does the Company have in-house Y Y Y Y Y Y NA Y Y
structure to implement the policy/
policies?
Does the Company have a grievance Y Y Y Y Y Y NA Y Y
redressal mechanism related to
the policy/policies to address
stakeholders’ grievances related to the
policy/policies?
Has the Company carried out Y Y Y Y Y Y NA Y Y
independent audit/evaluation of the
working of this policy by an internal or
external agency?
b. If answer to Sr. No.1 against any principle is ‘No’, please explain why
Question P1 P2 P3 P4 P5 P6 P7 P8 P9
The Company has not understood the NA NA NA NA NA NA NA NA NA
principles
The Company is not at a stage where NA NA NA NA NA NA NA NA NA
it finds itself in a position to formulate
and implement the policies on
specified principles
The Company does not have financial NA NA NA NA NA NA NA NA NA
or manpower resources available for
the task
It is planned to be done within the NA NA NA NA NA NA NA NA NA
next six months
It is planned to be done within the NA NA NA NA NA NA There is no such policy formulated. The Company NA NA
next one year advocates from time to time, as a member of
various trade bodies, chambers and associations
to address issues related to the pharmaceutical
industry.

3. Governance related to Business Responsibility (BR)

Information with reference to BRR framework
Sr. Questions Information

No.
1. Indicate the frequency of review by the Board of Directors, Annually at the time of approving the Business Responsibility
Committee of the Board or CEO to assess the BR performance. Report
Within 3 months, 3-6 months, annually, more than 1 year
2. Does the Company publish a BR or a Sustainability Report? The Company publishes Business Responsibility Report which
What is the hyperlink for viewing this report? How frequently it forms part of the Annual Report. The same is available at
is published? https://www.abbott.co.in/investor-relations/financials.html
SECTION E : PRINCIPLE-WISE INFORMATION We impart ethics and compliance training to all employees.
Training topics cover anti-corruption and anti-commercial
Principle 1 : Businesses should conduct and bribery laws, corporate policies and the Abbott Code of
govern themselves with Ethics, Transparency and Business Conduct. Training programmes are delivered face-
Accountability to-face and through online training platform, and results for
the same are documented. In addition, the Office of Ethics and
The Company is committed to conducting business in an Compliance issues regular, all-employee communications on
ethical and legally compliant manner. It aims to meet the our ethics and compliance policies.
highest standards of ethical conduct in everything it does.
1.
Does the policy relating to ethics, bribery and
As part of a highly regulated industry, we make it a priority to corruption cover only the Company?
ensure that all employees understand Abbott values, policies No
and procedures, as well as our wider legal obligations. 2.
Does it extend to the Group/Joint Ventures/
The Code of Business Conduct (“the Code”) sets forth our Suppliers/Contractors/NGOs/Others?
commitment to ethics and compliance. It covers a wide range Yes
of principles and requirements that touch upon all aspects of 3.
How many stakeholder complaints have been
our business activities and operations. received in the past financial year and what
percentage was satisfactorily resolved by the
Our policies and procedures operate alongside our Code
management? If so, provide details thereof.
to guide employees as they conduct their day-to-day
activities. They encompass all relevant laws, regulations and
The Company received 33 stakeholder complaints
promotional standards. Our policies also consider industry during financial year 2019-20. Of these, 25 complaints
best practices, including provisions of global and local were investigated in accordance with the Internal
Investigations Policy and Compliance Programme
codes for medical devices and pharmaceuticals. Our Code of
and appropriately resolved; 8 complaints are pending
Conduct is available on our website. The Company’s Board
investigation as on March 31, 2020.
and leadership teams fully support the Code and the policies,
procedures and principles it embodies. Principle 2 : Businesses should provide goods
and services that are safe and contribute to
At Abbott India, we are committed to preventing corruption sustainability throughout their life cycle
in connection with our business activities and to continue The Company is committed to consistently delivering
working with third parties that share this commitment. products that are safe, effective and high quality.
The Office of Ethics and Compliance (OEC) has developed
We strive to enhance the health and well-being of patients and
a third-party compliance process to identify potential risks consumers by ensuring the highest standards of quality and
when doing business with third parties, and to address such safety in our products, in their manufacture and distribution.
risks where they do exist. We take alleged violations very Consumers trust our products, which help them live fulfilling
seriously, and if they are substantiated, offenders are subject lives through better health. We continue to embed quality
to disciplinary action. and safety throughout our value chain.
87
We use the Abbott Global Quality System as a foundation for Given the current concerns around antibiotics, we assessed
each of our business units, incorporating effective quality a few of our third-party manufacturers and suppliers of
management practices into every aspect of our daily work antibiotics for EHS performance during the year.
and complying with all applicable regulations and standards.
We have long-term targets to reduce employee injuries and
Protecting the authenticity of our products is another
incidents. We at Abbott India are aligned to support the
important part of earning people’s trust. We proactively
science-based environmental targets set by Abbott global
take action to ensure that counterfeit, illegally diverted and
for 2030. A major component of these targets is looking at
stolen Company products are kept out of the marketplace.
the entire product life cycle and bringing in environmental
We provide healthcare professionals and institutions the
sustainability in the same, with the focus on recycling and
information they need in order to use Company products
beneficial use of materials.
safely and effectively. We have established a procedure
for product actions and recalls, which require completion 1. List up to three of your products or services whose
of a health hazard assessment, medical assessment and a design has incorporated social or environmental
corrective and preventive action plan. concerns, risks and/or opportunities.
The Company’s manufacturing plant at Goa and commercial • Duphalac and Cremaffin
sites adhere to auditing and reporting requirements, which • Digene Gel and Tablets
serve as a baseline for quality, health and safety performance.
Each site is regularly evaluated against the following criteria : • Brufen Tablets
• Health and safety policy and programme 2. For each such product, provide the following details
in respect of resource use (energy, water, raw
• Strategic planning
material, etc.) per unit of product :
• Self-assessment/risk assessment
(a)
Reduction during sourcing/production/
• Business integration distribution achieved since the previous year
• Training and awareness throughout the value chain?
• Communication and information Being a multiproduct facility, product-wise

resource consumption is not measured, yet the
• Performance measures
plant continuously takes measures to reduce energy,
• Assurance reviews water and raw material consumption. The plant
• 30 Global Environment, Health and Safety standards has been constantly increasing manufacturing
yields in order to reduce the wastage of precious
• Local regulatory compliance
raw materials, packaging materials and solvents.
We are also committed to driving our suppliers to uphold
(b) Reduction during usage by consumers (energy,
standards that align with our supply chain management
water) that has been achieved since the
and sustainability strategies. Abbott’s Supplier Guidelines
previous year?
outline the principles and expectations we set to establish
strong business relationships and ensure our sustainability Measuring product-wise reduction of energy
values are upheld in our purchasing process. Similarly, and water is not feasible; however environmental
they define the minimum standards our suppliers and their footprint reduction is a key goal at the
suppliers must maintain when conducting business with manufacturing site. We continue to run the boilers
the Company, including expectations of ethical behavior, on Biomass. With focused efforts and with
business integrity and fair competition, human rights, production on an upswing, the site has been able to
privacy, labour rights and worker protection, animal welfare, reduce its absolute environmental footprint. All the
environmental stewardship, and health and safety practices. waste generated is disposed of responsibly through
By striving for excellence in our supplier relationships, Government approved agencies, selected after a
we seek to foster economic opportunity, shared value and robust audit process. The current focus is to recycle
sustainable market growth. the waste to the maximum possible extent.

The table below shows water consumption, CO2 to cement factories which utilize these as fuel for
emissions and waste generated during the year manufacturing cement, thereby recovering the energy.
2019-20 at the plant. With a philosophy of more All non-hazardous waste like paper, glass, metals, etc.
with less, we continue manufacturing efficiently are sent to approved vendors for recycling.
using less natural resources.
Our Goa plant retains its certification of Zero Waste
Sr. Parameter Unit Quantity to Landfill (ZWL) in purview of waste disposal.
No.
In 2019-20, 60% of the total waste was sent for recycling
1. Total water used KL 36,304
and for beneficial use, 2% was composted on site, 38% of
2. Waste generated MT 265 the waste, which was hazardous, was co-processed with
3. Total CO2 equivalent MT 4,153 energy recovery.
emissions from purchased
electricity Principle 3 : Businesses should promote the well-
being of all employees
3.
Does the Company have procedures in place for
sustainable sourcing (including transportation)? The Company cares for and is concerned about the health and
If yes, what percentage of your inputs was sourced well-being of its employees. Its success is directly dependent
sustainably? Also, provide details thereof. upon the skill, dedication and productivity of its employees.
Yes, the Company has been working on increasing the It addresses their diverse needs, reward their efforts and help
sourcing of local packaging materials, thereby reducing them build their best career at Abbott.
the need for transportation and the resultant vehicular Our promise to each of these employees is to provide a
emissions. For example, the bottles for liquid products workplace environment that :
are now pre-sleeved and procured locally from a
vendor close to the plant. We are increasingly localising • Promotes diversity and inclusion
the supply chain through the alternative vendor • Offers extensive professional development, mentoring
development process. and training programmes
4.
Has the Company taken any steps to procure • Encourages and supports work-life harmony
goods and services from local and small • Offers competitive compensation and benefits
producers, including communities surrounding • Provides means to listen to employees
their place of work? • Commits to employee health and safety and offers
The Company does procure goods and services from wellness programmes
local and small producers, particularly, those located
A Diverse and Inclusive Workplace
near its manufacturing plant at Goa, in accordance
with the established procedures and requirements. We We foster gender partnership and collaboration to promote a
have also identified new local sources for supplying truly inclusive work environment.
voluminous raw material that is used in the production
We work to build increasing inclusivity for all, regardless of
process. Now most of the bottles used for liquid filling
race, gender, age, sexual orientation, disability or nationality,
are procured from a supplier based in the local area.
across the Company. Our Human Resource team works
Services like housekeeping and gardening are provided
closely with the leadership and line managers to create an
by local contractors.
understanding and buy-in for improving gender diversity in
5. Does the Company have a mechanism to recycle the organization. There are special efforts taken at the hiring
products and waste? If yes, what is the percentage of stage to increase diversity right at the base of the organization’s
recycling of products and waste (separately as <5%, pyramid. To ensure we are on top of these efforts, we continue
5-10%, >10%). Also, provide details thereof. to benchmark ourselves with industry best practices.
Yes, wherever feasible, the wastes are recycled. There is The Women Leaders of Abbott (WLA) employee network
a continuous focus on the 3Rs–namely reduce, recycle is designed to help female employees further their careers,
and re-use. Being pharmaceuticals, the products are not empower themselves, and they receive encouragement to
recycled. Hazardous waste and sludge are dispatched take on leadership roles at the Company through structured
89
training, development and networking events tailored to The development journey is designed and executed by
their specific needs. Initiatives and allowances are provided creating critical experiences to bridge the journey for
by Abbott to give our women employees adequate support at readiness to one’s aspired future roles. These programmes
critical life stages. are a blend of distinct learning approaches like instructor led
training, digital learning, on-the-job training reinforced by
The Unconscious Bias training programme helps in building
tie-ups with top class academic institutions.
awareness so that all employees are able to make better, more
inclusive, decisions at work. Through this programme the Our customised global leadership development programmes
participants explore ways to take right actions and make the such as Global Citizen Development Programme, Emerging
Company a place where everyone can do their best and feel a Leaders Programme, etc. emphasize on building global
sense of inclusion. These workshops are designed to enable leaders from within the organization and accelerating
employees to have open dialogue and recognize any potential their development journey through holistic best-in-
barriers for selecting and leading the very best talent. class interventions.
Employee Development, Training and Talent All the employees have complimentary access to the
Management platforms like Career Connect and global training sites which
offer personalized tools and resources to help our employees
We are committed to helping our people fully realise their manage their careers and create a high-impact development
potential. We make that possible by leveraging the scale plan. The experience involves access to online learning
and diversity of our businesses to support their career resources on LinkedIn learning/Skillsoft/ Mindtools, on-the-
development. We provide unique career paths, customised job development and building global connections through
learning experiences, career development programmes, exploring role profiles and connecting with role advisors.
job-specific training and learning opportunities to help
We firmly believe that the biggest source of our competitive
employees be successful in their current roles and to develop
advantage is our people. From talent acquisition to on-
their potential for future career paths. All employees, from
boarding, nurturing and development, our efforts are geared
those working in commercial and operations to those in
to lending greater power to our employee value proposition–
research and development, have access to these training and
‘Grow with the Leader’.
development opportunities.
“Project Respect” focuses on building managerial capability
Our Learning and Development strategy is focused on
and creating a safe, conducive and performance-oriented
attracting and retaining the very best talent. In addition work environment.
to job-specific training and development available to
every employee worldwide, we offer several area-specific Work-Life Harmony
programmes in India. Our development journeys are also The Company offers flexible work schedules and office
tailored to specific functional requirements and involve timings to enable our employees to achieve balance in
specific functional curriculum targeted to bridge functional their work and personal responsibilities and activities.
capability gaps. Our key training programmes include We view these initiatives not only as important tools for
the professional development programme, development talent attraction and retention, but also as key components in
programmes and certification of managers, and capability- our approach to diversity and inclusion.
building programmes for Sales Managers. Abbott Sales
Compensation and Benefits
Training Academy provides structured training programmes
based on intensive customer research. Total Rewards
Abbott believes in “Total Rewards” philosophy that
Our robust talent management review is an ongoing process
encompasses compensation as well as benefits programmes.
to evaluate our internal leadership pipeline, identify the
It is a holistic approach that aims towards health, welfare
critical capabilities for success and execute development
and financial well-being of our employees. Our compensation
plans for high potential employees.
and benefits packages compare favorably with the pay
The Key Acceleration Programmes (In-Stride and FLDP- programmes of other leading healthcare companies, as well
Future Leaders Development Program), customized, act as a as other high performing companies outside the healthcare
catalyst for development of one’s career in the organization. arena. Our employees have a convenient and complete view of

their compensation and benefits through their personalized The products are offered to employees at a discounted
Total Rewards statement. Employees also have the flexibility rate, and employees can get them delivered to a desired
of making changes to their salary structure and opting location. The Abbott Shop makes the Company products
for additional retirement benefits through the Flexible available, accessible and more affordable to all employees
Compensation Plan. in the country.
Listening to Employees • Emotional Wellness : Wellness of the mind is as
At Abbott India, it is our constant endeavor to improve significant and essential as our overall wellness. Abbott
employee experience and this depends on multiple factors, aims to support its employees on this journey by offering
such as influence of the immediate manager, organizational avenues where employees can learn from and leverage
policies and procedures etc. Regular surveys are conducted the knowledge of experts through a host of programmes
to gather employee feedback about working at the Company addressing various aspects of emotional well-being.
to understand our employees’ level of engagement with our Mind Strong Programme is a dedicated programme that
business strategy. This is an opportunity to learn where we covers areas on Emotional Wellness. The Company is
can make meaningful improvements. Beside surveys, there very cognizant of the fact that work and personal life
are a variety of formal and informal channels to gather can bring pressures to all. Thus, we have an Employee
feedback from employees. Assistance Programme which is a 24x7 independent
To help us focus on the right levers and to listen to counselling and resource service sponsored by Abbott
our employees, the organization had rolled out an for its employees. Its features include counselling for
“Employee Survey” in to seek feedback and experience on work life balance, stress management, management
identified factors. skills, and family support, including legal and
financial information.
Basis the survey results, there are certain clear areas of
strength that the organization will sustain and certain areas • Financial Wellness : The Company arranges sessions
of opportunities that will collectively be worked upon to with experts to educate employees on financial planning
help build high performing and fully engaged teams.
under financial wellness to enable them to understand
Health and Well-being the basics of retirement planning or planning for
Health and Well-being are important for the organization financial uncertainties/debt management.
and to achieve this objective Abbott offers a Flexible Benefit • Social Wellness : The Company believes in inculcating a
programme which is over and above our core benefit offering culture where employees understand the broader sense
and is a platform created for employees to choose the benefits
of purpose. There are various initiatives that are run
that matter to them. Through this programme, we offer a
throughout the year that drive a sense of community
wide selection of benefits related to insurance, lifestyles
and align employees towards our corporate social
and personal development that work for employees at any
responsibility agenda.
stage of life. We believe in giving our employees the freedom
of choice and the security that they need with the help of We are committed to keeping employees safe by preventing
this programme. dangerous incidents in and around the workplace.
Wellness In educating our employees, we also empower them to
promote safer and healthier lives in their wider communities.
Abbott’s aim is to make it easy for employees to live a healthy We strive to maintain the highest standards of Environment,
lifestyle and achieve optimal health. Thus, we focus on all Health and Safety (EHS) practices.
Wellness across the four core areas of –
The Company has clear, consistent global policies and
• Physical Wellness : Health check-ups, on-site doctor,
standards regarding how we manage employee health, safety
vaccination drives and exercise challenges are
and productivity while also protecting the environment.
programmes that are provided for employees to focus
on the physical health. The Abbott Shop is an online The Company’s manufacturing plant and commercial sites
portal that gives employees access to the Company’s adhere to auditing and reporting requirements, which serve
medicines and nutrition products in one online location. as a baseline for health and safety performance worldwide.
91
1. Please indicate the total number of employees? ownership and efficacy. We also collaborate with
3,551 governments, international healthcare organizations,
community-focused NGOs, consumers and our own
2. Please indicate the total number of employees hired employees to leverage the best resources available to us.
on temporary/hired on contractual/casual basis?
This partnership-based approach to improving access to
During the year 7 Contractual employees were
healthcare helps expand the geographical reach of healthcare
hired. As on March 31, 2020, 84 employees were
products, advance understanding of emerging products
contractual employees.
and treatments, and empowers people through education,
3. Please indicate the number of permanent information, and inspiration.
women employees?
1.
Has the Company mapped its internal and
160 external stakeholders?
4. Please indicate the number of permanent employees Yes
with disabilities?
2.
Out of the above, has the Company identified the
The Company does not maintain any separate
disadvantaged, vulnerable and marginalized stake
information pertaining to employees with disabilities.
holders?
5. Do you have an employee association that is

Yes. The Company has identified and given a special
recognised by the management?
focus to disadvantaged, vulnerable and marginalized
Yes stakeholders through various initiatives.
6. What percentage of your permanent employees are 3.
Are there any special initiatives taken by the
members of this recognised employee association? Company to engage with the disadvantaged,
6
% vulnerable and marginalized stakeholders? - If so,
provide details thereof.
7. Please indicate the number of complaints related
to child labour, forced labour, involuntary labour, The Company has implemented several initiatives to
sexual harassment in the last financial year are engage disadvantaged, vulnerable, and marginalized
pending, as on the end of the financial year? stakeholders. One such initiative is the Company’s
1 complaint was received during the year under Malaria Elimination Programme, through which the
the Prevention of Sexual Harassment Act and was Company is supporting ‘Malaria No More’, a malaria
appropriately closed. elimination programme in the State of Odisha which
is aligned with the Prime Minister’s goal of malaria-
8. What percentage of your above-mentioned free India by the year 2030. With one million Rapid
employees were given safety and skill upgradation Diagnostic Tests (RDTs), technical expertise, and a cash
training in the last year? grant, the Company has helped strengthen Odisha’s
All new joinees are imparted training as a part of their malaria detection and surveillance system by effective
induction programme. data collection and monitoring methods. Survey results
show that the Malaria No More programme has enabled
Principle 4 : Businesses should respect the interests the state to achieve a 90% reduction in cases in the last
of, and be responsive towards all stakeholders, five years. We have now set up a multi-sectoral Malaria
especially those who are disadvantaged, vulnerable Action Coalition, which will help take the successful
and marginalized Odisha model to other affected states in the country.
The Company is committed to supporting the disadvantaged,
The Company has partnered with SEWA (Self-
marginalized and vulnerable populations, and in developing Employed Women’s Association), the world’s largest and
solutions to social challenges facing them that are both oldest trade union of women working in the informal
sustainable and scalable. While doing this, our fundamental sector. Through this engagement, Abbott has launched
goal is to empower communities for the highest order of a comprehensive, community-based healthcare

programme by establishing two clinics in Ahmedabad • Encouraging open communication between the
and Mehsana districts of Gujarat, which are focused on management and employees.
bringing quality and affordable primary, acute and Non-
It is the Company’s philosophy to maintain an open working
Communicable Diseases (NCDs) care to low income
environment that allows free exchange of information
populations. The programme also drives a proactive
through communication channels across the organization.
community outreach through Master Health Trainers,
All employees are allowed to share their concerns, problems,
who help build community awareness around the
questions or suggestions without any fear of retaliation, and
programme and NCDs, and facilitate access to screening
it is vital that these concerns are discussed and resolved in
and consultation.
a timely manner.
The Company strives to improve healthcare, build
awareness and improve access to diagnostics through The Company has policies on Ethics and Compliance and
education and health clinics. These health clinics on Prohibition of Harassment at Workplace.
address the need for prevention, early detection, and 1. Does the policy of the Company on human rights
management of diseases as part of the Company’s cover only the Company or extend to the Group/
commitment to doing business responsibly Suppliers/Contractors/NGOs/Others?
and sustainably.
The Company’s Code of Business Conduct covers the

The Company works relentlessly towards health guidelines on human rights and it is applicable to all
education, reaching out to the public at large through stakeholders of the Company.
various channels. These initiatives are part of the
Company’s unflinching dedication to reaching millions 2.
How many stakeholder complaints have been
of patients who have little awareness and information. received in the past financial year and what per cent
was satisfactorily resolved by the management?
Principle 5 : Businesses should respect and promote
human rights During the year, one complaint was received under the
Sexual Harassment and the same was disposed off.
The Company believes in the dignity of every human being
and respects individual rights. These principles are reflected Principle 6 : Businesses should respect, protect, and
in the Company’s mission and core values, and are reinforced make efforts to restore the environment
through our global employment, ethics and procurement
policies which also apply to suppliers. We contribute to the We are committed to safeguarding the environment
fulfilment of human rights through compliance with laws for everyone by reducing the environmental impacts
and regulations wherever we operate, as well as through our of our business. This commitment shapes the way we
policies and programmes. Our global guidelines include : source, manufacture, design and distribute our products.
A sustainable environment is essential for better health,
• Providing a healthy and safe working environment;
stronger communities and more fulfilling lives.
• Complying with child labor laws;
Our long-term Environment, Health and Safety (EHS)
• Promoting workforce diversity; not discriminating strategy aims to protect our people, our planet and our values.
against any employee for reasons such as race, religion, We achieve this by delivering across a number of core areas
color, age, gender, ethnicity, disability, marital status to reduce and mitigate environmental risks; deliver cost
and sexual orientation, in addition to any other status
efficiency and ensure business continuity.
protected by local law;
We have set clear environmental goals and made rapid
• Not tolerating harassment or harsh or inhumane
progress in using energy and water resources more
treatment in the workplace;
efficiently while minimizing waste. We support projects that
• Protecting individual privacy; generate energy from renewable sources at work and in our
• Providing compensation and benefits that are communities. We seek ways to reduce the environmental
competitive and comply with applicable laws for impact of our operations, such as through waste reduction,
minimum wages, overtime and mandated benefits; recycling and other activities to mitigate environmental
93
risks. We adhere to the environmental laws and regulations 3.

Does the Company identify and assess potential
applicable to our operations. Our Goa plant has implemented environmental risks? Y/N
innovative initiatives to reduce emissions, water use and Yes, there are internal standards based on ISO 14001/
waste and to make product packaging more sustainable. OHSAS 45001. Environmental risk assessments are
The Goa site received the internal prestigious Abbott Global updated and reviewed regularly. There is a process for
EHS Excellence Award for its waste reduction initiatives. internal risk management audit and CAPA (Corrective
And Prevention Actions) which also cover the potential
We continuously educate, create awareness and monitor
the EHS performance of our warehousing partners. During environmental risks. We have tied up with external
the year, eight warehouse partners were assessed for EHS agencies to provide EHS regulatory intelligence. The
performance and the learnings were shared with all the other Corporate EHS team conducts independent on-site
locations for improvement and safety. reviews and potential environmental risks are shared
with the top management for attention. No major
As a commitment under the Plastic Waste Management
environmental risks were identified during the year by
Rules, we have collected approximately 1400 MT of post-
the Internal Risk Management audits which happened
consumer waste through our partners under extended
at our plant, warehousing partners and selected third
producer responsibility. This waste is recycled or disposed of
party manufacturing partners.
in a scientific way.
1. Does the policy relating to Principle 6 cover only the 4. Does the Company have any project related to Clean
Company or extend to the Group/Joint Ventures/ Development Mechanism? If so, provide details
Suppliers/Contractors/NGOs/others? thereof, in about 50 words or so. Also, if yes, whether
The EHS policy covers the Company and extended to any environmental compliance report is filed?
the Contractors. No projects are undertaken specifically under Clean
2. Does the Company have strategies, initiatives to Development Mechanism. However, there is emphasis
address global environmental issues such as climate on usage of clean energy (like Biomass at Goa plant).
change, global warming, etc.? If yes, please give CO2 emission reduction opportunities are formally
hyperlink for webpage etc. assessed, and emission reduction is part of annual site
Yes. The Company is committed to environmental targets and key performance indicators. During the year,
protection and has identified three environmental the Goa plant over achieved its target of environmental
priorities. In each one, we have set world-wide ambitious footprint reduction.
goals for reducing environmental impact by 2020, 5. Has the Company undertaken any other initiative
compared to 2010 levels and adjusted for sales.
on clean technology, energy efficiency, renewable
- Climate change : 40% reduction in carbon dioxide energy, etc.? If yes, please give hyperlink for web
equivalent (CO2) emissions (i.e., greenhouse gas page etc.
[GHG] emissions) associated with our business
operations and the electricity we purchase Yes. The Company is committed to environmental
(i.e., Scope 1 and 2 emissions) protection. Vermicomposting and rainwater harvesting
are being practiced. The Goa site is Zero Waste to
- Water usage : 30% reduction in total water intake
Landfill (ZWL) certified with more than 98% of the
- Waste management : 50% reduction in total waste
waste either being recycled or co-processed off-site for
The Company is already working on defining the energy recovery. During the year, the plant achieved
2030 science-based environmental targets, with a environment footprint of 40,722 MT, a reduction of 15%
focus on improving the environmental aspects in the vis-a-vis the targets. The energy efficiency initiatives
communities we operate. include optimization of air compressor efficiency for
As we grow our business, the measures that we take energy saving, replacement of all the street light fixtures
to reduce our environmental impact in this country with energy efficient LED fixtures along with variable
will play a vital role in helping us achieve these activation timings for energy saving, installation of
world-wide goals. Variable Frequency Drives (VFD) for surface aerator in

Effluent Treatment Plants (ETP) for optimum energy 1. Is your Company a member of any trade and chamber
usage and new process design developed by adding new or association? If yes, name only those major ones
energy efficient blower directly to filter press, as a result that your business deals with.
of which sludge drying per lot is reduced from three to Yes. The Company is a member of Federation of Indian
two days, thus saving 108 KWH per drying cycle. Chambers of Commerce & Industries (FICCI).
Water conservation initiatives include installation of 2.
Have you advocated/lobbied through above
new vacuum pump with Hydropack system, which associations for the advancement or improvement
cools and circulates water for vacuum pump operation, of public good? If yes specify the broad areas (drop
resulting in water saving of 2 kl/day. Installation of box : Governance and Administration, Economic
steam sanitizer for the washing of in-process container Reforms, Inclusive Development Policies, Energy
to reduce water consumption for container washing, Security, Water, Food Security, Sustainable
free flowing taps fitted with shower orifice that reduced Business Principles, Others)
water consumption by 25% in the washrooms and use
of treated water from waste water treatment plant
Yes. Broad areas are : Pricing implementation
in cooling towers for top up. As much as 1,379 kl of issues; OTC Guidelines, Taxation policies and Drug
rainwater was harvested at our plant. Regulatory matters.
6. Are the emissions/waste generated by the Company Principle 8 : Businesses should support inclusive
within the permissible limits given by CPCB/SPCB growth and equitable development
for the financial year being reported?
We aim to empower communities to take control of their
All the emissions/waste generated by the Company living environments for fuller, healthier lives. The Company’s
is within the permissible limits given by the Central CSR policy is focused on fostering economic, environmental
Pollution Control Board/State Pollution Control Board and social well-being.
for the financial year being reported. The sampling
is carried out and samples tested by independent We focus our philanthropic investments in areas where
government-approved laboratories on a regular basis as we can :
defined in the ‘Consent to operate’. • contribute with our business and our core capabilities
7. Number of show cause/legal notices received from • leverage our employees’ time and skills, and
CPCB/SPCB which are pending (i.e. not resolved to • bring on partners that can help us build sustainable and
satisfaction) as on end of Financial Year? scalable solutions
No show cause/legal notices received from CPCB/ We always start by listening to the needs of the people and to
SPCB are pending. the challenges facing sustainable solutions. We have worked
with this approach to identify several different focus areas
Principle 7 : Businesses, when engaged in advocating
for our philanthropic programmes. In each of these areas, we
for public and regulatory policy, should do so in a
partner with organizations that have the skills, knowledge,
responsible manner
and resources to complement our efforts. We are committed
The Company believes in a level playing field for all and to measuring the impact of our programmes so that we can
advocates fair and balanced policy decisions that are drive change sustainably and demonstrate scale.
beneficial for the patients and for the pharmaceutical
industry in India. 1. Does the Company have specified programmes/
initiatives/ projects in pursuit of the policy related
The Company is a member of industry bodies. The Company
to Principle 8? If yes, details thereof.
works with these associations regularly and actively and
submits views through them, when asked by the policy Health Clinics
makers/regulators on the existing or new policies pertaining Access to essential healthcare services and information
to the pharmaceutical sector. is an ever-increasing challenge for many in India.
The Company endorses inclusive policies and sustainable The Company has several programmes to address
development through its participation in CSR forums this. Through one such effort, the Company supports
and discussions. qualified doctors and healthcare professionals to expand
95
disease diagnosis and access to care. This includes 2. Are the programmes/projects undertaken through
programmes to raise awareness and improve care for in-house team/own foundation/external NGO/
epilepsy and liver diseases. government structures/any other organization?

Quality and Affordable Healthcare Delivery Health Clinics - Programmes Direct Implementation
Programme with SEWA to expand Awareness and
In partnership with SEWA (Self-Employed Women’s Access to Healthcare
Association), the Company is working on improving SEWA - Creating a Direct Implementation
access to quality and affordable healthcare among low Sustainable Healthcare
income populations by creating resilient systems and Delivery Model
processes for prevention, diagnosis and treatment of Malaria Elimination Direct Implementation
Non-Communicable Diseases (NCDs). This programme Programme with
not only helps meet the health needs of low-income Malaria No More
populations, but also creates employment and
entrepreneurship opportunities for SEWA members. In 3.
Have you done any impact assessment of your
2019-20, we launched two community-based clinics that initiative?
provide primary, acute and NCD care services across We are committed to measuring the impact of our
two districts in Gujarat. The clinics are supported by programmes so that we can drive change sustainably and
a proactive community outreach led by Master Health apply the lessons in helping other communities as well.
trainers who have been trained on various facets of
NCD prevention, diagnosis and treatment. These Master All our initiatives have a needs assessment, a mid-line
Health trainers engage SEWA families and create review and an end-line evaluation. As all the three
awareness on programme services and their benefits, programmes are currently running, we are conducting
with a special focus on its NCD component. The Company reviews to ensure meeting of timely milestones.
is strengthening the programme through partnerships Impact assessments will be conducted at the end of
with reliable healthcare service providers that support the programmes.
the programme across the continuum of care.
4.
What is your Company’s direct contribution to
Malaria No More community development projects and the details of
With a population of nearly 42 Million people, Odisha the projects undertaken)?
accounted for about 40% of India’s malaria burden and
Community Development Projects Contribution
one-third of South-east Asia’s malaria burden in 2016. (` in Lakhs)
In support of India’s 2015 commitment to be malaria-
Improving Access to Healthcare 4,42
free by 2030, the government of Odisha had prioritized
through Health Clinics
malaria control and elimination. The Company has
supported the partnership between the government of Quality and Affordable Healthcare 3,51
Odisha and Malaria No More by providing technology, Delivery Programme with SEWA
expertise, and funding support to advance efforts to end Malaria Elimination Programme with 3,44
malaria in the state. Malaria No More
In support of this collaboration the Company has
5. Have you taken steps to ensure that this community
supplied one million Rapid Diagnostic Tests (RDTs)
development initiative is successfully adopted by
and technical expertise to strengthen Odisha’s malaria
the community? Please explain in 50 words, or so.
detection and surveillance system. In addition to these,
the Company has provided cash grants to Malaria No For all the above projects, we have aimed at embedding
More to back its work with the Odisha government sustainability at the core of our engagement with
towards a comprehensive state malaria elimination beneficiaries. By engaging with the community members
strategy that has seen a sustained decline in the number upfront on planning and implementation and then
of malaria cases in Odisha in the last few years. handholding them through continuous training, and

monitoring of the various interventions, we are ensuring 2. Does the Company display product information on
that communities not only adopt our initiatives but also the product label, over and above what is mandated
embrace the benefits that they experience as a result. as per local laws?
List of -
Improving access to healthcare
Yes. The Company displays relevant information
activities through Health Clinics on product labels in accordance with applicable
in which -
Quality and Affordable Healthcare statutory requirements.
expenditure in Delivery Programme with SEWA
CSR has been - Malaria Elimination Programme 3. Is there any case filed/pending by any stakeholder
incurred : with Malaria No More against the Company regarding unfair trade
practices, irresponsible advertising and/or anti-
Principle 9 : Businesses should engage with and competitive behavior during the last five years and
provide value to their customers and consumers in pending as on end of financial year? If so, provide
a responsible manner details thereof.
We prioritize the health and well-being of our patients and A complaint was filed against the Company for the
consumers. We are committed to working with healthcare claims made under its TV commercial with the
professionals to provide them with timely and accurate Advertising Standards Council of India (“ASCI”),
information, to assist them in making decisions, and providing a voluntary self-regulation council. The Company
advice to their patients.
submitted its response along with detailed explanations
Our statements about our products, in all materials and and technical data. In review, however, ASCI upheld its
communications, are balanced and truthful and consistent original order.
with the approved label.
4. Did your Company carry out any consumer survey/
In promoting our products, we provide information that is consumer satisfaction trends?
consistent with scientific evidence, leading medical practice,
Yes
and the approved product labelling requirement.
For and on behalf of the Board
1. What percentage of customer complaints/consumer
cases are pending as on the end of financial year?
615 complaints (medical + non-medical) were received Munir Shaikh Rajiv Sonalker
by the Company and responded to as per Company Mumbai Chairman CFO and Whole-time Director
policies/procedures until March 31, 2020. August 7, 2020 DIN : 00096273 DIN : 07900178
97
CORPORATE GOVERNANCE REPORT
REPORT ON CORPORATE GOVERNANCE

COMPANY’S PHILOSOPHY ON CORPORATE GOVERNANCE
The Company’s philosophy on Corporate Governance is to conduct its business in a manner, which is ethical and transparent
with all the stakeholders of the Company, including members, creditors and employees. The Company operates in compliance
with all regulatory and policy requirements as well as industry ethical guidelines. The Company also has strict guiding
principles laid out and communicated through its Code of Business Conduct, which is subject to regular audits to ensure that
controls and compliances are maintained at a high standard. The Company’s philosophy on Corporate Governance is, thus,
concerned with the ethics, values and morals of the Company and its directors, who are expected to act in the best interests of
the Company and remain accountable to members and other beneficiaries for their actions.
BOARD OF DIRECTORS
a) As on the date of this Report, the Board comprises 8 Directors including 2 Executive and 6 Non-Executive Directors, of
which 3 are Independent.
b) The composition of the Board of Directors, their attendance at the Board Meetings held during the year under review and
at the last Annual General Meeting along with the number of directorships and memberships held in various committees
in other companies, as on the date of this Report are given in the table below :
Name of the Director Category of Total Attendance at Number of Number of
Directorship Board Board Annual Directorships Committee
Meetings Meetings General in other positions
held in held in Meeting companies1 held in other
2019-20 2019-20 (August 22, 2019) companies2
Mr Munir Shaikh Non-Executive 5 5# Yes 2 NIL
Chairman of the Board Director
Mr Anil Joseph Managing Director NA NA NA NIL NIL
(appointed as Managing Director
effective July 1, 2020)
Ms Anisha Motwani Non-Executive, 5 5 Yes 8 62
Independent Director
Mr Sudarshan Jain Non-Executive, 5 5 Yes 2 NIL
(appointed effective April 1, 2019) Independent Director
Ms Shalini Kamath Non-Executive, 5 2 NA 3 12
(appointed effective October 29, 2019) Independent Director
Mr Ambati Venu Non-Executive 5 5 Yes NIL NIL
(resigned as Managing Director effective Director
February 29, 2020 and appointed as
Non-Executive, Director effective
March 1, 2020)
Mr Kaiyomarz Marfatia Non-Executive 5 5 Yes NIL NIL
Director
Mr Rajiv Sonalker Executive Director 5 5 Yes NIL NIL
Whole-time Director
Mr Mark Murphy II Non-Executive 5 1 No NIL NIL
(resigned effective June 30, 2020) Director
Mr Krishna Mohan Sahni Non-Executive, 5 3 Yes NA NA
(retired effective October 28, 2019) Independent Director
Mr Jawed Zia Non-Executive 5 3 Yes NA NA
(resigned effective February 29, 2020) Director
#
Including 1 Meeting attended via video-conferencing.
1. Includes directorships in private and foreign companies and alternate directorship. However, it does not include directorships in
companies registered under Section 8 of the Companies Act, 2013.
2. Includes Memberships of Audit Committee and Stakeholders Relationship Committee, the details of which are given below :
- Ms Anisha Motwani holds the Membership of Audit Committee in Prataap Snacks Limited, Somany Home Innovation Limited,
India Shelter Finance Corporation Limited and Star Health and Allied Insurance Company Limited; Membership of Stakeholders
Relationship Committee in Prataap Snacks Limited and Angel Broking Limited.
- Ms Shalini Kamath holds the Membership of Audit Committee in Borosil Renewables Limited.

c) During the year under review, 5 Board Meetings were h) None of the Independent Directors of the Company
held on the following dates : serve as Independent Director in more than seven listed
companies or as whole-time director in any
May 27, 2019; August 8, 2019; August 22, 2019; November
listed company.
12, 2019 and February 7, 2020.
i) All material information was circulated to the Directors
The option for attending Board/Committee Meetings
before the meeting or placed at the meeting, including
via audio-visual means except for the items which are
minimum information required to be made available
specifically excluded for the same is provided
to the Board as prescribed under Part A of Schedule II
to the Directors.
of sub Regulation 7 of Regulation 17 of the Securities
d) Details of the Directors seeking appointment/ and Exchange Board of India (Listing Obligations and
re-appointment at the forthcoming Annual General Disclosure Requirements) Regulations, 2015.
Meeting as required under Regulation 36(3) of the
j) In the opinion of the Board and Nomination and
Securities and Exchange Board of India (Listing
Remuneration Committee, the Independent Directors
Obligations and Disclosure Requirements) Regulations,
fulfill the criteria of Independence as specified in the
2015 and Secretarial Standards issued by the Institute of
Companies Act, 2013 and Rules made thereunder and
Company Secretaries of India are annexed to the Notice
the Securities and Exchange Board of India (Listing
convening the Annual General Meeting, which forms
part of the Annual Report.
2015, and are independent of the Management.
e) There is no inter-se relationship between any
BOARD COMPETENCIES/EXPERTISE
of the Directors.
The Board has different sets of skills and expertise, ideal
f) Mr Sudarshan Jain along with his relatives, holds 250
mix of analytical, strategic and leadership skills that is
shares in the Company as on March 31, 2020.
required for its oversight role, meet the governance and
g) As required under Regulation 30 of the Securities and strategic needs. The Board constantly focuses on raising of
Exchange Board of India (Listing Obligations and the governance standards of the Company. The Directors
Disclosure Requirements) Regulations, 2015, the have a broad-based business knowledge, relationships,
Company has, from time to time, notified the BSE prominence and excellent reputations in their primary fields
Limited regarding all appointments/re-appointments/ of endeavor and are competent to bring value additions and
cessations of Directors during the year under review. different perspectives.
Board Competencies/Expertise
Name Skills/Competencies/Expertise/ Other Directorships
Mr Munir Shaikh Mr Shaikh has held several management and leadership positions in different geographies across
Chairman various businesses. He possesses vast knowledge of the industry and is a consummate team player
with an entrepreneurial flair. He has an extensive leadership and industry experience, including
a deep knowledge and understanding of the Company’s business operations, strategies and the
business environment in which the Company operates.
He has strong expertise in the areas of Finance, Marketing and Business Development.
He is Director in Abbott Laboratories (Pakistan) Limited and Sunshine Holdings PLC, Sri Lanka.
Mr Anil Joseph Mr Joseph has diversified experience mainly in driving revenue and income growth; business
Managing Director turnaround and managing emerging markets. He has exposure in Sales & Marketing and General
(effective July 1, 2020) Management. Besides, having managed both Developed and Emerging Markets, he holds exposure in/
different countries and market types.
He holds expertise in Sales & Marketing and Strategy Development in managing growth and sustaining
success.
99
Board Competencies/Expertise
Name Skills/Competencies/Expertise/ Other Directorships
Ms Anisha Motwani Ms Motwani is a Brand and Innovation expert with varied experience in marketing across diverse
industries. As a marketer and creator of multiple consumer-oriented strategies, she takes a very strong
interest in the topic of the Indian consumer – buying behavior, connect points, impact of the digital
revolution, new segments and sub-segments etc.
She has been in forefront of behavior change projects such as Swachh Bharat and Clean Ganga mission.
She is an active contributor to various corporate and industry boards/association.
She has immense knowledge and expertise on digital marketing and brand building, corporate
communications, consumer research & analytics and creative excellence. She provides thought
leadership on emerging digital business models and technologies to shape the digital future of the
enterprise.
She is Independent Director on the Boards of Welspun India Limited; Prataap Snacks Limited
and Somany Home Innovation Limited and Director on the Boards of Angel Broking Limited;
India Shelter Finance Corporation Limited; L&T Investment Management Limited; Star Health and
Allied Insurance Company Limited and Dvara Kshetriya Gramin Financial Services Private Limited.
Mr Sudarshan Jain Mr Jain is a veteran in the healthcare business. He has rich business experience in strategic
management, corporate affairs brand building and overall business operations in healthcare companies.
His experience covers Pharmaceutical, OTC, Hospital, Diagnostic and Nutrition businesses.
He has played active role in shaping the healthcare policy and improving access to healthcare in India
and has wide industry knowledge and extensive expertise in building market leading brands.
He is a Director on the Boards of ZCL Chemicals Limited and Healthium Medtech Private Limited.
Ms Shalini Kamath Ms Kamath holds expertise in three distinct fields - Human Resources, Business Development and
Social & Community Development and across two continents - India and Africa.
She also has extensive experience in building strong corporate brands, both externally and internally
and has handled tripartite partnership projects related to community-oriented income generation
programs.
She is also a certified and practicing “CEO & Leadership Coach’’.
She is Independent Director on the Boards of Graphite India Limited; Borosil Renewables Limited and
Ambit Finvest Private Limited.
Mr Ambati Venu Mr Ambati holds extensive experience in consumer goods, OTC and pharmaceutical businesses.
Having worked in various regions, one of the strongest assets is his ability to excel within diverse
socio-cultural environments.
He holds strong business acumen, strategic leadership, the ability honed in both developed and
emerging markets.
Mr Kaiyomarz Marfatia Mr Marfatia holds strong legal acumen and immense experience in corporate compliance functions,
litigation, industrial licensing, foreign collaborations, technology transfer arrangements, distribution
arrangements and IPR matters, among others, in Pharmaceutical/Healthcare and Engineering industries.
He has played a vital role in the acquisition of various brands and businesses and handled cross
functional projects such as manufacturing reconfiguration/optimization and corporate restructuring.
Mr Rajiv Sonalker Mr Sonalker has extensive financial experience in the Pharmaceutical, FMCG and Engineering industries
in India & Europe.
Besides in-depth knowledge about the Company, he has strong technical & analytical skills, and expertise
for leading the Corporate Finance function, including Risk & Internal Control. He has played a crucial
role in several projects such as the merger, acquisitions, integration & corporate restructuring. He was
instrumental in driving many automation & digitization projects critical for the Company.

FAMILIARISATION PROGRAMS FOR The composition of the Audit Committee, category of its
INDEPENDENT DIRECTORS Members, their attendance at the Committee Meetings held
during the year under review is given below :
As a part of Induction and Continuing Education Program
for Independent Directors, periodic presentations are Sr. Name of the Category Number of Meetings
made by the Managing Director/Commercial Directors/ No. Member 2019-20
Function Heads at the Board Meetings to apprise the
Held Attended
Directors with the Company’s business strategies, long term
plans, budgets, operations and performance, relevant legal/ 1. Ms Anisha Independent 4 4
regulatory updates in the laws and regulations applicable to Motwani Director
the Company. In addition, these presentations also provide Chairperson
insights into various growth opportunities for the Company,
operational and environmental challenges associated 2. Mr Munir Non-Executive 4 4
Shaikh Director (attended
with the Company’s business operations, products,
1 meeting
Management’s risk mitigation plans, human resources and
via video
CSR updates, etc.
conferencing)
The Directors are regularly briefed on the Company’s policies
and procedures, with regard to distribution channels, business 3. Mr Sudarshan Independent 4 4
Jain Director
model, cash and treasury management, accounting systems
and internal financial controls, etc. Plant visit is arranged 4. Ms Shalini Independent 4 2
for the Directors to acquaint them with the manufacturing Kamath1 Director
process and the products manufactured in-house.
5. Mr Krishna Independent 4 2
The Company also arranges various knowledge dissemination Mohan Sahni2 Director
sessions by external faculties and shares various industry
reports to keep the Directors updated with the current 1. appointed as Member effective October 29, 2019.
happenings, relevant news and legal/regulatory changes. 2. ceased to be Member effective close of business hours on
October 28, 2019.
Details of the programs conducted by the Company for the
Ms Krupa Anandpara, Company Secretary is the Secretary
financial year 2019-20 are available on the website of the Company
of the Committee.
at https ://www.abbott.co.in/investor-relations/policies.html
Role :
MEETING OF INDEPENDENT DIRECTORS The role of the Committee includes :
In terms of requirements of the Companies Act, 2013, Rules • oversight of the Company’s financial reporting process
framed thereunder and Regulation 25(3) of the Securities and and the disclosure of its financial information to ensure
Exchange Board of India (Listing Obligations and Disclosure that the financial statements are correct,
Requirements) Regulations, 2015, 2 meetings of Independent sufficient and credible;
Directors were held on May 27, 2019 and August 8, 2019
during the financial year 2019-20. The said Meetings were • recommendation for appointment, remuneration and
attended by all the Independent Directors. terms of appointment of auditors of the Company;
• approval of payment to statutory auditors for any other
AUDIT COMMITTEE services rendered by them;
The composition, role, terms of reference as well as powers of • reviewing, with the management, the annual financial
the Audit Committee of the Company are in compliance with statements and auditor’s report thereon before
the provisions of Section 177 of the Companies Act, 2013 and submission to the Board for approval, with
Regulation 18 of the Securities and Exchange Board of particular reference to :
India (Listing Obligations and Disclosure Requirements)
Regulations, 2015. All the members of the Audit Committee a. matters required to be included in the Directors’
are financially literate. Responsibility Statement to be included in the
Board’s Report in terms of clause (c) of sub-section 3
Composition : of Section 134 of the Companies Act, 2013;
The Committee comprises 3 Independent Directors and 1 b. changes, if any, in accounting policies and practices
Non-Executive Director as on the date of this Report. and reasons for the same;
101
c. major accounting entries involving estimates based • approval of appointment of Chief Financial Officer after
on the exercise of judgment by management; assessing the qualifications, experience and background,
d. significant adjustments made in the financial etc, of the candidate;
statements arising out of audit findings;
• reviewing the functioning of the Vigil Mechanism/
e. compliance with listing and other legal Whistle Blower Mechanism;
requirements relating to the financial statements;
• carrying out any other functions as may be prescribed
f. disclosure of any related party transactions;
under the Companies Act, 2013, Rules framed
g. modified opinion(s) in the draft audit report. thereunder and Regulation 18 of the Securities and
• reviewing, with the management, the quarterly Exchange Board of India (Listing Obligations and
financial statements before submission to the Disclosure Requirements) Regulations, 2015 or as may
Board for approval; be delegated by the Board, from time to time.
• reviewing and monitoring the auditor’s independence The Committee also reviews various information
and performance and effectiveness of audit process;
prescribed under Part C of Schedule II as referred in
• approval or any subsequent modification of transactions Regulation 18(3) of the Securities and Exchange Board of
of the Company with related parties; India (Listing Obligations and Disclosure Requirements)
• scrutiny of inter-corporate loans and investments; Regulations, 2015.
• valuation of undertakings or assets of the Company, Meetings :
wherever it is necessary;
During the year under review, the Committee met 4 times on
• evaluation of internal financial controls and risk
the following dates :
management systems;
• monitoring the end use of funds raised through public May 27, 2019; August 8, 2019; November 12, 2019 and
offers and related matters; February 7, 2020.
• reviewing with the management, performance of The Chief Financial Officer remains present at all the Audit
statutory and internal auditors, adequacy of the internal Committee Meetings. All the meetings are attended by the
control systems; Statutory Auditors. Internal and Cost Auditors are invited to
• reviewing the adequacy of internal audit function, if the Meetings, as and when required.
any, including the structure of the internal audit
department, staffing and seniority of the official heading Ms Anisha Motwani, Chairperson of the Audit Committee
the department, reporting structure, coverage and attended the Annual General Meeting held on August 22,
frequency of internal audit; 2019 in compliance with the requirements of Regulation
18(1)(d) of the Securities and Exchange Board of India
• discussion with internal auditors of any significant
findings and follow up thereon; (Listing Obligations and Disclosure Requirements)
Regulations, 2015.
• reviewing the findings of any internal investigations by
the internal auditors into matters where there is NOMINATION AND REMUNERATION COMMITTEE
suspected fraud or irregularity or a failure of internal
control systems of a material nature and reporting the The composition, role, terms of reference as well as powers of
matter to the Board; the Nomination and Remuneration Committee of the
• discussion with statutory auditors before the audit Company are in compliance with the provisions of
commences, about the nature and scope of audit as Section 178 of the Companies Act, 2013 and Regulation 19 of
well as post-audit discussion to ascertain any the Securities and Exchange Board of India (Listing
areas of concern; Obligations and Disclosure Requirements) Regulations, 2015.
• to look into the reasons for substantial defaults in Composition :
the payment to the depositors, debenture holders,
members (in case of non-payment of declared The Committee comprises 2 Independent Directors and 2
dividends) and creditors; Non-Executive Directors as on the date of this Report.

The composition of the Nomination and Remuneration • to consider any other matters as may be
Committee, category of its Members and their attendance at delegated by the Board.
the Committee Meetings held during the year under review
The role of the Committee in relation to Remuneration
is given below :
matters include :
Sr. Name of the Category Number of Meetings
No. Member 2019-20 • recommend to the Board a policy, relating to the
Held Attended remuneration for the Directors, Key Managerial
1. Mr Sudarshan Independent 2 1 Personnel and other employees. The Committee shall,
Jain Director while formulating the policy ensure that :
Chairman
- the level and composition of remuneration is
2. Mr Munir Non-Executive 2 2
reasonable and sufficient to attract, retain and
Shaikh Director (attended
motivate Directors of the quality, required to run
1 meeting
the Company successfully;
via video
conferencing) - relationship of remuneration to performance is
3. Ms Anisha Independent 2 2 clear and meets appropriate performance
Motwani Director benchmarks; and
4. Mr Ambati Non-Executive 2 NA
- remuneration to Directors, Key Managerial
Venu1 Director
Personnel and Senior Management involves a
5. Mr Jawed Zia2 Non-Executive 2 2 balance between fixed and incentive pay reflecting
Director short and long-term performance objectives
1. appointed as Member effective April 27, 2020. appropriate to the working of the
2. ceased to be Member effective close of business hours on Company and its goals.
February 29, 2020.
• recommend to the Board all remuneration, in whatever
Ms Krupa Anandpara, Company Secretary, is the Secretary form, payable to the Senior Management;
of the Committee.
• to consider any other matters as may be
Role : delegated by the Board.
The role of the Committee in relation to Nomination matters Meetings :
include :
• formulating criteria for identifying suitable candidates the following dates :
for Directors and Senior Management;
May 27, 2019 and October 22, 2019.
• identify persons who are qualified to become Directors
and appointed as the Senior Management in accordance Mr Sudarshan Jain, Chairman of the Committee attended
with criteria laid down and recommend to the Board the Annual General Meeting of the Company to answer the
their appointment and removal; Shareholders’ queries in compliance with the requirements of
Regulation 19(3) of the Securities and Exchange Board of
• formulating the criteria for determining the India (Listing Obligations and Disclosure Requirements)
qualifications, positive attributes and Regulations, 2015.
independence of a Director;
Performance Evaluation Criteria for Independent
• devising policy on the diversity of the Board; Directors :
• ensuring that there is an appropriate induction Performance Evaluation of Independent Directors is done by
programme in place for new Directors and reviewing the entire Board of Directors (except the Director whose
its effectiveness; evaluation is being done). The Board also evaluates if the
• formulating the criteria for evaluation of performance of Independent Directors fulfill the criteria of independence as
Board, its Committees and individual Directors and laid down in the Companies Act, 2013, Rules framed
review its implementation and compliance and whether thereunder and the Securities and Exchange Board of India
to extend or continue the term of appointment of the (Listing Obligations and Disclosure Requirements)
Independent Director on the basis of such assessment; Regulations, 2015.
103
Detailed mechanism and various criteria adopted for • review of measures taken for effective exercise of voting
evaluation of the Directors are provided in the Directors rights by shareholders;
Report. Please refer to disclosures on page no. 65.
• review of adherence to the service standards adopted by
STAKEHOLDERS RELATIONSHIP COMMITTEE the Company in respect of various services being
rendered by the Registrar and Share Transfer Agent;
The composition, role, terms of reference as well as powers of
the Stakeholders Relationship Committee of the Company • review of the various measures and initiatives taken by
are in compliance with the provisions of Section 178 of the the Company for reducing the quantum of unclaimed
Companies Act, 2013 and Regulation 20 of the Securities and dividends and ensuring timely receipt of dividend
Exchange Board of India (Listing Obligations and Disclosure warrants/annual reports/statutory notices by the
Requirements) Regulations, 2015.
shareholders of the Company.
Composition :
Meetings :
The Committee comprises 1 Independent Director and 2
Non-Executive Directors as on the date of this Report. During the year under review, the Committee met 4 times on
the following dates :
The composition of the Stakeholders Relationship Committee,
category of its Members and their attendance at the May 27, 2019; August 8, 2019; November 12, 2019 and
Committee Meetings held during the year under review February 7, 2020.
is given below :
A summary of complaints received and resolved by the
Sr. Name of the Category Number of Meetings Company to the satisfaction of the shareholders/investors
No. Member 2019-20 during the year under review, is given below :
Held Attended
Particulars Number
1. Mr Kaiyomarz Non-Executive 4 4
Marfatia Director Pending at the beginning of the year 1#
Chairman Received during the year 4#
2. Mr Ambati Non-Executive 4 4 Resolved during the year 5
Venu Director
Pending at the end of the year 0
3. Ms Shalini Independent 4 2
Kamath1 Director # pertains to letters received from the Securities and Exchange
Board of India (SCORES).
Mohan Sahni2 Director CORPORATE SOCIAL RESPONSIBILITY COMMITTEE
1. appointed as Member effective October 29, 2019. The composition, role, terms of reference as well as powers of
2. ceased to be a Member effective close of business hours on the Corporate Social Responsibility (“CSR”) Committee of
October 28, 2019. the Company are in compliance with the requirements of
Ms Krupa Anandpara, Company Secretary, is the Secretary of Section 135 of the Companies Act, 2013 and Companies
the Committee. She also acts as the Compliance and Nodal (Corporate Social Responsibility Policy) Rules, 2014.
Officer of the Company.
Composition :
Role :
The Committee comprises 1 Independent Director, 2 Non-
The role of the Committee includes : Executive Directors and 1 Executive Director, as on the date
• resolving the grievances of the shareholders including of this Report.
complaints related to transfer/transmission of shares,
non-receipt of annual report, non-receipt of declared The composition of the CSR Committee, category of its
dividends, issue of new/duplicate certificates, general Members and their attendance at the Committee Meetings
meetings, etc.; held during the year under review is given below :

Sr. Name of the Category Number of Meetings :

No. Member Meetings 2019-20
Held Attended the following dates :
1. Mr Munir Non-Executive 3 1
May 27, 2019; August 22, 2019 and November 12, 2019.
Shaikh1 Director
Chairman
RISK MANAGEMENT COMMITTEE
2. Mr Ambati Venu Non-Executive 3 3
Director The composition, role, terms of reference as well as powers of
Risk Management Committee of the Company are in
3. Ms Anisha Independent 3 3
compliance with the provisions of Regulation 21 of the
Motwani Director
Securities and Exchange Board of India (Listing Obligations
4. Mr Rajiv Whole-time 3 3 and Disclosure Requirements) Regulations, 2015.
Sonalker Director
Composition :
Mohan Sahni2 Director The Committee comprises 2 Independent Directors, 2 Non-
Executive Directors and 1 Executive Director as on the date
1. appointed as Chairman and Member effective October 29, 2019.
of this Report.
2. ceased to be Chairman and Member effective October 28, 2019.
The composition of the Risk Management Committee,
Ms Krupa Anandpara, Company Secretary, is the Secretary
category of its Members, their attendance at the Committee
of the Committee.
Meetings held during the year under review is given below :
Role :
Sr. Name of the Member Category Number of Meetings
The role of the Committee includes : No. 2019-20
Held Attended
• formulate and recommend for the acceptance of the
Board, the Corporate Social Responsibility Policy 1. Mr Ambati Venu Non-Executive 1 1
(“CSR Policy”) interalia, to include the CSR activities, Chairman Director
specify the modalities of execution, implementation 2. Mr Sudarshan Independent 1 1
schedules and recommend the same to the Jain1 Director
Board of Directors; 3. Ms Shalini Independent 1 1
Kamath1 Director
• identify the CSR projects/activities/programs to be 4. Mr Kaiyomarz Non-Executive 1 1
undertaken by the Company (“CSR activities”), in Marfatia Director
alignment with Company’s CSR Policy and Schedule VII 5. Mr Rajiv Sonalker Whole-time 1 1
of the Companies Act, 2013; Director
• review best practices in the key CSR areas by 6. Mr Krishna Independent 1 NA
appropriate internal/external analysis; Mohan Sahni2 Director
• recommend the amount of expenditure to be incurred 1. appointed as Member effective October 29, 2019.
on the CSR activities, for each financial year 2. ceased to be Member effective October 28, 2019.
of the Company; Ms. Krupa Anandpara, Company Secretary, is the Secretary
• devise suitable transparent Monitoring Mechanism for of the Committee.
monitoring progress/status of implementation of the Role :
CSR activities;
The role of the Committee includes :
• receive reports and review activities from executive and
• monitoring and implementing Risk Management Plans;
specialist groups managing CSR activities;
• ensure that the adequacy of the Company’s Risk
• monitor CSR Policy from time to time and revise the Management Framework is being assessed and that
same as and when needed; action is taken if it is inadequate;
• carry out such other functions, as may be prescribed by • reporting Risk Management activities and information,
the Companies Act, 2013 or CSR Rules or as may be including top risks and mitigation, to the Audit
delegated by the Board, from time to time. Committee and Board;
105
• understand the significant or high risks affecting During the year under review, Mr Munir Shaikh, Ms Anisha
Company and ensuring that processes to mitigate Motwani, Mr Sudarshan Jain, Ms Shalini Kamath and
them are effective; Mr Krishna Mohan Sahni were paid sitting fees amounting
to ` 10.50 Lakhs, ` 13.50 Lakhs, ` 12.00 Lakhs, ` 5.50 Lakhs
• reviewing and amending Risk Management Framework
and ` 9.00 Lakhs respectively, for attending Board and
from time to time;
various Committee Meetings.
• review of the Risk Management Plan by the Committee
None of the Non-Executive Directors had any material
and such other functions as it may deem fit and shall
pecuniary relationship or transactions with the Company.
specifically cover cyber security;
During the year, the Company availed professional services
• other functions as may be delegated by the Board from M/s Storm the Norm, in which Ms Anisha Motwani
from time to time. is a proprietor and remitted ` 2.16 Lakhs towards the same.
Considering the turnover of the Company as well as of
Meetings :
M/s Storm the Norm, this is not a material transaction.
During the year under review, the Committee met once on
Executive Directors
February 7, 2020.
The Executive Directors are paid remuneration in accordance
REMUNERATION OF DIRECTORS with the limits prescribed under the Companies Act, 2013
Non-Executive Directors and the Remuneration Policy of the Company. Such
Criteria of payment of sitting fees to Non-Executive Directors remuneration is considered and approved by the Nomination
are set out in the Remuneration Policy which is available on and Remuneration Committee, the Board of Directors and
the website of the Company. the Shareholders of the Company.
Details of remuneration paid to the Executive Directors for the financial year 2019-20 are as follows :
(` in Lakhs)
Terms of Agreement Mr Ambati Venu Mr Rajiv Sonalker
(resigned as Managing Director effective CFO and Whole-time Director
February 29, 2020)
Period of appointment 5 years 2 years

Date of appointment September 29, 2016 August 8, 2017
Salary and Other Allowances 2,78 1,85
Perquisites 3,31 83
Contribution to Provident Fund 12 11
Contribution to Superannuation Fund 1 -
Performance Linked Incentive 93 51
Notice Period Three Months Three Months
Severance Fees There is no separate provision for payment of severance fees.
Stock Option* NIL
*The Company does not have any Stock Option Plan for its employees. However, above Executive Directors are entitled to Stock Option of Abbott
Laboratories, USA under its “Incentive Stock Option Program” and are also eligible to purchase shares of Abbott Laboratories, USA, under its “Affiliate
Employee Stock Purchase Plan”, the perquisite value of which is included above.
The amount of performance bonus/commission payable to the Managing Director/Whole-time Director is calculated basis the
performance of the Company in general and the individual’s performance for the relevant financial year measured against
specific key result areas, which are aligned to the Company’s objectives and policies. The same is determined by the Board based
on the recommendation of the Nomination and Remuneration Committee in alignment with the Company policy.
The Company has entered into Agreements with Mr Ambati Venu (ceased as Managing Director on February 29, 2020),
Mr Rajiv Sonalker, Whole-time Director for a period from August 8, 2019 to June 30, 2021 and Mr Anil Joseph, Managing
Director for a period of 5 years from July 1, 2020 to June 30, 2025.

GENERAL BODY MEETINGS

Financial Year Date Time Location Number of Special Resolutions
2018-19 August 22, 2019 3.30 p.m. Y B Chavan Auditorium, General Jagannath -
Bhosale Marg, Mumbai 400 021
2017-18 July 18, 2018 3.30 p.m. RAMA WATUMULL AUDITORIUM, 1

K C College, 124, Dinshaw Wachha Road, (Re-appointment of Mr Munir Shaikh
Vidyasagar Prin. K. M. Kundnani Chowk, (DIN : 00096273), who has attained the
Churchgate, Mumbai – 400 020 age of Seventy-five years, as Director,
liable to retire by rotation)
2016-17 July 18, 2017 3.30 p.m. RAMA AND SUNDRI WATUMULL -
AUDITORIUM, K C College, 124, Dinshaw
Wachha Road, Vidyasagar Prin. K. M.
Kundnani Chowk, Churchgate,
Mumbai – 400 020
All the resolutions set out in the Notices of the Meetings, and leak of Unpublished Price Sensitive Information.
as aforesaid, were duly passed with requisite majority The amended Policy is available on the website of the Company
by the Members. at https://www.abbott.co.in/investor-relations/policies.html
During the year, no special resolution was passed MEANS OF COMMUNICATION
through postal ballot.
i)
The quarterly, half-yearly and annual results are
On April 27, 2020, the Company proposed a Special published in English daily newspaper (Business
Resolution, through Postal Ballot, seeking approval of the Standard-Pan India) and Marathi newspaper (Loksatta)
shareholders to advance loan(s) to any of the Company’s published from Mumbai. The quarterly results/
group entities in India in which any Director of the Company shareholding pattern/notice of Board Meetings/official
news releases are made available on the website of the
is or shall be deemed to be interested, upto an aggregate limit
Company at www.abbott.co.in and on the website of
of ` 300 Crores, in one or more tranches as per provisions of
the BSE Limited.
the Section 185 of the Companies Act, 2013. The Resolution
was approved with requisite majority on June 6, 2020. ii) During the year under review, the Company has, upon
request, had one-on-one/group meetings with a few
institutional investors. Prior intimations about these
VIGIL MECHANISM/WHISTLE BLOWER POLICY
meetings were made to the BSE Limited.
The Company has in place the Vigil Mechanism/Whistle No presentations were made in any such meetings.
Blower Policy called “Abbott India Limited – Procedure for
Internal Investigations” in terms of the requirements of the GENERAL SHAREHOLDER INFORMATION
Companies Act, 2013 and Regulation 22 of the Securities and i) Annual General Meeting
Exchange Board of India (Listing Obligations and Disclosure
Monday, September 7, 2020 through Video-
Requirements) Regulations, 2015. Adequate safeguards are Conferencing (VC)/Other Audio-Visual Means (OVAM)
provided against victimization of director(s) or employee(s) ii) Financial year
or any other person who raises concerns using such April 1, 2019 to March 31, 2020
mechanism. No employee has been denied access to the
Audit Committee. iii) Book Closure
Tuesday, September 1, 2020 to
During the year, the said Policy was amended in line with Monday, September 7, 2020 (both days inclusive)
the Securities and Exchange Board of India (Prohibition
of Insider Trading) (Amendment) Regulations, 2018 (“the iv) E-Voting Period
Insider Trading Regulations”), enabling employees to From 9.00 a.m. (IST) on Friday, September 4, 2020
report any violations under the Insider Trading Regulations Upto 5.00 p.m. (IST) on Sunday, September 6, 2020
107
v) Dividend Payment Date xii) Registrar and Share Transfer Agent

On and from September 14, 2020 KFin Technologies Private Limited
vi) Listing on Stock Exchange Unit : Abbott India Limited
BSE Limited
Phiroze Jeejeebhoy Towers, Selenium Tower B, B-24, Rajabhadur Mansion,
Dalal Street, Mumbai – 400 001 Plot 31-32, Gachibowli, 6, Ambalal Doshi Marg,
Telephone No. : +91-22-2272 1233/4, +91-22-6654 5695 Financial District, Behind BSE Limited,
Fax : +91-22-2272 1919 Nanakramguda, Fort, Mumbai - 400 001
Website : www.bseindia.com Hyderabad – 500 032 Tel No. : +91-22-6623 5412
Tel No. : +91-40-6716 2222;
Email : [email protected]
Fax No. : +91-40-2300 1153
vii) The annual listing fees for the financial year 2019-20
was paid to the BSE Limited as per Regulation 14 of the Email : [email protected]
Securities and Exchange Board of India (Listing Website : www.kfintech.com
Obligations and Disclosure Requirements)
Details of various centers of KFin are available on
Regulations, 2015.
www.kfintech.com
viii) International Securities Identification Number (ISIN)
xiii) Share Transfer System
INE358A01014
ix) Stock Code (BSE) Share Transfer Committee comprising the Directors
500488 and officials of the Company attend to the share transfer
formalities at least once in a fortnight. The said Committee
x) Market Price Data (High/Low) on BSE
(`) also considers requests received for duplicate certificates,
Month High Low split/consolidation, dematerialization, rematerialization
April, 2019 8,067.50 7,230.00 and transmission of shares.
May, 2019 8,087.40 7,150.00
All the requests received as specified above, are normally
June, 2019 8,975.00 7,728.15
July, 2019 8,998.95 8,299.80 processed as per the prescribed timelines upon receipt
August, 2019 9,400.00 8,317.50 of complete set of documents.
September, 2019 11,000.00 9,180.05 xiv) Distribution of Shareholding as on March 31, 2020
October, 2019 12,150.00 10,350.00
November, 2019 13,200.00 11,369.30 Distribution Number of % to Number of % to
December, 2019 13,450.05 12,350.00 Shareholders Total Shares held Total
January, 2020 13,428.25 12,405.75
February, 2020 16,661.25 12,218.10 (1) (2) (3) (4) (5)
March, 2020 16,869.00 12,500.00 Upto 500 50,065 97.32 16,49,759 7.76
xi) Performance in comparison to broad based indices
501 to 1000 725 1.41 5,25,595 2.47
April 1, 2019 to March 31, 2020 Normalised (100)
1001 to 2000 357 0.70 5,10,609 2.40
Abbo Stock Price Sensex Healthcare Index
230 2001 to 3000 109 0.21 2,66,772 1.26

200 3001 to 4000 57 0.11 2,00,305 0.94
170
4001 to 5000 39 0.08 1,75,243 0.83
140
110
5001 to 10000 36 0.07 2,57,097 1.21
80 ABOVE 54 0.10 1,76,63,922 83.13

50
10000
TOTAL 51,442 100.00 2,12,49,302 100.00

xv) Shareholding Pattern as on March 31, 2020 accrued thereon shall be transferred by the Company to
the IEPF Authority in accordance with provisions of
Category of Shareholders Number of % to Total
Shares
Section 124(5) and (6) of the Companies Act, 2013 and
Rules framed thereunder. The voting rights in respect of
Promoters 1,59,34,048 74.99
such shares shall remain frozen till the rightful owner
Banks 4,889 0.02 claims such Equity Shares.
Financial Institutions 68,196 0.32
xvii)
In terms of requirements of Section 124(6) of the
Foreign Portfolio Corporation 3,48,692 1.64 Companies Act, 2013 read with the Investor Education
Insurance Companies 35,994 0.17 and Protection Fund Authority (Accounting, Audit,
Mutual Funds 10,17,895 4.79 Transfer and Refund) Rules, 2016, all shares in respect
of which dividend has not been paid or claimed for
Domestic Companies 2,48,679 1.17
seven consecutive years or more are required to be
Non-Domestic Companies 471 0.00
transferred to the Investor Education and Protection
Non-Resident Indians 1,04,622 0.49 Fund Authority (“IEPF Authority”).
Directors and Relatives 250 0.00
During the year, the Company has transferred 31,212
Unclaimed Suspense Account 4,711 0.02 Equity Shares held by 239 Members to the IEPF
Investor Education and 96,925 0.46 Authority in July 2019. The details of shares so
Protection Fund (IEPF) transferred is available on the Company’s website under
Authority the Investor Section at https://www.abbott.co.in/investor-
Others 33,83,930 15.93 relations/other-information/unclaimed-dividend.html
TOTAL 2,12,49,302 100.00 The Members whose shares/unclaimed dividends, etc.
xvi)
In terms of requirements of Regulation 39(4) and have been transferred to IEPF may claim the shares by
Schedule VI of the Securities and Exchange Board of making an application to IEPF Authority in Form IEPF-5
India (Listing Obligations and Disclosure Requirements) (available on www.iepf.gov.in) along with requisite fee
Regulations, 2015, shares which remained unclaimed in as decided by the Authority from time to time. The
the custody of the Company are required to be Member can file only one consolidated claim in a financial
transferred to the Suspense Account opened by the year as per the IEPF Rules and amendments thereto.
Company.

During the year, 7 claims were received from
Accordingly, details of the unclaimed shares lying in shareholders, details of which are as follows :
the Company’s Unclaimed Suspense Account are
Particulars Number of Number of
as follows : Shareholders Shares
Particulars Number of Number of Aggregate number as at 396 66,989
Shareholders Shares
April 1, 2019
Aggregate number as at 187 23,993
April 1, 2019 Transferred to IEPF Authority 239 31,212
Number of shares claimed 1 165 during the year
and transferred from the Claims brought forward 3 812
Unclaimed Suspense Accounts
during the year Claims received from 7 1,305
Number of shares transferred 148 19,117 Shareholders during the year
to Investor Education and Claims processed by IEPF 5 1,276
Protection Fund Authority
March 31, 2020 Claims pending with IEPF 5 841
Authority
All benefits accruing on such shares shall be credited
to Unclaimed Suspense Account for a period of seven
March 31, 2020
years. Thereafter, the said shares including all benefits
109
xviii) Dematerialisation of Shares as on March 31, 2020 OTHER DISCLOSURES

and liquidity a) There were no Related Party Transactions entered into
The shares of the Company are compulsorily traded in by the Company during the year that had potential
electronic mode and are available for trading with both conflict with the interests of the Company at large.
the Depositories in India namely, National Securities b) Policies on Dealing with Related Party Transactions
Depository Limited (NSDL) and Central Depository and Materiality and on Determination of Materiality
Services (India) Limited (CDSL). of Event or Information for Disclosure are
disclosed on the website of the Company at
2,08,81,564 Equity Shares representing 98.3% of the
Company’s total paid-up share capital were held in The details of transactions entered into with Related
dematerialized mode, as on March 31, 2020. Parties is disclosed in Note No. 40 of the
xix) The Company has not issued any GDR/ADR or Financial Statements.
Warrants or any other convertible instruments. c)
In the preparation of Financial Statements, no
xx) Foreign exchange risk and hedging activities differential treatment from that prescribed in the
Accounting Standards has been followed.
The Company has foreign exchange exposure and
hedging is done for a significant portion of the same. d)
Pursuant to the disclosures made by the Senior
Management to the Board, there were no material
xxi) Plant Location financial and commercial transactions entered into by
L-18/19, Verna Industrial Estate, Goa them where they have personal interest and which could
have potential conflict with the interest of the
xxii) Address for correspondence
Company at large.
e) The Company has obtained a certificate from
CIN : L24239MH1944PLC00730
Ms Neena Bhatia, Practising Company Secretary
(Membership No. FCS 9492 and Certificate of Practice
Registered office : Corporate Office :
No. 2661), confirming that none of the Directors on the
3, Corporate Park, Shares Department
Board is debarred or disqualified from being appointed
Sion-Trombay Road, 16th Floor, Godrej BKC,
Mumbai – 400 071 Plot C – 68, ‘’G’’ Block, or continuing as Director of the Company by the
Tel No. : +91-22-6797 8888 Bandra Kurla Complex, Board/Ministry of Corporate Affairs or any such
Near MCA Club, Statutory Authority.
Bandra (East), f)
There were no instances of non-compliance by the
Mumbai – 400 051 Company, no penalties/strictures imposed on the
Tel No. : +91-22-5046 1000/2000 Company by the Stock Exchange or the Securities and
Fax : +91-22-5016 9400 Exchange Board of India or any statutory authority on
Email : [email protected] any matters related to the capital markets during the
Website : www.abbott.co.in last three years.
KFin Technologies Private Limited g)
In terms of requirement of Regulation 17(8) of the
Unit : Abbott India Limited Securities and Exchange Board of India (Listing
Selenium Tower B, B-24, Rajabhadur Mansion, 2015, Chief Financial Officer (CFO) has made a
Plot 31-32, Gachibowli, 6, Ambalal Doshi Marg, certification to the Board of Directors in the prescribed
Financial District, Behind BSE Limited, format, which has been reviewed by the Audit
Nanakramguda, Fort, Mumbai - 400 001 Committee and taken on record by the Board.
Hyderabad – 500 032 Tel No. : +91-22-6623 5412 h) Code of Business Conduct for Board of Directors and
Tel No. : +91-40-6716 2222 Senior Management (“Code”) lays down various principles
Fax : +91-40-2344 0674 of ethics and compliance. The Code has been posted on the
Company’s website https://www.abbott.co.in/investor-
Email : [email protected]
relations/policies.html The confirmations to the Code
Website : www.kfintech.com
have been received from all the Directors and

Senior Management. The Certificate issued by o) During the financial year, there was no instance where
Mr Rajiv Sonalker, Whole-time Director and CFO to this the Board has not accepted any recommendation of any
effect forms part of this report. Committee of the Board.
i) The Company has complied with all the Corporate p) Total fees paid to the Statutory Auditors and all the
Governance requirements specified in Regulations 17 to entities in their network firm/network entities for all
23 and 25 to 27 and clauses (b) to (i) of sub-regulation (2) services rendered by them during the financial year
of Regulation 46 of the Securities and Exchange Board 2019-20 is ` 1,99 Lakhs including all the taxes, as may
of India (Listing Obligations and Disclosure be applicable.
Requirements) Regulations, 2015. The Company does
q) During the year, one complaint was filed under the
not have any subsidiary and therefore Regulation 24 is
Sexual Harassment of Women at Workplace (Prevention,
not applicable to the Company.
Prohibition and Redressal) Act, 2013 and the same was
j) There has been no instance of any non-compliance of appropriately disposed off.
any requirement of corporate governance report of
Compliance with discretionary requirements :
sub-paras (2) to (10) of Part C of Schedule V of the
Securities and Exchange Board of India (Listing i) The quarterly and half yearly financial results are
Obligations and Disclosure Requirements) published in two newspapers as prescribed by the
Regulations, 2015. Securities and Exchange Board of India (Listing
k) The Company does not deal in commodity(ies) and Obligations and Disclosure Requirements) Regulations,
hence disclosure relating to commodity price risks and 2015, and are also available on the website of the
commodity hedging activities does not apply Company at www.abbott.co.in Therefore, the results
to the Company. were not separately circulated to all the Members.
l) The Company has not raised any funds through ii) Reporting of Internal Auditors is directly to the
preferential allotment or Qualified Institutional Audit Committee.
Placement during the financial year ended iii) The Company has its financial statements with
March 31, 2020. unmodified audit opinion.
m) The Company has not obtained any Credit Ratings For and on behalf of the Board
during the year.
n) The Company has complied with all the mandatory
requirements of the Securities and Exchange Board Munir Shaikh Rajiv Sonalker
of India (Listing Obligations and Disclosure Mumbai Chairman CFO and Whole-time Director
Requirements) Regulations, 2015. August 7, 2020 DIN : 00096273 DIN : 07900178
DECLARATION UNDER SCHEDULE V (D) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA
(LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015
Pursuant to Regulation Schedule V (D) of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, I, Rajiv Sonalker – Whole-time Director and CFO of Abbott India Limited, do hereby affirm
that, all the Board Members and Senior Management Personnel of the Company have affirmed Compliance with the Abbott
India Code of Conduct for the year ended March 31, 2020.
Rajiv Sonalker
March 31, 2020 CFO and Whole-time Director
Mumbai DIN : 07900178
111
CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C Clause (10)(i) of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015).
To, Sr. Name of Director DIN Date of Appointment

No. in Company
The Members,
Abbott India Limited 1. Munir Shaikh 00096273 02/03/2001
Unit No. 3, Corporate Park, 2. Anisha Motwani 06943493 25/04/2018
Sion Trombay Road,
Chembur, Mumbai 400071 3. Sudarshan Jain 00927487 01/04/2019
I have examined the relevant registers, records, forms, 4. Shalini Kamath 06993314 29/10/2019
returns and disclosures received from the Directors of Abbott 5. Ambati Venu 07614849 01/03/2020
India Limited having CIN : L24239MH1944PLC007330 and
having their registered office at Unit No. 3, Corporate Park, 6. Kaiyomarz Marfatia 03449627 01/03/2011
Sion Trombay Road, Mumbai 400071 (hereinafter referred to 7. Rajiv Sonalker 07900178 08/08/2017
as ‘‘the Company’’), produced before me by the Company for
the purpose of issuing this Certificate, in accordance with 8. Mark Murphy II 08385393 01/04/2019
Regulation 34(3) read with Schedule V Para C sub clause 10(i)
Ensuring the eligibility for the appointment/continuity of
of the Securities and Exchange Board of India (Listing
every Director on the Board is the responsibility of the
Obligations and Disclosure Requirements) Regulations, 2015.
management of the Company. My responsibility is to express
In my opinion and to the best of my information and according an opinion on these based on my verification. This certificate
to the verifications (including Directors Identification is neither an assurance as to the future viability of the
Number (DIN) status at the portal www.mca.gov.in) as Company nor of the efficiency or effectiveness with which
considered necessary and explanations furnished to me by the management has conducted the affairs.
the Company and its officers, I hereby certify that none of the
Directors on the Board of the Company as stated below for
the financial year ending on March 31, 2020 have been Neena Bhatia
debarred or disqualified from being appointed or continuing Practicing Company Secretary
as Directors of companies by the Securities and Exchange Place : Mumbai Membership No. FCS 9492
Board of India, Ministry of Corporate Affairs or any such Date : June 8, 2020 Certificate of Practice No. 2661
other Statutory Authority. UDIN : F009492B000323993
INDEPENDENT AUDITOR’S REPORT ON COMPLIANCE WITH THE CONDITIONS OF CORPORATE

GOVERNANCE AS PER PROVISIONS OF CHAPTER IV OF THE SECURITIES AND EXCHANGE BOARD OF
INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED
The Members of Management’s Responsibility
3, Corporate Park, 2. The preparation of the Corporate Governance Report
Sion-Trombay Road, is the responsibility of the Management of the
Mumbai – 400 071. Company including the preparation and maintenance
of all relevant supporting records and documents.
1. The Corporate Governance Report prepared by Abbott This responsibility also includes the design,
India Limited (hereinafter the “Company”), contains implementation and maintenance of internal control
details as specified in regulations 17 to 27, clauses (b) to relevant to the preparation and presentation of the
(i) of sub – regulation (2) of regulation 46 and para C,
Corporate Governance Report.
D, and E of Schedule V of the Securities and Exchange
Board of India (Listing Obligations and Disclosure 3. The Management along with the Board of Directors
Requirements) Regulations, 2015, as amended (“the are also responsible for ensuring that the Company
Listing Regulations”) for the year ended March 31, 2020 complies with the conditions of Corporate Governance
as required by the Company for annual submission to as stipulated in the Listing Regulations, issued by the
the Stock Exchange. Securities and Exchange Board of India.

Auditor’s Responsibility vii. Obtained the schedule of related party transactions

4. Pursuant to the requirements of the Listing Regulations, during the year and balances at the year end.
our responsibility is to provide a reasonable assurance Obtained and read the Minutes of the Audit
in the form of an opinion whether, the Company has Committee Meeting where in such related party
complied with the conditions of Corporate Governance transactions have been pre-approved prior by the
as specified in the Listing Regulations. Audit Committee.
viii. Performed necessary inquiries with the
5. We conducted our examination of the Corporate management and also obtained necessary specific
Governance Report in accordance with the Guidance Note representations from management.
on Reports or Certificates for Special Purposes and the
The above-mentioned procedures include examining
Guidance Note on Certification of Corporate Governance,
evidence supporting the particulars in the Corporate
both issued by the Institute of Chartered Accountants
Governance Report on a test basis. Further, our scope
of India (“ICAI”). The Guidance Note on Reports or
of work under this report did not involve us performing
Certificates for Special Purposes requires that we comply
audit tests for the purposes of expressing an opinion
with the ethical requirements of the Code of Ethics issued
on the fairness or accuracy of any of the financial
by the Institute of Chartered Accountants of India.
information or the financial statements of the Company
6. We have complied with the relevant applicable taken as a whole.
requirements of the Standard on Quality Control Opinion
(SQC) 1, Quality Control for Firms that Perform Audits
and Reviews of Historical Financial Information and 8. Based on the procedures performed by us, as referred
Other Assurance and Related Services Engagements. in paragraph 7 above and according to the information
and explanations given to us, we are of the opinion
7. The procedures selected depend on the auditor’s that the Company has complied with the conditions
judgement, including the assessment of the risks of Corporate Governance as specified in the Listing
associated in compliance of the Corporate Governance Regulations, as applicable for the year ended
Report with the applicable criteria. Summary of March 31, 2020, referred to in paragraph 1 above.
procedures performed include :
Other matters and Restriction on Use
i. Read and understood the information prepared
9. This report is neither an assurance as to the future
by the Company and included in its Corporate
viability of the Company nor the efficiency or
Governance Report;
effectiveness with which the management has
ii. Obtained and verified that the composition of the conducted the affairs of the Company.
Board of Directors with respect to executive and
10. This report is addressed to and provided to the members
non-executive directors has been met throughout
of the Company solely for the purpose of enabling
the reporting period; it to comply with its obligations under the Listing
iii. Obtained and read the Register of Directors as Regulations with reference to compliance with the
on March 31, 2020 and verified that at least one relevant regulations of Corporate Governance and
independent woman director was on the Board of should not be used by any other person or for any other
Directors throughout the year; purpose. Accordingly, we do not accept or assume any
iv. Obtained and read the Minutes of the following liability or any duty of care or for any other purpose or
Committee Meetings/other Meetings held from to any other party to whom it is shown or into whose
April 1, 2019 to March 31, 2020 : hands it may come without our prior consent in writing.
We have no responsibility to update this report for
(a) Board of Directors;
events and circumstances occurring after the date
(b) Audit Committee;
of this report.
(c) Annual General Meeting;
(d) Nomination and Remuneration Committee; For S R B C & CO LLP
(e) Stakeholders Relationship Committee; Chartered Accountants
(f) Independent Directors Meeting; ICAI Firm Registration Number : 324982E/E300003
(g) Corporate Social Responsibility Committee;
(h) Risk Management Committee per Ravi Bansal
Partner
v. Obtained necessary declarations from the directors Membership Number : 49365
of the Company. UDIN : 20049365AAAACG1110
vi. Obtained and read the policy adopted by the Place of Signature : Mumbai
Company for related party transactions. Date : August 7, 2020
113
INDEPENDENT AUDITOR’S REPORT

To the Members of Abbott India Limited the Company in accordance with the ‘Code of Ethics’ issued
by the Institute of Chartered Accountants of India together
Report on the audit of the Ind AS Financial with the ethical requirements that are relevant to our audit of
Statements the financial statements under the provisions of the Act and
Opinion the Rules thereunder, and we have fulfilled our other ethical
responsibilities in accordance with these requirements and
We have audited the accompanying Ind AS financial the Code of Ethics. We believe that the audit evidence we
statements of Abbott India Limited (“the Company”), have obtained is sufficient and appropriate to provide a basis
which comprise the Balance Sheet as at March 31, 2020, for our audit opinion on the Ind AS financial statements.
the Statement of Profit and Loss, including the statement
of Other Comprehensive Income, the Cash Flow Statement Key Audit Matters
and the Statement of Changes in Equity for the year then Key audit matters are those matters that, in our professional
ended, and notes to the financial statements, including judgment, were of most significance in our audit of the
a summary of significant accounting policies and other Ind AS financial statements for the financial year ended
explanatory information. March 31, 2020. These matters were addressed in the context
In our opinion and to the best of our information and of our audit of the Ind AS financial statements as a whole
according to the explanations given to us, the aforesaid and in forming our opinion thereon, and we do not provide a
Ind AS financial statements give the information required separate opinion on these matters. For each matter below, our
by the Companies Act, 2013 (“the Act”) in the manner so description of how our audit addressed the matter is provided
required and give a true and fair view in conformity with in that context.
the accounting principles generally accepted in India, of the We have determined the matters described below to be
state of affairs of the Company as at March 31, 2020, its profit the key audit matters to be communicated in our report.
including other comprehensive income, its cash flows and the We have fulfilled the responsibilities described in the
changes in equity for the year ended on that date. Auditor’s responsibilities for the audit of the Ind AS financial
statements Section of our report, including in relation to these
Basis for Opinion matters. Accordingly, our audit included the performance
We conducted our audit of the Ind AS financial statements in of procedures designed to respond to our assessment of
accordance with the Standards on Auditing (SAs), as specified the risks of material misstatement of the Ind AS financial
under Section 143(10) of the Act. Our responsibilities under statements. The results of our audit procedures, including the
those Standards are further described in the ‘Auditor’s procedures performed to address the matters below, provide
Responsibilities for the Audit of the Ind AS Financial the basis for our audit opinion on the accompanying Ind AS
Statements’ Section of our report. We are independent of financial statements.
Key audit matter How our audit addressed the key audit matter
(a) Provision for non-saleable returns (as described in note 23 of the Ind AS financial statements)
The Company makes sales to stockists who further sells Our audit procedures included, amongst others,
products in the market. Stockist have a right of return in case • Obtained an understanding of management process for
goods expiring, while in supply chain till end consumers. making provision for non-saleable returns including
Return of these expired goods, result in deductions to gross related controls.
amounts invoiced in arriving at revenue and creation of
obligations for the Company to give credit for sales returns. • Tested the Company’s key controls relating to the
deductions made to gross sales for sales returns,
The amounts pertaining to such sales return are estimated at including those controls over booking of sales and sales
the time of sale and deducted from gross sales and recorded return process.
as provisions for sales returns. These estimates are based
on analysis of historical trends of sales return and shelf life • We obtained management’s calculations for provisions,
of the products. recalculated the amounts and validated the assumptions
used by reference to historical sales returns levels and
current trends.

Key audit matter How our audit addressed the key audit matter
The management has determined provision for sales returns • We considered the management’s estimates by comparing
amounting to ` 144,21.36 Lakhs which have been recorded historical accrued provisions and revenue deductions
at March 31, 2020 (including reimbursable sales return recorded to the actual amounts.
amounting to ` 57,56.81 Lakhs). • We tested the working of discounting of non-current
We focused on this area because establishing an appropriate provisions for sales return prepared by the management.
year-end position requires significant judgement and • We understood and assessed the Company’s revenue
estimation by the management. The assumptions required recognition accounting policies, including the recognition
for estimating provisions for sales returns are complex in and measurement of deductions to gross sales relating to
nature, the estimates may not be appropriate and, as a result, sales returns and related disclosures.
provisions and revenue may be incorrectly recorded.
(b) Evaluation of uncertain tax positions (as described in note 38 of the Ind AS financial statements)
The Company has litigations involving question of law and • We obtained an understanding of the management’s process
certain disallowances made by authorities in assessment for :
orders that the Company has appealed against before the - identification of tax matters initiated against the Company,
relevant appellate authorities. - assessment of accounting treatment for each such litigation
The Company has disclosed ` 73,43.74 Lakhs as Contingent identified under Ind AS 37 accounting principles, and for
liability (including uncertain tax positions for open assessment measurement of amounts involved.
orders) in accordance with Ind AS 37 Provisions, Contingent • We evaluated the design and tested the operating
Liabilities and Contingent Assets, based on management’s effectiveness of controls around the above process.
assessment in consultation with professional advice from the • We obtained an understanding of the nature of litigations
external legal counsel. pending against the Company and discussed the key
developments during the year with the management.
The eventual outcome of the legal proceedings is dependent
on the outcome of future events and unexpected adverse • We focused on the key developments in the tax litigation
outcomes could significantly impact the Company’s reported during the year, which could have materially impacted the
amounts recorded as provisions or disclosed as contingent
profits and Balance Sheet position.
liability in the financial statements. We reviewed the
Key judgments are also made by the management in demand notices, assessment orders received during the
estimating the amount of contingent liabilities related to year for all such cases and obtained grounds of appeal
aforementioned litigations. submitted by the management in consultation with their
Considering the degree of judgment, significance of the external legal counsel.
amounts involved, inherent high estimation uncertainty • We assessed the appropriateness of methods used and the
and reliance on external legal counsel, this matter has been reliability of underlying data for quantifying the amounts
identified as a key audit matter for the current year audit. involved. We also tested the arithmetical accuracy of
such calculations.
• We reviewed external legal counsel’s response to ensure
that the conclusions reached are supported by sufficient
legal rationale.
• We also tested the independence, objectivity and
competence of such external legal counsel involved.
• We have obtained direct confirmation for litigation cases
from the external legal counsel, to support the decisions
and rationale for disclosure of contingent liabilities in
respect of the litigation cases.
• We engaged internal tax specialists to evaluate
management assessment of the outcome of such litigation
cases. The tax specialists considered legal precedence and
other rulings in evaluating management’s position on such
litigation cases.
• We have evaluated the adequacy of disclosures
made by the Company in the financial statements in
view of the requirements as specified in the Indian
Accounting Standards.
115
Information Other than the Financial Statements The Board of Directors are also responsible for overseeing the
and Auditor’s Report Thereon Company’s financial reporting process.
The Company’s Board of Directors is responsible for the Auditor’s Responsibilities for the Audit of the Ind
Other information. The Other information comprises the AS Financial Statements
Director’s Report, Management Discussion and Analysis,
Corporate Governance Report but does not include the Our objectives are to obtain reasonable assurance about
Ind AS financial statements and our auditor’s report thereon. whether the Ind AS financial statements as a whole are free
The Other information is expected to be made available to us from material misstatement, whether due to fraud or error,
after the date of this auditor’s report. and to issue an auditor’s report that includes our opinion.
Reasonable assurance is a high level of assurance but is not
Our opinion on the Ind AS financial statements does not cover a guarantee that an audit conducted in accordance with SAs
the other information and we will not express any form of will always detect a material misstatement when it exists.
assurance conclusion thereon. Misstatements can arise from fraud or error and are considered
In connection with our audit of the Ind AS financial material if, individually or in the aggregate, they could
statements, our responsibility is to read the Other information reasonably be expected to influence the economic decisions of
identified as above and, in doing so, consider whether the users taken on the basis of these Ind AS financial statements.
other information is materially inconsistent with the Ind AS As part of an audit in accordance with Standards on Auditing
financial statements or our knowledge obtained in the audit (SAs), we exercise professional judgment and maintain
or otherwise appears to be materially misstated. professional skepticism throughout the audit. We also :
Responsibilities of Management for the Ind AS • Identify and assess the risks of material misstatement of
Financial Statements the Ind AS financial statements, whether due to fraud or
The Company’s Board of Directors is responsible for the error, design and perform audit procedures responsive to
matters stated in Section 134(5) of the Act with respect to those risks, and obtain audit evidence that is sufficient and
the preparation of these Ind AS financial statements that appropriate to provide a basis for our opinion. The risk
give a true and fair view of the financial position, financial of not detecting a material misstatement resulting from
performance including other comprehensive income, cash fraud is higher than for one resulting from error, as fraud
flows and changes in equity of the Company in accordance may involve collusion, forgery, intentional omissions,
with the accounting principles generally accepted in India, misrepresentations, or the override of internal control.
including the Indian Accounting Standards (Ind AS) specified • Obtain an understanding of internal control relevant
under Section 133 of the Act read with the Companies to the audit in order to design audit procedures that are
(Indian Accounting Standards) Rules, 2015, as amended. appropriate in the circumstances. Under Section 143(3)(i)
This responsibility also includes maintenance of adequate of the Act, we are also responsible for expressing our
accounting records in accordance with the provisions of the opinion on whether the Company has adequate internal
Act for safeguarding of the assets of the Company and for financial controls system in place and the operating
preventing and detecting frauds and other irregularities; effectiveness of such controls.
selection and application of appropriate accounting policies;
making judgments and estimates that are reasonable and • Evaluate the appropriateness of accounting policies used
prudent; and the design, implementation and maintenance and the reasonableness of accounting estimates and
of adequate internal financial controls, that were operating related disclosures made by management.
effectively for ensuring the accuracy and completeness of • Conclude on the appropriateness of management’s use of
the accounting records, relevant to the preparation and the going concern basis of accounting and, based on the
presentation of the Ind AS financial statements that give a audit evidence obtained, whether a material uncertainty
true and fair view and are free from material misstatement, exists related to events or conditions that may cast
whether due to fraud or error. significant doubt on the Company’s ability to continue as a
In preparing the Ind AS financial statements, management is going concern. If we conclude that a material uncertainty
responsible for assessing the Company’s ability to continue exists, we are required to draw attention in our auditor’s
as a going concern, disclosing, as applicable, matters related report to the related disclosures in the financial statements
to going concern and using the going concern basis of or, if such disclosures are inadequate, to modify our
accounting unless management either intends to liquidate opinion. Our conclusions are based on the audit evidence
the Company or to cease operations, or has no realistic obtained up to the date of our auditor’s report. However,
alternative but to do so. future events or conditions may cause the Company to
cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of Companies (Indian Accounting Standards) Rules,
the Ind AS financial statements, including the disclosures, 2015, as amended;
and whether the Ind AS financial statements represent
the underlying transactions and events in a manner that (e) On the basis of written representations received
achieves fair presentation. from the directors as on March 31, 2020, and taken
on record by the Board of Directors, none of the
We communicate with those charged with governance directors is disqualified as on March 31, 2020, from
regarding, among other matters, the planned scope and being appointed as a director in terms of Section
timing of the audit and significant audit findings, including
164 (2) of the Act;
any significant deficiencies in internal control that we identify
during our audit. (f) With respect to the adequacy of the internal
We also provide those charged with governance with a financial controls over financial reporting of the
statement that we have complied with relevant ethical Company with reference to these Ind AS financial
requirements regarding independence, and to communicate statements and the operating effectiveness of
with them all relationships and other matters that may such controls, refer to our separate Report in
reasonably be thought to bear on our independence, and “Annexure 2” to this report;
where applicable, related safeguards.
(g) In our opinion, the managerial remuneration for
From the matters communicated with those charged with the year ended March 31, 2020 has been paid/
governance, we determine those matters that were of most provided by the Company to its directors in
significance in the audit of the Ind AS financial statements for accordance with the provisions of Section 197 read
the financial year ended March 31, 2020 and are therefore the with Schedule V to the Act;
key audit matters. We describe these matters in our auditor’s
report unless law or regulation precludes public disclosure (h) With respect to the other matters to be included in
about the matter or when, in extremely rare circumstances, the Auditor’s Report in accordance with Rule 11 of
we determine that a matter should not be communicated the Companies (Audit and Auditors) Rules, 2014, in
in our report because the adverse consequences of doing so our opinion and to the best of our information and
would reasonably be expected to outweigh the public interest according to the explanations given to us :
benefits of such communication.
i. The Company has disclosed the impact of
Report on Other Legal and Regulatory Requirements pending litigations on its financial position in
1. As required by the Companies (Auditor’s report) Order, its Ind AS financial statements – Refer Note 38
2016 (“the Order”) issued by the Central Government to the Ind AS financial statements;
of India in terms of sub-Section (11) of Section 143 of
the Act, we give in the Annexure 1, a statement on the ii. The Company did not have any long-term
matters specified in paragraphs 3 and 4 of the Order. contracts including derivative contracts
for which there were any material
2. As required by Section 143 (3) of the Act, we report that : foreseeable losses; and
(a) We have sought and obtained all the information
iii. There has been no delay in transferring
and explanations which to the best of our
amounts, required to be transferred, to the
knowledge and belief were necessary for the
purpose of our audit; Investor Education and Protection Fund
by the Company.
(b) In our opinion, proper books of account as required
by law have been kept by the Company so far as it
appears from our examination of those books; For S R B C & CO LLP
Chartered Accountants
(c) The Balance Sheet, Statement of Profit and Loss
ICAI Firm Registration Number : 324982E/E300003
including the Statement of Other Comprehensive
Income, the Cash Flow Statement and Statement of
per Ravi Bansal
Changes in Equity dealt with by this Report are in
Partner
agreement with the books of account;
Membership Number : 49365
(d) In our opinion, the aforesaid Ind AS financial UDIN : 20049365AAAABG3251
statements comply with the Accounting Standards Place of Signature : Mumbai
specified under Section 133 of the Act, read with Date : June 8, 2020
117
ANNEXURE 1 TO THE INDEPENDENT AUDITOR’S REPORT OF EVEN DATE ON THE FINANCIAL

STATEMENTS OF ABBOTT INDIA LIMITED
(i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation
of fixed assets.
(b) Some fixed assets were physically verified by the management during the year in accordance with a planned
programme of verifying them once in three years which, in our opinion, is reasonable having regard to the size of the
Company and the nature of its assets. No material discrepancies were noticed on such verification.
(c) According to the information and explanations given by the management, the title deeds of immovable properties,
included in property, plant and equipment are held in the name of the Company, except for the following :
Sr. Asset Category Gross Block at Net Block at Remarks

No. March 31, 2020 March 31, 2020
(` in Lakhs) (` in Lakhs)
1 Buildings 6,41.98 5,39.52 The title deeds are in the erstwhile name of the
Company.
2 Buildings 30,50.61 27,01.88 The title deeds are in the name of the entities that
was merged with the Company.
(ii) The management has conducted physical verification of inventory at reasonable intervals during the year and no material
discrepancies were noticed on such physical verification. Inventories lying with third parties have been confirmed by them
as at year end and no material discrepancies were noticed in respect of such confirmations.
(iii) According to the information and explanations given to us, the Company has not granted any loans, secured or unsecured
to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189
of the Companies Act, 2013. Accordingly, the provisions of clause 3(iii) (a), (b) and (c) of the Order are not applicable to the
Company and hence not commented upon.
(iv) In our opinion and according to the information and explanations given to us, there are no loans, investments, guarantees,
and securities given in respect of which provisions of Section 185 and 186 of the Companies Act, 2013 are applicable and
hence not commented upon.
(v) The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies
(Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
(vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central
Government for the maintenance of cost records under Section 148 (1) of the Companies Act, 2013, related to the
manufacture of pharmaceutical products, and are of the opinion that prima facie, the specified accounts and records have
been made and maintained. We have not, however, made a detailed examination of the same.
(vii) (a) The Company is generally regular in depositing undisputed statutory dues including provident fund, employees’ state
insurance, income tax, duty of custom, goods and service tax, cess and other statutory dues applicable to it with
appropriate authorities, though there have been delays in few cases for payment of professional tax and provident fund.
(b) According to the information and explanations given to us, no undisputed amounts payable in respect of provident
fund, employees’ state insurance, income tax, duty of custom, goods and service tax, cess and other statutory
dues were outstanding, at the year end, for a period of more than six months from the date they became payable,
except as below :
Name of the Statute Nature of Amount Period to which the Due date Date of
Dues in ` Lakhs amount relates payment
The Jharkhand tax on Profession tax 0.17 April 2019-June 2019 July 15, 2019 May 29, 2020
Professions, Trades, Callings
and Employment Act, 2011

(c) According to the records of the Company, the dues of income tax, sales tax, service tax, duty of custom, duty of excise,
value added tax and cess on account of any dispute, are as follows :
Name of Statute Nature of Amount disputed Forum where dispute is Period to which the
Dues in ` Lakhs pending amount relates
(net of payments)
Income Tax Act, 1961 Income Tax 2,77.10 ITAT A.Y. 2006-07 and
A.Y. 2011-12
Income Tax Act, 1961 Income Tax 33,38.71 CIT(A) A.Y. 2004-05,
A.Y. 2016-17 and
A.Y. 2017-18
Central Excise Act, 1944 Excise Duty 3.20 Commissioner (Appeals) 1991-1992
3.56 Commissioner 1994 - 1995
2.51 Assistant Commissioner 1994 and 1997 to
2002
26.72 CESTAT 2005 to 2006
Customs Act, 1962 Custom Duty 4.43 Commissioner (Appeals) 1996
75.00 CESTAT 2011 to 2013
The Bombay Sales Tax Sales Tax 39.87 Deputy Commissioner of Sales 1999-2000
Act, 1959 Tax
Uttar Pradesh Value Value Added 1.50 Additional Commissioner 2008-09 and
Added Tax Act, 2008 Tax Appeal Grade- 2, Commercial 2009-10
Tax
The Assam Central Sales Tax 10.23 Commissioner of Commercial 2012-13
Sales Tax Act, 1956 Tax
Kerala General Sales Sales Tax 13.05 Sales Tax Appellate Tribunal, 2002-03
Tax Act, 1963 Additional Bench
Goa Value Added Tax Value Added 2.07 Additional Commissioner of 2006-07
Act, 2005 Tax Commercial Taxes, Panaji, Goa
Central Sales Tax, 1956 Sales Tax 6,33.91 Additional Commissioner of 2006-07 and
(Goa) Commercial Taxes, Panaji, Goa 2007-08
16.67 Assistant Commissioner of 2009-10
Commercial Taxes, Panaji, Goa
Central Sales Tax Act, Sales Tax 5.33 The Joint Commissioner of 2015-16 and
1956 (Gujarat) Taxes, Gujarat 2016-17
The West Bengal - Value Added 33.77 Additional Commissioner of 2016-17
Value Added Tax Rules, Tax Sales Tax, West Bengal
2005
The Central Sales Tax Sales Tax 2.70 Additional Commissioner of 2016-17
(West Bengal) Rules, Sales Tax, West Bengal
1958
Maharashtra Value Value Added 27,67.18 Deputy Commissioner of Sales 2011-12
Added Tax Act, 2002 Tax Tax (Appeals)
119
(viii) The Company did not have any outstanding loans or borrowing dues in respect of a financial institution or bank or to
government or dues to debenture holders during the year.
(ix) According to the information and explanations given by the management, the Company has not raised any money by way of
initial public offer/further public offer/debt instruments and term loans hence, reporting under clause (ix) is not applicable
to the Company and hence not commented upon.
(x) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements
and according to the information and explanations given by the management, we report that no fraud by the Company or no
material fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.
(xi) According to the information and explanations given by the management, the managerial remuneration has been paid/
provided in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the
Companies Act, 2013.
(xii) In our opinion, the Company is not a nidhi company. Therefore, the provisions of clause 3(xii) of the order are not applicable
to the Company and hence not commented upon.
(xiii) According to the information and explanations given by the management, transactions with the related parties are in
compliance with Section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the
notes to the financial statements, as required by the applicable accounting standards.
(xiv) According to the information and explanations given to us and on an overall examination of the Balance Sheet, the
Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures
during the year under review and hence, reporting requirements under clause 3(xiv) are not applicable to the Company
and, not commented upon.
(xv) According to the information and explanations given by the management, the Company has not entered into any non-cash
transactions with directors or persons connected with him as referred to in Section 192 of Companies Act, 2013.
(xvi) According to the information and explanations given to us, the provisions of Section 45-IA of the Reserve Bank of India
Act, 1934 are not applicable to the Company.
For S R B C & CO LLP

per Ravi Bansal

Partner
UDIN : 20049365AAAABG3251
Place of Signature : Mumbai
Date : June 8, 2020

ANNEXURE 2 TO THE INDEPENDENT AUDITOR’S REPORT OF EVEN DATE ON THE FINANCIAL

STATEMENTS OF ABBOTT INDIA LIMITED
Report on the Internal Financial Controls under Clause (i) Meaning of Internal Financial Controls over Financial
of Sub-Section 3 of Section 143 of the Companies Act, 2013 Reporting
(“the Act”)
A company’s internal financial control over financial reporting is
We have audited the internal financial controls over financial a process designed to provide reasonable assurance regarding the
reporting of Abbott India Limited (“the Company”) as of reliability of financial reporting and the preparation of financial
March 31, 2020 in conjunction with our audit of the financial statements for external purposes in accordance with generally
statements of the Company for the year ended on that date. accepted accounting principles.
Management’s Responsibility for Internal Financial Controls A company’s internal financial control over financial reporting
includes those policies and procedures that (1) pertain to the
The Company’s Management is responsible for establishing and
maintenance of records that, in reasonable detail, accurately
maintaining internal financial controls based on the internal
and fairly reflect the transactions and dispositions of the
control over financial reporting criteria established by the
assets of the Company; (2) provide reasonable assurance that
Company considering the essential components of internal
transactions are recorded as necessary to permit preparation
control stated in the Guidance Note on Audit of Internal Financial
of financial statements in accordance with generally accepted
Controls Over Financial Reporting issued by the Institute of
accounting principles, and that receipts and expenditures of the
Chartered Accountants of India. These responsibilities include
Company are being made only in accordance with authorisations
the design, implementation and maintenance of adequate
of management and directors of the Company; and (3) provide
internal financial controls that were operating effectively
reasonable assurance regarding prevention or timely detection
for ensuring the orderly and efficient conduct of its business,
of unauthorised acquisition, use, or disposition of the Company’s
including adherence to the Company’s policies, the safeguarding
assets that could have a material effect on the financial statements.
of its assets, the prevention and detection of frauds and errors,
the accuracy and completeness of the accounting records, and Inherent Limitations of Internal Financial Controls over
the timely preparation of reliable financial information, as Financial Reporting
required under the Companies Act, 2013.
Because of the inherent limitations of internal financial
Auditor’s Responsibility controls over financial reporting, including the possibility
of collusion or improper management override of controls,
Our responsibility is to express an opinion on the Company’s material misstatements due to error or fraud may occur and not
internal financial controls over financial reporting based on our be detected. Also, projections of any evaluation of the internal
audit. We conducted our audit in accordance with the Guidance financial controls over financial reporting to future periods
Note on Audit of Internal Financial Controls Over Financial are subject to the risk that the internal financial control over
Reporting (the “Guidance Note”) and the Standards on Auditing financial reporting may become inadequate because of changes
as specified under Section 143(10) of the Companies Act, 2013, in conditions, or that the degree of compliance with the policies
to the extent applicable to an audit of internal financial controls or procedures may deteriorate.
and, both issued by the Institute of Chartered Accountants of
India. Those Standards and the Guidance Note require that we Opinion
comply with ethical requirements and plan and perform the audit
In our opinion, the Company has, in all material respects,
to obtain reasonable assurance about whether adequate internal
an adequate internal financial controls system over financial
financial controls over financial reporting was established
reporting and such internal financial controls over financial
and maintained and if such controls operated effectively in all
reporting were operating effectively as at March 31, 2020,
material respects.
based on the internal control over financial reporting criteria
Our audit involves performing procedures to obtain audit established by the Company considering the essential
evidence about the adequacy of the internal financial controls components of internal control stated in the Guidance Note on
system over financial reporting and their operating effectiveness. Audit of Internal Financial Controls Over Financial Reporting
Our audit of internal financial controls over financial reporting issued by the Institute of Chartered Accountants of India.
included obtaining an understanding of internal financial
For S R B C & CO LLP
controls over financial reporting, assessing the risk that a material
weakness exists, and testing and evaluating the design and
operating effectiveness of internal control based on the assessed
risk. The procedures selected depend on the auditor’s judgement,
per Ravi Bansal
including the assessment of the risks of material misstatement of
Partner
the financial statements, whether due to fraud or error.
We believe that the audit evidence we have obtained is sufficient UDIN : 20049365AAAABG3251
and appropriate to provide a basis for our audit opinion on the Place of Signature : Mumbai
internal financial controls system over financial reporting. Date : June 8, 2020
121
BALANCE SHEET
BALANCE SHEET
AS AT MARCH 31, 2020
(All amounts in ` Lakhs, unless otherwise stated)
Notes As at March 31, 2020 As at March 31, 2019
ASSETS
Non-current Assets
Property, plant and equipment 3 100,21.57 103,10.89
Capital work-in-progress 3 1,64.21 73.14
Intangible assets 4 89.87 1,85.08
Right-of-use assets 41 168,71.31 -
Financial assets
Loans 5 16,78.21 16,10.70
Other financial assets 6 36,26.30 36,65.80
Deferred tax assets (net) 18 14,44.21 13,07.39
Other non-current assets 7 3,25.19 8,39.71
Total Non-current Assets 342,20.87 179,92.71
Current Assets
Inventories 8 527,16.51 606,78.83
Financial assets
Trade receivables 9 317,91.49 276,11.43
Cash and cash equivalents 10 145,13.79 137,00.61
Bank balances other than cash and cash equivalents 11 2052,23.67 1547,27.71
Loans 12 6,14.13 7,30.24
Other financial assets 13 72,37.56 73,34.39
Current tax assets (net) 26,87.31 6,97.10
Other current assets 14 56,79.53 106,18.14
Total Current Assets 3204,63.99 2760,98.45
TOTAL ASSETS 3546,84.86 2940,91.16
EQUITY AND LIABILITIES
Equity
Equity share capital 15 21,24.93 21,24.93
Other equity 16 2410,45.80 1987,33.59
Total Equity 2431,70.73 2008,58.52
Non-current Liabilities
Financial liabilities
Lease liabilities 41 139,20.32 -
Provisions 17 84,83.75 75,43.30
Total Non-current Liabilities 224,04.07 75,43.30
Current Liabilities
Financial liabilities
Lease liabilities 41 35,68.45 -
Trade payables 19
Due to micro and small enterprises 18,32.15 12,06.78
Due to others 639,45.03 651,44.79
Other financial liabilities 20 50,76.93 51,98.49
Other current liabilities 21 31,78.43 37,43.16
Provisions 22 107,44.94 95,33.36
Current tax liabilities (net) 7,64.13 8,62.76
Total Current Liabilities 891,10.06 856,89.34
TOTAL EQUITY AND LIABILITIES 3546,84.86 2940,91.16
Significant accounting policies 2
The accompanying notes are an integral part of the financial statements.
For and on behalf of the Board of Directors
As per our report of even date
For S R B C & CO LLP SUDARSHAN JAIN AMBATI VENU
Chartered Accountants Director Director
ICAI Firm Registration No. 324982E/E300003 DIN : 00927487 DIN : 07614849
per RAVI BANSAL RAJIV SONALKER KRUPA ANANDPARA
Partner CFO and Whole-time Director Company Secretary
Membership No. 49365 DIN : 07900178 Membership No. ACS 16536
Place : Mumbai Place : Mumbai
Date : June 8, 2020 Date : June 8, 2020

STATEMENT OF PROFIT AND LOSS

FOR THE YEAR ENDED MARCH 31, 2020
For the year ended For the year ended

Notes March 31, 2020 March 31, 2019
INCOME
Revenue from operations 24 4093,14.41 3678,60.30
Other income 25 114,38.58 113,28.60
TOTAL INCOME 4207,52.99 3791,88.90
EXPENSES
Cost of materials consumed 26 451,75.97 40,640.20
Purchases of stock-in-trade 27 1802,64.23 168,437.85
Changes in inventories of finished goods, stock-in-trade and work-in-progress 28 61,24.98 (2,18.48)
Employee benefits expense 29 476,10.69 435,58.24
Finance costs 30 8,53.23 2,24.84
Depreciation and amortisation expense 31 59,60.91 16,92.13
Other expenses 32 544,93.83 549,68.71
TOTAL EXPENSES 3404,83.84 3093,03.49
PROFIT BEFORE TAX 802,69.15 698,85.41
TAX EXPENSES
Current tax expense 18 208,03.56 248,45.92
Tax adjustment for earlier years 18 24.65 (2,58.43)
Deferred tax - charge/(credit) 18 1,47.68 2,64.74
TOTAL TAX EXPENSES 209,75.89 248,52.23
PROFIT FOR THE YEAR 592,93.26 450,33.18
Other Comprehensive Income
Items that will not be reclassified subsequently to profit or loss :
Remeasurement gains/(losses) of defined benefit plan 33 (5,40.62) (3,20.99)
Income tax on above 18 45.27 1,12.17
Total Other Comprehensive Income, net of tax (4,95.35) (2,08.82)
Total Comprehensive Income for the year, net of tax 587,97.91 448,24.36
EARNINGS PER EQUITY SHARE 34
Basic and Diluted - ` (Face value of ` 10 each) 279.04 211.93

Significant accounting policies 2
123
STATEMENT OF CHANGES IN EQUITY
STATEMENT OF CHANGES IN EQUITY

A. EQUITY SHARE CAPITAL :
Equity shares of ` 10 each issued, subscribed and fully paid Number of shares Amount
As at April 1, 2018 2,12,49,302 21,24.93
Increase/(decrease) during the year - -
As at March 31, 2019 2,12,49,302 21,24.93
Increase/(decrease) during the year - -
As at March 31, 2020 2,12,49,302 21,24.93
B. OTHER EQUITY :
Items of
Other
Reserves and Surplus (Refer Note 16) Comprehensive
Total
Income
Other
(Refer Note 16)
Equity
Capital Share Based Remeasurement
Amalgamation Capital General Retained
Redemption Compensation of defined
Reserve Reserve Reserve Earnings
Reserve Reserves benefit plan
Balances as at April 1, 2018 37.82 5,22.62 2,52.48 20,95.22 337,25.95 1309,12.39 (3,95.36) 1671,51.12
Profit for the year ended March 31, 2019 - - - - - 450,33.18 - 450,33.18
Remeasurement of defined benefit plan
(net of tax) - - - - - - (2,08.82) (2,08.82)
Total Comprehensive Income for the year - - - - - 45,033.18 (2,08.82) 44,824.36
Transfer from Profit and Loss to General
Reserve - - - - 45,03.32 (45,03.32) - -
Dividend for the year ended March 31, 2018
(Refer Note 15) - - - - - (116,87.12) - (116,87.12)
Dividend distribution tax (Refer Note 15) - - - - - (24,02.32) - (24,02.32)
Share based compensation to employees
(Refer Note 29) - - - 8,47.55 - - - 8,47.55
Transfer from Share Based Compensation
Reserve to General Reserve - - - (1,68.13) 1,68.13 - - -
Balances as at March 31, 2019 37.82 5,22.62 2,52.48 27,74.64 383,97.40 1573,52.81 (6,04.18) 1987,33.59
Profit for the year ended March 31, 2020 - - - - - 592,93.26 - 592,93.26
Remeasurement of post employment
benefits (net of tax) - - - - - - (4,95.35) (4,95.35)
Total Comprehensive Income for the year - - - - - 592,93.26 (4,95.35) 587,97.91
Transfer from Profit and loss to General
reserve - - - - 59,29.33 (59,29.33) - -
Dividend for the year ended March 31, 2019
(Refer Note 15) - - - - - (138,12.05) - (138,12.05)
(Refer Note 29) - - - 8,76.75 - - - 8,76.75
Transfer from Share based compensation
reserve to General Reserve - - - (75.83) 75.83 - - -
Impact due to adoption of Ind AS 116
Leases under modified retrospective
approach (Refer Note 41) - - - - - (9,50.52) - (9,50.52)
Deferred tax impact due to adoption
of Ind AS 116 Leases under modified
retrospective approach (Refer Note 41) - - - - - 2,39.23 - 2,39.23
Balances as at March 31, 2020 37.82 5,22.62 2,52.48 35,75.56 444,02.56 1933,54.29 (10,99.53) 2410,45. 80
Significant accounting policies (Refer Note 2)


STATEMENT OF CASH FLOWS

March 31, 2020 March 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Profit before tax 802,69.15 698,85.41
Adjustments to reconcile profit before tax to net cash flows :
Depreciation and amortisation expense 59,60.91 16,92.13
Unrealised exchange (gain)/loss (net) 2,32.92 (3,05.09)
Loss on sale/write off of Property, plant and equipment (net) 55.67 14.21
Gain on sale of property classified as ‘held for sale’ - (9,78.36)
Gain on early termination of leases (4.18) -
Interest income (113,15.20) (101,44.74)
Finance costs 8,53.23 2,24.84
Amortisation of deferred lease rentals - 1,44.04
Allowance for credit impaired debts 38.70 49.69
Allowance/(write back) for credit impaired advances and deposits 62.03 (48.44)
Provision for likely sales returns, date expiry and damaged products (net) 15,15.72 7,58.20
Share based compensation expense 8,76.75 8,47.55
Operating Profit before working capital changes 785,45.70 621,39.44
Working capital changes :

(Increase)/ Decrease in Trade receivables (41,96.32) (13,10.00)
(Increase)/ Decrease in Inventories 79,62.32 (21,46.11)
(Increase)/ Decrease in other current and non-current assets 46,36.38 (26,61.32)
Increase/ (Decrease) in Trade payables (8,51.02) 185,99.88
Increase/ (Decrease) in current and non-current liabilities and provisions (5,69.10) 9,58.58
Cash generated from operations 855,27.96 755,80.47
Income tax paid (net of refunds) (229,17.05) (256,67.40)
Net cash flows from operating activities (A) 626,10.91 499,13.07
CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of Property, plant and equipment (including capital work-in-progress,
capital creditors and capital advances) (15,73.10) (12,31.35)
Purchase of intangible assets - (17.59)
Proceeds from sale of property classified as ‘held for sale’ - 15,59.32
Proceeds from sale of Property, plant and equipment 17.17 1,35.93
Investment in fixed deposits maturing beyond 3 months (net) (505,96.52) (554,09.34)
Loan repaid by a related party - 200,00.00
Interest received on deposits (interest income) 120,33.38 92,62.55
Net cash flows used in investing activities (B) (401,19.07) (257,00.48)
125

March 31, 2020 March 31, 2019
CASH FLOWS FROM FINANCING ACTIVITIES
Dividend paid (138,12.05) (116,87.12)
Dividend distribution tax paid (28,39.11) (24,02.32)
Payment of lease liabilities (50,04.90) -
Interest paid, other than on lease liabilities (22.60) (1,90.25)
Net cash flows used in financing activities (C) (216,78.66) (142,79.69)
Net increase/(decrease) in cash and cash equivalents (A+B+C) 8,13.18 99,32.90

Cash and cash equivalents at the beginning of the year 137,00.61 37,6 7.71
Cash and cash equivalents at the end of the year (Refer Note 10) 145,13.79 137,00.61
Significant accounting policies (Refer Note 2)

Notes :
1. Cash Flow Statement has been prepared under the Indirect Method, as set out in Ind AS 7 ‘Statement of Cash Flows’,
whereby profit for the year is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals
of past or future operating cash receipts or payments and item of income or expenses associated with investing
or financing cash flows. The cash flows from operating, investing and financing activities of the Company are
segregated.
2. As per Ind AS 7 - Statement of Cash Flow requires the entities to provide disclosures that enable users of financial statements
to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flows and non-
cash changes, suggesting inclusion of a reconciliation between the opening and closing balances in the Balance Sheet for
liabilities arising from financing activities, to meet the disclosure requirement. There is no item for which any disclosure
is required to be made.



NOTES TO THE FINANCIAL STATEMENTS

1. COMPANY INFORMATION purpose of current/non-current classification
of assets and liabilities. An asset is treated as
Abbott India Limited (‘The Company’) is a public current when it is :
limited company domiciled and incorporated in India
under the provisions of the then Companies Act, 1913. yy Expected to be realised or intended to be
The Company is listed and traded on the Bombay Stock sold or consumed in normal operating cycle
Exchange. It is traded on the National Stock Exchange
under the “permitted category”. The registered office of yy Held primarily for the purpose of trading
the Company is 3, Corporate park, Sion-Trombay road, yy Expected to be realised within twelve
Mumbai - 400 071, India. months after the reporting period
The Company is one of the leading multinational yy Cash or cash equivalent unless restricted
pharmaceutical companies in India and operates with from being exchanged or used to settle a
an owned manufacturing facility in Goa and various liability for at least twelve months after the
independent contract/third party manufacturers based reporting period
across the country. The Company sells its products
through independent distributors primarily within India. All other assets are classified as non-current.
2.
SUMMARY OF SIGNIFICANT ACCOUNTING A liability is current when :
POLICIES
yy It is expected to be settled in normal
2.1 Statement of Compliance operating cycle
The financial statements are prepared on the yy It is held primarily for the purpose of trading
accrual basis of accounting and in accordance
with the Indian Accounting Standards (Ind yy It is due to be settled within twelve months
AS) notified under the Companies (Indian after the reporting period
Accounting Standards) Rules, 2015 (as amended)
and presentation requirements of division II of yy There is no unconditional right to defer the
Schedule III of the Companies Act, 2013. settlement of the liability for at least twelve
months after the reporting period
2.2 Basis of preparation
All other liabilities are classified
The financial statements have been prepared on as non-current.
a historical cost basis, except for certain financial
assets and liabilities measured at fair value. Deferred tax assets and liabilities are
classified as non-current assets and liabilities.
The financial statements are presented in ` and all
values are rounded to the nearest Lakhs (` 000,00) b) Foreign currency translation
upto two decimal, except when otherwise indicated. Functional and presentation currency
The financial statements are approved for issue by Items included in the financial statements
the Company’s Board of Directors on June 8, 2020.
of the Company are measured using
2.3 Summary of significant accounting the currency of the primary economic
policies environment in which the Company operates
(‘the functional currency’). The financial
a) Current and non-current classification statements are presented in Indian Rupee
(`), which is the Company’s functional and
All assets and liabilities are presented in
presentation currency.
the Balance Sheet based on current or non-
current classification as per the Company’s Transactions and balances
normal operating cycle and other criteria set
out in Schedule III of the Companies Act, Monetary assets and liabilities denominated
2013. Based on the nature of products and in foreign currencies at the reporting date
the time between the acquisition of assets for are translated into the functional currency
processing and their realisation into cash and at the exchange rate at that date. Exchange
cash equivalent, the Company has ascertained differences arising on the settlement of
its operating cycle as twelve months for the monetary items or on translating monetary
127
items at rates different from those at which value hierarchy, described as follows, based
they were translated on initial recognition on the lowest level input that is significant to
during the period or in previous period are the fair value measurement as a whole :
recognised in the Statement on Profit and
loss in the period. yy Level 1 — Quoted (unadjusted) prices
in active markets for identical assets
Non-monetary assets and liabilities or liabilities.
denominated in a foreign currency and
measured at historical cost are translated at yy Level 2 (if level 1 feed is not available/
the exchange rate prevalent at the date of the appropriate) — Valuation techniques
for which the lowest level input that is
initial transaction.
significant to the fair value measurement is
c) Fair value measurement directly or indirectly observable.
The Company measures financial instruments yy Level 3 (if level 1 and 2 feed is not available/
such as derivatives at fair value at each Balance appropriate) — Valuation techniques
Sheet date. Fair value is the price that would be for which the lowest level input that is
received on sale of an asset or paid to transfer significant to the fair value measurement
a liability in an orderly transaction between is unobservable.
market participants at the measurement date.
The fair value measurement is based on the For financial assets and liabilities maturing
presumption that the transaction to sell the within one year from the Balance Sheet date
and which are not carried at fair value, the
asset or transfer the liability takes place either :
carrying amount approximates fair value due
yy In the principal market for the asset to the short maturity of these instruments.
or liability, or
The Company recognises transfers
yy In the absence of a principal market, in between levels of fair value hierarchy at
the most advantageous market for the the end of reporting period during which
asset or liability change has occurred.
The principal or the most advantageous d) Property, plant and equipment

market must be accessible by the Company. Property, plant and equipment are stated
The fair value of an asset or a liability is at cost of acquisition less accumulated
measured using the assumptions that market depreciation and impairment in value, if any.
participants would use when pricing the asset Cost for additions comprises the purchase
or liability, assuming that market participants price and any other attributable cost of
act in their economic best interest. bringing the asset to its working condition
for its intended use. Subsequent expenditures
A fair value measurement of a non-financial
are added to its gross book value only if it
asset takes into account a market participant’s
increases the future benefits from the existing
ability to generate economic benefits by using
asset beyond its previously assessed standard
the asset in its highest and best use or by
of performance and cost of the item can be
selling it to another market participant that
measured reliably.
would use the asset in its highest and best use.
The Company identifies and determines cost
The Company uses valuation techniques that of each component/part of the Property, plant
are appropriate in the circumstances and for and equipment separately, if the component/
which sufficient data are available to measure part has a cost which is significant to the total
fair value, maximising the use of relevant cost of the plant and equipment and has useful
observable inputs and minimising the use life that is materially different from that of the
of unobservable inputs. Where required/ remaining plant and equipment.
appropriate, external valuers are involved.
An item of property, plant and equipment is
All assets and liabilities for which fair value derecognised upon disposal or when no future
is measured or disclosed in the financial economic benefits are expected to arise from
statements are categorised within the fair the continued use of the asset. Gains or

losses arising from derecognition of tangible The cost of assets not put to use before
Property, plant and equipment are measured such date are disclosed under ‘Capital
as the difference between the net disposal work-in-progress’.
proceeds and the carrying amount of the
asset and are recognised in the Statement of e) Intangible assets
Profit and Loss.
Intangible assets that are acquired by the
Depreciation of these assets commences Company and that have finite useful lives
when the assets are ready for their intended are measured at cost less accumulated
use. Depreciation is recognised on the cost of amortisation and accumulated impairment
assets (other than Capital work-in-progress) losses, if any. Cost of an intangible asset
less their residual values on straight-line comprises of purchase price and attributable
method over their useful lives as indicated in expenditure on making the asset ready for its
Part C of Schedule II of the Companies Act, intended use. Subsequent expenditures are
2013 and based on technical parameters/ capitalised only when they increase the future
assessments. The management believes that economic benefits embodied in the specific
useful lives currently used fairly reflect its
asset to which they relate.
estimate of the useful lives and residual values
of property, plant and equipment, though Amortisation is recognised on a straight-
these lives in certain cases are different from line basis over the estimated useful lives
lives prescribed under Schedule II. of intangible assets. Intangible assets that
Leasehold improvements are depreciated over are not available for use are amortised
period of the lease agreement or the useful from the date they are available for use.
life, whichever is shorter. Intangible assets are carried at cost, net of
accumulated amortisation and impairment
The estimated useful lives are as follows : losses, if any.
Type of assets Useful life in Intangible assets acquired separately are

years measured on initial recognition at cost.
Leasehold Land Over lease period Intangible assets are amortised over the
i.e. 95 years useful economic life and intangible assets
Buildings are assessed for impairment whenever there
Factory Building* 29 years 11 months is an indication that the intangible asset may
Residential Buildings 50 years be impaired. The amortisation period and
the amortisation method for an intangible
Plant and Equipment*
asset are reviewed at least at the end of each
Anaesthetic Equipment 5 years
reporting period. The amortisation expense
Others 5 to 20 years on intangible assets is recognised in the
Furniture and Fixtures 10 years Statement of Profit and Loss.
Office Equipment
The estimated useful lives are as follows :
Computers* 2 to 5 years
Others 5 to 10 years Type of assets Useful life in years
Vehicles* 5 years Software 5 years
Trade Marks 5 years
* In respect of these assets, the management
estimate of useful lives, based on technical Intangible assets are de-recognised either on
assessment is lower than the useful life their disposal or where no future economic
prescribed under part C of Schedule II to the benefits are expected from their use. Gains
Companies Act, 2013. or losses arising from derecognition of
The residual values, useful lives and methods such intangible assets are measured as the
of depreciation of Property, plant and difference between the net disposal proceeds
equipment are reviewed at each financial year and the carrying amount of the asset and are
end and adjusted prospectively, if appropriate. recognised in the Statement of Profit and Loss.
129
f) Financial instruments profit or loss’, transaction costs that are

attributable to the acquisition of the financial
A financial instrument is any contract that liabilities. Financial liabilities are classified,
gives rise to a financial asset of one entity and at initial recognition, as either ‘Financial
a financial liability or equity instrument of liabilities at fair value through profit or loss’
another entity. or ‘Other financial liabilities’.
Financial assets For purposes of subsequent measurement,
Recognition and measurement financial liabilities are classified in
following categories :
All financial assets are recognised initially at
fair value plus, in the case of financial assets (a) Financial liabilities are classified
not recorded at ‘Fair value through profit or as ‘Financial liabilities at fair value
loss’, transaction costs that are attributable to through profit or loss’, if they are held
the acquisition of the financial asset. Financial for trading or if they are designated as
assets are classified, at initial recognition, as financial liabilities at fair value through
financial assets measured at fair value or as profit or loss. These are measured
‘Financial assets measured at amortised cost’. initially at fair value with subsequent
For purposes of subsequent measurement, changes recognised in Statement of
financial assets are classified in Profit and Loss.
following categories :
(b) Other financial liabilities are
yy Financial assets at amortised cost subsequently measured at amortised
cost, are determined based on the
yy Financial assets at fair value Effective Interest Rate (EIR) method.
A financial asset is measured at amortised Interest expense that is not capitalised as
cost net of impairment, if the objective of part of costs of an asset is included in the
the Company’s business model is to hold the ‘Finance costs’ line item in the Statement
financial asset to collect the contractual cash of Profit and Loss.
flows and the contractual terms of the financial
asset give rise on specified dates to cash flows Derecognition
that are solely payments of principal and
A financial liability is derecognised when the
interest on the principal amount outstanding.
obligation under the liability is discharged
All other financial assets are measured at fair or cancelled or expires. When an existing
value through Statement of Profit and Loss. financial liability is replaced by another from
the same lender on substantially different
Derecognition terms, or the terms of an existing liability are
The Company derecognizes a financial asset substantially modified, such an exchange or
only when the contractual rights to the cash modification is treated as the derecognition
flows from the asset expires or it transfers of the original liability and the recognition
the financial asset and substantially all the of a new liability. The difference between
risks and rewards of ownership of the asset. the carrying amount of the financial liability
On derecognition of a financial asset in derecognised and the consideration paid and
its entirety, the difference between the payable is recognised in profit or loss.
asset’s carrying amount and the sum of
the consideration receives recognised in Offsetting of financial instruments
Statement of Profit and Loss if such gain or loss.
Financial assets and financial liabilities are
Financial liabilities offset and the net amount is reported in the
Balance Sheet if there is a legally enforceable

Recognition and measurement
right to offset the recognised amounts and
All financial liabilities are recognised initially there is an intention to settle on a net basis
at fair value plus, in the case of financial or realise the assets and settle the liabilities
liabilities not recorded at ‘Fair value through simultaneously.

g) Impairment is any indication of impairment. If any such

Financial assets indication exists or when annual impairment
testing for an asset is required, then the
A financial asset is assessed at each reporting asset’s recoverable amount is estimated.
date to determine whether there is any An impairment loss is recognised, as an
objective evidence that it is impaired. A expense in the Statement of Profit and Loss,
financial asset is considered to be impaired, for the amount by which the asset’s carrying
if objective evidence indicates that one or amount exceeds its recoverable amount.
more events have had a negative effect on the The recoverable amount is the higher of an
estimated future cash flows of that asset. asset’s fair value less cost to sell and value
In accordance with Ind AS 109, the Company in use. Value in use is ascertained through
applies Expected Credit Loss (ECL) model for discounting of the estimated future cash
measurement and recognition of impairment flows using a discount rate that reflects the
loss on the following financial assets and current market assessments of the time value
credit risk exposure : of money and the risk specific to the assets.
For the purpose of assessing impairment,
a) Trade receivables or any contractual assets are grouped at the lowest levels into
right to receive cash or another financial cash generating units for which there are
asset that result from transactions that separately identifiable cash flows.
are within the scope of Ind AS 115
An impairment loss recognised in prior
b) Other financial assets which are
years are reversed if there has been a change
measured at amortised cost
in the estimates used to determine the
The Company follows simplified approach for recoverable amount. An impairment loss is
recognition of impairment loss allowance on reversed only to the extent that the asset’s
Trade receivables. The Company recognises carrying amount does not exceed the carrying
impairment loss allowance based on lifetime amount that would have been determined,
ECLs at each reporting date, right from its net of depreciation or amortisation, if no
initial recognition. impairment had been recognised in
previous years.
For recognition of impairment loss on other
financial assets and risk exposure, the h) Leases
Company determines that whether there has
been a significant increase in the credit risk The Company assesses at contract inception
since initial recognition. If credit risk has not whether a contract is, or contains, a lease.
increased significantly, twelve month ECL is That is, if the contract conveys the right to
used to provide for impairment loss. However, control the use of an identified asset for a
if credit risk has increased significantly, period of time in exchange for consideration.
lifetime ECL is used. If, in a subsequent period, Company as a lessee
credit quality of the instrument improves such
that there is no longer a significant increase The Company applies a single recognition and
in credit risk since initial recognition, then measurement approach for all leases, except
the entity reverts to recognising impairment for short-term leases. The Company recognises
loss allowance based on twelve month ECL. lease liabilities to make lease payments and
ECL are measured in a manner that they Right-of-use assets representing the right to
reflect unbiased and probability weighted use the underlying assets.
amounts determined by a range of outcomes,
taking into account the time value of money i) Right-of-use assets
and other reasonable information available as The Company recognises Right-of-use
a result of past events, current conditions and assets at the commencement date of the
forecasts of future economic conditions. lease (i.e., the date the underlying asset is
Non-financial assets available for use). Right-of-use assets are
measured at cost, less any accumulated
The carrying amount of non-financial assets depreciation and impairment losses,
other than inventories are assessed at each and adjusted for any remeasurement
reporting date to ascertain whether there of lease liabilities. The cost of Right-of-
131
use assets includes the amount of lease a change in an index or rate used to
liabilities recognised, initial direct costs determine such lease payments) or a
incurred, and lease payments made at or change in the assessment of an option
before the commencement date less any to purchase the underlying asset.
lease incentives received. Right-of-use The Company’s lease liabilities are
assets are depreciated on a straight-line included in Financial Liabilities
basis over the shorter of the lease term (Refer Note 41).
and the estimated useful lives of the
assets, as follows : iii)
Short-term leases
yy Buildings : 2 to 9 years The Company applies the short-

term lease recognition exemption
yy Furniture & Fixtures : 3 to 6 years to its short-term leases of buildings
yy Motor vehicles : 2 to 5 years (i.e. those leases that have a lease
term of 12 months or less from the
If ownership of the leased asset commencement date and do not
transfers to the Company at the end contain a purchase option). Lease
of the lease term or the cost reflects payments on short-term leases are
the exercise of a purchase option, recognised as expense.
depreciation is calculated using the
estimated useful life of the asset. Company as a lessor
The Right-of-use assets are also subject
Leases in which the Company does not
to impairment. Refer to the accounting
transfer substantially all the risks and rewards
policies in Note 2.3 (g) Impairment of
incidental to ownership of an asset are
non-financial assets.
classified as operating leases. Rental income
ii)
Lease Liabilities arising is accounted for over the lease terms.
Initial direct costs incurred in negotiating
At the commencement date of the lease, and arranging an operating lease are added
the Company recognises lease liabilities to the carrying amount of the leased asset and
measured at the present value of lease recognised over the lease term on the same
payments to be made over the lease basis as rental income.
term. The lease payments include fixed
payments (including in substance fixed i) Inventories
payments) less any lease incentives
Inventories consists of raw materials, packing
receivable. The lease payments also
materials, work-in-progress, stock-in-trade
include the exercise price of a purchase
and finished goods. Inventories are valued at
option reasonably certain to be exercised
lower of cost and net realisable value. Cost is
by the Company and payments of
determined on First-In-First-Out basis.
penalties for terminating the lease, if
the lease term reflects the Company Cost of raw materials and packing materials
exercising the option to terminate. includes cost of purchase and other costs
incurred in bringing the inventories to their
In calculating the present value of
present location and condition.
lease payments, the Company uses
its incremental borrowing rate at the Cost of work-in-progress and finished
lease commencement date because goods includes direct materials, labour and
the interest rate implicit in the lease proportion of manufacturing overheads based
is not readily determinable. After the on the normal operating capacity, wherever
commencement date, the amount of applicable. Cost of finished goods further
lease liabilities is increased to reflect includes excise duty and other costs incurred
the accretion of interest and reduced for in bringing the inventories to their present
the lease payments made. In addition, location and condition.
the carrying amount of lease liabilities
is remeasured if there is a modification, Cost of stock-in-trade includes cost of
a change in the lease term, a change purchase and other costs incurred in
in the lease payments (e.g., changes bringing the inventories to their present
to future payments resulting from location and condition.

Net realisable value is the estimated selling yy a present obligation that arises from past
price in the ordinary course of business, less events but is not recognised because :
estimated costs of completion and estimated
costs necessary to make the sale. However, −− it is not probable that an outflow
materials and other items held for use in the of resources embodying economic
production of inventories are not written benefits will be required to settle
down below cost if the finished products in the obligation; or
which they will be used are expected to be
−− the amount of the obligation cannot be
sold at or above cost.
measured with sufficient reliability.
j) Cash and cash equivalents
l) Revenue
Cash and cash equivalents in the Balance Revenue from contracts with customers
Sheet comprise cash at banks and on hand
and short-term deposits with a maturity
Revenue from contracts with customers is
of three months or less, which are subject recognised when control of the goods or
to an insignificant risk of changes in value. services are transferred to the customer at
For the purpose of the Statement of Cash an amount that reflects the consideration to
Flows, cash and cash equivalents consist which the Company expects to be entitled
of cash and short-term deposits, as defined in exchange for those goods or services. The
above, net of outstanding bank overdrafts, if Company has concluded that it is the principal
any, as they are considered an integral part of in all of its revenue arrangements since it
the Company’s cash management. is the primary obligor in all the revenue
arrangements as it has pricing latitude and is
k) Provisions and contingencies also exposed to inventory risks.
Provisions Goods and Services Tax (GST) is not received
A provision is recognised if, as a result of a by the Company on its own account. Rather,
past event, the Company has a present legal it is tax collected on value added to
or constructive obligation that is reasonably the commodity by the seller on behalf
estimable, and it is probable that an outflow of of the government. Accordingly, it is
resources embodying economic benefits will excluded from revenue.
be required to settle the obligation. Provisions Sale of products
are determined by discounting the expected
future cash flows at a pre-tax rate that reflects Revenue from sale of products (including sale
current market assessments of the time value of products under co-marketing agreement) is
of money and the risks specific to the liability. recognised at the point in time when control
of the asset is transferred to the customer,
Provision for sales return and date expiry generally on delivery of the products.
Invoices are payable within contractually
The Company as per trade practice accepts agreed credit period.
returns from market which are primarily in
the nature of expired or near expiry products. The Company considers whether there
Provisions for such returns are estimated are other promises in the contract that are
on the basis of historical experience, market separate performance obligations to which
conditions and specific contractual terms and a portion of the transaction price needs to
are provided for. be allocated. In determining the transaction
price for the sale of products, the
Contingencies
Company considers the effects of variable
A contingent liability is : consideration (if any).
yy a possible obligation that arises from Revenue from sale of products is stated
past events and whose existence will be exclusive of Goods and Services Tax
confirmed only by the occurrence or non- (GST). Revenues are net of sales returns,
occurrence of one or more uncertain future discounts, provision for anticipated returns
events not wholly within the control of on expiry, made on the basis of management
the Company; or expectations.
133
Sales returns an amount of consideration is due) from the

customer. If a customer pays consideration
The Company accounts for sales returns before the Company transfers goods or
accrual by recording an allowance for sales services to the customer, a contract liability is
returns concurrent with the recognition recognised when the payment is received from
of revenue at the time of a product sale. customer or due, whichever is earlier. Contract
This allowance is based on the Company’s liabilities are recognised as revenue when the
estimate of expected sales returns. With Company performs under the contract.
respect to established products, the Company
considers its historical experience of Interest income
sales returns, levels of inventory in
the distribution channel, estimated Interest income from a financial asset is
shelf life, product discontinuances, recognised when it is probable that the
price changes of competitive products, economic benefits will flow to the Company
and the introduction of competitive and the amount of income can be measured
new products, to the extent each of reliably. Interest income is accrued on a
these factors impact the Company’s time basis, by reference to the principal
business and markets. With respect outstanding and at the effective interest rate
to new products introduced by the applicable, which is the rate that exactly
Company, such products have historically discounts estimated future cash receipts
been either extensions of an existing through the expected life of the financial
line of product where the Company has asset to that asset’s net carrying amount
historical experience or in therapeutic on initial recognition. Interest income is
categories where established products exist included in ‘Other Income’ in the Statement of
and are sold either by the Company or the Profit and Loss.
Company’s competitors.
Income from assignment of trademarks

Rendering of services Income from assignment of trademarks is
recognised in the Statement of Profit and
Service income is recognised as per the terms Loss on fulfilment of obligations as per the
of the contracts/arrangements when related underlying agreement with the buyer.
services are performed and is stated net of GST.
Contract balances m) Employee benefits
Trade receivables Short-term employment benefits

A receivable represents the Company’s All employee benefits payable within twelve
right to an amount of consideration that is months of service such as salaries, wages,
unconditional (i.e., only the passage of time is bonus, ex-gratia, medical benefits, sick leave,
required before payment of the consideration casual leave etc. are recognised in the year
is due). Also refer to the accounting policies in which the employees render the related
Note 2.3 (f) financial instruments - financial service and are presented as current employee
assets - recognition and measurement. benefit obligation within the Balance
Contract assets Sheet. Termination benefits are recognised
as an expense as and when incurred.
A contract asset is the right to consideration Short-term leave benefit is provided
in exchange for goods or services transferred at undiscounted amount during the
to the customer. If the Company performs by accounting period based on the service
transferring goods or services to a customer rendered by employees.
before the customer pays consideration or
before payment is due, a contract asset is Defined contribution plan
recognised for the earned consideration that
is conditional. Contributions to defined contribution schemes
such as State governed Provident Fund and
Contract liabilities Employee Pension Scheme, Employees’
A contract liability is the obligation to transfer State Insurance Scheme, Superannuation,
goods or services to a customer for which Employees’ Deposit Linked Insurance and
the Company has received consideration (or Group Life Insurance are charged as an

expense based on the amount of contribution

Past service costs are recognised in
required to be made as and when services Statement of Profit and Loss in the period of
are rendered by the employees. The above a plan amendment. The net interest cost is
benefits are classified as defined contribution calculated by applying the discount rate to the
schemes and the Company has no further net balance of the defined benefit obligation
defined obligations beyond the contributions. and the fair value of plan assets. This cost
is included in employee benefit expense in
If the contribution payable to the scheme for Statement of Profit and Loss.
service received before the Balance Sheet date
exceeds the contribution already paid, the Actuarial gains and losses arising from
deficit payable to the scheme is recognised experience adjustments and changes in
as a liability after deducting the contribution actuarial assumptions are charged or credited
already paid. If the contribution already paid to OCI in the period in which they arise
exceeds the contribution due for services and is reflected immediately in retained
received before the Balance Sheet date, then earnings and is not reclassified to Statement
excess is recognised as an asset to the extent of Profit and Loss.
that the pre-payment will lead to a reduction
in future payment or a cash refund. When the benefits of the plan are changed, or
when a plan is curtailed or settlement occurs,
Defined benefit plan the portion of the changed benefit related to
past service by employees, or the gain or loss
The Company has defined benefit plan in on curtailment or settlement, is recognised
the form of Gratuity, Long Service Benefits immediately in the Statement of Profit and
and Post Retirement Medical Benefits as Loss when the plan amendment or when a
per policies of the Company. The liability in curtailment or settlement occurs.
respect of defined benefit plans is calculated
using the projected unit credit method with Other employee benefits
actuarial valuations being carried out at
the end of each annual reporting period. Other employee benefits comprise of
leave encashment which is provided
The Company’s net obligation in respect
for, based on the actuarial valuation
of the defined benefit plan is calculated by
carried out as at the end of the year.
estimating the amount of future benefit that
Liabilities recognised in respect of other
employee has earned in exchange of their
employee benefits are measured at the present
service in the current and prior periods and
value of the estimated future cash outflows
discounted back to the current valuation date
expected to be made by the Company in
to arrive at the present value of the defined
respect of services provided by employees up
benefit obligation. The present value of the
to the reporting date.
defined benefit obligation is deducted from
the fair value of plan assets, to arrive at the net n) Income Tax
asset/(liability), which need to be accounted
Current income tax
for in the books of accounts of the Company.
Income Tax expense comprises of current and
As required by Ind AS 19 ‘Employee Benefits’, deferred tax and includes any adjustments
the discount rate used to arrive at the present related to past periods in current and/or
value of the defined benefit obligations is deferred tax adjustments that may become
based on the Indian government security necessary due to certain developments or
yields prevailing as at the Balance Sheet date reviews during the relevant period. The
that have maturity date equivalent to the provision for current tax is made at the rate of
tenure of the obligation. tax as applicable for the income of the previous
year as defined under the Income tax Act, 1961.
The current service cost of the defined benefit
plan, recognised in the Statement of Profit and Current income tax relating to items
Loss as employee benefits expense, reflects recognised, either in other comprehensive
the increase in the defined benefit obligation income or directly in equity, is also recognised
resulting from employee service in the in other comprehensive income or in equity,
current year, benefit changes, curtailments as appropriate and not in the Statement of
and settlements. Profit and Loss. Management periodically
135
evaluates positions taken in the tax returns Development expenditures on an individual

with respect to situations in which applicable project are recognised as an intangible asset
tax regulations are subject to interpretation when the Company can demonstrate :
and establishes provisions where appropriate.
Current tax assets and current tax liabilities yy The technical feasibility of completing the
are offset when there is a legally enforceable intangible asset so that the asset will be
right to set off the recognised amounts and available for use or sale
there is an intention to settle the asset and the
yy Its intention to complete and its ability and
liability on a net basis.
intention to use or sell the asset
Deferred tax
yy How the asset will generate future
Deferred tax is recognised using the Balance economic benefits
Sheet approach on temporary differences
at the reporting date between the tax bases yy The availability of resources to
of assets and liabilities and their carrying complete the asset
amounts for financial reporting purposes at yy The ability to measure reliably the
the reporting date. expenditure during development
The carrying amount of deferred tax assets is
The amount capitalised comprises
reviewed at each reporting date and reduced
to the extent that it is no longer probable that expenditure that can be directly attributed
sufficient taxable profit will be available to or allocated on a reasonable and consistent
allow all or part of the deferred tax asset to basis to creating, producing and making the
be utilised. Unrecognised deferred tax assets asset ready for its intended use. Property,
are re-assessed at each reporting date and are plant and equipment utilised for research
recognised to the extent that it has become and development are capitalised and
probable that future taxable profits will allow depreciated in accordance with the policies
the deferred tax asset to be recovered. stated for Property, plant and equipment
and depreciation.
Deferred tax assets and liabilities are
measured at the tax rates that are expected p) Earnings per equity share
to apply in the year when the asset is realised
or the liability is expected to be recovered or The Company presents basic and diluted
settled, based on tax rates and tax laws that earnings per share (‘EPS’) data for
have been enacted or substantively enacted at its equity shares.
the reporting date.
Basic EPS is computed by dividing the net
Deferred tax relating to items recognised, profit after tax for the year attributable to
either in other comprehensive income the equity shareholders of the Company by
or in equity, is also recognised in other weighted average number of equity shares
comprehensive income or in equity, as outstanding during the year.
appropriate and not in the Statement of
Profit and Loss. Diluted EPS is computed by dividing the net
profit attributable to equity holders of the
Deferred tax assets and deferred tax liabilities Company by the weighted average number
are offset, if a legally enforceable right exists of equity shares considered for deriving
to set-off current tax assets against current basic earnings per equity share and also the
tax liabilities. weighted average number of equity shares
that could have been issued upon conversion
o) Research and development
of all dilutive potential equity shares. The
Revenue expenditure pertaining to research dilutive potential equity shares are adjusted
is charged to the Statement of Profit and for the proceeds receivable had the equity
Loss. Development costs of products are shares been actually issued at fair value (i.e.
also charged to the Statement of Profit the average market value of the equity shares).
and Loss unless a product’s technical Dilutive potential equity shares are deemed
feasibility has been established, in which converted as of the beginning of the period
case such expenditure is capitalised. unless issued at a later date.

q) Share based compensation Lease, Appendix A of Ind AS 17 Operating Leases-

Incentives and Appendix B of Ind AS 17 Evaluating
Abbott Laboratories, USA, being the Ultimate the Substance of Transactions Involving the
Holding Company, has given restricted stock Legal Form of a Lease). The standard sets out
option plan to the employees of the Company. the principles for the recognition, measurement,
Pursuant to Ind AS 102 ‘Share-based Payment’, presentation and disclosure of leases and requires
the Company recognises an expense based on lessees to recognise most leases on the Balance
the fair value of the stock options as at grant Sheet. Lessor accounting under Ind AS 116
date. The expenses are amortised over the is substantially unchanged from Ind AS 17.
vesting period. The corresponding credit is Lessors will continue to classify leases as
given to equity because the award represents either operating or finance leases using similar
in substance equity contribution by the principles as in Ind AS 17. Therefore, Ind AS 116
Parent Company. The cumulative expense does not have an impact for leases where the
recognised for stock options at each reporting Company is the lessor.
date until the vesting date reflects the extent The Company adopted Ind AS 116 using the
to which the vesting period has expired and modified retrospective method of adoption, with
the Company’s best estimate of the number of the date of initial application on April 1, 2019.
equity instruments that will ultimately vest. The Company elected to use the transition
r) Dividend distribution to equity practical expedient to not reassess whether a
shareholders contract is, or contains, a lease at April 1, 2019.
Instead, the Company applied the standard only to
The Company recognises a liability to make contracts that were previously identified as leases
cash distributions to equity holders when the applying Ind AS 17 and Appendix C of Ind AS 17
distribution is authorised and the distribution at the date of initial application. The Company
is no longer at the discretion of the Company. also elected to use the recognition exemptions for
As per the corporate laws in India, a lease contracts that, at the commencement date,
distribution is authorised when it is approved have a lease term of 12 months or less and do not
by the shareholders. A corresponding amount contain a purchase option (short-term leases)
is recognised directly in equity in the (Refer Note 41).
year of approval.
Appendix C to Ind AS 12 Uncertainty over
2.4 Summary of significant accounting Income Tax treatment
policies
The appendix addresses the accounting for income
New and amended standards taxes when tax treatments involve uncertainty that
affects the application of Ind AS 12 Income Taxes.
The Company applied Ind AS 116 for the first time. The Company determines whether to consider each
The nature and effect of the changes as a result of uncertain tax treatment separately or together
adoption of these new accounting standards are with one or more other uncertain tax treatments
described below. Several other amendments apply and uses the approach that better predicts the
for the first time from April 1, 2019, but do not resolution of the uncertainty. The Company applies
have an impact on the financial statements of the significant judgement in identifying uncertainties
Company. The Company has not early adopted any over income tax treatments.
standards, amendments that have been issued but
are not yet effective/notified. Upon adoption of the Appendix C to Ind AS 12,
the Company considers any uncertain tax position
Ind AS 116 Leases on receiving assessment order from the taxation
authorities. Further, the Company considers
Ind AS 116 supersedes Ind AS 17 Leases including
the same principle of tax treatment for all open
its appendices (Appendix C of Ind AS 17
assessment years (Refer Note 38).
Determining whether an Arrangement contains a
137
3. PROPERTY, PLANT AND EQUIPMENT

Plant and
Buildings Furniture
Leasehold Leasehold Equipment Office
(Refer Note and Vehicles Total
Land Improvements (Refer Equipment
(b) and (e)) fixtures
Note (a))
Gross carrying value
As at April 1, 2018 37.55 84.38 19,99.34 75,90.42 4,51.84 15,73.67 54.67 117,91.87
Additions (Refer Note (c) below) - - 58.62 8,11.59 51.96 4,07.52 - 13,29.69
Other adjustments (Refer Note (d) below) - - 30,34.11 - - - - 30,34.11
Disposals - (22.10) (0.16) (2,39.69) (12.56) (42.50) (37.67) (3,54.68)
As at March 31, 2019 37.55 62.28 50,91.91 81,62.32 4,91.24 19,38.69 17.00 158,00.99
Additions (Refer Note (c) below) - - 17.59 6,25.66 48.87 7,01.42 - 13,93.54
Disposals - - (1.80) (1,54.68) (24.60) (46.06) - (2,27.14)
As at March 31, 2020 37.55 62.28 51,07.70 86,33.30 5,15.51 25,94.05 17.00 169,67.39
Accumulated depreciation
As at April 1, 2018 1.50 19.82 2,44.41 23,76.51 2,37.66 10,00.06 53.35 39,33.31
Depreciation charge for the year 0.50 12.89 1,83.88 9,56.85 42.12 3,82.46 1.32 15,80.02
Other adjustments (Refer Note (d) below) - - 1,81.31 - - - - 1,81.31
Disposals - (9.78) (0.06) (1,14.73) (11.94) (30.36) (37.67) (2,04.54)
As at March 31, 2019 2.00 22.93 6,09.54 32,18.63 2,67.84 13,52.16 17.00 54,90.10
Depreciation charge for the year 0.50 8.21 1,58.47 9,40.14 38.20 4,64.50 - 16,10.02
Disposals - - (0.27) (96.08) (16.68) (41.27) - (1,54.30)
As at March 31, 2020 2.50 31.14 7,67.74 40,62.69 2,89.36 17,75.39 17.00 69,45.82
Net carrying value

As at March 31, 2020 35.05 31.14 43,39.96 45,70.61 2,26.15 8,18.66 - 100,21.57
As at March 31, 2019 35.55 39.35 44,82.37 49,43.69 2,23.40 5,86.53 - 103,10.89
Details of Capital work-in-progress

As at March 31, 2020 As at March 31, 2019
Capital work-in-progress 1,64.21 73.14
1,64.21 73.14
Notes :
a) Included in Plant and Equipment are anaesthetic equipments, installed at various hospitals free of cost with the intention
of procuring business for the Company’s products :
Class of Asset Net Block

Plant and Equipment 3,58.25 3,87.74
* *
b) Included in Buildings is an amount of ` 0.00 Lakhs (March 2019 : ` 0.00 Lakhs) representing value of shares in co-
operative housing society.
c) Additions include capital expenditure of ` 12.19 Lakhs (March 31, 2019 : ` 0.84 Lakhs) incurred at Company’s inhouse
R&D facility at Goa.
d) Other adjustments represents assets that were earlier classified as ‘Asset held for sale’, reclassified to Property, plant and
equipment in the previous year.
e) The title deed of building having net book value of ` 32,41.41 Lakhs (March 31, 2019 : ` 33,31.64 Lakhs) are in erstwhile
name of the Company or in the name of the entity that got merged with the Company.
f) The amount of contractual commitments for the acquisition of Property, plant and equipment is disclosed in Note 38 (a).
*
below ` 500/-


4. INTANGIBLE ASSETS
Software Trade Marks Total

Gross carrying value
As at April 1, 2018 5,46.53 86.84 6,33.37
Additions 17.59 - 17.59
Disposals (0.43) - (0.43)
As at March 31, 2019 5,63.69 86.84 6,50.53
Additions - - -
Disposals (5.08) - (5.08)
As at March 31, 2020 5,58.61 86.84 6,45.45
Accumulated amortisation
As at April 1, 2018 3,41.92 11.85 3,53.77
Amortisation for the year 94.74 17.37 1,12.11
Disposals (0.43) - (0.43)
As at March 31, 2019 4,36.23 29.22 4,65.45
Amortisation for the year 77.79 17.42 95.21
Disposals (5.08) - (5.08)
As at March 31, 2020 5,08.94 46.64 5,55.58
Net carrying value

As at March 31, 2020 49.67 40.20 89.87
As at March 31, 2019 1,27.46 57.6 2 1,85.08
5. NON-CURRENT FINANCIAL ASSETS - LOANS

Deposits with body corporates and others :
For premises with a related party (Unsecured, considered good)
(Refer Note 40 (D)) 14,57.29 13,28.99
For premises with others (Unsecured, considered good) 1,00.24 87.19
Against tenders (Refer (a) below) 1,20.68 1,94.52
16,78.21 16,10.70
(a) Deposits against tenders :

Secured, considered good - -
Unsecured, considered good 1,20.68 1,94.52
Credit impaired advances and deposits 4,09.71 3,47.6 8
5,30.39 5,42.20
Less : Allowance for credit impaired advances and deposits (4,09.71) (3,47.68)
1,20.68 1,94.52
6. NON-CURRENT FINANCIAL ASSETS - OTHERS (UNSECURED, CONSIDERED GOOD)

Margin deposit and deposit against guarantees and tenders 5,38.06 4,46.88
Expected reimbursement towards likely sales return - reimbursable
(Refer Note 17) 30,88.24 32,18.92
36,26.30 36,65.80
139

7. OTHER NON-CURRENT ASSETS (UNSECURED, CONSIDERED GOOD)
Capital advances 1,33.94 45.45
VAT deposits 1,91.25 1,87.86
Deposit against co-marketing agreement - 5,50.00
Deferred lease assets* - 56.40
3,25.19 8,39.71
*
Previous year figure includes ` 40.77 Lakhs towards deposit given to a related party (Refer Note 40 (D)). In current year,
deferred lease asset is considered alongwith Right-of-use assets on implementation of Ind AS 116 Leases.
8. INVENTORIES (AT LOWER OF COST OR NET REALISABLE VALUE)

Raw materials and packing materials # 77,72.04 96,09.38
Work-in-progress 20,52.61 40,55.43
Finished goods 97,51.74 62,60.27
Stock-in-trade @ 331,40.12 407,53.75
527,16.51 606,78.83
#
Includes goods in transit ` 14,42.15 Lakhs (March 31, 2019 : ` 22,01.56 Lakhs)
@
Includes goods in transit ` 15,34.84 Lakhs (March 31, 2019 : ` 22,12.37 Lakhs)
During the year ended March 31, 2020, ` 28,53.53 Lakhs (March 31, 2019 : ` 11,33.57 Lakhs) was recognised as an expense
towards provision for slow moving, expired and near expiry inventories.
9. TRADE RECEIVABLES
Trade receivables 292,88.45 221,66.39

Receivables from related parties (Refer Note 40 (D)) 25,03.04 54,45.04
317,91.49 276,11.43
Break-up for Trade receivables :
Trade receivables
Secured, considered good - -
Unsecured, considered good 317,91.49 276,11.43
Credit impaired 11,31.17 11,19.09
329,22.66 287,30.52
Less : Allowance for credit impaired debts (11,31.17) (11,19.09)
317,91.49 276,11.43
There are no trade or other receivables which are due from directors or other officers of the Company either severally or
jointly with any other person. Also, there are no trade or other receivables which are due from firms or private companies,
in which any director is a partner, a director or a member.
For terms and conditions relating to related party receivables, refer Note 40.
For information on financial risk management objectives and policies, refer Note 44.


10. CASH AND CASH EQUIVALENTS
Balances with banks

In current accounts 23,13.79 107,00.61
Deposits with original maturity of less than three months @ 122,00.00 30,00.00
145,13.79 137,00.61
@
Represents time deposits at fixed rates maintained with various banks by the Company.
11. BANK BALANCES OTHER THAN CASH AND CASH EQUIVALENTS
Margin deposit and deposit against guarantees and tenders 2,15.38 1,70.02
Earmarked bank balance towards dividend # 3,40.71 3,50.09
Term deposits with original maturity of more than three months but less than
twelve months @ 2046,67.58 1542,07.60
2052,23.67 1547,27.71
#
These balances are available for use only towards settlement of corresponding unpaid dividend liabilities.
@
Represents time deposits at fixed rates maintained with various banks by the Company.
12. CURRENT FINANCIAL ASSETS - LOANS (UNSECURED, CONSIDERED GOOD)
Deposits with body corporates and others :
For Premises 6,14.13 7,30.24
6,14.13 7,30.24
13. CURRENT FINANCIAL ASSETS - OTHERS (UNSECURED, CONSIDERED GOOD)

Interest accrued but not due on bank deposits 18,54.69 27,13.79
Receivables from related parties (Refer Note 40 (D)) 7,84.08 6,13.94
Expected reimbursement towards likely sales return - reimbursable (Refer Note 23) 26,68.57 27,90.73
Other receivables 19,30.22 12,15.93
72,37.56 73,34.39
14. OTHER CURRENT ASSETS

Prepaid expenses 5,63.60 6,22.27
Advances to employees and suppliers 18,81.25 31,62.94
Balance with customs and excise on current account 13.51 14.88
GST receivables 30,59.59 6 5,47.6 3
Deferred lease assets* - 1,08.84
Others 1,61.58 1,61.58
56,79.53 106,18.14
*
Previous year figure includes ` 97.91 Lakhs towards deposit given to related parties (Refer Note 40 (D)). In current year,
deferred lease asset is considered alongwith Right-of-use assets on implementation of Ind AS 116 Leases.
141

15. EQUITY SHARE CAPITAL
Authorised share capital :
Equity shares of ` 10 each
Number of shares Amount
As at April 1, 2018 2,75,00,000 27,50.00
Changes during the year - -
As at March 31, 2019 2,75,00,000 27,50.00
As at March 31, 2020 2,75,00,000 27,50.00
Terms/rights attached to equity shares
The Company has only one class of equity shares with voting rights having a par value of ` 10 per share. The Company
declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval
of the shareholders in the ensuing Annual General Meeting. The remittance of dividend outside India is governed by
Indian law on foreign exchange and is subject to applicable distribution taxes.
In the event of liquidation of the Company, the shareholders of equity shares will be entitled to receive remaining assets of
the Company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity
shares held by the shareholders.
Issued, Subscribed and Paid up Capital :

Equity shares of ` 10 each fully paid
Number of shares Amount
As at April 1, 2018 2,12,49,302 21,24.93
As at March 31, 2019 2,12,49,302 21,24.93
As at March 31, 2020 2,12,49,302 21,24.93
Details of Equity shares of ` 10 each fully paid held by the Holding As at As at

Company and subsidiaries of the Ultimate Holding Company : March 31, 2020 March 31, 2019
i) 1,07,19,097 (March 31, 2019 : 1,07,19,097) Abbott Capital India Ltd., U.K.
(Holding Company) 10,71.91 10,71.91
ii) 37,44,951 (March 31, 2019 : 37,44,951) Abbott Healthcare Products Ltd.,
U.K. (Subsidiary of the Ultimate Holding Company) 3,74.50 3,74.50
iii) 14,70,000 (March 31, 2019 : 14,70,000) British Colloids Ltd., U.K.
(Subsidiary of the Ultimate Holding Company) 1,47.00 1,47.00
The Ultimate Holding Company is Abbott Laboratories, USA.

Details of shareholders holding more than Number of % Holding Number of % Holding
5% shares in the Company shares shares
i) Abbott Capital India Ltd., U.K. 1,07,19,097 50.45% 1,07,19,097 50.45%

ii) Abbott Healthcare Products Ltd., U.K. 37,44,951 17.62% 37,44,951 17.62%
iii) British Colloids Ltd., U.K. 14,70,000 6.92% 14,70,000 6.92%
1,59,34,048 74.99% 1,59,34,048 74.99%


Dividend paid and proposed March 31, 2020 March 31, 2019
Dividend on equity shares declared and paid :
Final dividend for the year ended March 31, 2019 : ` 50 per share 106,24.65 106,24.65
(March 31, 2018 : ` 50 per share)
Special dividend for the year ended March 31, 2019 : ` 15 per share 31,87.40 10,62.47
(March 31, 2018 : ` 5 per share)
Dividend distribution tax on proposed dividend 28,39.11 24,02.32
Date of approval (date of Annual General Meeting) August 22, 2019 July 18, 2018
Proposed dividend on equity shares :
Final dividend for the year ended March 31, 2020 : ` 107 per share 227,36.75 106,24.65
(March 31, 2019 : ` 50 per share)
Special dividend for the year ended March 31, 2020 : ` 143 per share 303,86.50 31,87.40
(March 31, 2019 : ` 15 per share)
Dividend distribution tax on proposed dividend - 28,39.11
Proposed dividends on equity shares are subject to approval at the Annual General Meeting and are not recognised as a
liability (including dividend distribution tax thereon) as at March 31, 2019 and March 31, 2020.
Effective April 1, 2020, in view of the changes made under the Income Tax Act, 1961, by the Finance Act, 2020, dividends
distributed by the Company shall be taxable in the hands of the shareholders. Hence, there will be no liability on the
Company towards the dividend distribution tax on proposed dividend.
16. OTHER EQUITY
Items of Other
Reserves and Surplus Comprehensive
Total
Income
Other
Capital Share Based Remeasurement
Amalgamation Capital General Retained Equity
Redemption Compensation of defined
Reserve Reserve Reserve Earnings
Reserve Reserve benefit plan
As at April 1, 2018 37.82 5,22.62 2,52.48 20,95.22 337,25.95 1309,12.39 (3,95.36) 1671,51.12
Profit for the year - - - - - 450,33.18 - 450,33.18
(net of tax) - - - - - - (2,08.82) (2,08.82)
Reserve - - - - 45,03.32 (45,03.32) - -
Dividend for the year ended March 31,
2018 (Refer Note 15) - - - - - (116,87.12) - (116,87.12)
(Refer Note 29) - - - 8,47.55 - - - 8,47.55
reserve to General Reserve* - - - (1,68.13) 1,68.13 - - -
As at March 31, 2019 37.82 5,22.62 2,52.48 27,74.64 383,97.40 1573,52.81 (6,04.18) 1987,33.59
Profit for the year - - - - - 592,93.26 - 592,93.26
(net of tax) - - - - - - (4,95.35) (4,95.35)
Reserve - - - - 59,29.33 (59,29.33) - -
Dividend for the year ended March 31,
2019 (Refer Note 15) - - - - - (138,12.05) - (138,12.05)
(Refer Note 29) - - - 8,76.75 - - - 8,76.75
reserve to General Reserve* - - - (75.83) 75.83 - - -
Impact due to adoption of Ind AS 116
Leases under modified retrospective
approach - - - - - (9,50.52) - (9,50.52)
Deferred tax impact due to adoption
of Ind AS 116 Leases under modified
retrospective approach - - - - - 2,39.23 - 2,39.23
As at March 31, 2020 37.82 5,22.62 2,52.48 35,75.56 444,02.56 1933,54.29 (10,99.53) 2410,45.80
*
On account of cancellation of share options awarded to employees
143

Nature and purpose of components of other equity :
1. Amalgamation Reserve
This was created on amalgamation of Beem Healthcare Limited and Valencia Pharmaceuticals Limited, wholly owned
subsidiary of the Company with appointed date as July 1, 1998. All assets and liabilities of erstwhile Beem Healthcare
Limited and Valencia Pharmaceuticals Limited were transferred to the Company and all shares held by the Company
in erstwhile Beem Healthcare Limited and Valencia Pharmaceuticals Limited were cancelled. The amalgamation was
accounted under ‘Pooling of Interests method’ as prescribed in then Accounting Standard 14 issued by the Institute of
Chartered Accountants of India.
2. Capital Reserve
This was created on amalgamation of Lenbrook Pharmaceuticals Limited, a wholly owned subsidiary of the Company with
the appointed date as October 1, 2003. All the assets and liabilities of erstwhile Lenbrook Pharmaceuticals Limited were
transferred to the Company and all shares held by the Company in the erstwhile Lenbrook Pharmaceuticals Limited were
cancelled. The amalgamation was accounted under the ‘Purchase Method’ as prescribed in then applicable Accounting
Standards 14 issued by the Institute of Chartered Accountants of India.
3. Capital Redemption Reserve
This was created according to Section 77A of the Companies Act, 1956 by transferring the face value of shares bought back
during the period 2003 to 2008 from free reserves.
4. Share Based Compensation Reserve
The Company’s employees are awarded Restricted Stock Units (RSUs) of the Ultimate Holding Company, Abbott
Laboratories, USA. The Share Based Compensation Reserve is used to recognise the fair value of the RSUs awarded to the
employees. The award represents in substance equity contributions by the Ultimate Holding Company.
5. General Reserve
General Reserve is used from time to time to transfer profits from retained earnings for appropriation purposes.
General Reserve is created by a transfer from one component of equity to another and is not an item of Other
Comprehensive Income (OCI).
6. Retained Earnings
Retained Earnings are the profits the Company has earned till date, less any transfer to General Reserve, dividends or
other distributions paid to the shareholders.
7. Remeasurement of defined benefit plan
Differences between the interest income on plan assets and the return actually achieved, and any changes in the liabilities
over the year due to changes in actuarial assumptions or experience adjustments within the plans, are recognised in OCI
and subsequently not reclassified to the Statement of Profit and Loss.
17. NON-CURRENT PROVISIONS
Provision for employee benefits :
Post retirement medical benefits 2,99.81 2,44.01
Long service benefits 1,87.15 1,62.59
Others :
For likely sales returns and date expiry (Refer Note 23) 49,08.55 39,17.78
For likely sales returns - reimbursable (Refer Note 23) 30,88.24 32,18.92
84,83.75 75,43.30


18. INCOME TAXES
The major components of income tax expense for the years ended March 31, 2020 and March 31, 2019 are :
Extract of Statement of Profit and Loss :
Profit and Loss Section :
March 31, 2020 March 31, 2019
Current income tax :
Current tax expense 208,03.56 248,45.92
Tax adjustment for earlier years 24.65 (2,58.43)
Deferred tax :
Relating to origination and reversal of temporary differences 1,47.68 2,64.74
Income tax expense reported in the Statement of Profit and Loss 209,75.89 248,52.23
Other Comprehensive Income (OCI) Section - Deferred tax related to items recognised in OCI during the year :
March 31, 2020 March 31, 2019
Net loss/(gain) on remeasurement of defined benefit plans 45.27 1,12.17
Income tax expense charged to OCI 45.27 1,12.17
Reconciliation of tax expense and the accounting profit multiplied by India’s domestic tax rate for March 31, 2020
and March 31, 2019 :
March 31, 2020 March 31, 2019
Accounting profit before income tax 802,69.15 698,85.41
802,69.15 698,85.41
At India’s statutory income tax rate of 25.168%
(March 31, 2019 : 34.944%) 202,02.14 244,20.76
Adjustments in respect of current income tax of previous years 24.65 (2,58.43)
Impact of change in income tax rate on deferred tax 2,74.97 -
Non-deductible expenses for tax purposes 4,74.13 6,89.90
209,75.89 248,52.23
At the effective income tax rate of 26.132% (March 31, 2019 : 35.561%)
Income tax expense reported in the Statement of Profit and Loss 209,75.89 248,52.23
Deferred tax :
The tax effect of significant temporary differences that resulted in deferred income tax assets and liabilities are as follows :
Balance Sheet Statement of Profit and Loss
As at As at For the year ended For the year ended
March 31, 2020 March 31, 2019 March 31, 2020 March 31, 2019
Deferred tax assets
Provision for compensated absences 8,21.05 10,08.59 1,87.54 (1,21.45)
Gratuity and other employee benefits 3,57.95 4,05.10 47.15 (6.01)
Allowance for credit impaired debts 2,84.69 3,91.05 1,06.36 6.80
Other items of disallowance under Section
43B and 40(a)(ia) of the Income Tax Act, 1961 7,01.86 8,30.05 1,28.19 0.98
Other items giving rise to temporary differences 1,76.00 62.84 (1,13.16) 48.90
Deferred tax liabilities
Depreciation (7,48.43) (11,73.98) (4,25.55) 2,48.74
Other items giving rise to temporary differences (1,48 .91) (2,16.26) (67.35) (25.39)
Net deferred tax assets/(liabilities) 14,44.21 13,07.39
Deferred tax charge/(income) (1,36.82) 1,52.57
Deferred tax charge/(income) recognised in Profit and Loss 1,47.68 2,64.74
Deferred tax charge/(income) recognised in OCI (45.27) (1,12.17)
Deferred tax charge/(income) taken to retained earnings (2,39.23) -
(1,36.82) 1,52.57
145

Reflected in the Balance Sheet as follows :
Deferred tax assets 23,41.55 26,97.63
Deferred tax liabilities (8,97.34) (13,90.24)
Deferred tax assets (net) 14,44.21 13,07.39
Reconciliation of deferred tax assets (net) :
March 31, 2020 March 31, 2019
Opening balance as of April 1 13,07.39 14,59.96
Tax income/(charge) during the period recognised in Profit and Loss (1,47.68) (2,64.74)
Tax income/(charge) during the period recognised in OCI 45.27 1,12.17
Tax income/(charge) taken to retained earnings 2,39.23 -
Closing balance as at March 31 14,44.21 13,07.39
19. TRADE PAYABLES

Due to micro and small enterprises (Refer (a) below) 18,32.15 12,06.78
Due to related parties (Refer Note 40 (D)) 101,03.31 127,75.77
Due to others 538,41.72 523,69.02
657,77.18 663,51.57
For terms and conditions relating to related party payables, refer Note 40.
For information on financial risk management objectives and policies, refer Note 44.
(a) Details of dues to Micro and Small Enterprises under the Micro, Small and Medium Enterprises Development
Act, 2006 (MSMED Act, 2006)* :
(i) The principal amount remaining unpaid to any supplier (but within due
date as per the MSMED Act, 2006) 18,32.15 12,06.78
(ii) Interest due on above remaining unpaid - -
(iii) Interest paid by the Company in terms of Section 16 of the Micro,
Small and Medium Enterprises Development Act, 2006, alongwith the
amount of the payment made to the supplier beyond the appointed day
during the year - -
(iv) Interest due and payable for the period of delay in making payment (which
have been paid but beyond the appointed day during the year) but without
adding interest specified under the Micro, Small and Medium Enterprises
Development Act, 2006 - -
(v) Interest accrued and remaining unpaid - -
(vi) Interest remaining due and payable even in the succeeding years, until such
date when the interest dues as above are actually paid to the small enterprises - -
*
The above information has been determined to the extent such parties have been identified on the basis of information
available with the Company.
20. CURRENT FINANCIAL LIABILITIES - OTHERS
Deposits from a customer 60.35 60.35
Unclaimed dividend # 3,40.71 3,50.09
Salaries, wages, incentives and bonus payable to employees 42,26.71 41,98.70
Deposit from a related party (Refer Note 40 (D)) 44.66 44.66
Others 4,04.50 5,44.69
50,76.93 51,98.49
#
In respect of the amounts as mentioned under Section 125 of the Companies Act, 2013, no dues are required to be credited
to the Investor Education and Protection Fund as on March 31, 2020 and March 31, 2019.


21. OTHER CURRENT LIABILITIES
Statutory dues including provident fund and tax deducted at source 13,37.01 11,85.71
GST payable 1,89.93 9,05.41
Contract liabilities (Refer Note 24 (d)) 5,00.51 5,35.00
Others (mainly provision against disputed cases) 11,50.98 11,17.04
31,78.43 37,43.16
22. CURRENT PROVISIONS
Provision for employee benefits :
Compensated Absences 32,62.28 28,86.31
Post Retirement Medical Benefits 28.39 23.03
Long Service Benefits 27.80 19.90
Gratuity 8,79.09 7,09.75
Superannuation 1,22.81 1,13.30
Provision for likely sales returns and date expiry (Refer Note 23) 37,56.00 29,90.34
Provision for likely sales returns - reimbursable (Refer Note 23) 26,68.57 27,90.73
107,44.94 95,33.36
23. DISCLOSURE PURSUANT TO IND AS 37 ‘PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT

ASSETS’ TOWARDS PROVISIONS FOR SALES RETURN, DATE EXPIRY AND DAMAGED PRODUCTS
Likely sales Likely sales
returns & date returns - Total
expiry reimbursable
Carrying Amount as at April 1, 2018 59,41.29 35,53.01 94,94.30
Add : Net amount provided/(written back) during the year @ 9,66.83 24,56.64 34,23.47
Carrying Amount as at March 31, 2019* 69,08.12 60,09.65 129,17.77
Add : Net amount provided/(written back) during the year @ 17,56.43 (2,52.84) 15,03.59
Carrying Amount as at March 31, 2020* 86,64.55 57,56.81 144,21.36
@
Includes unwinding of discount and effect of changes in discount rate on provision of ` 2,40.71 Lakhs
(March 31, 2019 : ` 2,08.63 Lakhs) (Refer Note 30).
*
Carrying Amount comprises of :
Non-current provision
Current provision
144,21.36 129,17.77
Nature of provision :
The provision is for anticipated returns on expiry which is made on the basis of management expectation taking into
account historical experience and market conditions.
The expected timing of any resulting outflows of economic benefits ranges from 1 month to 39 months.
147

24. REVENUE FROM OPERATIONS
March 31, 2020 March 31, 2019
Sale of products (including excise duty) (Refer (a) below) 4054,46.74 3640,30.02
Rendering of services (Refer (b) below) 23,12.19 22,01.71
4077,58.93 3662,31.73
Other operating revenue
Sale of scrap 76.15 69.04
Insurance, customs and carriers claims 97.18 2,15.31
Miscellaneous income
Duty drawback 22.93 22.57
Others 13,59.22 13,21.65
Total other operating revenue 15,55.48 16,28.57
4093,14.41 3678,60.30
(a) Sale of products :
March 31, 2020 March 31, 2019
Tablets 1648,48.62 1421,76.71
Injectables 1617,17.62 1507,14.24
Liquids 593,07.98 512,56.44
Capsules 133,30.64 130,25.44
Ointments 13,98.55 15,92.34
Granules 10,21.26 9,56.65
Powder 7,23.96 7,58.01
Others 30,98.11 35,50.19
4054,46.74 3640,30.02
(b) Rendering of services includes : (Refer Note 40 (C))
March 31, 2020 March 31, 2019
hared and support services rendered to Abbott Healthcare Private
S
Limited, India 16,26.00 16,26.00
Shared and support services rendered to Abbott Products Operations
AG., Switzerland 3,70.75 5,08.51
Shared and support services rendered to Abbott Laboratories S.A., Dubai 1,26.94 33.60
Shared and support services rendered to Abbott Laboratories
(Singapore) Pte Ltd., Singapore 1,26.94 33.60
Shared and support services rendered to St Jude Medical India Private
Limited, India 61.56 -
23,12.19 22,01.71
(c) Revenue from contracts with customers :
March 31, 2020 March 31, 2019
India (Goods) 3998,11.60 3587,65.09
Outside India (Goods) 56,35.14 52,64.93
India (Services) 16,87.56 16,26.00
Outside India (Services) 6,24.63 5,75.71
Total revenue from contracts with customers 4077,58.93 3662,31.73
Timing of revenue recognition

Goods transferred at a point in time 4054,46.74 3640,30.02
Services transferred at a point in time 23,12.19 22,01.71
Total revenue from contracts with customers 4077,58.93 3662,31.73


(d) Contract Balances :
March 31, 2020 March 31, 2019
Trade receivables (Refer Note 9) 317,91.49 276,11.43
Contract assets - -
Contract liabilities (Refer Note 21) (5,00.51) (5,35.00)
Net contract balances 312,90.98 270,76.43
Contract liabilities include short-term advances received from
customers for sale of products/services.
Reconciling the amount of revenue recognised in the Statement of

Profit and Loss with the contracted price :
Revenue as per contracted price 4182,17.45 3744,63.09
Less : Adjustments
- Sales Return 83,64.45 71,80.31
- Discounts 20,94.07 10,51.05
Net revenue from sale of products and rendering of services 4077,58.93 3662,31.73
Information about the Company’s performance obligations are summarized below :
Sale of products :
The performance obligation is satisfied upon delivery of the product and payment is generally due within six months
from delivery and are non-interest bearing.
Sale of services :
The performance obligation is satisfied when related services are performed.
25. OTHER INCOME
March 31, 2020 March 31, 2019
Interest income on financial assets carried at amortised cost :
Interest income on loan to a related party (Refer Note 40 (C)) - 12,54.80
Interest income on fixed deposits 111,16.43 87,16.86
Interest income on others (from employees and other receivables) 57.85 31.07
Other non-operating income :
Gain on sale of property classified as ‘held for sale’ - 9,78.36
Rental income from a related party (Refer Note 40 (C)) 1,14.52 1,14.53
Interest income on security deposits 1,40.92 1,42.01
Gain on early termination of leases (Refer Note 41) 4.18 -
Others (includes octroi refund) 4.68 90.97
114,38.58 113,28.60
26. COST OF MATERIALS CONSUMED

March 31, 2020 March 31, 2019
Inventory at the beginning of the year 96,09.38 76,81.75
Add : Purchases during the year 433,38.63 425,67.83
Less : Inventory at the end of the year (77,72.04) (96,09.38)
451,75.97 406,40.20
149

27. PURCHASES OF STOCK-IN-TRADE
March 31, 2020 March 31, 2019
Tablets 234,07.92 169,88.24
Injectables 1363,95.31 1302,07.49
Liquids 146,29.56 155,75.09
Capsules 11,63.42 8,34.74
Ointments 4,51.35 5,43.91
Granules 3,62.92 3,72.25
Powder 4,48.46 2,37.09
Others 34,05.29 36,79.04
1802,64.23 1684,37.85
28. CHANGES IN INVENTORIES OF FINISHED GOODS, STOCK-IN-TRADE AND WORK-IN-PROGRESS

March 31, 2020 March 31, 2019
Opening Stock
Finished goods 62,60.27 62,37.72
Stock-in-trade 407,53.75 442,45.94
Work-in-progress 40,55.43 3,67.31
Less : Closing Stock
Finished goods (97,51.74) (62,60.27)
Stock-in-trade (331,40.12) (407,53.75)
Work-in-progress (20,52.61) (40,55.43)
61,24.98 (2,18.48)
29. EMPLOYEE BENEFITS EXPENSE

March 31, 2020 March 31, 2019
Salaries, wages and bonus 431,46.85 394,37.48
Contribution to provident and other funds 26,92.98 25,20.59
Share based compensation to employees 8,76.75 8,47.55
Staff welfare expense 8,94.11 7,52.62
476,10.69 435,58.24
30. FINANCE COSTS

March 31, 2020 March 31, 2019
Interest expense on lease liabilities (Refer Note 41) 5,89.92 -
Interest expense, other than on lease liabilities 22.60 16.21
Unwinding of discount and effect of changes in discount rate on provisions
(Refer Note 23) 2,40.71 2,08.63
8,53.23 2,24.84
31. DEPRECIATION AND AMORTISATION EXPENSE

March 31, 2020 March 31, 2019
Depreciation of Property, plant and equipment (Refer Note 3) 16,10.02 15,80.02
Amortisation of intangible assets (Refer Note 4) 95.21 1,12.11
Deferred lease expense on security deposits (Refer Note 41) 1,30.99 -
Amortisation of Right-of-use assets (Refer Note 41) 41,24.69 -
59,60.91 16,92.13


32. OTHER EXPENSES
March 31, 2020 March 31, 2019
Consumption of stores 8,81.40 5,53.57
Power and fuel 13,73.33 12,60.86
Rent (Refer Note 41) 17.61 47,68.52
Repairs to buildings 1,10.77 34.65
Repairs to plant and machinery 4,37.65 5,19.23
Repairs (others) 4,02.70 3,34.98
Insurance 2,89.48 2,76.02
Rates and taxes 17,94.64 20,20.23
Advertising, publicity and sales promotion 146,35.88 118,20.21
Freight and forwarding charges 31,50.94 25,46.97
Travelling and business meetings 110,12.70 110,15.86
Commission to carrying and forwarding agents 44,19.59 47,47.87
Exchange loss (net) 8,07.86 4,29.25
Bad debts written off 26.62 69.13
Less : Adjusted against earlier year’s provision (26.62) (69.13)
- -
Professional fees and other services 77,03.16 84,94.13
Loss on sale/write off of Property, plant and equipment (net) 55.67 14.21
Payment to auditors (Refer (a) below) 1,53.22 1,39.74
CSR expenditure (Refer (b) below) 11,64.36 11,28.46
Miscellaneous expenses 60,44.17 48,14.26
544,93.83 549,68.71
(a) Payment to auditors :
March 31, 2020 March 31, 2019
As auditor :
Audit fees 70.60 6 7.00
Tax audit fees 15.00 15.00
Limited review 28.00 27.00
In other capacity :
Other services (including certification fees) 33.36 25.35
Reimbursement of expenses 6.26 5.39
1,53.22 1,39.74
(b) Details of Corporate Social Responsibility (CSR) expenditure :
The Company believes that innovative, responsible and sustainable business plays an important role in building a
healthy, thriving society. The CSR policy of the Company is focused on fostering economic, environmental and social
well-being. Through CSR initiatives, the Company strives to enhance people’s health and well-being and provide
lasting solutions to development challenges.
As a part of its CSR obligations, the Company undertook following initiatives during the year :
(i) Quality and affordable healthcare delivery program with SEWA (Self Employed Women’s Association), to launch
a comprehensive, community based healthcare program, to improve access to quality primary, acute and NCD
(Non-Communicable Disease) care among low income populations
151

(ii) Malaria elimination program with Malaria No More, in partnership with Government of Odisha, Abbott is
supporting the program with technical expertise, diagnostic products and funding support to advance efforts to
end malaria in the state
(iii) Improving access to healthcare through health clinics.
March 31, 2020 March 31, 2019
Gross amount required to be spent by the Company during the year as
per Section 135 of the Companies Act, 2013 11,35.60 9,43.62
Yet to be
Amount spent during the year ending on March 31, 2020 : In cash paid in cash Total
i) Construction/ acquisition of any asset - - -
ii) Others
On various programmes to expand awareness and
access to healthcare 3,24.22 1,17.28 4,41.50
On SEWA (Self Employed Women’s Association) 3,39.64 11.80 3,51.44
On Malaria No More 3,44.27 - 3,44.27
Administrative expenses related to CSR activities 27.15 - 27.15
10,35.28 1,29.08 11,64.36
Yet to be
Amount spent during the year ending on March 31, 2019 : In cash paid in cash Total
i) Construction/ acquisition of any asset - - -
ii) Others
On various programmes to expand awareness and
access to healthcare 4,45.89 2,96.01 7,41.90
On SEWA (Self Employed Women’s Association) 3,32.10 - 3,32.10
On Malaria No More 18.69 - 18.69
Administrative expenses related to CSR activities 35.77 - 35.77
8,32.45 2,96.01 11,28.46
33. COMPONENTS OF OTHER COMPREHENSIVE INCOME (OCI)

March 31, 2020 March 31, 2019
Remeasurements of defined benefit plan : (Refer Note 36)
Gratuity (4,69.73) (1,70.38)
Post retirement medical benefit scheme (70.89) (1,50.61)
(5,40.62) (3,20.99)
The above has been aggregated in retained earnings of the respective periods.
34. EARNINGS PER EQUITY SHARE (EPS)
The following reflects the income and share data used in the Basic and Diluted EPS computations :
March 31, 2020 March 31, 2019
Profit attributable to equity holders for Basic/Diluted earnings 592,93.26 450,33.18
Weighted average number of equity shares for Basic/Diluted EPS* 2,12,49,302 2,12,49,302
Basic/Diluted EPS ` (Face value of ` 10 per share) 279.04 211.93
*
There have been no transactions involving equity shares or potential equity shares between the reporting date and the date
of authorisation of these financial statements.


35. SIGNIFICANT ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONS
The preparation of the Company’s financial statements in conformity with Ind AS requires management to make
judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities,
and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and
estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected
in future periods. The estimates and associated assumptions are based on historical experience and various other factors
that are believed to be reasonable under the circumstances existing when the financial statements were prepared. The
estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates is recognised in
the year in which the estimates are revised and in any future year affected.
i) Judgements
In the process of applying the Company’s accounting policies, management has made the following judgements, which
have the most significant effect on the amounts recognised in the financial statements :
Determining the lease term of contracts
The Company determines the lease term as the non-cancellable term of the lease, together with any periods covered by an
option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the
lease, if it is reasonably certain not to be exercised.
Leases - Estimating the incremental borrowing rate
The Company cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing
rate (IBR) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a
similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the Right-of-use asset
in a similar economic environment. The Company estimates the IBR using observable inputs i.e. bank borrowing interest
rates on secured assets.
ii) Estimates and assumptions
The key assumptions concerning the future and other key sources of estimation at the reporting date, which may cause a
material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.
The Company based its assumptions and estimates on parameters available when the financial statements were prepared.
Existing circumstances and assumptions about future developments, however, may change due to market changes
or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions
when they occur.
Provision for sales return and date expiry
The Company as per trade practice accepts returns from market which are primarily in the nature of expired or near
expiry products. Provisions for such returns are estimated on the basis of historical experience and market conditions and
are provided for accordingly. Also refer Note 23.
Useful lives of Property, plant and equipment
The Company reviews the useful life of Property, plant and equipment at the end of each reporting period. This reassessment
may result in change in depreciation expense in future periods. Refer Note 2.3 (d) for management estimate of useful lives.
Defined benefit plans (Gratuity benefits)
The cost of the defined benefit gratuity plan and other post employment medical benefits and the present value of the
gratuity obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions
that may differ from actual developments in the future. These include the determination of the discount rate, future salary
increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit
obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.
The parameter most subject to change is the discount rate. In determining the appropriate discount rate, the management
considers the interest rates of government bonds in currencies consistent with the currencies of the post employment
benefit obligation.
153

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at interval
in response to demographic changes. Future salary increase and gratuity increase are based on expected future inflation
rates in the country.
Further details about gratuity obligations are given in Note 36.
The fair value of restricted stock units plan is measured at the date of grant using the Black Scholes option pricing model.
The estimate also requires determination of the most appropriate inputs to the valuation model, including the volatility,
dividend yield, risk free interest rates, expected life of share option etc., which are disclosed in the Note 37.
Fair value measurement of financial instruments
When the fair values of financial assets and financial liabilities recorded in the Balance Sheet cannot be measured based
on quoted prices in active markets, their fair value is measured using appropriate valuation techniques. The inputs for
these valuations are taken from observable sources where possible, but where this is not feasible, a degree of judgement
is required in establishing fair values. Judgements include considerations of various inputs including liquidity risk, credit
risk, volatility etc. Changes in assumptions/judgements about these factors could affect the reported fair value of financial
instruments. Also refer Note 43.
Provision for inventories
Provision is made in the financial statements for slow and non-moving items based on estimates regarding their usability.
Further for finished goods and stock-in-trade, all inventories expiring within six months and not expected to be sold, have
been fully provided for. Also refer Note 8.
Impairment of trade receivables
For the purpose of measuring lifetime expected credit loss allowance of trade receivables, the Company has used a
practical expedient as permitted under Ind AS 109. This expected credit loss allowance is computed based on a provision
matrix which takes into account historical credit loss experience and adjusted for forward-looking information. The
loss allowance for other financial assets are based on assumptions about risk of default. The Company uses judgments
in making these assumptions based on its past history, existing market conditions and certainty of realisation.
Also refer Note 9.
Impairment of other financial assets
The loss allowance for other financial assets are based on assumptions about risk of default. The Company uses judgments
in making these assumptions based on its past history, existing market conditions and certainty of realisation. Also
refer Note 6 and 13.
Uncertainty over income tax treatment
The Company determines whether to consider each uncertain tax treatment separately or together with one or
more other uncertain tax treatments and uses the approach that better predicts the resolution of the uncertainty.
The Company applies significant judgement in identifying uncertainties over income tax treatments (Refer Note 38).
36. EMPLOYEE BENEFITS
(a) Defined contribution plans
i) Provident Fund/Employees’ Pension Fund
ii) Employees’ State Insurance
iii)
Superannuation Fund
iv) Employees’ Deposit Linked Insurance Scheme
v) Group Life Insurance Cover


The Company has recognised following amounts as expense in the Statement of Profit and Loss :
March 31, 2020 March 31, 2019
Included in contribution to Provident and Other Funds (Refer Note 29)
Employer’s contribution to Provident Fund/Employees’ Pension Fund 17,53.04 15,91.09
Employer’s contribution to Superannuation Fund 2,99.15 3,02.57
Included in staff welfare expenses (Refer Note 29)
Employer’s contribution to Employees’ Deposit Linked Insurance Scheme 43.45 43.54
Premium paid in respect of Group Life Insurance Cover 61.33 51.36
Premium paid in respect of Employees’ State Insurance Scheme 6.79 12.93
(b) Defined Benefit Plans

i. Gratuity : (Included as part of contribution to provident and other funds in Note 29 - Employee benefits expense)
Gratuity is payable to all eligible employees of the Company on retirement, death, permanent disablement and
resignation in terms of the provision of the Payment of Gratuity Act 1972, or Company’s Scheme whichever is
more beneficial. Benefits would be paid at the time of the separation based on employees’ salary and tenure of
employment with the Company.
ii. Post Retirement Medical Benefits (PRMB) : (Included as part of staff welfare expenses in Note 29 - Employee
benefits expense)
Under this scheme, select group of senior employees and their spouse are covered for hospitalisation benefits
after the employee has retired from the Company. The cover is available to these beneficiaries until they are
alive. The Company has procured a group hospitalisation cover from an insurance company for providing these
benefits to these beneficiaries.
iii. Long Service Benefits (LSB) : (Included as part of salaries and wages in Note 29 - Employee benefits expense)
Under this scheme, long service benefits accrues to the employee, while in service and is payable upon completion
of stipulated service with the Company.
Gratuity (Funded) Post Retirement Medical

Benefits (Non-funded)
For the For the For the For the
year ended year ended year ended year ended
I) Change in present value of defined benefit
obligation during the year
Present value of defined benefit obligation at
the beginning of the year 63,60.00 58,47.13 2,67.04 1,29.81
Interest cost 4,26.52 4,06.14 18.66 9.65
Current service cost 5,68.18 5,45.70 - -
Benefits paid (4,79.27) (6,39.36) (28.39) (23.03)
Actuarial changes arising from changes in
demographic assumptions (56.86) (62.66) - (10.71)
financial assumptions 4,68.61 3,17.89 15.41 8.83
experience adjustments 71.09 (54.84) 55.48 1,52.49
the end of the year 73,58.27 63,60.00 3,28.20 2,67.04
155

II) Change in fair value of plan assets during the year
Fair value of plan assets at the beginning of the year 56,50.25 49,99.35 - -
Interest income 3,85.66 3,52.06 - -
Contributions paid by the employer 9,09.43 9,08.19 28.39 23.03
Benefits paid from the fund (4,79.27) (6,39.36) (28.39) (23.03)
Return on plan assets excluding interest income 13.11 30.01 - -
Fair value of plan assets at the end of the year 64,79.18 56,50.25 - -
As at As at As at As at
III) Net (asset)/liability recognised in the
Balance Sheet
the end of the year 73,58.27 63,60.00 3,28.20 2,67.04
Fair value of plan assets at the end of the year
(unquoted insurer managed funds) (64,79.18) (56,50.25) - -
Amount recognised in the Balance Sheet/
Net funded obligation 8,79.09 7,09.75 3,28.20 2,67.04
Net liability - current (Refer Note 22) 8,79.09 7,09.75 28.39 23.03
Net liability - non-current (Refer Note 17) - - 2,99.81 2,44.01

IV) Expenses recognised in the Statement of
Profit and Loss for the year
Current service cost 5,68.18 5,45.70 - -
Interest cost on benefit obligation (net) 40.86 54.08 18.66 9.65
One Year Renewable Term Assurance (OYRTA)
Premium 37.70 31.07 - -
Total expenses included in Employee
benefits expense 6,46.74 6,30.85 18.66 9.65
V) Recognised in other comprehensive income
for the year
demographic assumptions (56.86) (62.66) - (10.71)
financial assumptions 4,68.61 3,17.89 15.41 8.83
experience adjustments 71.09 (54.84) 55.48 1,52.49
Return on plan assets excluding interest income (13.11) (30.01) - -
Recognised in other comprehensive income
for the year (Refer Note 33) 4,69.73 1,70.38 70.89 1,50.61


VI) Maturity profile of defined benefit obligation
Within the next 12 months (next annual
reporting period) 12,26.17 10,34.41 28.39 23.03
Between 2 and 5 years 28,52.89 27,57.99 1,13.73 93.64
Between 6 and 9 years 23,10.56 21,63.54 1,10.30 92.90
For 10 years and above 67,74.23 58,23.23 3,61.51 3,32.56
VII) Sensitivity analysis for significant assumption

is as below :
1. Increase/(decrease) on present value of
defined benefits obligation at the end of the
year
Impact of 50 bps increase in discount rate (3.46%) (3.28%) (3.65%) (3.66%)
Impact of 50 bps decrease in discount rate 3.69% 3.49% 3.91% 3.92%
Impact of 100 bps increase in healthcare cost - - 8.08% 8.16%
Impact of 100 bps decrease in healthcare cost - - (7.17%) (7.23%)
Impact of increase by 1 year in life expectancy - - 4.77% 4.47%
Impact of decrease by 1 year in life expectancy - - (4.70%) (4.42%)
Impact of 50 bps increase in rate of salary increase 3.18% 3.08% - -
Impact of 50 bps decrease in rate of salary increase (3.07%) (3.02%) - -
2. Sensitivity analysis method

The Sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit
obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

VIII) The major categories of plan assets as a

percentage of total
Insurer managed funds 100% 100% - -
The Trustees have taken Policy from Life Insurance Corporation of India (LIC) and pays premium. LIC in turn manages the
assets which is within the permissible limits prescribed in the insurance regulations. The Company does not foresee any material
risk from these investments.
157

IX) Actuarial assumptions

Discount rate 6.65% 7.30% 6.65% 7.30%
Salary escalation 10% until 10% until - -
year 2 year 2
inclusive, and inclusive, and
7% thereafter 7% thereafter
Mortality rate during employment Indian Indian - -
Assured Lives Assured Lives
Mortality Mortality
(2006-08) (2006-08)
Ult table Ult table
Rate of leaving service Age related Age related - -
Mortality post retirement rate - - S1PA (90) S1PA (90)
Mortality Mortality
table table
Annual increase in healthcare costs - - 6% 6%
Expected retirement age of employees (years) 58/60 years, 58/60 years,
as applicable as applicable 60 years 60 years
Expected contribution to the defined benefit plan (Gratuity) for the next annual reporting period is ` 8,80.00 Lakhs
(March 31, 2019 : ` 7,10.00 Lakhs)
The average duration of the defined benefit plan obligation at the end of the reporting period for Gratuity is 7.14 years
(March 31, 2019 : 6.76 years) and for PRMB is 7.55 years (March 31, 2019 : 7.58 years).
Notes :
(i) The actuarial valuation of plan assets and the present value of the defined benefit obligation were carried out as at March
31, 2020. The present value of the defined benefit obligation and the related current service cost and past service cost, were
measured using the Projected Unit Credit Method.
(ii) Discount rate is based on the prevailing market yields of Indian Government securities as at the Balance Sheet date for the
estimated term of the obligations.
(iii) The salary escalation rate is arrived after taking into consideration the seniority, the promotion and other relevant factors,
such as, demand and supply in employment market.
37. SHARE BASED COMPENSATION TO EMPLOYEES

a) International Stock Ownership Plan (Stocks of Abbott Laboratories, USA, being Ultimate Holding Company)
Abbott Laboratories, USA has an ‘Affiliate Employee Stock Purchase Plan’ (employee share purchase plan) whereby
specified employees of its subsidiaries have been given a right to purchase shares of Abbott Laboratories, USA. Every
employee who opts for the scheme contributes, by way of payroll deductions, up to 10% of his cash remuneration (i.e.
basic salary for officers and basic salary and dearness allowance for staff category) towards purchase of shares on a
monthly basis over the purchase cycle of six months.
The maximum that an employee can contribute to the plan is USD 12,500 per purchase cycle or USD 25,000 per
calendar year. At the end of the cycle, accumulated payroll deductions are used to purchase shares at a discounted
price. The purchase price of the share is 85% of the lesser of fair market value either on the first or last day of the


purchase cycle. The shares of Abbott Laboratories, USA are listed with the New York Stock Exchange, USA and are
purchased on behalf of the employees at market price less discount, allocated to participants as of last day of the
purchase cycle. The concession in the price of the shares is entirely borne by Abbott Laboratories, USA.
During the year ended March 31, 2020, 16,151 shares (March 31, 2019 : 15,088 shares) were purchased by employees
at weighted average fair value of US $ 67.16 (March 31, 2019 : US $ 53.98) per share.
b) Employees Restricted Stock Options Plan (Stocks of Abbott Laboratories, USA, being Ultimate Holding Company)
Abbott Laboratories, USA as part of the ‘Long-term Incentive Program’ has offered Restricted Stock Units (RSUs)
to specified employees of its subsidiaries, whereby the employees covered by the plan are granted units. The units
when vested, become shares of Abbott Laboratories, USA at a NIL Cost. The shares of Abbott Laboratories, USA are
listed with the New York Stock Exchange, USA. The grants issued are vested in one third instalments over a three
year period. Pursuant to Ind AS 102 ‘Share-based Payment’, the fair value of the RSUs have been recorded by the
Company. The fair value of the RSUs is estimated at the grant date using Black Scholes Option Pricing Model, taking
into account the terms and conditions upon which such RSUs were granted.
For the year ended March 31, 2020 For the year ended March 31, 2019
Number of Weighted Number of Weighted
options Average options Average
Exercise Price Exercise Price
US $ US $
Outstanding at the beginning of the year 45,396 NA 57,127 NA
Add : Granted during the year 16,685 NA 19,957 NA
Add : Transfers in during the year 1,686 NA 355 NA
Less : Exercised during the year (22,812) NA (23,521) NA
Less : Cancelled/Expired during the year (2,040) NA (7,228) NA
Less : Transfers out during the year (6,042) NA (1,294) NA
Outstanding at the end of the year 32,873 NA 45,396 NA
The weighted average share price at the date of exercise for stock options exercised during the year was US $ 88.64
(March 31, 2019 : US $ 74.92).
The following tables list the inputs to the models used for the Restricted Stock Option plan for the years ended
March 31, 2020 and March 31, 2019, respectively :
As at As at
March 31, 2020 March 31, 2019
Dividend yield (%) 0% 0%
Expected volatility (%) 19.30% 20.11%
Risk–free interest rate (%) 1.33% 2.46%
Expected life of Restricted Stock Units (years) 3 years 3 years
Weighted average share price (`) ` 6,235.19 ` 5,368.06
Model used Black Scholes Black Scholes
The expected life of the RSUs is based on historical data and current expectations and is not necessarily indicative of
exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a
period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome.
During the year, ` 5,32.31 Lakhs (March 31, 2019 : ` 4,32.79 Lakhs) withholding taxes has been deposited with tax
authorities against exercised options.
159

38. COMMITMENTS AND CONTINGENCIES
a. Commitments
As at As at
March 31, 2020 March 31, 2019
Estimated amount of contracts remaining to be executed on capital

account and not provided for (net of advances) 4,53.58 4,30.77
b. Contingent liabilities
(i) Claims against Company not acknowledged as debts
In February 1996, the Government had made a tentative claim for a sum of ` 11,11.66 Lakhs to be paid into the
Drugs Prices Equalisation Account (DPEA) on account of unintended benefit allegedly enjoyed by the Company
during the period May 1, 1981 to August 25, 1987. This was contested by the Company and subsequently during
the year ended November 30, 2005, a final demand was received for ` 3,46.64 Lakhs (including interest of
` 1,90.39 Lakhs upto March 31, 2004). The Company, being aggrieved of the said demand and based on legal
advice obtained in this regard, contested the above final demand of ` 3,46.64 Lakhs and filed a writ petition
before the Bombay High Court to restrain the government from recovering the said amount. The Bombay High
Court has admitted the writ petition and granted stay of the recovery of the amount subject to the Company
furnishing a bank guarantee in respect of the principal amount of ` 1,56.25 Lakhs. The said bank guarantee
has been furnished. The Company however, out of abundant caution and based on its understanding of the
facts and circumstances of the case provided for a sum of ` 1,19.58 Lakhs (March 31, 2019 : ` 1,15.68 Lakhs)
including interest liability till date.
As at As at
March 31, 2020 March 31, 2019
(ii) Income Tax 73,43.74 -

(iii) Sales Tax 33,00.35 35,13.86
It is not practicable for the Company to estimate the timings of cash outflows, if any, in respect of the above pending
resolution of the respective proceedings as it is determinable only on receipt of judgements/decisions pending with
various forums/authorities.
(iv) There are various interpretative issues relating to the Supreme Court (SC) judgement dated February 28,
2019 on Provident Fund especially retrospective application (before March 1, 2019). As per the Supreme
Court judgement, effective March 1, 2019 on a prospective basis, the Company has made payments in
accordance with the definition of contributory wages for Provident Fund (PF) for all eligible employees
and is in compliance of the judgment. Since the amount pertaining to retrospective application (before
March 1, 2019), if any, of Supreme Court Order is not ascertainable, the Company will update its provision
for the past period on receiving further clarity on the subject.
39. SEGMENT REPORTING
Operating segments are defined as components of an enterprise for which discrete financial information is available
that is evaluated regularly by the chief operating decision maker, in deciding how to allocate resources and assessing
performance. The Company’s chief operating decision maker is the Managing Director and the Company has only one
reportable business segment i.e. ‘Pharmaceuticals’


40. RELATED PARTY DISCLOSURE
A) Parties where control exists :
Ultimate Holding Company : Abbott Laboratories, USA
Holding Company : Abbott Capital India Ltd., UK
B) Other related parties with whom transactions have taken place during the year :
I) Fellow subsidiaries :
British Colloids Ltd., U.K.
Abbott Healthcare Products Ltd., U.K.
Abbott Healthcare Private Ltd., India
Abbott International LLC, USA
Abbott Products Operations AG., Switzerland
Abbott Laboratories (Singapore) Pte Ltd., Singapore
Abbott Manufacturing Pte Ltd., Singapore
Abbott GmbH, Germany
Alere Medical Private Limited, India
Abbott Laboratories S.A., Switzerland
Abbott Laboratories S.A., Dubai
Abbott Laboratories Services LLC, Sri Lanka Branch
St Jude Medical India Private Limited, India
II) Key Management personnel and Independent directors :
Mr. Ambati Venu, Non-executive Director (ceased to be the Managing Director effective close of business hours
on February 29, 2020)
Mr. Munir Shaikh, Chairman
Mr. Rajiv Sonalker, Whole-Time Director
Mr. Krishna Mohan Sahni, Independent Director (ceased to be the Director effective close of business hours on
October 28, 2019)
Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018)
Mr. Rajendra Shah, Independent Director (ceased to be the Director effective close of business hours on
March 31, 2019)
Mr. Sudarshan Jain, Independent Director (w.e.f. April 1, 2019)
Ms. Shalini Kamath, Independent Director (w.e.f. October 29, 2019)
C) Transactions during the year :
I) Transactions with the Holding Company during the year

March 31, 2020 March 31, 2019
Abbott Capital India Ltd., UK
Remittance of dividend 69,67.41 58,95.50
161

II) Transactions with fellow subsidiaries during the year
i) Remittance of dividend :
March 31, 2020 March 31, 2019
British Colloids Ltd., U.K.
Abbott Healthcare Products Ltd., U.K
ii) Sales to fellow subsidiaries :

March 31, 2020 March 31, 2019
Sales of stock-in-trade 56,85.73 56,24.56
Sales of raw materials 47,11.52 46,79.97
Sale of capital goods - 32.99
Sales of stock-in-trade 85.54 -
iii) Purchases from fellow subsidiaries :

March 31, 2020 March 31, 2019
Purchase of raw materials 4,91.58 4,93.78
Purchase of stock-in-trade 145,05.60 120,73.92
Purchase of raw materials 297,28.34 296,21.37
Purchase of stock-in-trade 80,03.73 35,46.38
iv) Purchase of capital goods from fellow subsidiary :

March 31, 2020 March 31, 2019
Purchase of capital goods - 12.09
v) Other expenses to fellow subsidiaries :

March 31, 2020 March 31, 2019
Promotional expenses 62.81 1,54.74
Conversion charges 16,63.05 9,15.63
Payment of lease liabilities* 32,88.60 -
Finance costs* 1,97.67 -
Electricity and communication expenses 72.00 72.00
Promotional expenses 5.63 2.22
*
In the current year, the Company adopted Ind AS 116 ‘Leases’, with the date of initial application as April 1, 2019.
vi) Interest from fellow subsidiary :

March 31, 2020 March 31, 2019
Interest income on loan (Refer Note 25) - 12,54.80


vii) Reimbursements to and from fellow subsidiaries :
Reimbursement to Reimbursement from
Shared and support services 10,14.00 10,14.00 - -
Rent expenses - 32,88.60 - -
Market research and other expenses - - 15.17 13.15
Abbott International LLC, USA
Employee benefits expense, travel and
other expenses 28.45 34.04 - -
Abbott Manufacturing Pte Ltd.,
Singapore
other expenses - - - 8.47
Abbott Laboratories (Singapore) Pte
Ltd., Singapore
other expenses 39.66 12.52 26.79 19.01
Abbott Products Operations AG.,
Switzerland
other expenses - - 1,60.37 1,20.35
Abbott Laboratories S.A., Switzerland
other expenses - - 9.51 6.30
Abbott GmbH, Germany
other expenses - - 10.49 -
Abbott Laboratories Services LLC, Sri
Lanka Branch
other expenses - - 25.30 -
viii) Income from fellow subsidiaries :
March 31, 2020 March 31, 2019
Shared and support services (Refer Note 24 (b)) 16,26.00 16,26.00
Rent income (Refer Note 25) 1,14.52 1,14.53
Shared and support services (Refer Note 24 (b)) 3,70.75 5,08.51
Abbott Laboratories S.A., Dubai
Shared and support services (Refer Note 24 (b)) 1,26.94 33.60
Abbott Laboratories (Singapore) Pte Ltd., Singapore
Shared and support services (Refer Note 24 (b)) 1,26.94 33.60
St Jude Medical India Private Limited, India
Shared and support services (Refer Note 24 (b)) 61.56 -
163

ix) Lease liabilities from fellow subsidiary :
March 31, 2020 March 31, 2019
Recognition of lease liabilities* 134,55.09 -
*
In the current year, the Company adopted Ind AS 116 ‘Leases’, with the date of initial application as
April 1, 2019.
x) Key management personnel remuneration* :
March 31, 2020 March 31, 2019
Mr. Ambati Venu, Non-executive Director (ceased to be
the Managing Director effective close of business hours on
February 29, 2020) 7,14.73 6,50.75
Mr. Rajiv Sonalker, Whole-Time Director 3,29.82 3,04.76
*
During the year, as a part of the ‘Long-term Incentive Program’, Restricted Stock Units of Abbott
Laboratories, USA carrying perquisite value of ` 3,64.49 Lakhs (March 31, 2019 : ` 2,69.88 Lakhs) have
been granted to the above employees. Also refer Note 37 (b).
Also, provision for post employment benefits as contribution to gratuity fund, leave encashment on
retirement and other defined benefits which are made based on actuarial valuation on an overall company
basis are not included in remuneration to key management personnel.
xi) Non-Executive, Other Directors’ sitting fees :

March 31, 2020 March 31, 2019
Mr. Munir Shaikh, Chairman 10.50 15.00
Mr. Rajendra Shah, Independent Director (ceased to be the
Director effective close of business hours on March 31, 2019) - 16.00
Mr. Krishna Mohan Sahni, Independent Director (ceased to be
the Director effective close of business hours on October 28, 2019) 9.00 14.50
Ms. Anisha Motwani, Independent Director (w.e.f. April 25, 2018) 13.50 13.00
Mr. Sudarshan Jain, Independent Director (w.e.f. April 1, 2019) 12.00 -
Ms. Shalini Kamath, Independent Director (w.e.f. October 29, 2019) 5.50 -
D) Outstanding :
As at As at
March 31, 2020 March 31, 2019
Trade payable to fellow subsidiaries (Refer Note 19)
Abbott Products Operations AG., Switzerland 86,30.69 109,66.44
Abbott Healthcare Private Ltd., India 14,69.88 18,05.45
Alere Medical Private Limited, India - 3.88
Abbott Laboratories (Singapore) Pte Ltd., Singapore 2.74 -
101,03.31 127,75.77
Lease Liabilities to fellow subsidiary (Refer Note 41)
Abbott Healthcare Private Ltd., India 133,17.75 -
133,17.75 -


As at As at
March 31, 2020 March 31, 2019
Other payable to fellow subsidiary (Refer Note 20)
Abbott Healthcare Private Ltd., India 44.66 44.66
44.66 44.66
Trade receivables from fellow subsidiaries (Refer Note 9)
Abbott Healthcare Private Ltd., India 24,76.57 54,45.04
Abbott Products Operations AG., Switzerland 26.47 -
25,03.04 54,45.04
Other receivables from fellow subsidiaries (Refer Note 13)
Abbott Products Operations AG., Switzerland 58.61 47.68
Abbott Healthcare Private Ltd., India 66.30 1,17.97
Abbott Laboratories Services LLC, Sri Lanka Branch 2.01 -
Abbott International LLC, USA 5,36.04 3,98.31
Abbott Laboratories S.A., Switzerland - 6.13
Abbott Laboratories S.A., Dubai 20.05 32.99
Abbott Laboratories (Singapore) Pte Ltd., Singapore 23.42 10.86
Abbott GmbH, Germany 11.16 -
St Jude Medical India Private Limited, India 66.49 -
7,84.08 6,13.94
Loan and deposit to fellow subsidiaries
Abbott Healthcare Private Ltd., India (Refer Note 5, 7, 14 and 41) 14,77.10 14,67.67
Terms and conditions of transactions with related parties :

All transactions with related parties are made in the ordinary course of business and the same is at arm’s length.
Outstanding balances at the year end are unsecured and interest free and settlement occurs in cash. The Company has
not recorded any impairment for receivables. This assessment is undertaken each financial year through examining
the financial position of the related parties and the market in which related parties operate.
41. LEASES
The Company adopted Ind AS 116 using the modified retrospective method of adoption, with the date of initial application
on April 1, 2019. The Company elected to use the transition practical expedient to not reassess whether a contract is, or
contains, a lease at April 1, 2019. Instead, the Company applied the standard only to contracts that were previously identified
as leases applying Ind AS 17 and Appendix C of Ind AS 17 at the date of initial application.
A) The effect of adoption of Ind AS 116 is as follows :

As at
April 1, 2019
i) Impact on Balance Sheet (increase/(decrease)) :
Assets
Right-of-use assets 62,85.86
Deferred tax asset 2,39.23
Total assets 65,25.09
Equity
Retained earnings (net of tax) 7,11.29
Total equity 7,11.29
Liabilities
Lease liabilities 72,36.38
Total liabilities 72,36.38
165
For the year ended

March 31, 2020
ii) Impact on Statement of Profit and Loss (increase/(decrease) in profit) :
Amortisation of Right-of-use assets (Refer Note 31) (41,24.69)
Rent expenses 50,04.90
Finance costs (Refer Note 30) (5,89.92)
Gain on early termination of leases (Refer Note 25) 4.18
Profit for the period 2,94.47
For the year ended

March 31, 2020
iii) Impact on statement of cash flows (increase/(decrease)) :
Finance costs (Refer Note 30) 5,89.92
Amortisation of Right-of-use assets (Refer Note 31) 41,24.69
Gain on early termination of leases (Refer Note 25) (4.18)
Net cash flows from operating activities 47,10.43
Payment of lease liabilities (50,04.90)

Net cash flows from financing activities (50,04.90)
There is no material impact on other comprehensive income or the basic and diluted earnings per share.
Upon adoption of Ind AS 116, the Company applied a single recognition and measurement approach for all leases for which it is
the lessee. The Company recognised lease liabilities to make lease payments and Right-of-use assets representing the right to
use the underlying assets. In accordance with the modified retrospective method of adoption, the Company applied Ind AS 116
at the date of initial application.
As at April 1, 2019 :
• Right-of-use assets were recognised and presented separately in the Balance Sheet.
• Lease liabilities were recognised and included under ‘Financial Liabilities’.
• Retained earnings decreased due to the net impact of these adjustments.
• Deferred tax asset increased because of the deferred tax impact of the changes in recognised lease related assets
and liabilities.
For the year ended March 31, 2020 :
• Depreciation expense increased because of the depreciation of additional assets recognised (i.e. increase in Right-of-use
assets, net of the decrease in ‘Property, plant and equipment’). This resulted in increases in depreciation and amortisation
expenses of ` 41,24.69 Lakhs.
• Rent expenses included in ‘Other expenses’, relating to previous operating leases, decreased by ` 50,04.90 Lakhs, due to
transfer of actual rent expenses to lease liabilities.
• Finance costs increased by ` 5,89.92 Lakhs relating to the interest expense on additional lease liabilities recognised.
• Income tax expense changed by ` NIL relating to the tax effect of these changes in expenses.
• Cash outflows from operating activities decreased by ` 47,10.43 Lakhs and cash outflows from financing activities
increased by ` 50,04.90 Lakhs relating to decrease in operating lease payments and increases in principal and interest
payments of lease liabilities.
• The weighted average incremental borrowing rate applied to lease liabilities as at April 1, 2019 is 9.81%.
B) Right-of-use assets :

The Company has lease contracts for various items of Buildings, Vehicles and Furniture & Fixtures used in its
operations. Leases of Buildings generally have lease terms between 2 to 9 years, Vehicles have lease terms between
2 to 5 years and Furniture & Fixtures have lease terms between 3 and 6 years. The Company’s obligations under its
leases are secured by the lessor’s title to the leased assets.


The changes in the carrying value of Right-of-use assets for the year ended March 31, 2020 are as follows :
Furniture
Buildings Vehicles and Total
Fixtures
Balance as at April 1, 2019 59,56.55 2,37.14 2,57.41 64,51.10
Additions 132,77.56 91.08 13,33.02 147,01.66
Deletions (19.24) (6.53) - (25.77)
Depreciation (38,50.80) (1,28.84) (2,76.04) (42,55.68)
Balance as at March 31, 2020 * 153,64.07 1,92.85 13,14.39 168,71.31
*
Includes ` 38.59 Lakhs (Balance as at April 1, 2019 includes ` 1,65.24 Lakhs) towards deferred lease assets. Out of
this deferred lease assets, ` 19.81 Lakhs (Balance as at April 1, 2019 includes ` 1,38.68 Lakhs) is towards deposit given
to a related party (Refer Note 40 (D)).
C) Lease liabilities :
Set out below are the carrying amounts of lease liabilities and the movements during the period :
As at April 1, 2019
Balance as at April 1, 2019 72,36.38
Additions 146,97.32
Accretion of interest 5,89.92
Termination (29.95)
Payments (50,04.90)
Balance as at March 31, 2020 * 174,88.77
Current 35,68.45
Non-current 139,20.32
*
Includes ` 133,17.75 Lakhs pertaining to lease liabilities towards related party (Refer Note 40 (D)).
The maturity analysis of lease liabilities are disclosed in Note 44.
D) Impact on Profit or Loss :
For the year ended
March 31, 2020
Amortisation of Right-of-use assets (Refer Note 31) 41,24.69
Deferred lease expense on security deposits (Refer Note 31) 1,30.99
Finance costs (Refer Note 30) 5,89.92
Expense relating to short-term leases (Refer Note 32) 17.61
Gain on early termination of leases (Refer Note 25) (4.18)
Total amount recognised in profit or loss 48,59.03
E) Company as lessor :

The Company has recognised rent income from leasing of a property amounting to ` 1,14.52 Lakhs
(March 31, 2019 : ` 1,14.53 Lakhs) in the Statement of Profit and Loss under ‘Other Income’ (Refer Note 25). The lease
agreement is of cancellable nature.
Future minimum rentals receivable under non-cancellable operating leases are as follows :
As at As at
March 31, 2020 March 31, 2019
Within one year 85.89 1,14.52
After one year but not more than five years - 85.89
More than five year - -
85.89 2,00.41
167
42 . DISCLOSURE PURSUANT TO SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) AND

SECTION 186 (4) OF THE COMPANIES ACT, 2013 :
During the previous year ended March 31, 2019, the Company had rolled over the loan of ` 200,00.00 Lakhs which was
granted to Alere Medical Private Limited, India, a fellow subsidiary on December 26, 2017, for a further period of six
months effective June 27, 2018, at an interest rate of 10% per annum in accordance with the provisions of Section 186 of the
Companies Act, 2013 and Rules made thereunder, for the purpose of working capital funding requirement. The same was
guaranteed by Abbott Laboratories, USA i.e. the Ultimate Holding Company. The said loan was repaid by Alere Medical
Private Limited on November 15, 2018 with outstanding interest up to that date.
Maximum balance Maximum balance
Purpose for which the loan
outstanding during outstanding during
Nature of the transaction is proposed to be utilised by
As at the year ended As at the year ended
recipient
March 31, 2020 March 31, 2020 March 31, 2019 March 31, 2019 @
Loan given to fellow
subsidiary :
Alere Medical Private Funding for working capital
Limited, India requirement - - - 208,92.60
@
Including accrued interest ` 9,91.78 Lakhs, net of TDS ` 8,92.60 Lakhs for the year ended March 31, 2019.
43. FAIR VALUE DISCLOSURE

A. The carrying value and fair value of financial assets/liabilities by categories are as follows :
Carrying value of the Fair value of the financial

financial assets/liabilities assets/liabilities
Particulars
Financial assets/liabilities at amortised cost

Financial assets at amortised cost
(non-current) :
Loans (Refer Note 5) 16,78.21 16,10.70 16,78.21 16,10.70
Other financial assets (Refer Note 6) 36,26.30 36,65.80 36,26.30 36,65.80
Financial assets at amortised cost (current) :
Trade and other receivables (Refer Note 9) 317,91.49 276,11.43 317,91.49 276,11.43
Cash and cash equivalents (Refer Note 10) 145,13.79 137,00.61 145,13.79 137,00.61
Bank balances other than cash and cash
equivalents (Refer Note 11) 2052,23.67 1547,27.71 2052,23.67 1547,27.71
Loans (Refer Note 12) 6,14.13 7,30.24 6,14.13 7,30.24
Other financial assets 67,96.13 73,34.39 67,96.13 73,34.39
Financial liabilities at amortised cost
(non-current) :
Lease liabilities (Refer Note 41) 139,20.32 - 139,20.32 -
Financial liabilities at amortised
cost (current) :
Lease liabilities (Refer Note 41) 35,68.45 - 35,68.45 -
Trade payables (Refer Note 19) 657,77.18 663,51.57 657,77.18 663,51.57
Other financial liabilities 50,76.93 48,63.78 50,76.93 48,63.78

Carrying value of the Fair value of the financial

financial assets/liabilities assets/liabilities
Particulars
Financial assets/liabilities at fair value

through Profit or Loss
Financial assets at fair value through
Profit or Loss (current) :
Forward contract receivable 4,41.43 - 4,41.43 -
Financial liabilities at fair value through
Profit or Loss (current) :
Forward contract payable - 3,34.71 - 3,34.71
B. Set out below, is a comparison by class of the carrying amounts and fair value of the Company’s financial assets/
liabilities, other than those with the carrying amounts that are reasonable approximations of fair values :
Carrying Fair value Fair value hierarchy

amount
Quoted
Particulars prices Significant Significant
in active observable unobservable
As at As at markets inputs inputs
March 31, 2020 March 31, 2020 Level 1 Level 2 Level 3
Loans (non-current)
Deposits given to fellow subsidiary
(Refer Note 5) 14,57.29 14,57.29 - - 14,57.29
Deposits for premises (Refer Note 5) 1,00.24 1,00.24 - - 1,00.24
Against tenders (Refer Note 5) 1,20.68 1,20.68 - - 1,20.68
Other financial assets (Refer Note 6) 36,26.30 36,26.30 - - 36,26.30
53,04.51 53,04.51 - - 53,04.51
Profit or Loss
Lease liabilities (Refer Note 41) 174,88.77 174,88.77 - - 174,88.77
174,88.77 174,88.77 - - 174,88.77
Total 227,93.28 227,93.28 - - 227,93.28
Financial assets at fair value through
Profit or Loss
Forward contract receivable 4,41.43 4,41.43 - 4,41.43 -
Total 4,41.43 4,41.43 - 4,41.43
169
Carrying Fair value Fair value hierarchy

amount
Quoted
Particulars prices Significant Significant
in active observable unobservable
As at As at markets inputs inputs
March 31, 2019 March 31, 2019 Level 1 Level 2 Level 3

Loans (non-current)
Deposits given to fellow subsidiary
(Refer Note 5) 13,28.99 13,28.99 - - 13,28.99
Deposits for premises (Refer Note 5) 87.19 87.19 - - 87.19
Against tenders (Refer Note 5) 1,94.52 1,94.52 - - 1,94.52
Other financial assets (Refer Note 6) 36,65.80 36,65.80 - - 36,65.80
Total 52,76.50 52,76.50 - - 52,76.50
Profit or Loss
Forward contract payable 3,34.71 3,34.71 - 3,34.71 -
Total 3,34.71 3,34.71 - 3,34.71 -
The following methods and assumptions were used to estimate the fair values :
Fair value of cash and bank balances, short-term loans, trade and other short-term receivables, trade payables, other
financial current liabilities approximate their carrying amounts largely due to the short-term maturities of these
instruments. Methods and assumptions used to estimate the fair values are consistent with those used for the year
ended March 31,2020.
During the reporting period ending March 31, 2020 and March 31, 2019, there were no transfers between Level 1 and
Level 2 fair value measurements.
The Company uses the following hierarchy for determining and disclosing the fair value of financial
instruments by valuation technique :
Level 1 : Quoted (unadjusted) prices in active markets for identical assets or liabilities
Level 2 : Other techniques for which all inputs which have a significant effect on the recorded fair value are observable,
either directly or indirectly
Level 3 : Techniques which use inputs that have a significant effect on the recorded fair value that are not based on
observable market data
The fair values of the foreign exchange forward contract has been determined using valuation techniques with
adequate observable inputs. This model incorporate various inputs including the credit quality of counter parties and
foreign exchange forward rates.


Description of significant unobservable inputs to valuation (Level 3) :
The following table shows the valuation techniques and inputs used for financial instruments that are not carried
at fair value :
a) Deposits for premises Discounted Discounted

cashflow cashflow
method using method using
interest rate for interest rate for
similar financial similar financial
instrument instrument
b) Lease liabilities Discounted -
cashflow method
using incremental
borrowing rate
c) Financial assets/liabilities other than above Expected Expected
cashflows for cashflows for
the financial the financial
instruments instruments
A one percentage point change in the unobservable inputs used in fair valuation of level 3 assets or liabilities does not
have significant impact in its value.
44. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Company’s activities expose it to variety of financial risks namely market risk, credit risk and liquidity risk. The
Company has various financial assets such as deposits, trade and other receivables and cash and bank balances directly
related to their business operations. The Company’s principal financial liabilities comprise of trade and other payables.
The Company’s senior management’s focus is to foresee the unpredictability and minimize potential adverse effects on the
Company’s financial performance. The Company’s overall risk management procedures to minimise the potential adverse
effects of financial market on the Company’s performance are as follows :
a) Market risk
Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of
changes in market prices. Market risk comprises three types of risks namely interest rate risk, currency risk and other
price risk, such as commodity risk. The Company is not exposed to other price risk whereas the exposure to currency
risk and interest risk is given below :
(i) Interest rate risk
Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate
because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest
rates relates primarily to the Company’s deposit accounts with banks.
Carrying Amount
As at As at
Particulars March 31, 2020 March 31, 2019
Fixed rate instruments
Financial assets 2168,67.58 1572,07.61
171

Fair value sensitivity analysis for fixed rate instruments :
The Company’s investments are primarily in fixed rate interest bearing investments. Hence, the Company is not
significantly exposed to interest rate risk.
(ii) Foreign currency risk
Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of
changes in foreign exchange rates and arises where transactions are done in foreign currency. It arises mainly
where receivables and payables exist due to transactions entered in foreign currencies.
The Company evaluates exchange rate exposure arising from foreign currency transactions and follows
established risk management policies including use of derivatives like foreign exchange forward contracts to
hedge foreign currency risk. The Company does not enter into financial instrument transactions for trading or
speculative purposes. Unhedged exposure at any point of time during the year is not material.
The Company’s exposure to foreign currency risk is as follows :
Particulars ( ` Lakhs) USD Euro GBP USD Euro
Trade receivables 1,82.11 - - 4,05.84 -

Other financial assets 18,45.29 - - 4,94.13 9,86.38
Trade payables 120,35.55 12.03 (0.61) 130,14.19 9,86.38
Foreign currency sensitivity

The following table demonstrate the sensitivity to a reasonably possible change in foreign exchange rates,
being the most transacted currencies with all other variables held constant. The exchange rate between Rupee
and other foreign currencies have changed substantially in the recent years and may fluctuate substantially in
the future. Consequently the results of the Company’s operations could be affected as the Rupee appreciates/
depreciates against these currencies.
Currency 1% Increase 1% Decrease 1% Increase 1% Decrease
USD (1,00.08) 1,00.08 (1,21.14) 1,21.14

Euro (0.12) 0.12 - -
GBP (0.01) 0.01 - -
Increase/(Decrease) in Profit or Loss (1,00.21) 1,00.21 (1,21.14) 1,21.14
b) Credit risk
Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer
contract, leading to a financial loss. Concentration of credit risk arises when counter parties are engaged in similar
business activities or have similar economic features that would cause the ability to meet contractual obligations
to be similarly affected by changes in economical, political or other conditions. Concentration of credit risk
indicate the relative sensitivity of the Company’s performance to developments affecting a particular industry.


Credit risk of company arises principally from the trade debts, loans and advances, trade deposits, other
receivables and balance with banks. The carrying amount of financial assets represents the maximum
credit exposure. The maximum exposure to credit risk was ` 2646,85.14 Lakhs as at March 31, 2020
(March 31, 2019 : ` 2093,80.87 Lakhs). Customer credit risk is managed for each business unit subject to the
Company’s established policy, procedures and control relating to customer credit risk management. Credit quality
of a customer is assessed based on an extensive credit rating scorecard and individual credit limits are defined
in accordance with this assessment. Further, significant sales of the Company are against advance payment/
collection on delivery terms. Outstanding customer receivables are regularly monitored and any shipments
to new overseas customers are generally covered by letters of credit or other forms of credit insurance. The
management continuously monitors the credit exposure towards the customers and makes provision against
those balances considered doubtful of recovery.
The ageing of trade receivables and allowance for credit loss is as follows :
Allowances for Allowances for

Particulars Gross credit losses Gross credit losses
Not yet due 214,58.97 18.76 202,84.17 0.34

Past due 1 - 30 days 68,85.19 - 36,40.08 8.03
Past due 31 - 60 days 10,50.86 93.47 12,26.64 4.57
Past due 61 - 90 days 2,24.23 - 7,52.40 8.29
Over 90 days 33,03.41 10,18.94 28,27.23 10,97.86
Total 329,22.66 11,31.17 287,30.52 11,19.09
Movement in allowance for credit loss :

As at As at
Particulars March 31, 2020 March 31, 2019
Balance at the beginning of the year 14,66.77 15,34.65
Allowance for credit impaired advances 62.03 (48.44)
Bad debts written off (26.62) (69.13)
Balance at the end of the year 15,40.88 14,66.77
The management believes that no further provision is necessary in respect of trade receivables based on
historical trends of these customers. Further, the Company’s exposure to customers is diversified and no single
customer has significant contribution to trade receivables balances.
The credit risk on liquid funds such as balances with banks in current and deposit accounts is limited because
the counter parties are banks with reasonably high credit ratings.
Financial assets other than trade receivables and bank balances are not exposed to any material credit risk.
173
c) Liquidity risk
Liquidity risk is the risk that company will not be able to meet its financial obligations as they fall due. Liquidity
risk arises because of the possibility that the Company could be required to pay its liabilities earlier than expected
or encounters difficulty in raising funds to meet commitments associated with financial liabilities as they fall due.
The Company’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due. The Company manages liquidity risk by maintaining sufficient cash and
bank balance and availability of funding through adequate amount of committed credit facilities.
The details of the contractual maturities of significant liabilities as at March 31, 2020 are as follows :
Carrying Less than More than
Particulars 1-3 years 3-5 years Total
Amount 1 year 5 years
Trade payables (Refer Note 19) 657,77.18 657,77.18 - - - 657,77.18

Other current financial
liabilities (Refer Note 20) 50,76.93 50,76.93 - - - 50,76.93
Lease Liabilities (Refer Note 41) 174,88.77 48,75.36 85,01.44 76,31.03 5,54.77 215,62.60
883,42.88 757,29.47 85,01.44 76,31.03 5,54.77 924,16.71
The details of the contractual maturities of significant liabilities as at March 31, 2019 are as follows :
Carrying Less than More than
Particulars 1-3 years 3-5 years Total
Amount 1 year 5 years
Trade payables (Refer Note 19) 663,51.57 663,51.57 - - - 663,51.57

Other current financial
liabilities (Refer Note 20) 51,98.49 5,198.49 - - - 51,98.49
715,50.06 715,50.06 - - - 715,50.06
45. CAPITAL MANAGEMENT

For the purpose of the Company’s capital management, capital includes issued equity capital and all other equity reserves
attributable to the equity holders of the Company. The primary objective of the Company’s capital management is to
safeguard the Company’s ability to remain as a going concern and maximise the shareholder value.
The Company manages its capital structure and makes adjustments in light of changes in economic conditions, annual
operating plans and long-term and other strategic investment plans. In order to maintain or adjust the capital structure,
the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders or issue new shares.
The current capital structure of the Company is equity based with no financing through borrowings. The Company is not
subject to any externally imposed capital requirements.
No changes were made in the objectives, policies or processes for managing capital during the year ended March 31, 2020
and March 31, 2019.
46.
During these unprecedented times caused by the COVID-19, as a pharmaceutical company, our focus remains to ensure
the uninterrupted supply of our products to meet the needs of our customers.
To help protect our Abbott employees, we have taken measures at our plant in Goa to limit exposure, implement social
distancing and provide a healthy work environment for the employees onsite. Office-based work is being conducted
remotely and the Company has implemented strict travel restrictions.
The Goa plant initially worked at a lower capacity but now is operating at sufficient capacity. Availability of raw materials
and finished stocks from third party manufacturers as well as supply chain and distribution were marginally impacted
initially due to the lockdown. However, sufficient levels of stocks have been maintained in the channel to cater to demand.

There has been no significant adverse impact on business operations. The Company has adequate liquidity to service its
obligations to its vendors and employees, as well as for payment of statutory dues.
The Management has exercised due care, made reasonable judgements and estimates, inter alia, in determining carrying
amounts of trade receivables, property, plant & equipment, inventories and other financial assets based on the information
available to date, while preparing the financial results as of and for the year ended March 31, 2020.
In view of the uncertainties regarding the extent and duration of the current COVID-19 situation, we are unable to
predict the future impact on the business operations. The Company will continue to closely monitor the situation and take
appropriate measures in an attempt to mitigate adverse impact.
47.
The Company has bank overdraft arrangement secured by hypothecation of all stocks and book debts, against which
there are no borrowings.
48. Previous year’s figures have been regrouped/reclassified to conform to the current year’s classification.


175
NOTICE
NOTICE
Notice is hereby given that the Seventy-sixth Annual General RESOLVED That pursuant to the provisions of
Meeting of Abbott India Limited will be held through Video- Section 148 and all other applicable provisions, if any,
Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”) of the Companies Act, 2013 and the Rules framed
on Monday, September 7, 2020 at 9.00 a.m. to transact the thereunder (including any statutory modification(s)
following business : or re-enactment(s) thereof for the time being in force),
remuneration of ` 7.50 Lakhs plus taxes as applicable and
ORDINARY BUSINESS :
reimbursement of reasonable out-of-pocket expenses, as
1. To receive, consider and adopt the Audited Financial approved by the Audit Committee and Board of Directors
Statements of the Company for the financial year ended of the Company, payable to M/s Kishore Bhatia &
March 31, 2020 together with the Reports of Directors Associates, Cost Accountants (Registration No. 00294),
and Auditors thereon. for conducting the Cost Audit of the Company for the
2. To declare a final dividend of ` 107/- and special dividend financial year 2020-21, be and is hereby ratified.
of ` 143/- per Equity Share for the financial year ended 6. Appointment of Ms Shalini Kamath (DIN : 06993314)
March 31, 2020.
as an Independent Director
3. To appoint a Director in place of Mr Kaiyomarz Marfatia
To consider and if thought fit, to pass with or without
(DIN : 03449627), who retires by rotation and being
modification(s), the following resolution as an Ordinary
eligible, offers himself for re-appointment.
Resolution :
4. To appoint a Director in place of Mr Munir Shaikh
RESOLVED That pursuant to the provisions of
(DIN : 00096273), who has attained the age of
Sections 149, 150, 152 and all other applicable provisions,
seventy-five years and, who retires by rotation and
if any, read with Schedule IV of the Companies Act, 2013
being eligible, offers himself for re-appointment.
and the Rules framed thereunder (including any statutory
To consider and if thought fit, to pass with or without modification(s) or re-enactment(s) thereof for the time
modification(s), the following resolution as a Special being in force) (“the Act”) and applicable provisions of
Resolution : the Securities and Exchange Board of India (Listing
RESOLVED That pursuant to the provisions of Obligations and Disclosure Requirements) Regulations,
Section 152 and all other applicable provisions, if any, 2015, as amended from time to time, Ms Shalini Kamath
of the Companies Act, 2013 and Rules framed (DIN : 06993314), who was appointed as Additional
thereunder (including any statutory modification(s) or Director by the Board of Directors effective October 29,
re-enactment(s) thereof for the time being in force) and 2019, in terms of the provisions of Section 161 of the Act,
the Securities and Exchange Board of India (Listing read with Article 113 of the Articles of Association of
Obligations and Disclosure Requirements) Regulations, the Company, to hold office upto the date of this Annual
2015, as amended from time to time, consent of the General Meeting and in respect of whom the Company
Company be and is hereby accorded to the re-appointment has received a notice in writing in terms of Section 160 of
of Mr Munir Shaikh (DIN : 00096273), who has attained the Act, from a Member proposing her candidature for the
the age of seventy-five years and who retires by rotation office of Director and who has submitted the declaration
at this Annual General Meeting and being eligible for that she meets the requisite criteria of independence,
re-appointment, as Director of the Company, liable to be and is hereby appointed as an Independent Director
retire by rotation. of the Company, not liable to retire by rotation, to
SPECIAL BUSINESS : hold office for a term of 3 (three) years effective
October 29, 2019.
5. Ratification of remuneration payable to M/s Kishore
Bhatia & Associates, Cost Auditors, for the financial 7. Appointment of Mr Ambati Venu (DIN : 07614849)
year 2020-21 as Director, liable to retire by rotation
To consider and if thought fit, to pass with or without To consider and if thought fit, to pass with or without
modification(s), the following resolution as an Ordinary modification(s), the following resolution as an Ordinary
Resolution : Resolution :

RESOLVED That Mr Ambati Venu (DIN : 07614849), approval of the Central Government and such other
who was appointed as Additional Director of approvals, as may be necessary, consent of the Company
the Company by the Board of Directors effective be and is hereby accorded to the appointment of
March 1, 2020, in terms of the provisions of Section Mr Anil Joseph (DIN : 08753233) as the Managing
161 of the Companies Act, 2013 and Rules framed Director, not liable to retire by rotation, for a period of 5
thereunder (including any statutory modification(s) or (five) years with effect from July 1, 2020, on such terms
re-enactment(s) thereof for the time being in force) (“the and conditions including remuneration as set out in
Act”), read with Article 113 of the Articles of Association the Explanatory Statement annexed to the Notice, with
of the Company, to hold office upto the date of this Annual liberty to the Board of Directors (hereinafter referred to
General Meeting and in respect of whom the Company as “the Board” which term shall include the Nomination
has received a notice in writing in terms of Section 160 and Remuneration Committee of the Board) to alter and
of the Act, from a Member proposing his candidature vary the terms and conditions of the said appointment
for the office of Director, be and is hereby appointed as a and/or remuneration as it may deem fit.
Director of the Company, liable to retire by rotation.
RESOLVED Further That the Board be and is hereby
8. Appointment of Mr Anil Joseph (DIN : 08753233) authorized to do all acts and take all such steps as may
as Director be necessary, proper or expedient to give effect to this
To consider and if thought fit, to pass with or without resolution.
modification(s), the following resolution as an Ordinary 10. Approval of transactions/contracts/arrangements
Resolution : with Related Party
RESOLVED That Mr Anil Joseph (DIN : 08753233),
who was appointed as Additional Director of the
modification(s), the following resolution as an Ordinary
Company by the Board of Directors effective July 1,
Resolution :
2020, in terms of the provisions of Section 161 of the
Companies Act, 2013 and Rules framed thereunder RESOLVED That pursuant to the provisions of
(including any statutory modification(s) or Regulation 23 of the Securities and Exchange Board of
re-enactment(s) thereof for the time being in force) (“the India (Listing Obligations and Disclosure Requirements)
Act”), read with Article 113 of the Articles of Association Regulations, 2015, as amended from time to time, (“the
of the Company, to hold office upto the date of this Annual Listing Regulations”), consent of the Company, be and is
General Meeting and in respect of whom the Company hereby accorded to the Audit Committee/Board of
has received a notice in writing in terms of Section 160 Directors to enter into transactions/contracts/
of the Act from a Member, proposing his candidature for arrangements with Abbott Healthcare Private Limited,
the office of Director, be and is hereby appointed as [a ‘Related Party’ as per the provisions of the Companies
Director of the Company. Act, 2013 (“the Act”) and the Listing Regulations], in the
9. Appointment of Mr Anil Joseph (DIN : 08753233) as ordinary course of its business and on arm’s length basis,
Managing Director for purchase and sale of products; goods; raw materials;
active pharmaceutical ingredients; stock-in-trade,
To consider and if thought fit, to pass with or without availing or rendering of services, reimbursement of
modification(s), the following resolution as an Ordinary expenses, recovery of cost, rent payments, buying/leasing
Resolution : of property, lending or borrowing of monies (as may be
RESOLVED That in accordance with the provisions of permissible under the applicable provisions of the Act) or
Sections 196, 197, 203 and all other applicable provisions, such other transactions on such terms and conditions as
if any, read with Schedule V of the Companies Act, 2013 may be mutually agreed upon between the Company and
and Rules framed thereunder (including any statutory the Related Party for an amount not exceeding ` 800
modification(s) or re-enactment(s) thereof for the time Crore (Rupees Eight Hundred Crores) in each financial
being in force) (“the Act”), read with Article 133 of the year for a period of 5 (five) years upto the financial
Articles of Association of the Company and subject to year 2024-25.
177
NOTICE
RESOLVED Further That the Audit Committee/Board conferred to any committee of Board of Directors or any
of Directors, be and is hereby severally authorised to one or more of the Directors of the Company, for giving
do all such acts, deeds, matters and things and to effect to this Resolution.
finalize the terms and conditions and execute such By Order of the Board
agreements, documents and writings and make such
filings as may be necessary or expedient to give effect to Krupa Anandpara
this Resolution. Mumbai Company Secretary
August 7, 2020 Membership No. : ACS 16536
11. Approval for increase in Foreign Investment limits
into the Company Registered Office :
CIN : L24239MH1944PLC007330
modification(s), the following resolution as a Special
3, Corporate Park, Sion-Trombay Road,
Resolution :
Mumbai - 400 071
RESOLVED That subject to the provisions of Foreign Telephone No. : +91-22-6797 8888/+91-22-5046 1000/2000
Exchange Management Act, 1999, Foreign Exchange Fax : +91-22-5016 9400
Management (Non-Debt Instruments) Rules, 2019 and Email : [email protected]
the Consolidated Foreign Direct Investment Policy Website : www.abbott.co.in
Circular of 2017 dated August 28, 2017 issued by the
Department of Industrial Policy and Promotion, Ministry NOTES :
of Commerce and Industry, Government of India and
i. In view of the prevailing situation due to
other applicable rules, guidelines, regulations,
COVID-19 pandemic and pursuant to the Circular
notifications, circulars, provisions, if any, (including any Nos. 14/2020 and 17/2020 dated April 8, 2020 and
amendment(s), or re-enactment(s) or re-notification(s) of April 13, 2020, respectively, followed
each of the above for the time being in force), and subject by Circular No. 20/2020 dated May 5,
to other statutory/regulatory compliances and approvals 2020, issued by the Ministry of Corporate
(including approval from the Central Government Affairs (“MCA Circulars”), the Annual General Meeting
for increase in sectoral cap for foreign investment of the Company (“the Meeting”) shall be held through
and any attendant conditions stipulated thereunder) Video-Conferencing (“VC”) or Other Audio-Visual
as may be necessary, consent of the Company be Means (“OAVM”).
and is hereby accorded for acquiring and holding equity
ii. Pursuant to the provisions of the Companies Act, 2013
shares of the Company, by the Foreign Institutional
(“the Act”), a Member entitled to attend and vote at the
Investors (FIIs)/Foreign Portfolio Investors (FPIs)/Non-
Meeting is entitled to appoint a proxy to attend and vote
Resident Indians (NRIs) under the portfolio scheme up
on his/her behalf and the proxy need not be a Member
to 5% of the total paid up share capital of the Company,
of the Company. Since this Meeting will be held through
provided that the composite cap for total foreign
VC/OAVM, in accordance with the MCA Circulars,
investment from all sources (including investments
physical attendance of Members has been dispensed
received under the Portfolio Investment Scheme, Foreign with. Accordingly, the facility for appointment of
Venture Capital Investors (FVCIs), Foreign Direct proxies by the Members will not be available for the
Investment (FDI) and indirect foreign investment, etc., Meeting and hence the Proxy Form and Attendance Slip
in any combination thereof ) shall not exceed 80% of the are not annexed to this Notice.
total paid up share capital of the Company, on a fully
iii. Corporate Members intending to have their
diluted basis.
representatives attend the Meeting pursuant to
RESOLVED Further That the Board of Directors of Section 113 of the Act, are requested to send to the
the Company, be and is hereby authorised to do all such Company, a certified copy of the relevant Board
acts, matters, deeds and things necessary or desirable in Resolution together with the specimen signature of the
connection with or incidental to give effect to the above representative(s) authorized to attend and vote on their
resolution and to delegate all or any of its powers herein behalf at the Meeting.

iv. A statement pursuant to Section 102(1) of the Act, relating For the Members, whose bank details are not updated/
to the Business to be transacted from Item Nos. 4 to 11 is registered as aforesaid, the Company shall withhold
annexed hereto. the demand drafts and shall dispatch the same once the
lockdown is lifted and postal services are normalized.
v. The additional details of Directors retiring by rotation/
seeking appointment/re-appointment, pursuant to xi. Members holding shares in electronic form are required
Regulation 36(3) of the Securities and Exchange Board to contact their Depository Participants to register/
of India (“SEBI”) (Listing Obligations and Disclosure change their nomination.
Requirements) Regulations, 2015 (“the Listing
Regulations”) and the Secretarial Standards issued by the Members holding shares in physical form are advised
Institute of Company Secretaries of India, are annexed to register nomination in respect of their shareholding
hereto. in the Company. Nomination Form (SH–13) is
available on the website of the Company at
vi. The Register of Beneficial Owners, Register of Members https://www.abbott.co.in/investor-relations.html
and Share Transfer Books of the Company will remain
closed from Tuesday, September 1, 2020 to Monday, xii. Members who have not encashed their dividend
September 7, 2020 (both days inclusive). warrants from the year 2013-14 or thereafter, are
requested to write to the Company/Registrar and
vii. Final dividend of ` 107/- and special dividend of ` 143/- Transfer Agent for issue of new demand drafts. Members
per Equity Share of ` 10/- each, as recommended by are requested to note that the unclaimed dividends
the Board of Directors, if approved by the Members at
will be transferred to the Investor Education and
the Annual General Meeting, will be paid on and from
Protection Fund (IEPF) after the below mentioned
September 14, 2020 to the Members whose names appear
due dates :
on the Register of Members as on September 7, 2020 and
to the Beneficial Owners of the Shares as on August 31, Dividend and Year Dividend per Due Date of
2020, as per the details furnished by the Depositories for Share Transfer to IEPF
this purpose.
56th Dividend 2013-14 23 30/08/2021
viii. The SEBI has mandated submission of Permanent
Account Number (“PAN”) by every participant in 57th Dividend 2014-15 31 27/08/2022
securities market. Accordingly, Members holding shares
58th Dividend 2015-16 35 16/08/2023
in electronic form are requested to submit their PAN
to their respective Depository Participants. Members 59th Dividend 2016-17 40 16/08/2024
holding shares in physical form can submit their PAN to
the Company/Registrar and Share Transfer Agent. 60th Dividend 2017-18 55 16/08/2025
ix. In view of the prevailing lockdown due to COVID-19 61st Dividend 2018-19 65 20/09/2026
pandemic, the Dividend will be paid electronically in
the bank accounts of the Members whose bank details In terms of the IEPF (Uploading of information regarding
are available with the Company/Registrar and Share unpaid and unclaimed amounts lying with companies)
Transfer Agent/Depositories. Rules, 2012, the Company has uploaded the required
information in respect of dividend remaining unpaid/
Members holding shares in electronic form are unclaimed (as on date of the last Annual General Meeting
requested to intimate change, if any, in their held on August 22, 2019) on the Company’s website under
registered address or bank details to their Depository
the Investor Section at https://www.abbott.co.in/investor-
Participants with whom they have Demat accounts.
relations/other-information/unclaimed-dividend.html
The Company or Registrar and Share Transfer Agent
cannot act on any request received directly from such xiii. In terms of requirements of Regulation 39(4) and
Members. Members holding shares in physical form are Schedule VI of the Listing Regulations, shares which
requested to intimate change, if any, in their registered remained unclaimed in the custody of the Company
address or bank details to the Company/Registrar and are required to be transferred to the Suspense Account
Share Transfer Agent. opened by the Company.
179
NOTICE
Accordingly, details of the unclaimed shares lying in relations/other-information/unclaimed-dividend.html

the Company’s Unclaimed Suspense Account are as The said details are also provided in the Corporate
follows : Governance Report.
Particulars Number of Number of The Members whose shares/unclaimed dividends, etc.
Shareholders Shares have been transferred to IEPF may claim the shares and
Aggregate number as at 187 23,993 unclaimed dividends by making an application to IEPF
April 1, 2019 Authority in Form IEPF-5 (available on www.iepf.gov.in)
Number of shares claimed 1 165 along with requisite fee as decided by the Authority from
and transferred from time to time. A Member can file only one consolidated
the Unclaimed Suspense
claim in a financial year as per the said Rules and
Accounts during the year
amendments thereto.
Number of shares transferred 148 19,117
to Investor Education and During the year, 7 claims were received from
Protection Fund Members, details of which are as follows :
Aggregate number as at 38 4,711 Particulars Number of Number of
March 31, 2020 Shareholders Shares
All benefits accruing on such shares shall be credited April 1, 2019
to Unclaimed Suspense Account for a period of seven Transferred to IEPF 239 31,212
years. Thereafter, the said shares including all benefits Authority during the year
accrued thereon shall be transferred by the Company Claims brought forward 3 812
to IEPF Authority in accordance with the provisions of Claims received from 7 1,305
Section 124(5) and (6) of the Act. The voting rights in Shareholders during the year
respect of such shares shall remain frozen till the rightful Claims processed by IEPF 5 1,276
owner claims such shares. Authority
xiv. As per Regulation 40 of the Listing Regulations, as Claims pending with IEPF 5 841
Authority
amended from time to time, securities of listed companies
can be transferred only in dematerialized form with effect Aggregate number as at 630 96,925
March 31, 2020
from April 1, 2019, except in case of request received for
transmission or transposition of securities. In view of this xvi. Members seeking any information or clarifications on the
and to eliminate all risks associated with physical shares, Annual Report are requested to send their queries to the
Members holding shares in physical form are requested Company on [email protected] at least
to consider converting their holdings to dematerialized one week prior to the Meeting to enable the Company
form. Members can contact the Company/Registrar and to compile the information and provide replies at the
Share Transfer Agent, for any assistance in this regard. Meeting.
xv. In terms of requirements of Section 124(6) of the Act, xvii. In case all the joint holders are attending the Meeting,
read with the Investor Education and Protection Fund the Member whose name appears as first holder in
Authority (Accounting, Audit, Transfer and Refund) the order of names as per Register of Members of the
Rules, 2016, all shares in respect of which dividend Company will be entitled to vote at the Meeting.
has not been paid or claimed for 7 (seven) consecutive
xviii. The Ministry of Corporate Affairs has undertaken
years or more are required to be transferred to the IEPF
a “Green Initiative in Corporate Governance”
Authority (“IEPF Authority”).
and allowed companies to share documents with its
During the year 2019-20, the Company has transferred shareholders through an electronic mode. In line with
31,212 Equity Shares held by 239 Members to the IEPF MCA Circulars and the SEBI Circular No. SEBI/HO/
Authority in July 2019. The details of shares so transferred CFD/CMD1/CIR/P/2020/79 dated May 12, 2020,
is available on the Company’s website under the Annual Report for the financial year 2019-20 along with
Investor Section at https://www.abbott.co.in/investor- the Notice of Seventy-sixth Annual General Meeting,

will be sent through electronic mode to the Members c. Mr Taizoon M. Khumri, Practicing Company
whose email addresses are available with the Company/ Secretary (CP No. 88) (Membership No. FCS
Depositories/Depository Participants. 993) has been appointed as the Scrutinizer to
scrutinize the voting process in a fair and transparent
The aforesaid documents shall also be available on the
manner.
Company’ website https://www.abbott.co.in/investor-
relations/financials.html and on the websites of the d. A person, whose name is recorded in the Register
BSE Limited at www.bseindia.com and NSDL at of Members or in the Register of Beneficial Owners
www.evoting.nsdl.com maintained by the Depositories as on the cut-off
date i.e. August 31, 2020 (“Cut-off date”) only shall
The Members whose email addresses are not
be entitled to avail the facility of remote e-voting
registered with the Company are requested to do so by
or voting at the Meeting, as the case may be, in
following the instructions given under Part E.
proportion to the shares held as on the Cut-off date.
xix. The relevant documents referred to in the accompanying
e. Any person who acquires the shares of the
Notice and Explanatory Statement will be provided
Company and becomes a Member of the
upon request, in electronic mode upto the date of
Company after dispatch of the Notice and
the Meeting. The Members are required to write to
holding shares as on Cut-off date, may obtain the
[email protected] with a subject
User ID and Password by sending a request at
“Inspection of Documents”.
[email protected] However, if he/she is already
xx. Voting through electronic means registered with NSDL for remote e-voting then he/
Pursuant to the provisions of Section 108 and other she can use his/her existing User ID and Password
applicable provisions, if any, of the Act read with the for casting the vote.
Companies (Management and Administration) Rules, f. The facility of voting will be provided at the
2015, Regulation 44 of the Listing Regulations and in Meeting for the Members attending the Meeting
line with the MCA Circulars, the Company is pleased and who have not cast their vote earlier by remote
to provide to its Members the facility to exercise their e-voting.
vote through electronic means i.e. ‘remote e-voting’
g. A Member can participate in the Meeting through
on resolutions proposed to be passed at the Meeting.
VC/OAVM even after exercising his right to vote
In line with the MCA Circulars, Members are required to
through remote e-voting but shall not be allowed to
communicate their assent or dissent through the remote
vote again at the Meeting
e-voting system only.
h. Once the Member has confirmed his voting on the
a. The facility for voting shall be provided at the
resolution, he will not be allowed to modify his vote
Meeting. Members attending the Meeting who have
or cast the vote again.
not cast their vote earlier by remote e-voting shall
be entitled to vote at the Meeting. A Member can i. The Scrutinizer shall, after the conclusion of
participate in the Meeting even after exercising his voting at the Meeting, first count the votes cast
right to vote through remote e-voting but shall not at the Meeting and thereafter unblock the votes
be allowed to vote again at the Meeting. cast through remote e-voting in the presence of at
least two witnesses, not in the employment of the
b. The remote e-voting facility will be available during
Company and shall submit, not later than forty-
the following voting period :
eight hours of the conclusion of the Annual General
Commencement of : From 9 a.m. (IST) on Meeting, a consolidated Scrutinizer’s Report of the
remote e-voting Friday, September 4, 2020 total votes cast in favour or against, if any, to the
Chairman or any other person authorized by him
End of remote : Upto 5 p.m. (IST) on
in writing, who shall countersign the same and
e-voting Sunday, September 6, 2020
declare the result of the voting forthwith.
181
NOTICE
j. The Results shall be declared by the Chairman or any

c) For Members holding EVEN Number followed by
other person authorized by him in writing within
shares in physical Form Folio Number registered
forty-eight hours from the conclusion of the Meeting. with the Company. For
The results declared shall alongwith the consolidated example if folio number
Report of the Scrutinizer be placed on the website is 001*** and EVEN is
of the Company i.e. www.abbott.co.in and on 101456 then User ID is
the website of NSDL at www.evoting.nsdl.com 101456001***
immediately after the declaration of results.
5. Your password details are given below :
The results shall simultaneously be forwarded to
the BSE Limited, Mumbai and also be displayed on a) If you are already registered for e-voting, then you
the Notice Boards of the Registered and Corporate can use your existing password to login and cast
Offices of the Company. your vote.
Process and Manner of remote e-voting : b) If you are using NSDL e-voting system for the first
time, you will need to retrieve the ‘initial password’
Part A : Instructions for login :
which will be communicated to you. Once you
1. Visit the e-voting website of NSDL. Open web browser by retrieve your ‘initial password’, you need to enter
typing the following URL : https://www.evoting.nsdl.com/ the ‘initial password’ and the system will force you
either on a Personal Computer or on a Mobile. to change your password.
2. Once the home page of e-voting system is launched, c) How to retrieve your ‘initial password’?
click on the icon “Login” which is available under
(i) If your email ID is registered in your demat
‘Shareholders section’.
account or with the Company, your ‘initial
3. A new screen will open. You will have to enter your password’ is communicated to you on your
User ID, Password and a Verification Code as shown on email ID. Trace the email sent to you from
the screen. NSDL from your mailbox. Open the email and
open the attachment i.e. pdf file. The password
Alternatively, if you are registered for NSDL e-services
to open the .pdf file is your 8 digit client ID
i.e. IDEAS, you can log-in at https://eservices.nsdl.com/
for NSDL account, last 8 digit of client ID for
with your existing IDEAS login. Once you log-in to NSDL
CDSL account or folio number for shares held
e-services after using your log-in credentials, click on
in physical form. The .pdf file contains your
e-voting and you can proceed to Step 2 i.e. Cast your vote
‘User ID’ and your ‘initial Password’.
electronically.
(ii) If your email ID is not registered, please
4. Your User ID details are given below :
follow steps mentioned below in process for
Manner of holding shares User ID those shareholders whose email ids are not
i.e. Demat (NSDL or registered.
CDSL) or Physical
6. If you are unable to retrieve or have not received the
a) For Members who hold 8 Character DP ID followed
“initial password” or have forgotten your password :
shares in demat account by 8 Digit Client ID. For
with NSDL. example if your DP ID is a) If you are holding shares in your demat account with
IN300*** and Client ID is NSDL or CDSL, click on “Forgot User Details/
12****** then your User ID Password?” option available on www.evoting.nsdl.com
is IN300***12******.
b) For Members who hold 16 Digit Beneficiary ID. b) If you are holding shares in physical mode, click on
shares in demat account For example if your “Physical User Reset Password?” option available
with CDSL. Beneficiary ID is on www.evoting.nsdl.com
12************** then your
c) If you are still unable to get the password by
User ID is 12**************
aforesaid two options, you can send a request at

[email protected] mentioning your demat account 3. In case of any queries, you may refer the Frequently
number/folio number, your PAN, your name and Asked Questions (FAQs) for Shareholders and e-voting
your registered address. user manual for Shareholders available at the download
section of www.evoting.nsdl.com or call on toll free
Members can also use the OTP (One Time
no. : 1800-222-990 or write to Ms Sarita Mote – Assistant
Password) based login for casting the votes on the
Manager at [email protected]/[email protected]/
e-voting system of NSDL. + 91 22 2499 4890/National Securities Depository Limited,
7. After entering your password, tick on Agree to “Terms Trade World, `A’ Wing, 4th Floor, Kamala Mills Compound,
and Conditions” by selecting on the check box and click Senapati Bapat Marg, Lower Parel, Mumbai - 400 013.
on “Login” button. Part D : Instructions for voting by the Members at
8. Thereafter Home page of e-voting will open. Meeting attended through VC/OAVM :
Part B : Instructions to cast your vote : 1. Only those Members, who will be present in the Meeting
through VC/OAVM facility and have not casted their
1. After successful login at Step 1, you will be able to see the
vote on the Resolutions through remote e-voting and are
Home page of e-voting. Click on e-voting. Then, click on
otherwise not barred from doing so, shall be eligible to
Active Voting Cycles and you will be able to see “EVEN”
vote through e-voting system in the Meeting.
of all the companies in which you are holding shares
and whose voting cycle is in active status. 2. Members who have voted through Remote e-voting will
be eligible to attend the Meeting. However, they will not
2. Select “EVEN” of Abbott India Limited.
be eligible to vote at the Meeting.
3. Cast your vote by selecting appropriate options i.e. assent
or dissent, verify/modify the number of shares for which 3. The Members may connect with Ms Sarita Mote –
you wish to cast your vote and click on “Submit” and also Assistant Manager - NSDL at [email protected] for
“Confirm” when prompted. any grievances/concerns relating to e-voting during the
Meeting.
4. Upon confirmation, the message “Vote cast successfully”
will be displayed. Part E : Instructions for registration of Email address :
5. You can also take the printout of the votes cast by you The Members whose email addresses are not registered with
by clicking on the print option on the confirmation page. the Company are requested to do so by following the process
given below :
6. Once you confirm your vote on the resolution, you will
not be allowed to modify your vote. - In case shares are held in physical mode, please provide
Part C : General Instructions : Folio No., Name of the shareholder, scanned copy of the
share certificate (front and back), PAN (self-attested
1. Institutional Shareholders (i.e. other than individuals, scanned copy), AADHAR (self-attested scanned copy) by
HUF, NRI etc.) are required to send scanned copy (PDF/ email to [email protected]
JPG Format) of the relevant Board Resolution/Authority
letter, etc. with attested specimen signature of the duly - In case shares are held in demat mode, please provide
authorized signatory(ies) who are authorized to vote, to DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary
the Scrutinizer by e-mail to [email protected] ID), Name, client master or copy of Consolidated
with a copy marked to [email protected] Account statement, PAN (self-attested scanned
copy), AADHAR (self-attested scanned copy) to
2. It is strongly recommended not to share your password [email protected]
with any other person and take utmost care to keep your
password confidential. Login to the e-voting website - Post successful registration of the email address, the
will be disabled upon five unsuccessful attempts to key Member would get soft copy of the Notice and the
in the correct password. In such an event, you will need procedure for e-voting along with the User ID and
to go through the “Forgot User Details/Password?” or the Password to enable e-voting for this Meeting.
“Physical User Reset Password?” option available on In case of any queries, Member may write to
www.evoting.nsdl.com to reset the password. [email protected]
183
NOTICE
xxi. Instructions for Members for attending the Meeting xxii. Considering the Meeting would be held through VC/
through VC/OAVM : OAVM, the route Map for the venue is not annexed to the
1. Member will be provided with a facility to attend Notice.
the Meeting through VC/OAVM through the STATEMENT PURSUANT TO SECTION 102(1) OF THE
NSDL e-voting system. Members may attend COMPANIES ACT, 2013
the Meeting and view the live webcast at
https://www.evoting.nsdl.com under shareholders/ Item No. 4
members login by using the remote e-voting
Mr Munir Shaikh (DIN : 00096273), Non-Executive Chairman
credentials. The link for VC/OAVM will be available
of the Board retires by rotation at this Annual General Meeting
in Shareholder/Members login where the EVEN
of Company will be displayed. Please note that of the Company in terms of provisions of Section 152 of the
the Members who do not have the User ID and Companies Act, 2013 and being eligible, offers himself for
Password for e-voting or have forgotten the User ID re-appointment.
and Password may retrieve the same by following In terms of the provisions of Regulation 17(1A) of the
the remote e-voting instructions mentioned in the
Securities and Exchange Board of India (Listing Obligations
Notice to avoid last minute rush. Further, Members
and Disclosure Requirements) 2015, as amended from time
can also use the OTP based login for logging into the
e-voting system of NSDL. to time, no person who has attained the age of seventy-five
years shall be appointed or continued as a Director unless
2. Facility of joining the Meeting through VC/OAVM a special resolution is passed approving such appointment
shall open 30 minutes before the time scheduled for or continuation. Considering that Mr Shaikh has attained
the Meeting and will be available for Members on
the age of seventy-five years, approval of the Members is
first-come-first-served basis.
sought through Special Resolution for his re-appointment
3. Members are encouraged to join the Meeting as Director, liable to retire by rotation.
through Laptops for better experience. Speakers
will be required to allow Camera and use Internet Mr Shaikh has held several management and leadership
with a good speed to avoid any disturbance during positions with Abbott since 1968 in different geographies
the Meeting. across various businesses. In his last role, from June 2005 until
his retirement in 2010, he was the Divisional Vice President,
4. Please note that Participants connecting from
Southeast Asia/Middle East/Africa, Abbott Nutrition
Mobile Devices or Tablets or through Laptop
International based in Singapore. He is a fellow of the Institute
connecting via Mobile Hotspot may experience
Audio/Video loss due to fluctuation in their of Chartered Accountants of England and Wales.
respective network. It is therefore recommended to As the Chairman of the Board of the Company since
use Stable Wi-Fi or LAN connection to mitigate any March 2001, Mr Shaikh brings to the Board extensive
kind of aforesaid glitches.
leadership and industry experience of over five decades,
5. Speaker Registration/Questions for the Meeting : including a deep knowledge and understanding of the
Company’s business operations, strategies and the
Members, who would like to express their
views/have questions are requested to opportunities and risks faced by the Company. His significant
send registrations along with the questions contribution and guidance to the Board in governance matters
in advance mentioning their name, demat account and strategic direction to the Management have helped the
number/folio number, email id, mobile number at Company achieve several milestones year-after-year.
[email protected] from Monday,
The Board, based on recommendation of the Nomination
August 24, 2020 to Monday, August 31, 2020.
and Remuneration Committee is of the view that his
Those Members who have registered themselves as a
speaker will only be allowed to express their views/ immense knowledge, independent perspective and continued
ask questions during the Meeting. The Company association will immensely benefit the Company and
reserves the right to restrict the number of questions/ therefore, recommend his re-appointment. Mr Shaikh is not
speakers depending on the availability of time for the related to the promoter companies. He does not hold any
Meeting. shares in the Company.

None of the Directors and/or Key Managerial Personnel of the Section 164 of the Act, and meets the criteria of independence
Company and their relatives, except Mr Shaikh, is concerned as prescribed under the applicable provisions of the Act
or interested, financially or otherwise, in the resolution set out and the Regulations. She has further confirmed that she has
at Item No. 4. registered herself in the database for Independent Directors.
The Board recommends the resolution set forth in Item No. 4 In the opinion of the Nomination and Remuneration
for the approval of Members as a Special Resolution. Committee and the Board, Ms Kamath is independent of the
Management.
Item No. 5
The Company has received a notice in writing under
The Board, based on the recommendation of the Audit Section 160 of the Act, from a Member proposing the
Committee, approved the appointment of M/s Kishore Bhatia candidature of Ms Kamath for the office of Director of the
& Associates, Cost Accountants (Registration No. 00294) as the Company.
Cost Auditors for conducting the Cost Audit of the Company
for the financial year 2020-21 at a remuneration of ` 7.50 Lakhs Ms Kamath has close to three decades of work experience in
plus taxes as applicable and reimbursement of reasonable three distinct fields–Human Resources, Business Development
out-of-pocket expenses. and Social & Community Development and across two
continents – India and Africa. She is a certified and practicing
Pursuant to the provisions of Section 148 and all other ‘CEO & Leadership Coach’.
applicable provisions, if any, of the Companies Act, 2013
and the Rules framed thereunder, remuneration payable to Ms Kamath’s Human Resources (HR) career spans close to a
M/s Kishore Bhatia & Associates, Cost Auditors, as stated decade and half with Group HR Head positions for Chevron
above, requires ratification by the Members. Texaco India, Star India, KPMG India and Ambit Holdings.
She was a key member of the Executive Leadership Team
None of the Directors and/or Key Managerial Personnel of
in each of her assignments. She was a ‘Strategic Partner’ to
the Company and their relatives is concerned or interested,
the businesses in providing business linked people solutions
financially or otherwise, in the resolution set out at Item No. 5.
through change, renewal and transformation. In addition,
The Board recommends the resolution set forth in Item No. 5 her role in managing the corporate communications function
for the approval of Members as an Ordinary Resolution. at Ambit Holdings has given her the experience in building a
strong corporate brand, both externally and internally.
Item No. 6
Prior to her roles in HR, Ms Kamath was the Deputy Marketing
The Board, based on recommendation of the Nomination
Director at Raytheon India. She began her working career in
and Remuneration Committee, appointed Ms Shalini
Zambia and Botswana. Over a decade, she worked with the
Kamath (DIN : 06993314) as Additional Director of the
Governments of both the countries on several educational
Company effective October 29, 2019, as per the provisions of
and social & community development projects. She acquired
Section 161 of the Companies Act, 2013 and Rules framed
extensive experience in tripartite partnership projects related
thereunder (“the Act”) read with Article 113 of the Articles of
to community-oriented income generation programs.
Association of the Company. She holds office upto the date of
this Annual General Meeting. Ms Kamath is Independent Director on the Boards of Graphite
India Limited (Listed), Borosil Renewables Limited (Listed)
Further, the Board as per the applicable provisions of the
and Ambit Finvest Private Limited.
Act and the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 Ms Kamath is an MBA graduate from Edinburgh Business
(“the Listing Regulations”) and based on recommendations School, UK. She has been trained at Harvard Business School
of the Nomination and Remuneration Committee, appointed in change and transformation. She is an alumnus of CSC
Ms Kamath as an Independent Director of the Company, not Global leadership program and a certified Zenger Folkman
liable to retire by rotation, for a term of 3 (three) years effective Leadership4you trainer & facilitator.
October 29, 2019, subject to approval of the Members at the The additional details of Ms Kamath as required under
Annual General Meeting of the Company.
Regulation 36(3) of the Listing Regulations and the Secretarial
Ms Kamath has given her consent to act as a Director of the Standards issued by the Institute of Company Secretaries of
Company. Also, as per confirmations received from her, she is India are set out in the Annexure forming part of this Notice.
not disqualified from being appointed as a Director in terms of Ms Kamath does not hold any shares in the Company.
185
NOTICE
The letter of appointment of Ms Kamath containing terms of appointment, he was the Vice President & General Manager
her appointment, is available for inspection by Members on for Middle East & North Africa where he spearheaded
the website of the Company at www.abbott.co.in commercial operations across seventeen countries in one of
the company’s fastest growing and most complex business
None of the Directors and/or Key Managerial Personnel of the environments.
Company and their relatives, except Ms Kamath, is concerned
or interested, financially or otherwise, in the resolution set out Mr Ambati is an alumnus of the Indian Institute of
at Item No. 6. Management, Ahmedabad and has a Bachelor’s degree in
Engineering (Mechanical) from the University of Bhopal.
The Board recommends the resolution set forth in Item No. 6
for the approval of Members as an Ordinary Resolution. The additional details of Mr Ambati as required under
Regulation 36(3) of the Securities and Exchange Board of
Item No. 7 India (Listing Obligations and Disclosure Requirements)
Regulations, 2015 and the Secretarial Standards issued by the
Mr Ambati Venu (DIN : 07614849) served as the Managing
Institute of Company Secretaries of India are set out in the
Director of the Company for over three and half years upto
Annexure forming part of this Notice. He does not hold any
February 29, 2020. He has been elevated to a new role within
shares in the Company.
the Abbott Group in India effective March 1, 2020.
None of the Directors and/or Key Managerial Personnel of the
The Board, with a view to continue to leverage extensive
Company and their relatives, except Mr Ambati, is concerned
experience held by Mr Ambati in the areas of pharmaceuticals
or interested, financially or otherwise, in the resolution set out
and his deep understanding and knowledge about the
at Item No. 7.
Company’s operations and based on recommendation of the
Nomination and Remuneration Committee, appointed him as The Board recommends the resolution set forth in Item No. 7
Additional Director of the Company effective March 1, 2020, for the approval of Members as an Ordinary Resolution.
as per the provisions of Section 161 of the Companies Act, 2013
Item Nos. 8 and 9
and Rules framed thereunder (“the Act”) read with Article 113
of the Articles of Association of the Company. He holds office The Board, based on the recommendation of the Nomination
upto the date of this Annual General Meeting. and Remuneration Committee, appointed Mr Anil Joseph
(DIN : 08753233) as an Additional Director with effect from
Mr Ambati has given his consent to act as a Director of the
July 1, 2020 in terms of Section 161 of the Companies Act, 2013
Company. Also, as per confirmation received from him,
he is not disqualified from being appointed as a Director in and Rules made thereunder (“the Act”) read with Article 113 of
terms of Section 164 of the Companies Act, 2013. the Articles of Association of the Company. He holds office up
to the date of this Annual General Meeting.
The Company has received a notice in writing under
Section 160 of the Act, from a Member proposing the The Board, based on recommendation of the Nomination
candidature of Mr Ambati for the office of Director of the and Remuneration Committee also appointed Mr Joseph as
Company. the Managing Director, not liable to retire by rotation, for a
Prior to joining the Company in September 2016, Mr Ambati term of 5 (five) years with effect from July 1, 2020, subject to
held over 24 years of extensive experience in consumer the approval of the Central Government and Members of the
goods and OTC products with GlaxoSmithKline Consumer Company.
Healthcare Limited (GSK Consumer) in various leadership
The Company has received a notice in writing from a Member
positions across the Indian sub-continent, Middle East, North
under Section 160 of the Companies Act, 2013 proposing the
Africa and Asia. His last role till September 2015 was Regional
candidature of Mr Anil Joseph for the office of Director of the
Vice President & General Manager–Asia, GSK Consumer.
Company.
Mr Ambati holds strong business acumen and the ability
honed in both developed and emerging markets. Having Mr Joseph has given his consent to act as the Managing
worked in various regions since joining GSK Consumer Director of the Company. Also, as per the confirmations
in 1992, one of his strongest assets is his ability to excel received from him, he is not disqualified from being appointed
within diverse socio-cultural environments. Prior to his Asia as a Director in terms of Section 164 of the Companies Act, 2013.

He satisfies all the conditions as set out under Part I of Schedule (b) Performance Linked Bonus : Performance Bonus
V and Section 196(3) of the Act for his appointment as Managing will be allowed in addition to Salary as stated above
Director. according to the Company policy and as may be
determined by the Board of Directors but shall not
Mr Joseph, comes with an excellent track record of over 25
exceed an amount equal to 100% of the Salary for
years working with reputable companies across different
the relevant period.
business sectors (predominately Healthcare & FMCG) driving
revenue and income growth; business turnaround and 2. Mr Joseph shall be entitled to furnished/non-furnished
residential accommodation in lieu of housing allowance
managing emerging markets. He has an extensive and broad-
which is part of his Base Salary, relocation expenses (one-
based experience in managing P&L, General Management and
time), club fees, telephone and such other perquisites/
Sales & Marketing including Strategy Development, Branding
benefits in accordance with the Company’s Rules. He will
& Position, Key Accounts and Distributor Management and be entitled for Abbott Laboratories, USA stocks under its
Sales Operations. “Long Term Incentive Plan” in the form of Restricted
Prior to joining the Company, Mr Joseph was working with Stock Unit, as per his eligibility. He is also eligible to
purchase shares of Abbott Laboratories, USA, under its
Abbott Laboratories, Singapore heading the Diagnostics
“Affiliate Employee Stock Purchase Plan”
Division (Transfusion Medicine) for APAC, China and Japan
since March 2016. At Abbott, he was instrumental in setting The Company’s contribution to provident fund, group
up the Transfusion Medicine Business Unit in Asia Pacific insurance and gratuity shall not be included in the
building a team, developing retention and growth strategies computation of the above ceiling on remuneration and
allowances/perquisites/benefits.
and executing a high-pressure environment to transition the
business. Prior to this, he has worked with Johnson & Johnson 3. The Board or any Committee of the Board shall, in
and Coca-Cola in various senior leadership positions, in accordance with the statutory limits/approvals as may be
India and across Asia Pacific markets. He brings diversified applicable for the time being in force, be at full liberty to
experience across different countries, market types and revise/alter/modify/amend the terms and conditions of
managing multiple functions – sales, marketing, finance, the remuneration, from time to time, as it may deem fit;
engineering, supply chain, etc. and has significant expertise in 4. Notwithstanding anything contained in this Agreement,
managing start-ups, turn around, managing explosive growth if in any financial year during the tenure of Mr Joseph
as well as sustaining success. as Managing Director, the Company has no profits or
its profits are inadequate, the remuneration payable to
Mr Joseph holds a Master’s in Business Administration (dual Mr Joseph shall be subject to the provisions of
specialization – Marketing and Human Resources) from Section 197 and Section II of Part II of Schedule V to the
Symbiosis Institute of Business Management, Pune University Act, or any other law or enactment for the time being or
and Bachelor of Science (Mathematics) from C.M.S College, from time to time in force;
MG University, Kottayam, Kerala. 5. Mr Joseph shall not directly or indirectly, engage himself
The significant terms and conditions of appointment of in any other business or occupation or employment
Mr Joseph are as under : whatsoever, without the approval of the Board.
PROVIDED HOWEVER, that it shall be permissible to
1. In consideration of the performance of his duties to the Mr Joseph to hold share(s) of any other company(ies);
Company, Mr Joseph shall be entitled to the following
6. So long as Mr Joseph functions as Managing Director,
remuneration subject to applicable taxes :
he shall not become interested or otherwise concerned
(a) Salary, allowances and perquisites : from ` 2.94 crore directly or through any of his relatives, if any, in any selling
per annum upto ` 4.25 crore per annum; to be paid agency of the Company, without the prior approval of the
monthly and/or annually, as may be approved by the Board;
Board. Increments in the annual salary shall be as 7. Mr Joseph shall not, during the continuance of his
per the Company’s policy and as may be determined employment hereunder or at any time thereafter divulge
by Board of Directors, from time to time, or disclose to any person whomsoever or make any use
187
NOTICE
whatsoever for his own purpose or for any purpose up to the date of this Annual General Meeting. The Members
other than that of the Company, of any information or may write an email to [email protected]
knowledge obtained by him during his employment as by mentioning “Request for Inspection” in the subject of the
to the business or affairs of the Company or its methods email.
or as to any trade secrets or secret processes of the
None of the Directors and/or Key Managerial Personnel of the
Company and he shall during the continuance of his
Company and their relatives, except Mr Joseph, is concerned
employment hereunder also use his best endeavors to
or interested, financially or otherwise, in the resolutions set
prevent any other person from so doing. PROVIDED
out at Item Nos. 8 and 9.
HOWEVER that any such divulgence or disclosure to
officers and employees of the Company shall not be Considering the rich and diversified experience of
deemed to be contravention of this Clause; Mr Joseph, the Board recommends the resolutions set forth
in Item Nos. 8 and 9 for the approval of Members as Ordinary
8. The employment of Mr Joseph shall forthwith be
Resolutions.
determined if he shall become insolvent or make any
composition or arrangement with his creditors or if he is Item No. 10
guilty of any misconduct or otherwise violates the Abbott
The Company is engaged in the business of manufacturing,
Code of Business Conduct;
selling, distribution and marketing of Pharmaceuticals.
9. In case of the demise of Mr Joseph during the course
The Company, in the ordinary course of its business and on
of his employment hereunder, the Company will pay to
arm’s length basis enters into various transactions, contracts,
his legal personal representatives the salary and other
arrangements with various Abbott affiliates. The Company
emoluments payable hereunder for the then current
and Abbott Healthcare Private Limited both being indirect
month and other dues together with any such further
subsidiaries of Abbott Laboratories, USA, are Related Parties
sum as the Board of Directors may determine;
as per the provisions of the Companies Act, 2013 (“the Act”)
10. Notwithstanding anything contained to the contrary and Regulation 2(1)(zb) of the Securities and Exchange Board
in this Agreement, either party shall be entitled to of India (Listing Obligations and Disclosure Requirement)
determine the Agreement by giving not less than 3 (three) Regulations, 2015 (“the Listing Regulations”).
months’ notice in writing in that behalf to the other party
The transactions with Abbott Healthcare Private Limited
without the necessity of showing any cause. However, the
interalia include purchase and sale of products; goods; raw
Company shall have the option to terminate the
materials; active pharmaceutical ingredients; stock-in-trade,
employment by giving 3 (three) months’ remuneration
availing or rendering of services, reimbursement of expenses,
including salary, allowances, benefits/perquisites in lieu
recovery of costs, rent receipts/payments, buying/leasing
of notice.
of property, lending or borrowing of monies, (as may be
11. The appointment of Mr Joseph as Director shall cease as permissible under the applicable provisions of the Act), etc.,
provided in Section 167(1)(c) and (d) of the Companies which are entered into in the ordinary course of business, at
Act, 2013 and simultaneously his employment with the arms’ length and in the best interest of the Company.
Company shall also come to an end.
In terms of Regulation 23 of the Listing Regulations, all
The additional details of Mr Joseph as required under material transactions (i.e. the transaction(s) to be entered
Regulation 36(3) of the Securities and Exchange Board of into individually or taken together with previous transactions
India (Listing Obligations and Disclosure Requirements) during a financial year, exceeds ten percent of the annual
Regulations, 2015 and the Secretarial Standards issued by the consolidated turnover of the Company as per the last audited
Institute of Company Secretaries of India, are set out in the financial statements) with a related party requires approval of
Annexure forming part of this Notice. Mr Joseph does not hold the Members through ordinary resolution.
any shares in the Company.
The Members at its Meeting held on July 18, 2017, approved
A copy of the agreement between Mr Joseph and the Company the transactions with Abbott Healthcare Private Limited upto
containing terms of his appointment referred in this Notice will a limit of ` 550 Crore in each financial year. Considering the
be available for inspection without any fees by the Members future business projections, the Company envisages that the

transactions with Abbott Healthcare Private Limited may exceed ` 800 Crore in each financial year for a period of 5 financial years
the said approved limits. Thus, by way of abundant caution, upto 2024-25. The annual value of the transactions proposed is
prior approval of the Members is being sought in terms of the estimated on the basis of the Company’s current transactions
Regulation 23 of the Listing Regulations for enhanced limits of and future business projections.
The particulars of the contracts/arrangements/transactions are as under :
Name of the Related Party Abbott Healthcare Private Limited

Name of Director(s) or Key Managerial Personnel who NA
is related
Nature of Relationship Abbott Healthcare Private Limited and the Company both are indirect
subsidiaries of Abbott Laboratories, USA
Material terms of the contracts/arrangements/ Purchase and sale of products; goods; raw materials; active
transactions pharmaceutical ingredients; stock-in-trade, availing or rendering of
services, reimbursement of expenses, recovery of costs, rent receipts/
payments, buying/leasing of property, lending or borrowing of
monies, (as may be permissible under the applicable provisions of the
Act) or such other transactions.
Are the transactions in the ordinary course of business Yes
Are the transactions on an arm’s length basis Yes

Whether the transactions would meet the arm’s length Yes
standard in the opinion of the Company’s Transfer
Pricing Consultants
Whether the transactions have been approved by the Yes
Audit Committee and the Board of Directors
Aggregate amount of transactions to be entered with Not exceeding ` 800 Crore (Rupees Eight Hundred Crores) in each
related party financial year for a period of 5 years upto 2024-25
The Company, from time to time, conducts third party review Item No. 11
for each category of transactions with Abbott Healthcare
In accordance with the provisions of the Foreign Exchange
Private Limited and basis which, determines that all such
Management Act, 1999, Foreign Exchange Management
transactions meet domestic transfer pricing norms enshrined
(Non-Debt Instruments) Rules, 2019 and the Consolidated
in the Income Tax Act, 1961 and are on arm’s length. The Foreign Direct Investment Policy Circular of 2017 dated
Audit Committee and the Board are of the opinion that August 28, 2017, issued by the Department of Industrial
the above transactions are entered in the best interests of the Policy and Promotion, Ministry of Commerce and
Company and accordingly have granted approval for enhancing Industry, Government of India and other applicable rules,
the limits of transactions with Abbott Healthcare Private guidelines, regulations, notifications, circulars, provisions,
Limited. if any, (including any amendments, or re-enactments or
None of the Directors and/or Key Managerial Personnel of the re-notifications of each of the above for the time being in
force), foreign investment in a company engaged in brown-
Company and their relatives, is deemed to be concerned or
field pharmaceutical sector up to 74% of the share capital of
interested, financially or otherwise, in the resolutions set out
the Company would fall under the automatic route, while
at Item No. 10.
foreign investment beyond 74% would require approval of the
The Board recommends the resolution set forth in Item No. 10 Department of Pharmaceuticals, Ministry of Chemicals and
for the approval of Members as an Ordinary Resolution. Fertilizers.
189
NOTICE
Members may please note that prior to the change in FDI Investors (FVCIs), Foreign Direct Investment (FDI), Indirect
Policy on October 19, 2012, foreign investment in a company Foreign Investment, etc., in any combination thereof ) shall not
engaged in brown-field pharmaceutical sector was permitted at any time exceed 80% of the total paid up share capital of the
up to 100% under the automatic route. Further, the Foreign Company on a fully diluted basis. In terms of Foreign Exchange
Direct Investment of 74.99% from the promoters of the Management (Non-Debt Instruments) Rules, 2019, this would
Company and other Foreign investment (held by FII/FPI and also require an approval of the Members by way of a Special
NRI repatriable) to the extent of 0.12% (out of total 1.34% Resolution.
held as on July 24, 2020 by FII/FPI and NRI repatriable) None of the Directors and/or Key Managerial Personnel of
were received prior to such change in policy in October 2012, the Company and their relatives, is deemed to be concerned
in compliance with the then applicable foreign exchange or interested, financially or otherwise, in the resolution set out
regulations. at Item No. 11.
Presently, the Foreign Institutional Investors (FIIs)/Foreign
The Board recommends the resolution set forth in Item
Portfolio Investors (FPIs) are unable to purchase additional
No. 11 for the approval of Members as a Special Resolution.
shares of the Company owing to the applicable sectoral limits
in terms of the SEBI Circular No. IMD/FPIC/CIR/P/2018/61 By Order of the Board
dated April 5, 2018, and therefore, it is pertinent to increase the
applicable limits for Foreign Investment into the Company, Krupa Anandpara
subject to receipt of approval from the Government. Mumbai Company Secretary
August 7, 2020 Membership No. : ACS 16536
In line with the Company’s commitment to be compliant with
the abovementioned regulatory regime for foreign investment Registered Office :
and giving headroom to the further foreign portfolio investment,
the Board on June 16, 2020, approved proposal to increase the
aggregate limit for investment by Foreign Institutional Investors CIN : L24239MH1944PLC007330
(FIIs)/Foreign Portfolio Investors (FPIs)/Non Resident Indians 3, Corporate Park, Sion-Trombay Road,
(repatriable) under the portfolio investment scheme, to the Mumbai - 400 071
proposed ceiling of 5% of the total paid up share capital of the Telephone No. : +91-22-6797 8888/+91-22-5046 1000/2000
Company, provided that the composite cap for total foreign Fax : +91-22-5016 9400
investment from all sources (including investments received Email : [email protected]
under the Portfolio Investment Scheme, Foreign Venture Capital Website : www.abbott.co.in

Details of Directors seeking appointment/re-appointment at the Seventy-sixth Annual General Meeting (pursuant to Regulation 36(3) of the
Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Secretarial standards
issued by the institute of Company Secretaries of India
Name of Director Mr Kaiyomarz Marfatia Mr Munir Shaikh Ms Shalini Kamath Mr Ambati Venu Mr Anil Joseph
Date of Birth November 22, 1956 March 1, 1943 December 15, 1964 May 26, 1969 January 31, 1975
Date of March 1, 2011 March 2, 2001 October 29, 2019 March 1, 2020 July 1, 2020
Appointment
Expertise in Specific Mr Marfatia has over Mr Shaikh possesses Ms Kamath has close Mr Ambati has Mr Joseph has an
Functional Area 40 years of diverse vast knowledge of to three decades of diversified experience expertise in managing
experience in the Legal the industry and work experience in handling P&L, General
and Secretarial is a consummate in three distinct International business Management and Sales
streams, of which team player with an fields – Human operations with an & Marketing including
about 24 years have entrepreneurial flair. Resources, Business excellent track record Strategy Development,
been with Abbott. Development and of success in building Branding & Position, Key
Social & Community and leading high Accounts and Distributor
Development and performing teams. Management and Sales
across two continents Operations.
– India and Africa.
CORPORATE OVERVIEW
Qualifications B.Com. from Lala Fellow of the MBA graduate from Alumnus of the M.B.A. with dual
Lajpat Rai College Institute of Chartered Edinburgh Business Indian Institute specialization –
and Law degree from Accountants in School, UK and an of Management, Marketing & Human
Government Law England and Wales Alumnus of CSC Ahmedabad and Resources from
College, Mumbai Global leadership Bachelor’s degree Symbiosis Institute of
program and a certified in Engineering Business Management,
Zenger Folkman (Mechanical) from the Pune University and
Leadership4you University of Bhopal B.Sc. (Mathematics)
trainer and facilitator from C.M.S College, MG
University, Kottayam,
Kerala
STATUTORY REPORTS
No. of shares held in NIL NIL NIL NIL NIL

the Company
Directorships None None 3 None None
in other Indian
Companies
Membership None None 1 None None
of Committees
in other Indian
Companies
Relationship None None None None None
between Directors
inter-se
FINANCIAL STATEMENTS
191
ABBOTT INDIA LIMITED
CIN : L24239MH1944PLC007330
3, CORPORATE PARK, SION-TROMBAY ROAD,
MUMBAI - 400 071, INDIA
© Abbott India Limited all rights reserved.

Reproduction in whole or part without written permission is strictly prohibited.

Abbott Annual Report

Uploaded by

Copyright:

Available Formats

Abbott Annual Report

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Abbott Annual Report

Uploaded by

Copyright:

Available Formats

Abbott India Limited Registered Office: Tel: (91-22) 5046 1000/2000

August 16, 2020

Scrip Code: 500488

You are requested to take the same on record.

A Passion to Deliver Excellence allows us to face

Our Passion to Deliver Innovation to our wide

And Passion to Deliver with Compassion remains the

Continuing on our journey to deliver on our commitment,

ABOUT THE REPORT

ABBOTT INDIA, A TRUSTED PARTNER

KEY THERAPY AREAS

4 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 5

OUR KEY BRANDS

16 OF OUR TOP 20 BRANDS RANK # 1 AND # 2 IN THEIR RESPECTIVE

Manage Vitamin D3 deficiency

Smarter technology. Better absorption

Disclaimer: All products displayed/mentioned in this Annual Report are for

25.4% > 95% 3,551 1 ` 12 Crore 2,879 KL

75 ~25,000 44,372 KWH

8 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 9

A consistent brand focus, changing product-mix, and

DELIVERING LONG-TERM During this challenging time,

12 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 13

MEASURING OUR PROGRESS

* Post Merger with Solvay Pharma India Limited

14 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 15

EVOLVED HEALTHCARE SOLUTIONS EBITDA ` IN CRORE we are working to improve patient

FOR A CHANGING WORLD to patients in the pre-and post-

DELIVERING ON OUR COMMITMENTS

RETURN (PAT) ON AVERAGE

450,33 1850,68 945

18 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 19

BUILDING FOR THE FUTURE We are sharpening our focus on

We have a legacy to grow here – a legacy of 167 4.4 531 12.6

MATERIAL COST OTHER EXPENSES PROPOSED DIVIDEND (INCLUDE

20 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 21

GROWING CONSISTENTLY AND WELL

OUR PURPOSE INPUTS OUTPUTS OUTCOMES

and operations to stay relevant and ahead of market trends.

PIONEERING STRENGTHENING THE CARE INSPIRE AND BUILD REMAIN DO GOOD

24 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 25

ADAPTING TO MARKET DYNAMICS

26 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 27

As a part of our program, we also developed India’s

BALANCE AWARENESS CHALLENGE

30 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 31

ITS FOGSI METABOLIC WOMEN’S

THE EXTENDED ABBOTT CLINILEAD PANCREOSCOPIE

32 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 33

As a leading player in several therapies, we have access

34 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 35

LIFESTYLE-INDUCED ACIDITY AND CHOOSE CREMAFFIN -

Gastroenterology Women's Health Central Pain Vaccines

36 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 37

IN FY 2019-20, 2,879 KL 44,372 KWH

MEASURES TO OPTIMIZE RESOURCES AND FOR

PROCESS EFFICIENCY MEASURES SAFETY ENERGY CONSERVATION

40 ABBOTT INDIA LIMITED | ANNUAL REPORT 2019-20 41

Our Plant at Goa

MATERIAL COST OTHER EXPENSES PROPOSED DIVIDEND (INCLUDE

• Communication and information Being a multiproduct facility, product-wise